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 Abstract 
The DNA damage response is an important barrier to tumorigenesis. Impairment of p53 
function is crucial to tumorigenesis by allowing evasion of p53 dependent responses. The 
mechanisms involve either (i) missense mutations, (ii) partial abrogation of signaling 
pathways or effector molecules that regulate p53, (iii) epigenetic deregulation. 
 
The tyrosine to cysteine mutation, Y220C, in p53 is found in around 100,000 new cancer 
cases per annum. This mutation destabilizes the core domain by 4 kcal mol-1 and 
destabilizes p53 under physiological conditions. The large to small mutation results in the 
fusing of two shallow pockets to create an extended surface cleft that a number of 
different fragments bind. 
 
The small molecule PK083, 1-(-ethyl-9H-carbazol-3-yl)-N-methanamine, binds the 
mutant-specific crevice with a KD = 150 µM and raised the protein mutant’s half-life to 
over 15 minutes vs. 4 minutes in the absence of the ligand. This presents an ideal starting 
point towards the design of a p53 rescuing drug. 
 
A library of carbazoles was designed and synthesized, guided by SAR studies, 
crystallographic information and computational chemistry, with the aim of optimizing the 
structure toward a more potent PK083 analogue. Affinity gains were achieved by 
exploitation of direct fluorine-protein interactions between PK9255 (N-methyl-1-(9-
(2,2,2-trifluoroethyl)-9H-carbazol-3-yl)methanamine), and the backbone carbonyls of 
Leu145 and Trp146  and the thiol of Cys220, resulting in a Kd = 28 µM.  
 
Further affinity gains were achieved through SAR studies targeting the proline-rich 
subsite II. Chemistry was optimized to allow a diversity-oriented synthesis toward 2,6,9-
substituted carbazoles. A small library of PK083 analogues, where the subsite II targeting 
group was a halogen, ether, ester, amide or heterocycle were synthesized, identifying the 
heterocyclic compounds as most potent. A scan of heterocyclic compounds was carried 
out to identify the most potent heterocyclic substitution. 
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Chapter 1 : Introduction 
Cancers are one of the leading causes of death worldwide, accounting for 8.2 million 
deaths in 2012 (GLOBOCAN 2012 (IARC)). The lifetime risk of developing cancer for 
those born since 1960 is now 1 in 2.1 Tumourigenesis, the process by which a normal 
human cell evolves progressively to a neoplastic state, is often likened to a process not 
dissimilar to Darwinian evolution, in which a succession of genetic changes confers some 
type of growth advantage over normal cells. Along the road to malignancy, cancer cells 
acquire a succession of hallmark capabilities that correspond to important barriers to 
tumourigenesis (Figure 1.1). These comprise of: sustaining proliferative signalling, 
evading growth suppressors, avoiding immune destruction, enabling replicative 
immortality, tumour promoting inflammation, activating invasion and metastasis, 
inducing angiogenesis, genome instability and mutation, resisting cell death and 
deregulation of cellular energetics.2 
 
 
Figure 1.1: The hallmarks of cancer. 2 Reproduced from Cell, 144 (5), D. Hanahan and R. Weinberg, ‘The Hallmarks 
of Cancer: The Next Generation,’ 646-674, Copyright (2011), with permission from Elsevier.  
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1.1 Treating Cancer 
Current clinical practice in the treatment of cancer is centred on 8 different approaches: 
surgery, radiotherapy, chemotherapy, immunotherapy, targeted therapy, hormone 
therapy, stem cell transplant and precision medicine. The efficacy of each treatment 
depends on the type of cancer; for example, surgery that works best for cancers which 
exhibit solid tumours that are contained in one area, however, would not be effective for 
leukaemia. Therapies are typically used in combination. 
 
1.1.1 Personalized Medicine 
Precision medicine or ‘personalized medicine’ is an emerging approach to patient care in 
which an individual’s characteristics, including their genetic profile, guide clinical 
decisions, aiming for a treatment programme tailored to have the maximum efficacy for 
a specific patient. This treatment course is particularly important for oncology where 
short-term toxicities and long-term functional implications are associated with surgical 
and chemo-radiotherapy treatments.  Personalized medicine has the power to maximise 
efficacy of treatment and reduce toxicity by targeting tumour molecular abnormality 
profile rather than tumour tissue type or anatomical site of origin. The ability to use this 
approach depends on identification of prognostic and predictive biomarkers that confer 
the ability to target treatments to patients most likely to benefit.  
 
One such example is the identification of cancer predisposition genes BRCA1 or BRCA2, 
where female carriers of mutations in these genes have a 45-65% chance of developing 
breast cancer by the age of 70.3 Screening is available for family members with a strong 
family history of breast cancer. Current treatment options include mastectomy, 
oophorectomy or chemical oestrogen deprivation. Although BRCA genes are associated 
with a high penetrance rate, 30% of carriers will not develop breast cancer, prompting 
difficult, highly personal decisions.  
 
Cells with BRCA mutations have non-functioning homologous recombination DNA 
repair mechanisms.4 However, base-excision DNA repair mechanisms remain functional, 
rescuing tumour cells from apoptotic death following DNA-damaging cancer therapy. 
PARP inhibitors prevent base-excision repair from functioning, producing tumour cell 
death in BRCA deficient cells but not in healthy cells with functional homologous 
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recombination pathways. The PARP inhibitors Olaparib and Rucaparib have both been 
granted FDA approval for the treatment of patients with germline mutated BRCA1/2 
ovarian cancer (Figure 1.2).   
 
Figure 1.2: Structure of PARP inhibitors Olaparib and Rucaparib. 
Another example is the TP53 gene that encodes the tumour suppressor p53. Evasion of 
p53-dependent responses is crucial to tumourigenesis with virtually all tumours 
displaying loss of p53 through either deleterious mutation or partial abrogation of 
signalling or effector molecules that regulate p53. Consequently, since its discovery in 
1979, efforts have been made to target p53 through various avenues toward personalised 
medicine approaches for cancer therapy.5 These are summarised in Section 1.7.  
1.2 Structural Biology of P53 
The p53 tumour suppressor protein acts primarily as a transcription factor that elicits cell 
cycle arrest, apoptosis or senescence in response to oncogene activation, DNA damage 
and other stress signals.6 For this reason, it has been termed ‘the guardian of the genome.’7 
Since its discovery, it has also been linked to ageing, metabolism, immunity, embryo 
implantation, autophagy, angiogenesis and cellular stress. P53’s increasingly complex 
multifaceted role in many signalling pathways is mirrored in its equally complex 
structural biology. P53 is biologically active as a homo-tetramer, comprising of 4 X 393 
amino acid residues (Figure 1.3). At the amino terminus, there is a natively unfolded 
transactivation domain which can be subdivided into two subdomains TAD1 and TAD2 
followed by a proline rich region (PRR). The structured DNA binding domain and 
tetramerization domain are connected through a flexible linker region. Like the TAD 
domain, the regulatory domain at the carboxy terminus is intrinsically disordered (CTD). 
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Figure 1.3: Structure of P53. Figure taken from The tumor Suppressor P53: From Structures to Drug Discovery, Joerger 
et al. 8 Copyright (2010) Cold Spring Harbor Laboratory Press, U.S.A.  
1.2.1 The DNA Binding Domain 
The DNA binding domain consists of a β-sandwich scaffold as well as a loop-sheet-helix 
motif and two large loops L2 and L3. The structure of L2-L3 is stabilised by a zinc ion 
which is tetrahedrally coordinated by Cys176, His179, Cys235 and Cys242.9–11  The 
human p53 core domain has low intrinsic thermodynamic stability and rapidly unfolds at 
body temperature with a half-life of 9 minutes.12–14 There are several lines of evidence 
suggesting that this is the result of an adaptive evolutionary process with important 
implications for protein turnover and binding to partner proteins.10,15,16 For example, low 
thermodynamic stability may allow for rapid cycling through folded and unfolded states, 
which may provide an additional layer of regulation of functionally active cellular protein 
levels. Additionally, it may also provide a certain element of structural plasticity required 
to bind many different partner proteins. However, this low intrinsic stability has profound 
implications on the susceptibility of human p53 to deleterious mutations and cancer 
development with many mutations reducing the half-life of p53 to minutes or even 
seconds, thus resulting in loss of functional p53.12,13  
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1.2.2 The Tetramerization Domain 
The structure of the individual sub-units of the tetramerization domain consists of a short 
β-strand followed by an α-helix which is connected through a sharp turn facilitated by 
Gly344. The p53 folding mechanism proceeds by formation of a dimeric intermediate 
that is stabilised by antiparallel β-sheet and helix packing interactions.17 This is followed 
by dimerization of dimers in a roughly orthogonal fashion via their hydrophobic helix 
interfaces to form a highly thermodynamically stable tetramer.18–20 At the centre of this 
tightly packed interface Leu344 side chains are in direct contact.21 Leucine 344 is part of 
a leucine-rich nuclear export signal. The overall effect of this is that the tetramerization 
domain does, in part, control nuclear levels of p53 through regulation of the 
oligomerization state. There is evidence that the oligomerization equilibrium of p53 is 
modulated via an intricate network of accessory proteins that can either have a positive 
or negative effect. For example, direct binding of apoptosis repressor with caspase 
recruitment domain (ARC) to the p53 tetramerization domain in the nucleus inhibits 
tetramerization and promotes nuclear export.22 In contrast, binding of dimeric 14-3-3 
proteins to the p53 carboxy-terminus, which is strengthened by phosphorylation of the 
latter, enhances tetramerization.23  
 
1.2.3 The Transactivation Domain 
The natively unfolded TAD domain is responsible for p53’s transcriptional activity with 
two regions of nascent secondary structure.24–26 Upon binding to the negative regulators 
murine double minute 2 or X (MDM2, MDMX) through residues 18-25, the TAD1 
subdomain has been observed to become fully helical.27,28 Likewise, regions within 
TAD2 assume amphipathic α-helices upon binding replication protein A.29 The 
interaction properties of the TAD are modulated by posttranslational modification. Out 
of p53’s 9 phosphorylation sites, 7 occur within the binding region of its regulatory 
proteins (Ser15, Thr18, Ser20, Ser33, Ser37, Ser46 and Thr55) where phosphorylation at 
different sites modulates affinity for these proteins. For example, phosphorylation of 
Thr18 significantly reduces the affinity of TAD for the negative regulator MDM2 because 
of electrostatic repulsion between the negatively charged phosphate group and a 
negatively charged section on the MDM2 surface.30–32 Conversely, affinity is 
significantly enhanced for the transcriptional co-activator p300.33–36 Therefore, 
phosphorylation of the TAD is responsible for the modulation of p53 activity in response 
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to genotoxic stress by modulation of affinity for competing regulatory proteins in the cell 
cycle by phosphorylation.  
 
1.2.4 The Carboxy-Terminal Regulatory Domain 
Like the TAD, posttranslational modifications in the CTD such as: Acetlyation, 
methylation, ubiquitination, sumolyation and methylation of Lys370, 372, 373, 381, 382 
and 386, as well as phosphorylation of Ser366, Ser378, Thr387 and Ser393; are 
responsible for modulation of p53 function and cellular protein levels.6,37,38 Additionally, 
as observed in TAD, intrinsic disorder facilitates binding promiscuity. However, 
conversely to TAD, in which sections of sequences adopt a specific secondary structure, 
CTD displays characteristics of a chameleonic sequence where the same sequence can 
adopt differing secondary structures depending on the structural environment. For 
example, residues 376-387 form an α-helix in complex with S100B, whereas, parts of the 
same sequence can adopt a β-sheet secondary structure when in complex with sirtuin 2 
(SIRT2).39,40 
1.3 P53’s Cellular Biology 
In healthy cells, p53 acts as a ‘cellular gatekeeper,’ acting to transmit a variety of stress-
inducing signals (DNA damage, oncogene activation or hypoxia) to different anti-
proliferative cellular responses (apoptosis, cell-cycle arrest, senescence).41 The process 
of activation of p53 in response to cellular stress comprises of three steps: stabilization 
of p53, sequence specific DNA binding and transcriptional activation of target genes.42 
P53 is primarily stabilized through disruption of its interactions with its negative 
regulator, MDM2. This may be by phosphorylation of specific amino acids in the TAD 
by various kinases (such as ATM, ATR, DNA-PK, Chk1 and Chk2, see Section 1.2.3), 
or through antagonism of the p53-MDM2 interaction by the tumour suppressor 
p14ARF.43,44 P53 then binds DNA in a sequence specific manner.45 However, several lines 
of evidence suggest that a significant proportion of p53 is bound to DNA in unstressed 
cells through the CTD, challenging the stress-induced sequence specific model of DNA 
binding.46 One rational is that binding the CTD facilitates DNA binding through the DBD 
and the search for p53 target sites. Additionally, studies have suggested that basal p53 
levels are required for assembly of the p21 pre-initiation complex in unstressed cells.47 
Thus, p53 has been observed to control gene expression in both stressed and unstressed 
cells.  
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1.3.1 Cell Cycle Arrest 
In mammalian cells, after double-strand breaks by ionizing irradiation, activation of the 
protein kinase ATM occurs that blocks p53-MDM2 binding through phosphorylation of 
p53’s TAD domain causing a rapid build-up of functional p53.48 P53-mediated cell-cycle 
arrest occurs mainly through the transcriptional activation of p21/WAF1.49,50 P53 binds 
to two sites 2.4 kb and 1.4 kb upstream of p21.51 The p21 mRNA is highly induced after 
p53 activation.49 P21 binds to the cyclin E/Cdk2 and cyclin D/Cdk4 complexes to cause 
G1 cell arrest.50 This is accomplished through p21 inhibition of Cdk2 and Cdk4 that 
blocks pRb phosphorylation. This promotes binding of pRb to E2F1, the functional effect 
of which is transcriptional silencing of E2F1 target genes which are essential to DNA-
replication and cell-cycle progression. Experimentally, p21 null mouse embryonic 
fibroblasts show deficiency in cell-cycle arrest following DNA damage suggesting that 
p21 is the main transcriptional target of p53 in cell-cycle arrest.52 However, p21 null cells 
are not completely defective for G1 arrest suggesting other p53 target genes.53  
 
Furthermore, p53 activation has been found to inhibit G2/M cell cycle progression. 
Transcriptional activation of p21, which inhibits cyclin B/Cdc2 causes inhibition of cell 
cycle progression through mitosis. Additionally, other p53 target genes such as 14-3-3σ 
may also play a part in blocking G2/M.54 P53 repression of cdc28C promoter has also 
been shown to promote G2/M arrest after DNA damage.55  
 
1.3.2 Senescence 
Chronic p53 activation in response to prolonged stress, such as telomere erosion or DNA 
damage, causes replicative senescence.  The ability of p53 to induce cell-cycle arrest is 
essential for senescence as p21 knockout prevents the induction of senescence by p53.56 
Furthermore, inactivation of p53 can cause senescent cells to re-enter the cell cycle 
suggesting that cellular senescence is a very stable state of cell cycle arrest but is not 
irreversible, despite the general belief.57 There are several mechanisms by which 
senescence can be sustained. For example, in cells that have persistent p21 gene 
expression and pRb activation, the level of heterochromatin on E2F1 may be sufficiently 
high to establish a self-sustaining positive feedback loop to be established.58,59 Formation 
of stable heterochromatin may play a role in persistent DNA damage signals, being 
recognized as DNA DSBs leading to constitutive p53 activation.60 Although p53 
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activation facilitates senescence by stress, p53 activation alone is not enough to induce 
senescence in most cases. Tumour cells in which p53 induction occurs by inhibiting 
p53/MDM2 only shows signs of reversible cell-cycle arrest.61 In fact, paradoxically, p53 
antagonism of many important proteins for senescence induction, such as pRb, NF-κB, 
and mTor, may limit senescence. For example, p53 has complex cross-talk through 
MDM2/pRb binding.62 Treatment with Nutlin, a p53/MDM2 inhibitor, causes down-
regulation of pRb in a p53/MDM2 dependent fashion that may limit the formation of 
senescent-associated chromatin.61,63 P53 also inhibits NF-κB, and mTor, both of which 
are required for the initiation of senescence.64 Therefore, p53 may facilitate or inhibit 
senescence depending on the cellular context and pathway cross talk. 
 
1.3.3 Apoptosis 
There are several convergent mechanisms by which p53 can induce apoptosis (Figure 
1.4), these can generally be separated into intrinsic and extrinsic. Extrinsically, p53-
mediated induction of apoptotic machinery proceeds via the induction of death receptors 
Fas and Dr5 by promoting dimerization, which leads to activation of pro-caspase 8 and 
ultimately, executioner caspase 3 and 7.65–67 Intrinsically, p53 induction of apoptosis may 
be transcription dependent, acting as a transcription factor in the nucleus, or independent, 
functioning through direct interactions with Bcl2 family proteins in the mitochondria.  
 
Transcription dependent p53-mediated apoptosis proceeds via induction of BH3 domain 
only pro-apoptotic proteins that causes mitochondrial outer membrane permeabilization 
(MOMP).68 MOMP is determined by the balance of pro- and anti-apoptotic proteins. Bax 
and Bak are activated by interaction with tBid and Bim that insert into the outer 
membrane and oligomerize to form pores to allow the release of cytochrome C (cyt C). 
Cyt C binds to ATP and Apaf1 promoting oligomerization to form the apoptosome. The 
apoptosome recruits and activates procaspase 9 that leads to the activation of executioner 
caspase 3 and 7. P53 has been found to target multiple stages of the MOMP regulatory 
mechanism. Bcl2, BclXL and Mcl1 prevent activation of Bax and Bak by sequestering 
Bim. By signalling for transcription of derepressors Puma and Noxa, p53 can also 
promote apoptosis by releasing Bax, tBid and Bak from BclXL and Mcl1. 
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In mammalian cells, a fraction of p53 can be found in the mitochondria preceding MOMP 
and caspase activation through transcription-dependent mechanisms.69,70 Transcription-
independent p53-mediated apoptosis functions through the direct interactions of p53 with 
anti-apoptotic and pro-apoptotic proteins. P53 binds BclxL through charge-mediated 
interactions.71,72 Additionally, it can interact directly with pro-apoptotic Bak, relieving it 
from anti-apoptotic Mcl1.73,74  
 
Uniquely, transcription-dependent and independent p53 activities may cooperate to 
induce apoptosis in mammalian cells. It has been hypothesised that the structural 
flexibility of p53 may provide an explanation for this. P53’s low thermodynamic stability 
and high intrinsic disorder may allow the structural plasticity required to bind new 
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Figure 1.4: Mechanisms by which p53 induces apoptosis. 
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partners without compromising the DNA-binding activity when coupled with high body 
temperatures in mammalian cells.13,75  
1.4 Tumour Suppression Function of p53 
Numerous studies have investigated how p53 acts as a tumour suppressor, with early 
emphasis aimed at attributing p53’s roles in cell cycle arrest and apoptosis as its key 
tumour suppression mechanisms. For example, p53 null mice (p53-/-) are prone to develop 
spontaneous thymic lymphomas. Thymoctes ability to undergo apoptosis after irradiation 
is p53-dependent suggesting that apoptosis is involved in p53’s tumour suppression 
action.76 Additionally, in choroid plexus brain tumour induced by the SV40 T antigen, 
mutant antigens defective for p53 binding induced slow-growing tumours that exhibited 
frequent apoptosis.77 Wild-type T antigen, a p53 inhibitor, induces rapid-growing 
tumours. Deletion of p53 in the mutant antigen resulted in rapid growth and reduced 
apoptosis further suggesting p53 limits tumours by inducing apoptosis.  
 
Several p53 mutants found in human tumours or in the germline of Li-Fraumeni patients 
have partial transcriptional activity.78,79 Of these, R175P, E180K and R181L fail to 
execute apoptosis targets but retain p21 induction suggesting an important role for 
apoptosis in blocking human tumours. Human derived p53 mutations were introduced 
into the mouse germline, for example R175P. R172P in humans. R175P mutant mice 
were largely protected from spontaneous thymic lymphomas which suggests apoptosis is 
not necessarily needed for tumour suppression.80 However, this mutation only provided 
partial protection against Myc-Induced-B-cell lymphoma which suggests that apoptosis 
is important in this context.81 Perhaps, the mechanism by which p53 serves as a tumour 
suppressor differs according to tumour type and cellular context? Furthermore, E180R 
(E177R in humans) mutant mice, which are deficient for cooperative DNA binding and 
apoptosis, but not cell-cycle arrest, senescence, and the ability to regulate metabolic target 
genes, are protected from spontaneous thymic lymphomas and tumours that arose in other 
organs often remain benign.82 Hence, apoptosis may not needed to supress thymic 
lymphoma.  
 
Whilst using p53 missense mutations as a model for examining how p53 acts as a tumour 
suppressor provides valuable information, to a certain extent, all p53 activities are 
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compromised to various degrees by mutation. It is unlikely to have a clean separation of 
apoptosis and cell function.  
 
When apoptosis is blocked in Eµ-Myc mouse by expression of Bcl2, selection pressure 
to inactivate p53 during lymphoma development was eliminated, showing that in this 
model for apoptosis, p53-mediated apoptosis is important for blocking tumour 
progression.83 Furthermore, Eµ-Myc-induced lymphomas were accelerated by the 
knockout of Puma which suggests p53 blocks tumour development through apoptosis.84  
Blocking of Myc-induced lymphomas with Bcl2 followed by treatment of established 
lymphomas with cyclophosphamide caused p53-dependent senescence and tumour 
regression.83 Additionally, restoration of normal p53 expression in hepatocellular 
carcinomas induced by activated H-rasV12 mutant caused tumour regression by 
senescence.85 Furthermore, restoration of p53 expression in sarcomas that developed in 
the absence of p53 lead to senescence and tumour regression.86,87 All these results point 
to tumour suppression through p53-mediated cell-cycle arrest, senescence and apoptosis 
in a context dependent manner. However, recent studies have shown that whilst these 
mechanisms of action in tumour suppression are undoubtedly important, p53 can supress 
spontaneous tumour development without inducing apoptosis and cell cycle arrest.  
 
Three p53 acetylation sites are important for the transactivation of classic p53 target 
genes such as p21 and Puma (K117, K161 and K162). The p533KR mice showed defects 
in apoptosis and cell-cycle arrest but were free from early onset tumours.88 The p533KR 
mice retain the ability to regulate target genes involved in energy metabolism and anti-
oxidant response. Furthermore, in another triple knockout mouse model, in which 
p21/Puma/Noxa were knocked out, p53 was found to block spontaneous tumour 
development showing that the tumour suppressive functions of p53 are not solely 
dependent on its cell-cycle arrest and apoptotic function.89 One possible explanation of 
this enigma is that p53 may induce different target genes to block different stages of 
tumour development (Figure 1.5).  
12 
 
 
1.5 Lessons from Development of P53 Mouse Models: Ageing vs Tumour 
Suppression 
There are numerous mouse models that demonstrate that there exists a delicate balance 
between the effect that p53 has on tumour suppression and ageing and longevity. P53 null 
mice develop normally but a subset of the mice exhibit an overgrowth of neural tissue in 
the region of the mid-brain to cause exencephaly because of defective apoptosis.90 
Furthermore, whilst the mice appear to mature to adulthood normally, the majority seem 
to develop cancer by 6 months old.91 Heterozygous p53+/- mice also succumb to cancer, 
albeit at a later stage than p53-/-.92 Neither mouse model is very useful in studying later 
onset cancers (which the majority of human cancers are) or ageing and longevity.  
 
P53+/m (mutant p53 allele, 7-11 exons) mice, generated by a spontaneous recombination 
event which deleted a stretch of DNA upstream of p53, which included exons 1-6 of the 
p53 coding system, were strikingly resistant to cancer at 18 months compared to p53+/+ 
mice.93 However, the p53+/m mice has a 20-30% shorter lifespan as well as showing signs 
of accelerated ageing including tissue atrophy. However, due to the low expression level 
of the m-allele, no m-derived protein could be detected. Furthermore, in subsequent 
experiments that characterized the upstream stretch of DNA that was deleted, 24 
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upstream genes have been identified.94 It is possible that the accelerated ageing 
phenotypes and increased cancer resistance in the p53+/m mice could be caused by the 
absence of one or more of these genes.  
 
Transgenic mice that overexpress p44 (a short, naturally occurring p53 isoform that lacks 
the main transactivation domain) had a very low incidence of cancer but signs of 
premature ageing as young as 4 months.95 By one year of age, most of the mice had died, 
whereas, non-transgenic mice were healthy. The authors attributed this to p53 
hyperactivity which up-regulated the activity of the IGF-signalling pathway which has 
been linked to drive ageing in diverse organisms such as nematodes, fruit flies and mice.96  
 
However, ‘super-p53’ mice, in which transgenic mice have extra copies of the wt-p53 
gene, display up-regulated p53 activities including cancer resistance as well, yet, have a 
normal lifespan and show no accelerated signs of ageing.97 Notably, both p53+/m and p44 
mice lack the amino-terminal transactivation domain, which is responsible for p53’s 
interactions with MDM2 and hence are not subject to negative regulation. The full-length 
protein encoded by the super-p53 mice is subject to negative regulation by MDM2. 
 
Mice that express 30% of the normal level of MDM2 (MDM2puro/Δ7-12) owing to 
possessing one hypomorphic and one null allele, showed increased basal levels of 
p53.98,99 Upon p53 activation they showed increased expression of p53 target genes and 
increased apoptosis. MDM2puro/Δ7-12 mice were highly resistant to cancer but did not show 
signs of accelerated ageing. Taken together, it seems that increased p53 levels alone, as 
observed in the super-p53 mice and the MDM2puro/Δ7-12 mouse model, will not 
automatically lead to development of an ageing phenotype.  
 
Epidermal specific loss of MDM2/p53 signalling in an MDM2-conditional mouse model 
results in increased p53 levels and increased expression of p53 target genes that are 
involved in regulating senescence.100 The mice display hallmarks of early ageing 
including thinning of epidermal layer, reduced integrity of skin, and widespread and 
progressive loss of hair. Analysis of the epidermis indicated increased cellular senescence 
in the follicular bulge region and a reduction of skin epidermal stem cell numbers and 
functions.  
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Therefore, it appears that increased p53 levels will only be toxic when the levels exceed 
the capacity of those proteins which serve to keep p53 activity under tight control. Further 
research is need to elucidate exact mechanism behind this accelerated ageing phenotype. 
However, the link between tumour suppression and accelerated ageing hints at potential 
on-target side-effects of clinical intervention strategies aimed at increasing p53 levels. 
1.6 Inactivation of P53 
Impairment of p53 function is crucial to tumorigenesis by allowing evasion of p53-
dependent responses. There are several mechanisms responsible: through partial 
abrogation of signalling pathways or effector molecules which regulate p53, by point 
mutations of p53 itself, and through epigenetic deregulation. 
 
1.6.1 Overexpression of MDM Proteins 
A key feature of many tumours is the amplification of MDM genes or altered expression 
of MDM proteins.101–108 Tumorigenic increased MDM protein expression is not solely 
caused by gene amplification, for example, tumours that exhibit high MDM levels 
without gene amplification are melanoma,108 Ewing’s sarcoma,109 colon carcinoma,102 
and retinoblastoma.110,111 Hence, it has been suggested that MDM transcription and 
translation maybe dependent on tissue type. 
 
As mentioned previously, both MDM2 and MDMX can inhibit p53 transactivation 
function through engaging its amino-terminal TAD via related N-terminal hydrophobic 
pockets.27,110,112 However, key differences between MDM proteins affect their ability to 
regulate p53 as well as their biochemical functions. MDM2 homo-oligomers exhibit E3 
ubiquitin ligase activity that targets p53 for ubiquitin dependent degradation by the 
proteasome, acting as a crucial negative regulator.113 MDM2 also inhibits p53 function 
by preventing its interaction with general transcription machinery. P53 activates the 
transcription of MDM2, which leads to a decrease in p53 levels, which in turn leads to 
the transactivation of MDM2 in a crucial negative feedback loop (Figure 1.6).  
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MDMX is a structural homologue of MDM2 that possesses an 18 amino-acid N-terminal 
extension.114,115 MDMX does not homo-oligomerise and has no intrinsic ubiquitin ligase 
activity. MDMX increases or decreases MDM2 levels depending on MDMX 
abundance.116 Hetero-oligomerization of MDM2 and MDMX is crucial during 
embryonic development.117,118 Aromatic residues in their RING-proximal domains are 
required for recruitment of E2-ubiquitin-conjugating enzymes; hence, together they can 
form more effective inhibitor of p53.119–121 Although activated p53 was thought to 
exclusively up-regulate MDM2 through its promoter P2, new evidence has revealed p53-
dependent upregulation of MDMX under certain conditions.115 For example, p53 
activation in response to a plethora of p53-activating agents induces the transcription of 
a novel MDMX mRNA transcript from the MDMX-P2 promoter that is more efficiently 
translated than that expressed for the MDMX-P1 promoter which controls basal levels of 
MDM proteins. This encodes a long form of the MDMX protein called MDMX-L that 
cooperates with MDM2 to promote ubiquitination of p53 hence, p53-induced 
transcription of MDMX may also play a role in the attenuation of the p53 response.  
  
In addition to MDM transcriptional regulation by p53, levels of MDM proteins are subject 
to post-transcriptional regulation by microRNA’s and post-translational modifications. 
For example, some p53-induced mRNA’s (mir-192, mir-194, and mir-215) contribute to 
the down-regulation of MDMs.122 Additionally, multiple kinases are known to 
phosphorylate both MDM proteins such as DNA-PK, which phosphorylates MDM2 at 
Ser17,123 and ABL, which phosphorylates MDMX at Tyr99,124 both PTMs lead to the 
dissociation of p53 from MDM proteins. Furthermore, following DNA damage, ATM 
Figure 1.6: Mechanism of regulation of p53 by MDM proteins and ARF. 
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and CHK kinases phosphorylate multiple serine residues in or close to the RING domain 
causing destabilisation of oligomers and hence activating the p53 response.125–129  
 
In cancers, these post-transcriptional regulatory mechanisms are most commonly found 
to stabilise MDM proteins leading to inhibition of p53 and evasion of p53-dependent 
responses. For example, in multiple myelomas, p53 is wild-type and can induce mir-192, 
mir-194 and mir-215 which usually down-regulate MDM2 expression.122 However, 
epigenetic hypermethylation of the promoter region of all three mRNA’s impairs MDM2 
down-regulation.  Furthermore, some PTM’s can lead to the stabilisation of MDM 
proteins which leads to p53 inhibition. For example, AKT kinases are activated in human 
cancers and are found to target both MDM proteins through phosphorylation of serine 
residues (MDM2 Ser166 and Ser186 and MDMX Ser367), the functional effect of which 
is stabilisation.130,131 Additionally, using mouse knock-out models, mutation of serine 
residues usually phosphorylated by ATM and CHK is associated with 
tumourigenesis.132,133  
 
Early transgenic mouse models showed that MDM2 overexpression could induce 
carcinomas and lymphomas or sarcomas.134,135 Furthermore, in p53 null mouse models, 
MDM2 overexpression does not seem to accelerate the onset of tumorigenesis, hence, 
MDM2’s major oncogenic effect must be through p53 inhibition. Conversely, mouse 
models of MDMX overexpression have yielded conflicting results whereby differences 
in transgene induction strategies and mouse genetic backgrounds providing likely 
explanations for conflicting results, indicating a role of tissue specificity in the oncogenic 
activity of MDMX. However, in vitro studies point towards the necessity of the p53-
biding domain of MDMX suggesting it exerts its oncogenic role in the same manner as 
MDM2.136,137 For example, transduction of normal human and mouse fibroblasts with 
oncogenic RAS variants leads to senescence which is generally p53-dependent. Co-
expression of MDMX leads to transformation.138,139 For example, melanocyte-specific 
expression of MDMX and RAS resulted in early onset tumours that were more 
aggressive.108 Thus, seeking to antagonize the MDM-p53 protein-protein interaction is 
an attractive target for drug development. A summary of current strategies is provided in 
Section 1.7.1.  
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In addition to transcriptional regulation by p53, MDM2 is under tight surveillance by the 
nucleolar tumour suppressor protein, p14ARF that is encoded by the INK4b-ARF-INK4a 
locus.140,141 Abnormal proliferation in response to oncogene activation signals for the 
transcription of p14ARF that directly binds MDM2 at a site distinct from the p53 binding 
site and inhibits ubiquitin ligase function and sequesters MDM2 into the nucleus.142 
Together with p53 and pRb, p14ARF represents one of the most frequently inactivated 
tumour suppressors in human cancer.143 Thus, loss of p14ARF can lead to evasion of p53-
dependent responses.  
 
In over 50% of tumours that exhibit p53 inactivation, it is found that overexpression of 
MDM2/MDMX as well as deletion of p14ARF lead to loss of p53 function.  
 
1.6.2 TP53 Mutation 
In the other proportion of tumours, p53 is inactivated through mutation.  The prevalence 
of p53 mutation varies significantly according to cancer type and the developmental stage 
of the tumour (Figure 1.7). In contrast to other tumour suppressor genes that are mainly 
altered by truncating mutations, most TP53 mutations are missense resulting from single 
nucleotide substitutions. Other alterations in TP53 include frameshift insertions and 
deletions, nonsense mutations, silent mutations and other infrequent alterations.144 TP53 
missense mutations found in cancer can broadly be divided into two categories, those 
which remove essential DNA interaction sites, or contact mutations, and those which 
perturb the structure of the DBD, structural mutations (Figure 1.8).  
 
Contact mutations arise from nucleotide substitutions at highly mutable CpG 
dinucleotides, at codons encoding residues that play essential structural and chemical 
roles in p53’s sequence specific DNA binding (contact mutations).145,146 Mutations of any 
of the three key arginine residues in the p53 DNA-binding surface, Arg248, Arg273, or 
Arg280, result in the loss of sequence specific DNA binding and transcriptional 
activity.147,148 For example, contact mutations R273C and R273H both remove a 
guanidinium group that forms important contacts with the DNA backbone at the centre 
of the p53-DNA interface with little effect on p53 structure or stability.149–152  
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Furthermore, the R248W mutation not only removes a key interacting residue but also 
directly blocks DNA binding by the introduction of a large hydrophobic residue.  
 
 
Figure 1.8: Missense mutations in p53 as characterized by X-ray crystallography. Figure taken from Joerger et al.153 
Copyright (2006) National Academy of Sciences, U.S.A. 
Structural mutations differ significantly in their destabilizing effect on the p53-DBD 
depending on the location of the mutation and the type of mutation.147,154Large to small 
residue mutations, such as V143A and F270L are highly destabilising as they create large 
internal cavities and result in the loss of hydrophobic interactions.150 In contrast, the small 
to large oncogenic V157F mutation results in an energetically unfavourable repacking of 
the hydrophobic core of the DBD around the mutation site.155 The common feature of 
these mutations is that they destabilise the core domain by 3-4 kcal mol-1, resulting in 
lowering the melting temperature of the protein by 5-7 °C.12,147 As the wild-type core 
domain is only marginally stable and has a melting point only slightly above 
physiological temperature, highly destabilized mutants are unfolded under physiological 
conditions and are no longer functional.14 However, many structural mutations in the 
DNA-binding surface are not associated with temperature sensitive phenotypes because, 
in addition to destabilising the protein, they induce local structural changes that impair 
DNA binding in the folded state. Disruption of the Arg249-mediated hydrogen bond 
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network by the R249S mutation perturbs the hairpin conformation of the L3 loop that is 
crucial for the correct positioning of the DNA-contact residue Arg248.149,156  
 
Mutations that result in the loss of zinc are particularly deleterious as they impair DNA 
binding as the zinc is crucial for the integrity of the L2-L3 region that interacts with the 
minor groove of DNA response elements.147 These mutations either effect the zinc 
ligands, such as C176F, H179R, C238Y and C242S or residues in close proximity to the 
zinc coordination sphere, such as R175H. 148 
1.6.2.1 Spotlight on Y220C 
 
Figure 1.9: Crystal structure of T-p53-Y220C. (A) Stereoview of the mutation site at the periphery of the β-sandwich 
in T-p53-Y220C superimposed on the structure of T-p53C. (B) Molecular surface of T-p53C around Tyr-220. (C) 
Molecular surface of T-p53-Y220C (view the same as B). The position of Tyr-220 in T-p53-C is shown as a stick 
model. Copyright (2006) National Academy of Sciences, U.S.A. 
The most common mutation outside the DNA-binding domain is Y220C, which occurs 
in around 100,000 patients per annum.154 The missense mutation occurs at the far end of 
the β-sandwich, at the start of the loop connecting β-strands S7 and S8. It has been found 
that Y220C destabilises the core domain by 4 kcal mol-1 and thus destabilises p53 under 
physiological conditions.150 The benzene of Tyr-220 (Y220) forms part of the 
hydrophobic core of the β-sandwich, with the hydroxyl group pointing towards solvent. 
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The crystal structure of T-p53C-Y220C, an engineered stable variant of p53 possessing 
the Y220C mutation, showed that the Y220C mutation creates a solvent accessible cleft 
but leaves the overall structure of the core intact (Figure 1.9). The structural changes upon 
mutation lead to the ‘fusion’ of two shallow clefts to create a crevice, which has its 
deepest point at the Y220C mutation. The positions of the peripheral hydrophobic side 
chains are conserved; however, the mutation leads to a loss of hydrophobic interactions.  
1.6.2.2 Li-Fraumeni Syndrome 
Li-Fraumeni Syndrome (LFS) is a rare inheritable cancer predisposition syndrome which 
is caused by heterozygous germline mutations in TP53.157 Individuals with LFS are pre-
disposed to develop a number of cancers including soft tissue and bone sarcomas, breast 
cancer, CNS tumours, adrenocortical carcinomas and acute leukaemia’s as well as a 
spectrum of other neoplasms that occur less commonly but at higher frequencies and at 
younger ages compared with the general population.158–163 It is currently estimated that 
the mutation carrier rate is 1 in 5,000.164 LFS is more common in southern Brazil because 
of the presence of the R337H founder mutation that has a high population prevalence of 
0.3%.165–167 This mutation occurs at exon 10, which codes for the TAD. Its functional 
effect is to destabilize the TP53 tetramer in a pH sensitive manner.168 The spectrum of 
LFS-associated TP53 mutations can be separated into two general categories: gain of 
function and loss of function. Gain of function mutations are missense alterations in the 
DNA binding domain which confer a dominant-negative effect on wt-p53 function as 
well as to enable mutated p53 to acquire additional activities that promotes cancer 
development. Loss of function mutations are nonsense or frame shift mutations, as well 
as partial or whole gene deletions.169 
 
1.6.3 Protein Aggregation 
Probably more important than the thermodynamic instability of destabilized mutants is 
that p53 aggregates in cells.170,171 The inactivation of p53 and its mutants in vitro proceeds 
rapidly at temperatures below the melting temperature. The DBD unfolds and then 
aggregates irreversibly to various morphologies depending on the experimental 
conditions. 12–14,147,172–174 The aggregate forms faster on thermal denaturation of 
destabilized mutants.13 The negative dominance of unstable protein mutants has been 
suggested to be linked with aggregation by denatured mutant nucleating aggregation of 
wild type in mixed hybrids.175,176 There is a nucleation-prone sequence surrounding 
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Ile254 in the DBD that becomes exposed on unfolding, which, it has been suggested, 
nucleates the aggregation of p63 and p73 and forms co-aggregates in cell lines.177 The 
kinetics of aggregation are unusual, involving an initiation event in which two molecules 
of p53 unfold extensively and condense to start a chain of events in which amyloid-
containing structures are formed.178,179 A cell-penetrating peptide designed to block the 
amyloidogenic sequence in the DBD has recently been shown to restore p53 tumour 
suppressor function in ovarian carcinoma.180   
 
1.6.4 Polymorphisms in TP53 
Most confirmed TP53 polymorphisms are intronic and display no cancer-related 
phenotypes. However, theoretically, they may affect p53 function through enhanced 
mutability due to DNA sequence context, increased cryptic splicing events, altered 
transcript stability, translations or tissue-specific expression.181,182  
 
Out of the 19 confirmed polymorphisms in the TP53 coding sequences, 8 are 
synonymous. Whilst they do not change the amino-acid sequence or have no effect on 
protein structure, in theory, modifications in the base sequence could affect protein 
expression, folding and function as well as provoking new splicing events.183–185 For 
example, a synonymous mutation at codon 36 (CCG to CCT) was shown to reduce the 
ability of p53 to activate apoptosis by lowering the affinity of TP53 RNA for MDM2 
(Table 1.1).183  Taken together with the finding that MDM2 binds to p53 RNA and 
facilitates its translation, this polymorphism leads to a reduction in functional p53.  
 
The 11 remaining polymorphisms are non-synonymous and result in a change in the 
amino-acid sequence of p53 which, as for mutation, can affect the ability of p53 to bind 
to response elements of target genes, alter recognition motifs for PTMs or alter the protein 
stability and interactions with other proteins.186–188 
 
Whilst there is undoubtedly a link between SNPs and an increased cancer risk, attempts 
at associating specific polymorphisms with an increased risk of specific cancers has often 
provided contradictory results. For example, links between homozygous R72 carriers and 
increased susceptibility to cervical cancer by associating its increased degradation by the 
E6 protein of HPV16 over P72 have largely proved statistically insignificant.189,190 
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Regardless, it is likely that future studies in TP53 SNPs will help provide predictive 
biomarkers for prevention and early intervention strategies.  
 
Polymorphism Variation Effect Outcome Reference 
Codon 36 CCG – 
CCT 
• Lowers affinity of TP53 
RNA for MDM2. 
Reduction in functional p53. 183 
Codon 47 CCG – 
TCG 
(P47S) 
• Reduction in 
phosphorylation by 
proline-directed kinase 
p38 MAPK 
• Decreased ability to 
transactivate PUMA and 
p53 AIP1 
Reduction in apoptotic 
function through alteration 
in recognition motifs for 
PTMS 
191 
Codon 72 CGC – 
CCC 
(R72P) 
• R72 has greater capacity 
to interact with MDM2. 
• Facilitates nuclear export 
into mitochondria. 
 
R72 more efficient at 
inducing apoptosis than P72 
through enhanced 
interactions with other 
proteins. 
 
192 
Table 1.1: Common polymorphisms in TP53 and their functional effect. 
1.6.5 Epigenetic Deregulation 
Epigenetic modifications such as DNA methylation are well-known to cause a decrease 
in the expression of thousands of genes. Methylation of coding gene sequences as well as 
their promoters abolishes gene transcription until a complex process of demethylation 
restores the expression. During the process of tumorigenesis DNA methylation pattern 
changes.193,194 P53 can be inactivated through deregulation of the DNA methylation of its 
regulatory genes or through direct epigenetic modification in the P1 basal promoter region 
of TP53.  
 
As p53 is one of the most commonly mutated genes in human cancer, the effect of 
methylation on the wild-type allele is of importance. Unlike the majority of tumour 
suppressor genes that are mutated in human tumours, wt-p53 is seldom transcriptionally 
silenced through methylation but instead, is lost from the genome through deletions of 
various degrees on chromosome 17.195  In contrast, epigenetic deregulation of p53 target 
genes or mRNAs is more commonly observed and has a direct impact on functional p53 
levels. For example, p53 activated the expression of hypermethylated in cancer 1 (HIC1) 
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which in turn regulates sirtuin 1 (SIRT1) to modulate p53-dpenedent DNA damage 
responses. HIC1 expression in various cancers is silenced by DNA hypermethylation. 
Loss of HIC1 lead to up-regulated SIRT1 expression in cancer cells. SIRT1 deactelyated 
and inactivated p53 resulting in cell survival through evasion of p53-dependent 
responses.195,196  
 
However, cytosine methylation of the basal promoter region of TP53 has been shown to 
reduce the expression of the reporter gene.197 Indeed, DNA methylation of TP53 gene or 
its regulatory sequences have been linked to many cancers including: Ewing’s 
sarcoma,198 glioblastoma,199 acute lymphoblastic leukemia,200 human hepatocellular 
carcinoma,201 ovarian cancer,202 breast cancer203 and multiple myeloma.204,205 
Conversely, lack of DNA methylation of TP53 has been linked to cutaneous squamous 
cell carcinomas,206 sporadic adrenocortical cancers207 and myelodysplastic syndromes.208    
In all examples, direct or indirect activation of the p53 pathway was observed following 
treatment with the demethylating agent 5-aza-2’-deoxycitidine, followed by an increase 
in apoptosis.200 In breast cancer, telomere shortening was correlated with a different level 
of hypermethylation of TP53.209 However, the direct mechanism by which TP53 
methylation status correlates with tumourigenesis is yet to be elucidated. Furthermore, 
although DNA methylation is most commonly linked with decreased gene expression, 
TP53 mutation has been shown to correlate with the TP53 hypomethylation status of 
exons 5-8.210,211 
 
Whilst targeting epigenetic deregulation provides an attractive target for 
chemoprevention of tumours, proof-of-principle it is yet to be established. Methylation 
of TP53 exons 5-8 can be increased in rat liver and colon mucosa by dietary 
selenomethionine, which may influence the preservation of intact TP53 sequence.212 It 
remains to be seen if a similar effect could be achieved in human tumours.  
1.7 Targeting p53 For Cancer Therapy 
In the 40 years since p53’s discovery, numerous drug discovery projects aimed at 
targeting p53 for cancer therapy have been established. These can be divided into two 
broad approaches, firstly through targeting p53’s modulators and secondly, through 
targeting mutant p53.  
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1.7.1 MDM2/MDMX Inhibitors 
As discussed previously, MDM2 and MDMX are frequently overexpressed in many 
tumours which leads to loss of functional p53.213 Therefore, inhibiting either or both of 
these protein-protein interactions is a viable strategy for the treatment of cancers that 
exhibit this hallmark.214,215   
 
The small molecule RITA has been suggested to activate the p53 response by blocking 
the p53-MDM2 interaction by directly binding the p53 N-terminal domain (Figure 
1.10).216 However, NMR studies have failed to detect in vitro binding and there is 
evidence to suggest that RITA’s mode of action may be p53 independent, with RITA-
induced cell death being triggered by DNA cross-linking.  
 
Inhibitors of the E3 ligase activity of the MDM2 RING domain have been identified 
however, it has been suggested that inhibiting E3 ligase activity is not sufficient to fully 
restore p53 function and would need to be co-administered with an MDMX antagonist to 
achieve the desired therapeutic effect in cancer.103,217,218  
 
Figure 1.10: Structure of p53-MDM2/X inhibitors. 
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The first breakthrough in MDM protein inhibitor drug discovery projects was the nutlins, 
which block the p53 binding site in the N-terminal domain of MDM2 by mimicking three 
key residues of p53 TAD, Phe19, Trp23 and Leu26 (Figures 1.10 and 1.11A).219 Since 
then, numerous classes of small-molecules have been identified to bind to the N-terminal 
domain of MDM2. The most potent and selective MDM2 inhibitor, AM-7209, binds with 
a KD of 38 pM and has shown promising anti-tumour activity in vivo (Figures 1.10 and 
1.11B).220 The structure of AM-7209-MDM2 reveals that the intrinsically flexible N-
terminal lid region of MDM2 (residues 6-24) is ordered and folds back onto the ligand in 
an orientation that would interfere with p53 binding (Figure 1.11B).221 Indeed, there are 
numerous examples of potent MDM2 inhibitors stabilizing or inducing refolding of the 
N-terminal lid region. Hence, targeting transient protein states of MDM2 may help in 
further optimization of MDM2 inhibitors of this type.222 
 
A B 
C D 
Figure 1.11: X-Ray co-crystal structures of MDM2/MDMX antagonists. (a) Co-crystal structure of Nutlin 3a- bound 
to MDM2 N-terminal domain, lid region shown in teal (PDB: 4HG7); (b) Co-crystal structure of AM-7209 with 
MDM2 N-terminal showing the rearrangement of the lid region (teal)(PDB: 4WTZ); (c) RO-2443 binding MDM2 
(grey) and MDMX (lilac) (PDB: 3U15); (d) Structure of the α-helical SAH-p53-8 (PDB: 3V3B).   
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There are several MDM2/X antagonists in clinical trials, Table 1.2 summarizes these. 
Class and 
Specificity 
Nature of Compound Compound Status P53 NCT Identifier Company 
Small molecule 
MDM2 
antagonists 
Cis-imidazoline 
 
RG7112 
Phase I in advanced solid and 
haematological cancers and 
liposarcoma (completed) 
n/a NCT00559533 
Roche 
RG7112 with 
cytarabine 
Phase I in acute myelogenous 
leukemia (completed) 
n/a NCT01635296 
RG7112 with 
doxorubicin 
Phase I in soft tissue sarcoma 
(completed) 
n/a NCT01605526 
RO5503781 
Phase I in advanced solid cancers 
(completed) 
n/a NCT01462175 
RO5503781 with 
cytarabine 
Phase I in acute myelogenous 
leukemia (active but not recruiting) 
n/a NCT01773408 
RO5503781 with 
abiraierone 
Phase I/II in advanced prostate 
cancer (recruiting) 
n/a CRUKE/12/032 
Spiro-oxindole 
SAR405838 
Phase I in advanced solid cancers 
(active but not recruiting) 
n/a NCT01636479 
Sanofi-
Aventis SAR405838 with 
pimasertib 
Phase I in advanced solid cancers 
(recruiting) 
n/a NCT01985191 
Imidazothiazole DS-3032b 
Phase I in advanced solid cancers 
(recruiting) 
n/a NCT01877382 
Daiichi 
Sankyo 
Dihydroisoquinolinone CGM-097 
Phase I in advanced solid tumours 
(recruiting) 
Wtp53 NCT01760525 
n/a HDM201 
Phase I in advanced solid and 
haematological cancers (recruiting) 
Wtp53 NCT02143635 Novartis 
Piperidines 
HDM201 with 
ribociclib 
PhaseIb/II in liposarcoma 
(recruiting) 
Wt053 NCT02343172 
Merck 
MK4828 with 
cytarabine 
Phase I in acute myelogenous 
leukemias (terminated) 
n/a NCT01451437 
Piperidinone 
AMG232 
Phase I in advanced solid cancers 
and multiple myeloma (recruiting) 
n/a NCT01723020 
Amgen AMG232 with 
trametinib and 
dabrafenib 
Phase Ib/IIa in metastativ 
melanoma (recruiting) 
n/a NCT02110355 
Pyrrolidine RG7388 
Phase 1 in polycythemia vera and 
essential ihrombocythemia 
(recruiting) 
n/a NCT02407080 Pegasys 
Stapled peptide 
MDM2/X inibitor 
Peptide ALRN-6924 
Phase I in advanced solid cancers 
(recruiting) 
Wtp53 NCT02264613 Aileron 
Table 1.2: Overview of current MDM2/X anagonists in clinical trials. Figure adapted from: Clinical Overview of 
MDM2/X Targeted Therapies, Burgess et al.223 
In some examples toxicities have been reported. For example, 30% of patients in the 
clinical trial of RG7112 (Figure 1.10) in liposarcoma experienced grade 4 neutropenia 
with 15% experiencing prolonged grade 4 thrombocytopenia, however, it is unknown 
whether this correlates with prior exposure to genotoxic drugs or is entirely RG7112 
dependent.224,225 Furthermore, there are reports of increased p53 mutation following 
nutlin-3a exposure, causing concern for future development of new cancers in these 
patients.226,227  
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Theoretically, inhibition of the MDM2-p53 interaction is not specific to cancer cells and 
normal cells could experience p53 stabilization and increased apoptosis. Furthermore, 
inhibition of MDM2 could lead to the loss of ability to ubiquitinate other proteins, such 
as the steroid hormone receptors and pRb, as well as interfering with MDM2’s role in 
DNA repair and modifying chromatin structure.213 The clinical relevance of these 
potential long-term on-target toxicities is yet to be elucidated owing to the relative youth 
of ongoing early phase trials.  
 
Owing to distinct differences in the Leu26 sub-pocket of MDM2 and MDMX, most 
developed MDM2 inhibitors are weak binders of MDMX. However, there is growing 
evidence that for full reactivation of the p53 pathway, both MDM proteins require 
effective inhibition.213 Consequently, small-molecule antagonists are being developed 
which bind both MDM proteins.228,229 RO-2443 binds both proteins with low nanomolar 
affinity (Figure 1.10). Binding induces homo- and hetero-dimerization of the MDM2 and 
MDMX N-terminal domains, which is stabilized by aromatic stacking of two inhibitor 
molecule and a tyrosine from each of the protein chains (Figure 1.11C).228 This class of 
antagonists reactivates the p53 pathway in cancer cell lines overexpressing MDMX that 
are resistant to conventional MDM2 inhibitors.228  
 
In addition to small-molecules, hydrocarbon-stapled α-helical peptides are being 
developed for treating MDM overexpressed cancers.230–232 The introduction of a 
hydrocarbon staple at residues 14-29 of the p53 TAD domain drastically increases the α-
helicity of the peptide, and results in a 400-fold affinity increase for MDM2 over the 
native protein (Figure 1.11).230 Together with additional mutations added for improved 
cell permeability, SAH-p53-8 binds MDMX and MDM2 with affinities of 2.3 nM and 55 
nM respectively (Figure 1.10, 1.11D).231,233 SAH-p53-8, and other similar stapled 
peptides, have been shown to restore p53 function in MDM2/MDMX overexpressing 
cancer cell lines.232,233  
 
1.7.2 Targeting Other p53 Modulators 
P53’s large network of regulatory pathways provides a large choice of potential targets 
for cancer therapy. For example, SIR1 downregulates p53 activity by deacetylation of 
Lys382 and is overexpressed in a number of cancer cell lines, including chronic 
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myelogenous leukemia stem cells which have wt-p53 status.234–236 SIR1 inhibition by 
tenovin-6 in mouse models of chronic myelogenous leukemia led to tumour regression, 
and was confirmed to selectively kill leukemia stem cells.236 Alternatively, wild-type p53-
induced phosphatase-1 (Wip1) downregulates p53 via the stabilization of MDM2 and 
modulation of p53-MDM2 binding affinity, and is overexpressed in several cancers.237,238 
GSK2830371 is a small molecule allosteric inhibitor of Wip1 that prevents 
dephosphorylation of phospho-p53 and induces growth inhibition in both hematopoietic 
cancer cell lines and Wip1 upregulated breast carcinoma cells with wild-type p53 status 
(Figure 1.12).238  
 
Figure 1.12: Structure of the allosteric Wip1 inhibitor GSK2830371. 
1.7.3 Targeting Mutants 
The targeting of p53 mutants with stabilizing small molecules should in theory, stabilize 
the protein and shift the equilibrium toward the folded state. Therefore, such compounds 
should restore the active conformation of classical p53 structural mutants. If these 
mutants have been found to retain wild-type like conformation in their folded states then 
theoretically, treatment of p53 mutants with stabilizing compounds should lead to 
reactivation of p53-dependent responses. Stabilizing small molecules can be targeted 
either against a binding surface shared by the wild-type protein and a subset of mutants 
or against a mutation-induced lesion on the surface of a particular mutant. Designing 
molecules for the former is more challenging because of the lack of well-defined binding 
pockets on the DBD.  
1.7.2.1 Alkylating Agents and DNA Intercalators 
The first small molecule reported to restore mutant p53 function was CP-31398 (Figure 
1.13).239 However, subsequent analyses in vitro did not detect binding or stabilization of 
mutant p53 by CP-31398 but instead, showed that the compound acted as a DNA 
intercalator, which is consistent with cell-based studies demonstrating p53-independent 
toxicity of the compound.240,241  
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Figure 1.13: Structures of CP-31398 and PRIMA-1 (and its methylated form APR-246). 
PRIMA-1 upregulates several p53 target genes and induces apoptosis in mutant p53 
cancer cell lines potentially via reactivation of a mutant and is currently in Phase Ib/II 
clinical trials (Figure 1.13).242,243 Although the anti-cancer properties of PRIMA-1 and 
related compounds have been extensively documented, its exact mode of action is still 
being investigated. In cells, PRIMA-1MET is converted to methylene quinuclidinone, 
which contains a reactive αβ-unsaturated ketone.243 This structural motif is known to react 
with nucleophilic cysteines.244 The alkylation of wild-type and mutant p53 DBD by 
PRIMA-1 increases the thermostability of the protein, which supports the hypothesis that 
alkylating agents may play a part in reactivating conformationally unstable mutants. 
However, the alkylating agent N-ethylmaleimide preferentially modifies Cys182 and 
Cys277 of the p53 DBD, with further alkylation then triggering cooperative modification 
of the remaining cysteines in the DBD, unfolding the protein.244,245 Hence, 
hyperalkylation interferes with correct folding and function. Furthermore, p53-induced 
apoptosis stimulated by alkylating agents has been reported for contact mutants R273H 
and R248Q.243,246,247 Structurally, it is unlikely that cysteine modification would result in 
restoration of sequence-specific DNA binding in these mutants. Taken together with the 
fact that p53 is only one of a myriad of potential alkylating targets in the cell, it seems 
likely that the mode of action of alkylating agents on mutant p53 may not clear cut.   
1.7.2.2 Rescue of Zinc-binding-deficient mutants with metallochaperones 
The transcriptional activity of p53 depends on its zinc-binding state; loss of zinc binding 
results in unfolding, however, an excess of zinc can lead to misfolding and the 
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aggregation of p53 through binding to non-native sites.248 Thiosemicarbazone ZMC1 
(NSC319726) induces mutant specific growth inhibition and apoptosis in cancer cell lines 
that possess the zinc-binding deficient R175H mutant (Figure 1.14).249 ZMC1 acts as a 
metallocaperone, by binding and transporting zinc ions across the cell membrane as a 
transition-specific ionophore, increasing intracellular zinc levels to a concentration that 
suits the repopulation of the distorted zinc-binding site of R175H.250,251 ZMC1 also exerts 
a zinc independent effect, potentially involving iron chelation, which affects the redox 
state of the cell and increases levels of reactive oxygen species (ROS).  
 
Reactivation of mutant p53 has also been reported for a curcumin-based Zn2+ complex by 
restoration of protein conformation and expression of p53 target genes in both the zinc-
deficient R175H mutant and the contact mutant R273H (Figure 1.14).252 However, given 
that the DNA-contact mutant R273H should be unable to transactivate p53 target genes 
irrespective of its zinc occupancy, the stabilizing effect of zinc metallochaperone may be 
related to their DNA-intercalating properties, their reactive Michael acceptor moiety, or 
both.253  
 
 
1.6.2.3 Targeting the tetramerization domain 
Most therapeutic concepts are aimed at targeting the most frequently observed mutations, 
all of which occur in p53’s DBD. However, the most frequently inherited mutation, 
R337H, is found in the tetramerization domain and destabilizes the tetramer in a pH 
dependent manner.168 Owing to link between this mutation and Li-Fraumeni Syndrome, 
which is typified by high penetrance, early onset cancer development, several therapeutic 
approaches are being perused.  
ZMC1 Curcumin 
Figure 1.14: Chemical structures of ZMC1 and curcumin. 
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Figure 1.15: Structures of calix arene stabilizers of R337H mutant. 
The R337H mutation disrupts a structurally important intermolecular salt bridge between 
Arg337 and Asp352.254 The tetrameric state of this mutant can recovered by binding with 
tetraguanidiniomethylcalix[4]arene (Figure 1.15).255 Computational and biophysical 
measurements suggest that two ligand molecules bind to opposite ends of the tetramer 
and stabilize it through ionic interactions of the guanidinium groups and through 
hydrophobic interactions of the loops and the lower rim.255 More recently, an imidazole-
calix[6]arene derivative showed improved recovery of the tetrameric state at 
physiological conditions, and restoration of transcriptional activity of this mutant in cells 
(Figure 1.15).256 The tetramerization domain is also being targeted through gene therapy. 
A replication-defective, TP53-producing adenovirus, Gendicine was granted clinical 
approval in China but not in the rest of the world.257 One of the potential limitations of 
gene therapy is the formation of heterotetramers of reduced activity between wild-type 
and mutant p53. A potential solution to this is to swap the tetramerizaiton domain for an 
engineered coil-coil dimerization domain of the breakpoint cluster region protein that 
forms homo-oligomers without interacting with endogenous BCR or p53.257 
Oligomerization domain swapping may be combined with stabilizing mutations in the 
DBD or mutations in the transactivation domain that selectively prevent MDM protein 
binding to create a ‘super p53’ for future gene therapy.  
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1.7.2.4 Small Molecule Stabilisers of Y220C 
The oncogenic Y220C mutant presents an ideal test case for the design of a mutant-
specific drug. The mutation of a tyrosine (Y) to cysteine (C) results in the loss of 
hydrophobic interaction which destabilises the protein by 4 kcal mol-1 and creates a 
shallow pocket that can be selectively targeted by small molecules.150 Most importantly, 
the mutation site is distant from the functional interfaces of the protein, minimizing 
inhibitory effects from binding that could be the case for DNA-contact mutations in the 
DBD.  
 
Figure 1.16: PK083 bound to p53-Y220C (PDB: 2VUK). Mutation induced cavity is subdivided into: Subsite I (red), 
Subsite II (green), central cavity (cyan), Y220C mutation (yellow) and subsite III (pink). 
The binding site can be subdivided into a central cavity and three subsites, I, II and III 
(Figure 1.16). The central cavity consists of several prolines (Pro151, Pro222 and Pro223) 
which form a hydrophobic interaction surface with Val147 and Thr150.  Subsite I is a 
shallow, solvent exposed subsite that is largely polar. Subsite II is proline rich with 
Pro153, and several backbone carbonyls (Cys220, Pro151 and Pro152) forming a 
hydrophobic interaction surface. Subsite III is a transiently open subsite which is 
essentially modulated by the conformational state of Cys220.258  
 
Generally, the compounds which bind Y220C can be classified into two distinct 
categories, those which bind the closed state of subsite III and those which bind the open 
state of subsite III as summarized in Figure 1.17.258 
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The lead structure PK7088, is biologically active in cancer cells harbouring the Y220C 
mutation, increasing the amount of correctly folded mutant protein with wild-type 
conformation restoring its transcriptional functions and inducing p53-Y220C-dependent 
apoptosis.259  Furthermore, aggregation can effectively be inhibited for Y220C because 
the designed ligands that stabilize the protein also may slow the kinetics of aggregation.260 
These data provide proof of concept that rescuing the function of structural mutants with 
small-molecule stabilizers is a promising potential cancer therapy strategy. The small 
molecule PK083, 1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine, has been 
identified as one such molecule that binds the mutant-specific crevice. It is found to 
stabilise the mutant Y220C (KD = 150 µM) and raise the melting point of p53-Y220C by 
2K, as well as increasing the mutant protein’s half-life to over 15 minutes compared to 
Figure 1.17: Lead compounds which bind Y220C. (A) Structure of PK083 and other classes of fragments which bind 
Y220C in the closed subsite III state; (b) Structure of PK7242 and other compounds which bind Y220C in the open 
subsite III state; (d) co-crystal structure of PK083 in Y220C (PDB: 2VUK); (E) Co-crystal structure of PK7242 in 
Y220C (PDB: 3ZME); (F) Superposition of Y220C in the ‘open - green’ and ‘closed - blue’ subsite III states showing 
the rearrangement of Cys220. 
A B 
D E F 
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approximately 4 minutes in the absence of the ligand.261 A co-crystal structure of p53-
Y220C with PK083 showed that the central N-Et functionality is buried in the mutant 
specific hydrophobic cleft, and the NHMe anchor forms a crucial hydrogen bond with the 
main chain C=O of Asp228  in subsite I (Figure 1.18). 
1.8 Thesis Aims 
The moderate affinity coupled with the low molecular weight of PK083 presents an ideal 
starting point for fragment based drug discovery towards the synthesis of a small 
molecule p53-Y220C stabilizing drug. 
 
 
Figure 1.18: Co-crystal structure of PK083 in Y220C showing hydrogen bond between benzylic amine and Asp228 
backone C=O, shown in dashed orange line. (PDB: 2VUK). 
From examination of PK083 bound to p53-Y220C (Figure 1.18), key points on the 
carbazole scaffold were identified through which to grow the fragment to target key sub-
pockets and/or residues with the aim of enhancing affinity toward p53-Y220C (Figure 
1.19).   
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Figure 1.19: Structure of a generic carbazole with key growth vectors highlighted. 
This body of work seeks to develop chemistry towards compounds with substitution 
patterns described in Figure 1.19 and to use the established chemistry to introduce and 
optimize PK083 towards p53-Y220C.  
1.9 Subsite I: Existing SAR 
Optimization of R2 through extension of the amine side chain seeking to probe for 
potential interactions with the negatively charged Asp228 side chain that at present, the 
existing anchor is too short to reach is described in Figure 1.20 and Table 1.3.* The first 
approach was to use rigid aliphatic amines or aromatic amines that, due to the restricted 
rotation, would not compromise the existing entropically favoured binding mode. 
Unfortunately, none of these showed a marked increase in Y220C binding affinity. In 
fact, in most cases, they were worse stabilizers.  
 
The extension of the amine side chain to include acyclic aliphatic side chains largely 
showed similar binding and stabilisation as for PK083. PK211 possesses an extra 
hydroxyl group that could interact favourably with Asp228 but does not surpass the 
affinity of PK083. A co-crystal structure of PK211 with p53-Y220C has been solved. The 
benzylic amine forms a hydrogen bond between the amine N-H and the C=O of Asp 228. 
The hydroxyl groups forms an extra hydrogen bond between the –OH group and the 
Asp228 side-chain. In all known crystal structures, Asp228 points towards bulk solvent 
so the desolvation penalty is likely to be large. Additionally, the added flexibility of the 
side chain is bound to be detrimental to binding entropy.  
 
                                               
* Unpublished results, R.Wilcken. 
37 
 
Subsite I also possess a tryptophan (Trp146). Attempts were made to target this residue 
through π-stacking interactions. PK214 exhibits the largest affinity increase. Its side chain 
features an imidazole ring that is far enough away from the central carbazole scaffold to 
interact with Trp146. Substitution of the imidazole with a mercaptomethyltetrazole shows 
a decrease in affinity and results in a less potent stabiliser than in PK083.  
 
Figure 1.20: Generic structure of carbazoles for targeting Asp228 and Trp146 
Compound 
ID 
R2 
DSF Tm [250 µM] 
K 
KD NMR 
(µM) 
KD ITC 
(µM) 
PK211 
 
0.58 127 199 
PK214 
 
0.90 80 98 
Table 1.3: SAR of previously tested carbazoles 
The failure to make any marked improvements on affinity by targeting subsite I through 
functionalization of R2 despite over ~30 compounds synthesized, led to prioritisation of 
targeting the mutant specific Cys220 mutation through functionalization of R and R1 
(Figure 1.19).  
 
 
 
 
 
  
N
H
OH
N
H
N
N
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Chapter 2 : Strategies in Improving PK083: Limits of the Cys220 Sub-pocket 
The compounds described in Section 1.9 failed to exhibit a meaningful SAR, however, 
most of the compounds designed and tested were aimed at enhancing potency through 
targeting Asp228 and Trp146 via functionalization of R2. Notably, simpler compounds, 
which seek to establish the effect on potency arising from variation of the methylation 
state of the benzylic amine at R2 (e.g. NH2, NHMe, NMe2), have not been described.  
 
Following the lack of a meaningful SAR in targeting subsite I for affinity improvements, 
the mutant specific cavity in Y220C was targeted. Growth at vector R allows targeting of 
the mutant specific Cys220 hydrophobic subpocket through simple alkylation chemistry, 
which should confer mutant selectivity and increased affinity (Figure 2.1), or through 
functionalization of R1, where R1 is small, hydrophobic and targets Cys220.  
 
Figure 2.1: Generic structure of synthesised compounds in Chapter 2. 
2.1 Methods of Targeting Cysteine Residues 
Targeting of non-catalytic cysteine residues is gaining increasing attention from drug 
discovery scientists owing to the identification of cysteine mutations in several oncogenic 
proteins.262 By far the most powerful method of targeting cysteines is via the design of 
covalent modification compounds, or ‘irreversible’ inhibitors. Whilst this is the most 
powerful method of gaining substantial affinity increases, off-target toxicities are 
commonly reported which are related to lack of specificity.263–267 Paradoxically, some 
acrylamide-based modification compounds have been reported to reversibly bind cysteine 
residues.268 By tuning the reactivity of the Michael acceptor, by incorporation of a nitrile 
group in the 3-position, the 1,4-conjugate addition not only seems to be energetically 
favourable but rapidly reversible. Cysteine also makes an attractive target for non-
covalent interactions such as halogen bonding. The relative efficiency of each method is 
discussed below. 
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2.1.1 Irreversible Covalent Modification  
The design of covalent modification compounds is conceptually very attractive, however, 
it is very hard to achieve the right balance between reactivity and selectivity. Most 
covalent inhibitors need to incorporate a highly electrophilic reactive species, such as an 
α,β-unsaturated ketone (Figure 2.2).269 However, incorporation of such highly reactive 
functional groups often leads to toxicities associated with non-specificity, such as 
alkylation of other macromolecules in vivo leading to formation of protein adducts that 
have been linked to hepatotoxicity,265 mutagenicity,267,270 carcinogenicity271 and 
immunogenicity.271–274 Prediction of these off-target toxicities is very difficult, hence, 
there has been a strong historical bias against the rational development of irreversible 
inhibitors.275  
 
Figure 2.2: Generic structures of common covalent modification warheads. 
Pro Con 
Increased biochemical efficiency. Off-target toxicity. 
Lower doses. 
Potential immunogenicity could cause allergic reaction or drug 
hypersensitivity. 
Decreased sensitivity to pharmacokinetics 
(PK). 
 
Potential to avoid resistance mechanisms.  
Longer duration of action.  
Table 2.1: Pros and cons of irreversible inhibitors. 
The potential pros and cons of irreversible inhibition are presented in Table 2.1.276 
Particularly pertinent to oncology is the potential to avoid resistance mechanisms. 
Inhibitors of human epidermal growth factor receptor tyrosine kinases EGFR and HER-
2, Gefitinib and Erlotinib, are not active against the EGFR mutant T790M whereas the 
irreversible inhibitor Neratinib retains low nanomolar affinity (Figure 2.3).277 The T790M 
mutation results in an increase in affinity of EGFR for ATP of an order of magnitude. For 
inhibitors, Gefitinib and Erlotinib, which both have an ATP-competitive mechanism of 
action this is deleterious, however, Neratinib does not compete with ATP as its mode of 
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action involves irreversible inhibition by reaction between its α,β-unsaturated ketone 
moeity and Cys797, and hence retains activity (Figure 2.3). 
 
In the 1970s much effort was concentrated on the design of ‘suicide substrates’ that 
contain masked reactive groups that could be activated according to the drug’s 
mechanism of action seeking to minimize potential off-target toxicities.278–280 For 
example, Omeprazole is a covalent modification pro-drug which targets gastric H+/K+-
ATPase, the enzyme responsible for proton transport as the final step in gastric acid 
secretion.281 It is converted under the stomach’s acidic conditions into a tetracyclic 
sulfonamide intermediate that binds covalently to cysteine residues in H+/K+-ATPase to 
form disulfide adducts (Scheme 2.1).282–284 
 
Figure 2.3: Human EGFR tyrosine kinase inhibitors. (a) Structure of reversible inhibitors Gefitinib and Erlotinib and 
irreversible inhibitor Neratinib. (b) Neratinib bound to EGFR-T790M (PDB: 2JIV). Colour Scheme: Neratinib, 
carbons shown in green, EGFR-T790M, carbons shown in grey.  
A 
B 
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Such drugs are extremely challenging to rationally design and are often discovered 
serendipitously and hence, do not offer a solution to mitigating risk.  
Recently, advances in chemical proteomics has led to the development of tool compounds 
that possess clickable tags, such as alkynes or azides, that allow the evaluation of target 
selectivity of covalent inhibitors in vivo within live cells and organisms.285–288 In the case 
that incorporation of an alkyne into a covalent inhibitor does not disrupt binding 
interactions or affect cell membrane permeability, click chemistry activity-based protein 
profiling can be used to screen for selectivity. The alkyne analogue of a covalent modifier 
can be administered to mice and the tissue area of interest can be harvested and subjected 
to click chemistry conjugation with the desired reporter tag (e.g. rhodamine or biotin) for 
identification of target proteins.289,290 The development of activity-based probes may 
provide a method of de-risking covalent modification compounds.  
 
 
 
Omeprazole 
Scheme 2.1: Mechanism of action of the prodrug Omeprazole in a highly acidic environment. 
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2.1.2 Reactivity of p53’s cysteines towards covalent modification  
P53 has 10 cysteine residues (11 in Y220C), most of which are found in the DNA-binding 
core domain (Figure 2.4). Kaar et al. discovered fragments 2.1 and 2.2 bind T-p53-
Y220C, raising the melting point by 2 °C (Figure 2.5).291 Confirmation of the hits by 
15N/1H HSQC indicated a shift in residues L114, H115, T123, Q136, C277, R282 and 
R280, at a site remote from the mutation induced pocket close to the DNA binding domain 
suggesting a mutation-independent mechanism of action.245 The effect of 2.1 and 2.2 on 
other highly destabilised mutants such as R249S, G245S, R282W and R175H using 
thermal denaturation scanning fluorimetry was determined and indicated that the melting 
point of each increased (Tm = 1.0 – 3.6 °C) with increasing concentration of 2.1 or 2.2 
confirming a mutation independent mechanism. Crystallographic studies detected the 
alkylation of several cysteine residues indicating various degrees of covalent 
modification by addition of fragment 2.1 and 2.2 to the α,β-unsaturated double bond.  
 
 
Figure 2.5: Structure of fragments 2.1 and 2.2. 
Figure 2.4: p53-Y220C x-ray structure (PDB: 2J1X) with cysteines highlighted. 
2.1 2.2 
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The reactivity of the 11 cysteine residues in p53-Y220C was assessed by analysing tryptic 
digests of the modified proteins via data-dependent LC-MS/MS and MALDI-TOF MS at 
compound to protein ratios of 20:1, 50:1 and 100:1. Mass spectrometric analysis of tryptic 
fragments of T-p53-Y220C modified by a molar ratio of 20:1 found C124 and C141 to 
be alkylated indicating they were the most reactive. Modification at a ratio of 50:1 found, 
in addition to C124 and C141, C135, C182 and C277 to be modified. Modification of 
C176 and C275 was only observed at the highest compound to protein ratio indicating 
that they were the least reactive. Modification of C275 and C277 seem to be linked as 
only one of these sites, not both could be modified under these conditions.  
 
Residue Solvent-accessible surface (Å2) pKa 
Cys124 10.6 13.8 
Cys135 0.1 39.1 
Cys141 0.1 24.5 
Cys176 3.9 10.1 
Cys182 21.9 11.7 
Cys220 9.7 11.8 
Cys229 14.9 12.7 
Cys238 0.2 24.6 
Cys242 9.3 14.5 
Cys275 5.1 20.0 
Cys277 19.4 8.3 
Table 2.2: Predicted accessibility and pKa of each cysteine in p53-Y220C according to the local protein environment. 
Solvent accessibility was calculated using the ProtSA server. Theoretical pKa values of cysteing were calculated using 
the H++ server, which employs a standard continuum electrostatic methodology. Figure adapted from Kaar et al.245 
The reactivity of cysteines in proteins is modulated by their accessibility, and their 
nucleophilicity. Intuitively, the reactivity of a cysteine residue towards covalent 
modification by a drug is greatly affected by the location of the cysteine in the global 
protein structure. For a reaction to happen, the targeted cysteine should be located at the 
solvent accessible surface. Additionally, the formation of disulfide bonds between 
cysteine residues within proteins prevents the targeting of cysteines towards covalent 
modification. The nucleophilicity of a cysteine residue is greatly affected by the 
neighbouring residues.  Both factors can be quantified using predictions of the solvent-
accessible surface and pKa of the cysteine in its particular environment (Table 2.2). 
Residues C176, C238 and C242 are relatively inert as they are protected against 
modification by co-ordination to zinc with modifications only occurring at high 
concentrations. Surprisingly, the buried residues C135 and C141 were quite reactive. 
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Modification of C124 could facilitate local rearrangement allowing access and 
subsequent alkylation of C135 and C141.  C182 and C277 are highly solvent accessible 
and hence are more reactive than C275 which is partly buried. One of the biggest surprises 
is that C220 is not modified at all. However, fragment 2.1 is polar and the mutation pocket 
is very hydrophobic and hence fragment 2.1 would struggle to reach C220.  The design 
of a more hydrophobic compound, based on PK083 bearing a Michael acceptor may 
alkylate C220.261 However, the development of a covalent modification PK083 analogue 
should be accompanied by 15N/1H HSQC and crystallographic studies in order to ascertain 
whether any stabilising effect is Y220C specific or mutant independent owing to the high 
reactivity of a number of p53’s cysteine residues.   
 
2.1.3 σ-Hole bonding 
The introduction of halogens in drug molecules is widespread with estimations that one 
or more halogens are contained in around 20% of drugs. Historically, halogenation, in 
particular fluorination, of compounds in hit-to-lead or lead-to-drug optimisations has 
sought to modulate the LogP, metabolic stability, basicity and bioavailability of 
compounds. The so termed ‘halogen bonding’ or σ-hole bonding phenomenon has 
attracted growing attention owing to several systematic studies of halogen bonds in 
protein-ligand complexes deducing that they can serve as a powerful tool with which to 
increase binding affinity and selectivity. Hence, there has been a steady rise of the use of 
halogen bonding in rational design of compounds seeking to directly exploit these 
interactions to improve ligand binding affinity. 
 
The term halogen bonding refers to the intermolecular interaction between a covalently 
bound halogen atom (RX) and a negatively polarised site (B), such as a lone pair of a 
Lewis base or an anion (Figure 2.6). It is not a new phenomenon; complexes of Cl2, Br2 
and I2 with amines have been observed as early as the 19th century.292,293 However, 
particularly important was the observation made by Murray-Rust et al., that, from 
crystallographic surveys, it appeared that covalently-bound halogens can interact 
attractively and with high anisotropy with both nucleophiles (B) and electrophiles (E) 
(Figure 2.6).294,295 Observations based on computed electrostatic potentials revealed that 
regions of positive electrostatic potential, σ-holes, along the extensions of the covalent 
bond are responsible for interactions with donors of electron density (anion or neutral 
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species possessing at least one nucleophilic region) and areas of negative electrostatic 
potential that occur equatorially are responsible for interactions with electrophiles (Figure 
2.6, B).296 The term halogen bonding only refers to the former, XB or σ-hole bonding.  
 
Figure 2.6: Generic depiction of halogen bonding. (A) Representation of how halogens can interact with high anisotropy 
with negative centers (B) and postitive centers (E). (B) Depiction of electrostatic potential showing the sigma hole. 
Blue represents electropositive, re represents electronegative. R = any group and X = I, Br, Cl. 
The ability of chlorine, bromine and iodine to form halogen bonds is well documented; 
however, halogen bonding involving fluorine is seldom reported owing to its high 
electronegativity and lack of polarizability. Recent studies have suggested that under 
certain circumstances, as a result of the polarization of fluorine’s electron cloud by a 
powerful electron withdrawing group, fluorine has the capability to form halogen 
bonds.297–299 Other factors that influence the strength of the interaction include the size of 
the σ-hole, the angle of the interaction, donor atom properties and the internuclear 
distance between the halogen and donor. The size of the σ-hole depends on two factors, 
the polarizability of the halogen and the chemical environment around the halogen. 
Heavier atoms tend to possess greater polarizability by virtue of their size and hence 
follows the trend I > Br > Cl > F.300–302 Additionally, larger σ-holes occur when there is 
an electron-withdrawing group near the halogen.303,304  
 
The angle Θ1 greatly influences the strength of interaction with the ideal geometry being 
a ‘head-on’ contact between the σ-hole of a halogen to the halogen bond acceptor with a 
R-X---B angle of 180 ° (Figure 2.7). Angle deviations of 25-30 ° correspond to a 50% 
reduction in halogen bond strength and angle deviations of greater than 40 ° cause a 
deleterious effect.305–307  
δ+ δ
- 
46 
 
 
 
Figure 2.7: Preferred geometry of halogen bonding. 
The preferred value for angle Θ2 depends on the nature of the acceptor atom B, for 
example, Θ2 for a carbonyl oxygen would be around 120 °.307  
2.1.3.1 Sulfur . . . Halogen interactions 
Recent statistical evaluations, in which the PDB has been searched for ligand-protein 
halogen bonds, have indicated that the two major occurrences of halogen bonding are 
between the carbonyl of the protein backbone (53%) and X…π interactions (33%). 
Contacts involving sulfur are far less common (5%).308 Owing to the serendipitous nature 
in which most ligand-protein halogen bonds are discovered, and the much higher natural 
occurrence of carbonyls within protein structures than sulfur containing amino-acids, the 
relatively low incidence of sulfur-halogen bonding does not necessarily correspond with 
the interaction being unfavourable.  
 
Quantum chemical calculations using ligand model systems and different molecular 
representations of methionine using DFT-D, MP2 and CCSD(T) with large basis sets 
characterized R-X…S interaction strengths and found an order of strength Cl < Br < I.309 
Interestingly, all halogen bonds showed an X…B distance below the Van der Waals radii 
of both atoms. The equilibrium distances of all X…S bonds were quite similar (3.4 Å) 
indicating that substitution of Cl for Br or I should be feasible despite the differences in 
size. Comparison of XB interaction with that of moderate hydrogen bonds, such as a 
phenol OH…S, considering desolvation, revealed that X…S bonds can outperform 
hydrogen bonds with complex formation energies of -1.4 kJ/mol and -11.3 kJ/mol 
respectively.  
 
Although much work has been done computationally to attempt to quantify the strength 
of S…X, very few examples of S…X bonding have been noted experimentally to increase 
Θ1 
Θ2 
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ligand-protein affinity. However, the limited SAR associated with 2.4, an inhibitor of c-
jun N-terminal kinases (JNKs) 1-3, suggests a positive effect for S…Cl bonding (Figure 
2.8).310 The interaction formed between the pyrimidine chlorine and the sulfur of the 
gatekeeper residue Met146 results in IC50 of 57 nM vs JNK3 whereas replacing the 
chlorine with a methyl group results in a 7-fold reduction in potency, with an IC50 of 410 
nM.  
 
 
IC50 (nM) 
2.3 2.4 
JNK1 320 13 
JNK2 250 25 
JNK3 410 57 
 
 
Figure 2.8: Structure of JNK3 inhibitors 2.3 and 2.4. (A) SAR of two JKN3 inhibitors, (B) Inhibitor 2.4 bound to JNK3 
(PDB: 2P33). For clarity, only the gatekeeper residue Met146 is shown. Halogen bond shown in purple with angle C-
Cl…S highlighted.  
Targeting the Cys220 sub pocket in p53 through halogen bonding, to seek to improve 
ligand-protein affinity, is particularly attractive owing to the hydrophobicity of the 
mutation induced pocket. It was previously noted that particularly polar fragments failed 
to reach Cys220 and hence, groups at R and R1, which have bond vectors that can target 
Cys220, should be relatively hydrophobic. As halogenation of compounds is commonly 
used to modulate LogP, this may present an ideal method of targeting the mutation-
induced sub pocket. In addition to targeting cysteine for halogen bonding, backbone 
carbonyls of residues L145, W146, V147 may be targeted.  
A 
B 
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2.1.3.2 Sulfur . . . Aromatic interactions 
Additionally to halogens, elements of groups IV-VI also possess σ-holes and hence many 
non-bonding interactions between these elements and donor atoms, e.g. S…O, S…N and 
S…π can be attributed to σ-hole bonding.311,312 Sulfur…π bonding has been the topic of 
many computational and experimental studies by the use of model systems of cysteine 
(H2S) or methionine (Me2S) with aromatic rings.313–317 Generally, the overall consensus 
points to a preferred interaction distance of around 5 Å with a preferred geometry 
consisting of sulfur above the ring plane with either hydrogen atoms or methyl groups 
more proximal to the π-face and the sulfur atom more distal. These experiments suggest 
that the S…π interaction is relatively weak with stabilisation energies of 1-2 kcal/mol. 
Experimental studies, in which S…π interaction energies of methionine or cysteine 
residues in peptides were assessed, imply a role for other atoms bound to sulfur in the 
overall free binding energies, for example S-H…π H-bonding.318,319 As for S…X bonding, 
examples in the pdb of S…π interactions which contribute favourably to binding affinity 
of ligand-protein complexes are discovered serendipitously. For example, a specific S…π 
interaction was highlighted in the discovery of selective JNK2 and 3 inhibitors.320 A 
crystal structure of 2.5 bound to JNK3 revealed an S…π interaction between Met146 and 
the naphthalene moiety, which the authors reasoned was responsible for isoform 
selectivity as well as potency (Figure 2.9).   
 
 
 IC50 (nM) 
JNK1 420 
JNK2 97 
JNK3 16 
 
Figure 2.9: Example of S...π interactions of 2.5 with JNK3. (A) SAR of JNK3 inhibitor 2.5, (B) Inhibitor 2.5 bound to 
JNK3 (PDB: 3OY1). S…π interactions shown in purple dashed bonds. For clarity, Met146 side chain is shown. Distance 
of interaction shown on top of each interaction (3.6 and 3.5 Å).  
A B 
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By incorporation of aromatic groups at R, a complementary strategy to S…X bonding may 
be considered in PK083 analogue design. Further rationalization of this approach from 
existing SAR in the mutational cavity is offered in Section 2.3. 
2.2. Multipolar Interactions 
As mentioned in Section 2.1.3, fluorine rarely forms halogen bonds, however there are 
numerous examples of direct protein-fluorine interactions reported.321,322 A scan of the 
PDB reveals that fluorinated ligands are frequently found to interact with proteins in 
different ways. This may be through polar interactions with hydrogen bond donors, 
hydrophobic interactions with lipophilic side-chains or orthogonal multipolar 
interactions.323 Orthogonal multipolar interactions are typified by a close orthogonal 
contact between two dipolar functional groups, for example, C=O and C-F.324 Theoretical 
studies have deduced that, in an orthogonal relationship, the dipole contribution to 
interaction energy is zero such that higher order electrostatic and dispersion terms must 
be responsible for the attractiveness of the interaction.325 Fluorine and other halogens can 
interact with carbonyls via the carbon or oxygen via multipolar interactions or halogen 
bonding respectively depending on the geometry of the interaction and the halogen 
involved. Surveys of the Cambridge structural database (CSD) for C=O…X where X-C 
or X-O is less than the Van der Waals contact reveals information about the nature of 
these interactions.326 For fluorine, there is no orientation dependence and appears to 
approach the carbonyl from any angle. However, for chlorine there are two distinct 
distributions for halogen bonding and multipolar interactions which appear to occur at 
roughly the same frequency. Halogen bonding, as discussed previously, has a preferred 
angle C-X…B of between 160-180° corresponding to a roughly in-plane orientation. 
Multipolar interactions have a preferred angle C=O…X of between 60-80°, adopting a 
side-on above the plane orientation (Figure 2.10). 
 
Figure 2.10: Difference in geometry between halogen bonding and multipolar interactions formed by chlorine. 
There are numerous examples of SAR’s which link multipolar interactions with positive 
effects on free binding energy. The Abelson murine leukemia viral homolog 1 (abl) kinase 
inhibitor Nilotinib forms a multipolar interaction between the CF3 moiety the backone 
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C=O of Ala380 as well as polar interactions with His361 N-H and the C-H of Ile293 
(Figure 2.11).327 The CF3 is 5-fold more active than its methylated analogue in an 
autophosphorylation assay. 
 
 
 
Figure 2.11: (A) Nilotinib chemical structure, (B) Nilotinib 
bound to abl kinase (PDB: 3CS9). Multipolar interaction with 
Ala380 backbone C=O shown in green dashed line, polar 
interactions with His361 N-H and Ile293 C-H shown in blue 
dashed lines.  
Inhibitors of kinesin spindle protein (KSP) display a dramatic increase in affinity for 
fluorinated analogues.328 Figure 2.12 shows the increase in potency between the 
methylated (2.6) and fluorinated forms (2.7). The aryl-fluoro ring forms a multipolar 
contact with Gly217.  
 
 
Figure 2.12: (A) SAR of KSP inhibitors 2.6 and 2.7. (B) X-ray of 2.7 bound to able kinase (PDB: 2FL6). Multipolar 
interaction for F with C=O of Gly217 shown in green dashed line. Polar interactions with Glu116, Ile136 and Leu160 
shown in blue dashed lines.  
It is clear that orthogonal multipolar interactions can positively impact free binding 
energies however, it remains to be ascertained whether this is solely due to multipolar 
contacts or is more complex involving changes in residual mobility, desolvation and 
A B 
A B 
2.6 2.7 
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hydrophobic interactions. Perhaps, rather than seeking to target the protein backbone for 
multipolar interactions, potentially ‘fluorophillic’ pockets should be identified and 
targeted according to a set of criteria involving hydrophobics, solvation among other 
parameters.  
2.3 Existing SAR in the Central Cavity - Fragments 
Basse et al., explored the ligand binding sites of T-p53-Y220C, an engineered stable 
variant of p53 possessing the Y220C mutation, by screening against a chemically diverse 
fragment library of 1900 compounds using waterLOGSY and thermal denaturation 
scanning fluorimetry.291 They identified 252 hits, of which 87 were confirmed using 
15N/1H HSQC (Table 2.3). By examination of structural similarities, such as: the number 
of rings in the central scaffold and the spacing between them, the aromaticity of the ring 
system, the number of molecules in each ring, and the size of substituent groups, they 
could be grouped into 7 unique groups depending on their displayed pharmacophore 
(Figure 2.13).  
Variable WaterLOGSY Thermal Denaturation Scanning Fluorimetry 
Number of fragments screened 1895 1895 
Number of identified hits 205 47 
Number of hits confirmed by 15N/1H HSQC 70 17 
Final hit ratio, % 3.7 0.9 
Table 2.3: Fragment hits from WaterLOGSY and thermal denaturation scanning fluorimetry.291 
 
Figure 2.13: Fragments hits grouped according to identified pharmacophore. 
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For fragments 2.9, 2.18 and 2.22 co-crystal structures were solved which identified their 
mode of action (Figure 2.14). Generally, the fragments’ aromatic rings are sandwiched 
between Pro151 and Val147 or Pro222 and Pro223. In order to accommodate the ligands, 
the cysteine flips into a different conformation to that which is observed in the native, 
ligand-free structure, deepening the pocket by a maximum of 2 Å. This cysteine flip also 
causes Val147, Ile 232, Thr150 and Pro222 to shift. Interestingly, for fragment 2.9, the 
Figure 2.14: Binding modes of fragments 2.22, 2.18 and 2.9.(A) Fragment 2.22 bound to the Y220C pocket (PDB: 
2X0U) and the comparison of the residues in the bound protein (grey) and ligand-free protein (PDB: 2J1X, cyan); (B) 
Fragment 2.18 bound to Y220C (PDB: 2X0W)and comparison of Y220C in the bound protein (grey with ligand-free 
protein (cyan); (C) Fragment 2.9 bound to the Y220C pocket (PDB: 2X0V) and comparison of key residues in the 
bound protein (grey) and ligand-free protein (cyan). Hydrogen bonds are shown as orange dashed lines.  
A 
B 
C 
a b 
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pocket is occupied by two ligand molecules at opposite ends which both have the CF3 
group oriented towards Cys220. Ligand a sits between Val147 and Pro222 forming 
hydrogen bonds between the aniline and the C=O of Leu145 and a conserved water and 
the other, b, sits between Pro153 and Pro222. The CF3 group orientation towards the 
cysteine hints at the mutation induced sub-pocket as possessing a ‘fluorophillic’ 
characteristic.  
 
This fragment screen indicates a role for exploiting p53-Y220C’s structural plasticity by 
designing molecules which target the transiently open subsite III. For example the 
fragments 1.1 and 1.2 do not induce cysteine flipping, however, their structural analogues 
1.3 and 1.4 both exhibit induced-fit ligand binding (Figure 2.15).258  
 
 
B C 
A 
Figure 2.15: Comparison of binding modes of fragments 1.1, 1.3 and 1.2 and 1.4. (A) Chemical structure of fragments 
1.1, 1.2, 1.3 and 1.4. (B) Comparison of binding modes of fragments 1.2 (PDB: 4AGL) and 1.4 (PDB: 5AOJ) in p53-
Y220C. Colour scheme: 1.2, yellow (carbon), grey (p53-Y220C), 1.4, green (carbon), cyan (p53-Y220C). (C) 
Comparison of binding modes of fragments 1.1 (PDB: 5AB9) and 1.3 (PDB: 5AOI) in p53-Y220C. Colour scheme: 
1.1, orange (carbon), grey (p53-Y220C), 1.3, yellow (carbon), cyan (p53-Y220C). Note the cysteine position is altered 
(comparison of grey vs cyan) in both B and C. 
B C 
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Fragment 1.4 adopts the same binding pose as 1.2, where the aromatic ring is sandwiched 
between Pro22, Pro223, Pro151 and Val147. The pyrrole substitution ortho- to both 
iodine atoms in fragment 1.4 forces the mutant specific Cys220 into the ‘open’ 
conformation. In this example, this is a favourable effect as there is an observed increase 
the KD from 820 µM in fragment 1.2 to 21 µM for fragment 1.4. Conversely, the SAR for 
indoles 1.1 and 1.3, the effect of introduction of bulky hydrophobic groups, bromine on 
the benzene ring and methyl on the indole, results in a shift in binding position. Fragment 
1.1 sits between Pro223 and Val147 where the ethyl group is buried in the deep 
hydrophobic mutation site. Fragment 1.3 flips position with the ethyl group pointing 
towards subsite II and the bromine atom oriented toward Cys220, forcing it into the 
‘open’ conformation. The overall effect is a reduction in affinity with KD’s of 470 µM 
and 940 µM for fragments 1.1 and 1.3 respectively. 
 
2.4 Design of PK083 Analogues 
Comparison of PK083 and fragment 2.22 in the Y220C pocket reveals that the central 
aromatic core of PK083 is shifted towards subsite I compared with fragment 2.22 (Figure 
2.16). The carbazole aromatic system sits much higher in the pocket compared to the 
benzothiazole scaffold of fragment 2.22 owing to the functionalisation of the central 
nitrogen. The effect of this is that the rigid benzothiazole scaffold forces the cysteine to 
flip into the ‘open’ conformation whereas the cysteine in the PK083-Y220C structure sits 
in the ‘closed’ conformation, albeit with some fluxionality.  
 
Figure 2.16: Comparison of binding modes of PK083 (PDB: 2VUK) and fragment 2.22 (PDB: 2XOU) in the central 
cavity and subsite III. 
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The fluxionality of the cysteine in PK083-Y220C suggests that there is potential for 
growth at R through the introduction of hydrophobic groups. Hence, the first method of 
targeting the mutational cavity should be to establish, through SAR, what is the maximum 
size hydrophobic group at the central nitrogen tolerated?  
 
Figure 2.17: Summary of compounds synthesised. 
To address this question, two approaches were adapted (Figure 2.17). Firstly, through 
sequential chain growth at R by introduction of larger flexible aliphatic hydrocarbon 
groups and secondly, through the introduction of rigid aromatic groups. The latter aimed 
at affinity increases through targeting the transiently open subsite III, as well as seeking 
for potential S…π interactions.  
 
From the identification of the Cys220 sub-pocket as ‘fluorophillic’ through the binding 
of fragment 2.9, fluorinated analogues of PK083 were designed seeking to increase 
affinity through fluorination of R1. Additionally, Cys220 was targeted directly for S…X 
bonding through chlorination at R1 (Figure 2.17).  
 
Furthermore, by variation of the benzylic amine at the solvent exposed subsite I (R2), 
additional SAR could be established which can inform the effect of the amino-exposed 
side-chain on overall potency (Figure 2.17).  
 
Covalent modification compounds were designed and synthesised by Dr’s A. Close and 
B. Springett and are not discussed in this work. 
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2.5 Carbazole – Discovery, Applications and Chemistry 
Carbazole was first described in 1872 by Graebe and Glaser who obtained significant 
quantities from the anthracene fraction of coal tar distillate.329 However, it was not until 
the antimicrobial properties of murrayanine (3-formyl-1-methoxycarbazole), which was 
isolated from the plant Murraya koenigii, were discovered that there was interest from 
chemists and biologists in this privileged structure.330–332 Since then, naturally occurring 
carbazoles and synthetic derivatives have formed the scaffold of approved drugs and 
many ‘lead’ compounds targeting a plethora of diseases (Figure 2.18). For example, the 
marketed drug carprofen is a non-steroidal anti-inflammatory drug used as a supportive  
 
Figure 2.18: Chemical structures of pharmacologically active carbazoles. 
treatment for various conditions in animals.333 Carprofen reduces inflammation by 
inhibition of COX-1 and COX-2. The Curaxins are a family of carbazole compounds 
being developed as an anti-cancer therapy that bind the heterodimeric protein complex 
facilitates chromatin transcription (FACT), the sequestration of which causes p53 
activation and NF-κB inhibition leading to tumour cell death without DNA damage. 334 
Carvedilol (Coreg) is a non-selective β- and α-adrenergic blocker used to treat 
cardiovascular disease.335  Carbazole derivatives have also been discovered as potential 
treatments of neurodegenerative diseases such as Parkinson’s disease. The small 
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molecule P7C3 (an aminopropyl carbazole) blocks 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) mediated cell death of dopaminergic neurons in the substantia 
migra of adult mice, a model for Parkinson’s disease.336 Additionally, a carbazole based 
fluorophore SLM is being investigated as a potential treatment for Alzheimer’s disease.337 
Aggregation of amyloid β to form neurotoxic plaques leading to cognitive deficits is one 
possible mechanism of Alzheimer’s disease. SLM binds and inhibits aggregation of 
amyloid β. Owing to the pharmacological importance of carbazole synthetic derivatives 
and natural products, there has been an enormous development in chemistry towards the 
synthesis of highly functionalized carbazole scaffolds.  
 
2.5.1 Functionalization of Carbazole 
Owing to its highly electron rich nature, carbazole is a modest nucleophile that can be 
readily functionalized with a wide variety of electrophiles. Its reactivity can be viewed 
analogously to diphenylanilines, in which the central nitrogen group directs ortho- or 
para- the central nitrogen.338 The electrophilic aromatic substitution of carbazole leads to 
1,3,6,8 substituted scaffolds (Figure 2.19). Functionalization of the 9- position can be 
achieved through treatment with base to afford a nitrogen nucleophile which reacts with 
a plethora of electrophiles to generate N-alkylated carbazoles. The nuances in carbazole 
reactivity towards electrophiles are discussed below. 
2.5.1.1 Electrophilic Aromatic Substitution  
Carbazole is reactive towards a plethora of electrophilic aromatic substitution reactions, 
for example, bromination, nitration, etc. The most reactive positions are 3 and 6 followed 
by 1 and 8. Owing to the high level of symmetry, formation of poly-substituted carbazoles 
is common depending reaction conditions. For example, bromination of carbazole with 
N-bromosuccinimide (NBS) can be controlled by varying the molar equivalents of NBS 
(Scheme 2.2).339  
 
Figure 2.19: Reactivity of the carbazole ring towards electrophilic aromatic substitution reactions. 
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Scheme 2.2: Bromination of carbazole. (a) NBS, DCM, DMF, rt. One equivalent of NBS gives 95% 3-bromocarbazole, 
two equivalents of NBS gives 96% 3,6-dibromocarbazole 
However, when the reaction conditions are severe, as in nitration, control over regio-
selectivity is challenging and the formation of a mixture of isomers is common (Scheme 
2.3).340  
 
Scheme 2.3: Nitration of carbazole. (a) HNO3, AcOH, 50 °C, 3 h. 
The reaction is suggested to go through formation of a 9-nitroso intermediate, which, 
under the strong oxidizing conditions is converted to a 9-nitro intermediate which rapidly 
rearranges to form 1- or 3-nitrocarbazole in a 3:7 ratio. By alkylation of position 9, the 
reaction proceeds with greater regio-isomeric control (1:9) via direct nitration of the 
aromatic ring in contrast to nitrosation of free carbazole (NH).340  
 
Furthermore, examination of indole and carbazole’s reactivity towards Vilsmeier-Haack 
formylation and Mannich aminomethylation reveals a much higher preference for 
reactivity at the N-H of carbazole over the N-H of indole (Scheme 2.4).  Vilsmeier-Haack 
formylation of both indole and carbazole yields N-acylated products however, the 
reaction with carbazole yields almost exclusively N-acetylated product, whereas, for 
indole, N-aceylation only accounts for 2% of the overall yield.341  
 
Scheme 2.4: Reactivity of carbazole and indole towards Vilsmeier-Haack acetylation. 
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This pattern of reactivity is extended to Mannich aminomethylation reactions. Indole 
reacts with Eschenmoser’s salt to yield both N- and C-substituted benzylic amines in a 
ratio of 1:7.7, whereas, carbazole exclusively reacts to form the N-substituted 
derivative.342,343 Kinetics studies have calculated rate constants of N-acteylation of indole 
(3.3 X 104 mol-1 s-1) and carbazole (24.3 mol-1 s-1) indicating carbazole undergoes N-
acetylation ca. 7 times faster than indole.344 The authors attributed this to the differences 
in the overall loss of aromaticity in the transition state as approximated by the Wheland 
intermediates. The nitrogen quaternisation arising from the direct attack of the 
electrophile on the nitrogen atom leads to a larger degree of bond fixation in indole (only 
one aromatic ring to delocalize into) than in carbazole (two aromatic rings). 
 
2.5.1.2 Nucleophilic Substitution Reactions of Carbazole 
Carbazole is reactive in nucleophilic substitution reactions at position 9. The pKa of 
carbazole (N-H) is around 20 and hence is weakly acidic and can only be deprotonated 
(N-H) by strong bases such as sodium hydride. The generated nitrogen nucleophile can 
then undergo a nucleophilic substitution reaction with an electrophile, such as an alkyl 
halide to give N-functionalised carbazoles (Scheme 2.5). 
 
 
Scheme 2.5: Reaction of carbazole nucleophile with electrophile to yield N-functionalized products. 
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2.5.2 Synthesis of Carbazole  
Functionalization of the carbazole scaffold is limited to the formation of 1,8- and 3,6- 
substituted carbazoles. If functionalization of positions 2,4,5 or 7 of the ring is required 
or unsymmetrical substitution patterns then synthesis of the carbazole scaffold bearing 
the desired substitution pattern is required. Numerous methods of carbazole synthesis that 
exhibit a broad range of different frameworks and functional groups have been developed. 
By far the most common method of carbazole synthesis is by construction of the central 
pyrrole ring from biaryls with an ortho- substituted nitrogen substituent or diarylamines. 
Named reactions are discussed below.  
2.5.2.1 Fischer-Borsche Synthesis 
A large number of carbazole syntheses involve the formation of 1,2,3,4-
tetrahydrocarbazole as an intermediate which is then reduced using chloranil or palladium 
on carbon to yield carbazole.345,346  
 
The Fischer method of indole synthesis by indolization of an arylhydrazone by treatment 
with an acid catalyst was applied to the synthesis of tetrahydrocarbazoles by Borsch 
(Scheme 2.6A).347,348 Condensation of cyclohexanone with phenyl hydrazines affords 
aryl hydrazones which, upon protonation by an acid catalyst, forms a new C-C bond via 
[3,3]-sigmatropic rearrangement and elimination of ammonia to afford 
tetrahydrocarbazoles (Scheme 2.7). 349 
 
Scheme 2.6: (A) Fischer-Borsche synthesis of carbazole from cyclohexanone and phenyl hydrazine. (B) Fisher-Borsch 
synthesis of carbazole using the Japp-Klingemann reaction to form the aryl hydrazine intermediate. (a) aq AcOH, 
reflux, (b) chloranil or Pd/C. (c) aq NaOAc, MeOH, (d) N2H4.H2O, KOH, reflux.  
Alternatively, the hydrazone can be prepared by a Japp-Klingemann reaction by retro-
Claisen condensation of 2-formylcyclohexanone with aryldiazonium salts (Scheme 
2.6B).350–353 The resulting hydrazine undergoes Fischer-Borsche cyclization followed by 
A 
B 
61 
 
deoxygenation to yield tetrahydrocarbazole which can be reduced to carbazole as 
previously. The Japp-Klingemann hydrazone synthesis increases the yield of the aryl 
hydrazone.  
 
Scheme 2.7: Mechanism of the Fischer-Borsche carbazole synthesis. 
2.5.2.2 Graebe-Ullmann Synthesis 
The Graebe-Ullmann synthesis of carbazole, where N-phenyl-1,2-diaminobenzene reacts 
with nitrous acid to form 1-phenylbenzotriazole, which is unstable and undergoes 
thermolysis to yield carbazole, proceeds in almost quantitative yield (Scheme 2.8).354–356 
However, the reaction is very sensitive to substitution and hence is not commonly used 
to prepare highly substituted carbazole scaffolds. Only a little is known about the 
mechanism of the reaction, but it most likely a diradical intermediate is involved in the 
thermolysis of triazole.  
 
Scheme 2.8: Graebe-Ullmann synthesis of carbazole from N-phenyl-1,2-diaminobenzene. (a) HNO2; (b) neat, ∆. 
2.5.2.3 Cadogan Synthesis 
The reductive cyclization of ortho-nitrobiphenyls in triethylphosphite under reflux is 
known as the Cadogan synthesis (Scheme 2.9).357 The widely accepted mechanism for 
this transformation involves the exhaustive deoxygenation of the nitro group to a nitrene 
than undergoes C- H insertion (Scheme 2.10).358,359 The reaction has high functional 
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group tolerance allowing the formation of highly substituted carbazoles. However, the 
resulting compound is often contaminated with N-ethylated carbazole derivatives which 
are generated from the reaction of triethyl phosphite or the triethyl phosphate by-product 
from the reaction and the resulting mixture is often difficult to purify. Recently, this 
transformation has been carried out more efficiently using carbon monoxide or other 
organophosphorous reagents such as triphenyl phosphine as stoichiometric reducing 
agents.360,361 The most challenging derivatives to couple are those bearing powerful 
ortho- electron-withdrawing groups. However, through microwave-assisted chemistry 
these compounds can be accessed.  
 
Scheme 2.9: Cadogan synthesis of carbazole starting from an o-nitrobiphenyl. (a) P(OEt)3, reflux. 
 
Scheme 2.10: Mechanism of Cadogan reductive cyclization reaction. 
2.6 Microwave-assisted organic synthesis 
There are very few methods of speeding up an organic reaction; one such way is using 
microwave-assisted organic synthesis (MAOS). Typically, MAOS is described as high-
yielding. This is theorized to occur due to the fact that uniform heating is observed as the 
reaction vessel is not heated directly (Figure 2.20).362 Instead, the microwave radiation 
passes through the walls and heats the solvent and reactants directly. This can lead to less 
by-products and/or decomposition products.  
63 
 
 
Figure 2.20: The temperature profile after 60 s as affected by microwave irradiation (left) compared to treatment in an 
oil bath (right).362 Reproduced from Ref. 362 with permission from the Royal Society of Chemistry. 
Microwave irradiation is composed of an oscillating electric and magnetic field with 
wavelengths between 300 MHz and 300 GHz. In an organic reaction, the reaction medium 
(reactants, solvent, and substrate) is believed to interact with the electric field component. 
These interactions may be attributed to dipolar polarization and conduction 
mechanisms.363 Dipolar polarization generates energy by the mismatch created as a 
molecular dipole oscillates slightly out of phase with the electric field 
component. Conduction mechanisms originate from collision theory and describe the 
increased expenditure of energy related to the rapid movement of ions in a superheated 
medium. The ability of a solvent to absorb microwave energy and convert this energy 
into heat can be summarized by a specific loss angle (incorporation of a loss factor and 
the dielectric constant of the solvent). This is turn is dependent on a specific 
solvent relaxation time (time it takes for one molecule to return to 36.8% of its original 
situation when the electric field is turned off). The relaxation time is temperature 
dependent and decreases as temperature increases. Since the loss angle is dependent 
on the relaxation time, the ability of the solvent to convert microwave energy into heat 
will be dependent on the frequency and temperature. This phenomenon is called 
superheating and results in a solvent being heated to 26°C above its conventional boiling 
point and is largely believed to be responsible for the rate increases observed. 
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2.7 Results and Discussion 
Firstly, compounds which sought to inform the influence of the benzylic amine were 
synthesised preferentially to dictate the nature of R2 for the synthesis of all subsequent 
compounds. Secondly, the maximum tolerance of the mutational cavity was sought.†  
 
2.7.1 Retrosynthetic Disconnection of Target Compounds 
Disconnection of generic PK083 gives two simple routes to compounds which show 
diversity at R and R2 in Scheme 2.11. The synthesis starts from the commercially 
available 3-bromocarbazole. Lithium-halogen exchange followed by reaction with DMF 
is reported to give 9H-carbazole-3-carbaldehyde in moderate yields (50%).364 Reductive 
amination with the appropriate amine gives intermediate 2.37 which, following treatment 
with base, undergoes nucleophilic substitution reaction with a range of electrophiles to 
introduce diversity and give PK083 analogues. Alternatively, for R = heteroaromatic, 
copper-mediated cross coupling reactions have been reported for carbazole between the 
generated nitrogen nucleophile and bromo- or iodoinated heterocycles such as 
thiophene.365  
 
Scheme 2.11: Retrosynthetic disconnection towards compounds targeting subsite I and the mutational sub-pocket. 
When R = Me, Et, Pr, iPr, Bn, the N-functionalized 3-aldehyde intermediate was 
commercially available and hence the synthesis was simplified to a one-step reductive 
amination towards target compounds.  
 
Disconnection of Cys220 targeting compounds (Figure 2.17, pink box) with a 1,6,9-
substitution pattern results in the 4-step synthesis described in Scheme 2.12. Suzuki 
                                               
† Contributions to collaborative research summarized in section 2.7 is as follows. Compound MB016 was synthesised 
by Matthias Baud (LMB) and PK9277 was synthesised by Bradley Springett (UoS). All other compounds were 
designed and synthesised by myself. DSF and HSQC measurements on compounds with the identifier PK80xx were 
carried out by Rainer Wilcken. All other DSF and ITC measurements were carried out by Matthias Bauer (LMB).  
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coupling of 3-formylphenyl boronic acid with fluoro- or chloro- aromatic nitro bromides 
yields o-nitrobiaryl intermediates.366  
 
Cadogan cyclization yields the unsymmetrically substituted carbazoles which are then N-
ethylated using a nucleophilic substitution reaction to yield 1,6,9-substituted carbazole, 
that, upon reductive amination yields the target compounds.361,367  
 
Scheme 2.12: Reterosynthetic disconnection of Cys220 targeting compounds described in Figure 2.17, pink box. 
 
2.7.2 Synthesis and SAR of a Subsite I Target Compound 
Starting from 9-ethyl-carbazole-3-carbaldehyde, which was obtained from commercial 
sources, reductive amination using titanium (IV) isopropoxide and sodium borohydride 
yielded the target compound 2.23 in an 82% yield (Scheme 2.13).  
 
 
Scheme 2.13: Synthesis of compound 2.23 via reductive amination. (a) HNMe2, Ti(OiPr)4, Et3N, EtOH/DCM, rt 18 h 
then NaBH4, rt, 8 h. 
Compound 2.23 was assayed as a benzylic amine-HCl salt to aid aqueous solubility. Its 
effect on the p53-Y220C DNA-binding domain was assessed using differential scanning 
fluorimetry (DSF) and the dissociation constant was determined using isothermal 
scanning calorimetry (ITC) (Table 2.4). Correlation between the two assays was perfect 
2.23, 82% 
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(-1). The substitution pattern of the solvent exposed amine had a minor effect on affinity, 
with the dimethylamine resulting in a 30% drop in affinity.  
 
 
. 
  
 
 
Despite the slight drop in affinity, subsequent compounds were synthesised with 
dimethylated benzylic amines owing to the improved yield over reductive amination with 
methylamine, which is much less nucleophilic. Crystallographic rationalization for this 
reduction in affinity is provided in the co-crystal structure of MB065, which also possess 
a dimethylated benzylic amine.  
 
2.7.3 Synthesis and SAR of Compounds 2.24-2.27 
Analogous to Section 2.7.2, compounds 2.24-2.27 were synthesised in parallel from 
commercially available N-functionalized 3-aldehyde-substituted carbazoles via reductive 
amination with titanium (IV) isopropoxide and sodium borohydride (Scheme 2.14) in 
moderate yields (20-50%, Table 2.5).367 
 
 
Scheme 2.14: Synthesis of compounds 2.24-2.27. (a) 
HNMe2, Ti(OiPr)4, Et3N, EtOH/DCM, rt 18 h then 
NaBH4, rt, 8 h. 
Compound R2 DSF ∆Tm at 125 µM ITC KD (µM) 
PK083  0.8 124  
PK8017 (2.23) 
 
0.6 169  
Table 2.4: DSF and ITC data for compounds PK083 and 2.23. DSF and ITC assay conditions are described in Chapter 
6. Correlation between DSF stabilization and ITC dissociation constant = -1 (perfect negative). 
Compound R Yield (%) 
2.24 Me 20 
2.25 Pr 29 
2.26 iPr 27 
2.27 Bn 54 
Table 2.5: Yields of reductive amination for compounds 2.24-2.27. 
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Compound R DSF ∆Tm [250 µM] HSQC Kd (µM) 
PK8017 (2.23)  0.96 197 
PK8018 (2.24)  0.29 1600 
PK8021 (2.25)  0.87 250 
PK8020 (2.26) 
 
0.25 2500 
PK8016 (2.27) 
 
0.49 / 
Table 2.6: DSF and HSQC data for compounds 2.24-2.27 compared with 2.23. DSF and HSQC assay conditions are 
described in Chapter 6. Correlation between DSF stabilization and HSQC dissociation constant = -0.95. 
Compounds were tested for their effect on p53-Y220C DBD using DSF and their 
dissociation constants were determined by 15N/1H HSQC NMR (Table 2.6), an example 
of which is shown in Figure 2.21. Correlation between the two assays was excellent, 
showing a negative correlation of -0.95. 
 
The SAR reveals that substitution of R has a dramatic effect on affinity and hence 
stabilization. When R < Et, there is a dramatic reduction in affinity which is due to a much 
worse fit of the hydrophobic anchor in the mutant induced pocket. When R > Et, a 
reduction in affinity is observed of the order nPr < iPr. From the x-ray structure of PK083 
bound to p53-Y220C, N-Et does not fully occupy the Cys220 sub-pocket and hence 
substitution for N-Pr was expected to lead to an increase in affinity arising from a better 
fit of the hydrophobic sub-pocket. However, the introduction of an extra rotatable bond 
leads to a greater degree of entropy, hence any modest increase in affinity due to a better 
fit of the hydrophobic pocket may be outweighed by the entropic penalty of an extra 
rotatable bond, leading to a decrease in affinity.  
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The SAR around the size of substituent R revealed that if R > Et, a reduction in affinity 
occurs, hence this limitation was considered when designing all subsequent compounds.  
 
2.7.4 Cys220 Targeting Compounds 
Synthesis of 2.34 and 2.35 according the protocol described in Scheme 2.15 afforded the 
desired compounds. Suzuki-Miyaura cross-coupling of the appropriate aryl bromide with 
3-formylphenyl boronic acid afforded intermediates 2.28 and 2.29. Initial attempts at the 
Cadogan cyclization using conditions described by Freeman et al. failed to afford 
intermediates 2.30 and 2.31, however, by the use of microwave-mediated synthesis these 
intermediates were accessed.368 A nucleophilic substitution reaction with ethyl iodide 
using sodium hydride as a base afforded compounds 2.32 and 2.33 which, upon reductive 
amination yielded final products 2.34 and 2.35.  
0 
145 
291 
582 
2000 
Concentration of 
2.23 in µM 
Figure 2.21: Overlay of 15N/1H HSQC NMR spectra of p53-Y220C without ligand (red) and increasing concentrations 
of 2.23 (145 µM, yellow; 291 µM, green; 582 µM, cyan; 2000 µM, blue).  
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Scheme 2.15: Synthesis of 2.34 and 2.35. (a) Pd(dppf)Cl2.CH2Cl2 (5 mol%), K2CO3, toluene, H2O, 90 °C; (b) PPh3, 
DMA, µwave, 200 °C, 2h; (c) NaH, THF, rt, 10 mins then  CH3CH2I, 18 h; (d) HNMe2, NaBH(OAc)3, THF, rt, 18 h.   
The failure of the Cadogan cyclization under conventional heating is owing to the de-
activating effect of a powerful electron-withdrawing group ortho to the nitrogen. By 
accessing much higher reaction temperatures, this effect is overcome yielding the desired 
intermediate in modest yields.  
 
The effect of compounds 2.34 and 2.35 on p53-Y220C DBD was tested using DSF. The 
results are summarized in Table 2.7.  
 
 
Table 2.7: DSF data for 2.23 compared with 2.35 and 2.34. DSF assay conditions are described in Chapter 6. 
Compounds 2.34 and 2.35 both display a reduction in stabilization on the p53-Y220C 
DBD over the original hit PK083 indicating that this position is not optimal for targeting 
Cys220. Owing to the very small volume of available space between Cys220 and the 1-
position of the aromatic ring, attempts to target cysteine through this position were 
abandoned.  
Compound R1 DSF ∆Tm[250 µM] 
PK8017 (2.23) H 1.1 
PK9335 (2.35) Cl 0.3 
PK9336 (2.34) F 0.4 
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2.7.5 Synthesis and SAR of N-alkylated Cys220 Targeting Compounds 
Synthesis of intermediate 2.37, using the procedure outlined in Scheme 2.16, yielded 2.37 
in an overall yield of 58%.  
 
Scheme 2.16: Synthesis of privileged intermediate 2.37. (a) NaH, THF, rt then -78 °C, nBuLi, -78 - -35 °C then -78 
°C, DMF, THF, rt; (b) HNMe2, NaBH(OAc)3, THF, rt. 
Reductive amination using titanium (IV) isopropoxide and sodium borohydride was 
unsuccessful when the carbazole contained a free N-H. By the use of sodium 
triacetoxyborohydride as a reducing agent this problem was circumvented.369 The failure 
of the titanium method to successfully carry out the reaction is suspected to be due to the 
fact that carbazole can form complexes with titanium and hence is sequestered from 
activating the carbonyl species (Scheme 2.17).370 
 
Scheme 2.17: Mechanism for reductive amination with titanium (IV) isopropoxide. 
Reaction of the intermediate 2.37 using microwave-mediated Ullmann-coupling 
successfully yielded compound 2.38 (Scheme 2.18).365  
 
Scheme 2.18: Synthesis of compound 2.38 by a microwave-assisted Ullmann-coupling reaction. (a) CuI (10 mol%), 
Cs2CO3, DMF, µwave, 220 °C, 40 min. 
71 
 
The stabilizing effect of compound 2.38 as well as PK9277, (B.S) and MB016, (M.B) on 
p53-Y220C was tested by differential scanning fluorimetry and are summarized in Table 
2.8. 
 
 
 
 
 
 
 
 
 
 
Concentration[µM] DSF ∆Tm 
1000 0.7 
500 1.1 
250 1.0 
125 0.7 
62.5 0.3 
 
Table 2.9: DSF stabilization of MB016 on p53-Y220C DBD and different concentrations. 
Substitution for N-Et by small rigid heterocyclic groups in PK9334 and MB016 lead to a 
minor increase in stabilization as identified by DSF, however, introduction of a benzylic 
heterocyclic group lead to a reduction in affinity, presumably due to the increased steric 
bulk and introduction of an additional rotatable bond. The more lipophilic heterocycle 
(N-thiophene) in MB016 outperformed PK9334 (N-thiazole) presumably due to a 
difference in desolation penalty. However, MB016 did not appear to show concentration 
dependence which could be due to poor solubility or to interference with the assay (Table 
2.9). The subsequent validation of binding as well as design and synthesis of compounds 
where R = heterocycle was carried out by our collaborators at the LMB.  
 
 
Compound R DSF ∆Tm [250 µM] 
PK8017 (2.23)  0.6 
PK9334 (2.38) 
 
0.7 
MB016 
 
1.0 
PK9227 
 
0.5 
Table 2.8: DSF data for 2.23 and 2.38 as well as MB016 and PK9227. DSF assay conditions are described in Chapter 6. 
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2.8 Conclusions 
Attempts to target Cys220 and the mutational sub-pocket through non-covalent 
interactions did not lead to any confirmed affinity increases over the original hit PK083.  
 
Substitution of the solvent exposed subsite I mono-methylated at R2 with a dimethylated 
amine resulted in a 30% reduction in affinity. The structural reasoning for this is provided 
in Chapter 3.0.  
 
Attempts to target Cys220 through halogenation of position R1 resulted in a reduction in 
stabilization indicating that S…Cl or fluorine multipolar/hydrogen bonding did not occur. 
The space between position 1 on the carbazole ring at the bridge between the mutational 
sub-pocket and subsite II is small and hence the compounds 2.34 and 2.35 may cause a 
shift in the binding pose leading to the weakening or loss of the crucial hydrogen bond 
formed between the benzylic amine and the backbone carbonyl.  
 
The assay results of compounds 2.23-2.27, which were synthesized to establish the steric 
limit in the Cys220 mutational sub-pocket, indicate that the optimum group at R is ethyl. 
Substitution for nPr and iPr were tolerated but lead to a decrease in stabilization shown 
by DSF and 15N/1H HSQC. Furthermore, attempts to target the transient subsite III 
through arylation of position 9 showed an SAR that indicated a positive effect on 
stabilization. However, a lack of concentration dependence suggests promiscuous binding 
and/or solubility problems.    
Figure 2.22: Structure of compounds designed and synthesised in Chapter 3. 
Using the steric limitations derived from the SAR around the functionalization of R, 
Chapter 3 describes the design and synthesis of N-fluoroethylated PK083 analogues  
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which fall within these limitations and show increased potency towards p53-Y220C 
(Figure 2.22). 
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Chapter 3 : Harnessing Direct Fluorine-Protein Interactions in the Design of 
more Potent PK083 Analogues 
Fluorination of compounds has been exploited extensively in the design and development 
of pharmaceuticals, with 20-25% of drugs on the market containing at least one fluorine 
atom.371 The popularity of incorporation of fluorine into compounds is due to the 
predictable productive influence it has on: conformational restraint of ligands, pKa, 
membrane permeability, metabolism and pharmacokinetic (PK) properties (Figure 
3.3.1).372–376 In classical medicinal chemistry, fluorine substitution is typically used at the 
lead optimization of the drug discovery pipeline seeking to use its ability to modulate the 
aforementioned properties of lead compounds towards a drug candidate with a 
pharmacodynamic (PD) and PK profile within acceptable safety margins.376 
 
The demonstrable versatility of fluorine within medicinal chemistry has led to numerous 
examples of fluorination of molecules, in which, besides the influence on the properties 
aforementioned, serendipitous discovery of direct fluorine-protein interactions has had a 
positive influence on potency.377,378 Direct fluorine-protein interactions can be sub-
divided into: polar interactions with hydrogen bond donors (e.g. amide backbone NH, 
polarized Cα-H from polar side chains, protein bound H2O), hydrophobic interactions 
with lipophilic side chains and orthogonal multipolar interactions with a dipolar group 
(e.g. amide backbone C=O, amide containing side chains (Asn, Gln) and guanidinium 
groups (Arg) (reviewed in 2.2). As the nature of these interactions is becoming 
increasingly well understood, the use of fluorination as a tool to increase a compound’s 
potency towards its target in rational drug discovery is becoming widespread. Below, a 
review of the use of fluorine in medicinal chemistry is presented, concentrating on direct 
fluorine-protein interactions and their relative efficiency. This is followed by the 
9 
F      
Fluorine 
18.9984 
Metabolic 
Stability 
Physicochemical 
Properties 
Potency 
Figure 3.3.1: Key drug properties fluorine can influence. 
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description of the design and synthesis of a more potent fluorinated PK083 analogue in 
which affinity gains are attributed to direct fluorine-protein interactions.  
 
3.1 The Use of Fluorine in Medicinal Chemistry 
Modern medicinal chemistry is based on a multiparameter optimization (MPO) approach, 
where physicochemical properties, compound safety and pharmacokinetic parameters 
such as: adsorption, distribution, metabolism, and excretion, (ADME) are considered in 
equal measures alongside potency and selectivity. Consequently, methods of modulating 
compound properties are crucial to medicinal chemistry. Commonly, this is accomplished 
by isosteric substitution at strategic positions in lead compounds, seeking to affect the 
physicochemical properties that are linked with structure-property relationships related 
to poor compound PK. For example, a large number of drugs on the market or in 
development contain at least one or more basic nitrogen atoms.379 The ionization state of 
the nitrogen atom is not only important for potency, but affects lipophilicity, membrane 
permeation, and amphiphilicity.380 It also carries a potential liability for drug-induced 
phospholipidosis (intracellular accumulation of phospholipids with lamellar bodies, most 
likely from an impaired phospholipid metabolism of the lysosome)381 and interference 
with human ether-a-go-go-related gene (hERG), potassium ion channels and 
cardiovascular toxicity.382–384 Modulation of the basicity of the amine by proximal 
fluorination, using well-developed predictive rules and structure-property relationships, 
provides a rational method to achieve the right balance between potency, selectivity and 
toxicity and is a strategy commonly utilized.376  
 
Numerous examples exist where fluorine is employed as a hydrogen isostere to modulate 
compound properties that show comparable potency even though its Van der Waals radii 
is more similar to oxygen (Table 3.1)385 Spatially, the trifluoromethyl substitution is 
likened to anything from an iso-propyl group to a phenyl or tert-butyl group depending 
on the method used to estimate the volume.386,387 For example, rotational energy studies 
on o,o’-disubstituted biphenyl derivatives suggest that the CF3 group occupies a volume 
slightly larger than iPr.388,389 Conversely, x-ray data estimates the volume to be closer to 
an iso-butyl group.390,391 Regardless of the ambiguity in the isosteric mimicry that fluorine 
substitution has on steric bulk, it has a profound effect on the electronic properties of a 
compound owing to its high electronegativity.392  
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3.1.1 Metabolic Stability 
One of the major incentives for fluorine substitution in medicinal chemistry is the ability 
to enhance metabolic stability. Phase I drug metabolism by hepatic cytochrome P450 
monooxygenases, a group of heme-thiolate proteins, constitutes a common mechanism 
of drug clearance by decreasing lipophilicity through oxidation. Metabolism by 
cytochrome P450’s is one of the most common mechanisms of limiting compound 
efficacy. Substitution of a hydrogen atom in a C-H bond for a fluorine enhances metabolic 
stability by increasing the dissociation constant of the bond from 98.8 kcal/mol (C-H) to 
105.4 kcal/mol (C-F), blocking metabolically labile moieties.393 For example, 
fluorination of buspirone at the 5’ position of the pyrimidine, which is commonly 
metabolized by CYP3A4 by hydroxylation, increases the in vitro t1/2 from 4.6 min to 52 
min (Figure 3.2). 394 
  
Figure 3.2: Fluorination of buspirone at the 5'- pyrimidine position blocks metabolism and increases in vivo t1/2. 
 
 
 
Atom Van der Waals radii 
(Å) 
Pauling Electronegativity 
(χP) 
C 1.70 2.55 
H 1.20 2.20 
F 1.47 3.98 
O 1.52 3.44 
N 1.55 3.04 
Cl 1.75 3.16 
Table 3.1: Van der Waals radii and Pauling electronegativities. 
Compound 5-HT1A  
IC50 (nM) 
CYP3A4  
t1/2 (min) 
Buspirone 25 4.6 
F-Buspirone 63 52.3 
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3.1.2 Physicochemical Properties 
The physicochemical properties of drugs, such as partition coefficient (clogP and logD) 
and ionization constant (pKa), affect drug PK (ADME), toxicity, and efficacy. Predictive 
rules, seeking to generalize the physicochemical and structural properties of orally 
bioavailable drugs, such as Lipinski’s ‘rule of 5,’ provide medicinal chemists with helpful 
guidelines to develop drugs that have adequate human PK and safety after oral dosing 
and intestinal absorption (Figure 3.3).395 Consequently, there has been much interest in 
methods with which to modulate these properties to allow rational design of drugs that 
falls within these guidelines. 
  
3.1.2.1 Modulation of pKa 
The majority of drugs contain an ionizable group (Figure 3.4).396 The ionization state of 
a drug compound has a profound effect on efficacy, PK and toxicity. Changes in the 
ionization state of a compound can lead to positive (e.g. enhance the strength of 
interactions) or negative (e.g. increase the desolvation penalty) effects on potency. 
Furthermore, the pKa can affect solubility and permeability. Solubility is determined by 
both the intrinsic solubility of the neutral molecule and of the ionized species, of which 
the latter is much greater. Conversely, ionized molecules are less permeable than neutral 
molecules, hence, there is a need to strike the right balance between solubility and 
permeation to achieve drugs with good oral bioavailability.  Broadly, the modulation of 
the pKa of ionizable groups is accomplished through the introduction of electron-
withdrawing groups or electron-donating groups in close proximity to the acid or base. 
• H-bond donors > 5 
• Mw > 500 g/mol 
• ClogP > 5 
• H-bond acceptors > 10 
Lipinski’s Rule of 5 
Figure 3.3: Lipinski's Rule of 5. 
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Figure 3.4: Proportion of drugs with ionizable groups.396 
The powerful electron-withdrawing nature of fluorine affects the basicity or acidity of 
neighboring functional groups inductively, providing a method of pKa attenuation. 
Fluorine substitution usually increases the acidity of acids and decreases the basicity of 
bases (Table 3.2).393,397 The effect of sequential fluorination on linear aliphatic amines at 
the same carbon is approximately additive, where each fluorine substitution results in a 
reduction of pKa by 1.6 to 1.7 units. The effect is very powerful to the extent that 2,2,2-
trifluoromethylethylamine has a pKa of 5.7, which, is so weakly basic that the moiety has 
been used as an amide isostere (Table 3.2).398 The effect decreases exponentially as 
carbon chain homologation increases the distance between a fluorine atom and the amine 
(Table 3.3).376  
Acid pKa ΔpKa  Amine pKa ΔpKa  
CH3CO2H 4.8   CH3CH2NH2 10.7   
CH2FCO2H 2.6 -2.2  CH2FCH2NH2 9.0 -1.7  
CHF2CO2H 1.3 -1.3  CHF2CH2NH2 7.3 -1.7  
CF3CO2H 0.5 -0.8  CF3CH2NH2 5.7 -1.6  
Table 3.2: Effect of fluorine substitution on the pKa of acids and bases. 
 
 
 
 
 
 
Table 3.3: Effect of carbon chain homologation on modulation of pKa by fluorine. 
Basic
75%
Non-
ionizable
5%
Acidic
20%
n Position ΔpKa 
1 β - F -1.7 
2 γ - F -0.7 
3 δ - F -0.3 
4 ε - F -0.1 
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Fluorination of aromatic and heteroaromatic rings is a strategy primarily adopted to block 
metabolism (Figure 3.2), but it may also modulate pKa. The modulating power of 
fluorination of aromatic rings depends on an inductive effect (σF), and a resonance effect 
(σR), that is represented quantitatively by a net para-effect (σP). Isosteric substitution of 
(ar)C-H by (ar)C-F has a high electron-withdrawing inductive effect (σF = 0.45). 
However, this is substantially attenuated by a large resonance component (σR = -0.39) 
leading to a weak net para-effect (σP = 0.06). Substitution for CF3 leads to a much more 
powerful modulating effect on substituents as π-delocalization is not possible (Table 
3.4).375  
Substituent Para-effect 
(σP) 
Inductive effect 
(σF) 
Resonance Effect 
(σR) 
F 0.06 0.45 -0.39 
CF3 0.54 0.38 0.16 
Table 3.4: Substituent Hammet constants. 
 
3.1.2.2 Modulation of Lipophilicity 
Analogously to pKa, the lipophilicity of a compound has a considerable effect on 
compound PK, toxicity and potency dominantly through affecting solubility and 
permeability. Permeability is typically measured as the rate at which a molecule is 
passively diffused or actively transported (uptake/efflux) across membranes (x 10-6 cm/s). 
Passive diffusion is more common than active transport. Orally administered drugs 
adsorbed through passive diffusion must be small enough and lipophilic enough to pass 
through a cell’s apical lipid bilayer membrane but not so lipophilic that they get trapped. 
The lipophilicity of a drug can be expressed through its partition coefficient (logP) 
between octanol and water. Strategic fluorination of lead compounds is a common 
method used to influence permeation and solubility by modulating lipophilicity, 
association with pendent H-bond donors, or reduction of amine basicity. 
 
Most orally administered drugs have a logP of between 1-5.  A common misconception 
is that fluorination of compounds always increases lipophilicity. Fluorination of aliphatic 
hydrocarbons decreases the lipophilicity owing to the highly dipolar nature of the C-F 
bond (Table 3.5).399  Conversely, introduction of aromatic or vinyl fluorine typically 
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increases lipophilicity where differences arise from resonance electron donation for 
unsaturated fluorination (Table 3.6).399  
 
Compound LogP 
 CH3CH3 1.81 
CH3CHF2 0.75 
Table 3.5: Effect of fluorination on logP on aliphatic hydrocarbon groups. 
 
X Πx 
CH3 0.56 
CF3 0.88 
Table 3.6: Effect of fluorination on Hansch-Leo hydrophobic parameter of aromatic groups. ΠX = log (Px/PH) 
(octanol/H2O).  
There are numerous examples of successful fluorination introduction strategies to 
improve permeation through modulating lipophilicity, associating with H-bond donors or 
reducing basicity of amines. For example, during the development of the oral 
antihyperglycemic dipeptidyl peptidase-IV (DPP) inhibitor, Sitagliptin, 
trifluoromethylation of the triazole moiety resulted in a marked improvement in oral 
bioavailability (F) (Table 3.7).400 
 
R Clp (mL/min/kg) t1/2 (h) F (%) 
CH3CH2 70 1.7 2 
CF3 (Sitagliptin) 60 1.7 76 
Table 3.7: Fluorination of DPP-IV inhibitors increases oral bioavailability (F). 
Furthermore, increases in permeability were observed in the closely related factor Xa 
inhbitors 3.1 and 3.2 through isosteric substitution of hydrogen to fluorine ortho- to the 
anilide NH (Table 3.8).401 The increase in permeability observed for fluoro-susbstituted 
compounds 3.1b, d and 3.2b compared to their matched pairs 3.1a, c and 3.2a may be 
due to an electrostatic interaction between the fluorine atom and the pendant N-H that 
effectively masks the hydrogen bond donor capability, enhancing permeation. This is 
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further supported by the observation that the ortho-nitrile of compound 3.2c did not show 
enhanced permeability.  
 
Compound R R’ Caco-2 permeability (x 10-6 cm/s) 
3.1a H CH3 1.20 ± 0.09 
3.1b F CH3 3.14 ± 0.10 
3.1c H CF3 3.38 ± 0.08 
3.1d F CF3 4.86 ± 0.33 
3.2a H n/a 0.8 
3.2b F n/a 7.4 
3.2c CN n/a <0.1 
Table 3.8: Caco-2 permeability of factor Xa inhibitors 3.1a-d and 3.2a-c. A potential electrostatic interaction is formed 
between the pendant amine (blue) and R (blue) when R=F leading to an increase in potency. 
  
3.1.3 Conformational Control  
Beyond fluorine’s electron-withdrawing influence on compound properties, the 
introduction of aliphatic fluorine into compounds has the ability to increase potency and 
selectivity through the stabilization of preferential ligand-binding conformations.321 The 
high electronegativity of fluorine results in a highly-polarized C-F bond that presents both 
a strong dipole moment and a low-lying s*CF orbital available for hyper-conjugative 
donation. A combination of these effects results in a strong preference for vicinal 
functionality to align gauche to fluorine, where the dominant underlying contributions to 
the stabilizing interactions that constitute the gauche anti-periplanar conformation 
depends on the nature of the vicinal functionality X (Figure 3.5, Table 3.9).402 
Didactically, this may be considered a donor-acceptor interaction closely related to the 
anomeric effect in carbohydrates (Figure 3.5). 403–405 
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Utilization of the gauche effect towards enhancing potency and selectivity by restricting 
ligand conformation has been displayed in the design of superior inhibitors of cholesteryl 
ester transfer protein (CETP) towards a treatment to reduce the risk of atherosclerosis by 
improving lipid blood levels.406 Isosteric substitution of the 3-ethoxy moiety (3.3a) for a 
X Stabilization Energy 
(kcal/mol) 
Underlying interaction 
F 0.5-1.0 σCH ® σ*CF hyperconjugative donation 
OH 1.0-2.0 σCH ® σ*CF hyperconjugative donation and C-F…O-H 
electrostatic interaction 
NH2 0.9-1.0 Intramolecular C-F…H-N hydrogen bonding 
NH3+ 5.8 Electrostatic interaction between CFδ-…δ+ NH3+dipoles 
OAc 1.6 σAcO-H ® σ*CF hyperconjugative donation 
NHAc 1.8 Electrostatic interaction between Fδ-…δ+NH dipoles 
Table 3.9: Calculated energy differences between gauche and anti-isomers of selected X-substituted fluoroethane 
derivatives shown in Figure 3.5A.402 
 
A 
B C 
Figure 3.5: The gauche effect. (A) Newman projections of gauche and anti conformations. Additional stabilization where 
X is an electron deficient heteroatom (NH3+) shown by dashed line between partial charges. (B) Sawhorse representation 
showing molecular orbitals of the hyperconjugative component of the gauche effect showing donation from donor 
HOMO (σCH) to acceptor LUMO (σCF). (C) Molecular orbital representation of the analogous donor-acceptor anomeric 
effect in carbohydrates. 
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3-tetrafluoroethyoxy substituent (3.3b) led to a 8-fold improvement in potency (Table 
3.10). 
 
Compound R IC50 (µM) 
3.3a OCH2CH3 1.6 
3.3b OCF2CF2H 0.2 
Table 3.10: IC50 of compounds 3.3 against CETP. 
Molecular modelling suggested that the main reason behind the improvement in potency 
for 3.3b was due to the tetrafluoroethyl groups preference to adopt an out of plane 
orientation with respect to the phenyl ring (calculated Ar-O-CF2 bond angle to be 
perpendicular ~ 90 º) in contrast to the ethoxy group, which adopts a more co-planar 
conformation (Figure 3.6).406  
 
Figure 3.6: Out of plane orientation of tetrafluoroethyl group as calculated by Massa et al.406 
3.1.4 Direct Fluorine-Protein Interactions 
The use of fluorine to achieve desirable PK is widespread because of the well understood 
effect that fluorination has on ADME properties. In contrast, most examples of direct 
fluorine-protein interactions that improve potency are discovered serendipitously. 
Comparatively, the use of fluorination to improve potency through direct fluorine-protein 
interactions is far less well understood, resulting in a dearth of examples that use 
fluorination strategies in rational compound design for improving potency. Over the last 
decade, many systematic scans of protein-ligand structures (PDB) and small-molecule 
structures (CSD) that display F…R (R = protein or small molecule) close contacts have 
sought to statistically determine the nature and strength of these interactions, seeking to 
define a set of rules in order to utilize fluorination strategies towards improving ligand-
protein affinities.322,323,407,408 However, these studies have led to confusion arising from 
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differing conclusions made regarding fluorine’s ability to act as a hydrogen bond 
acceptor. For example, a highly-cited review by Dunitz and Taylor concluded that 
organofluorine hardly ever accepts hydrogen bonds,407 whereas, Bissantz et al. describes 
organofluorine as frequently forming weak hydrogen bonds with XH, where X = O, N.326 
Consequently, a comprehensive set of rules that define how fluorine forms intermolecular 
interactions remains elusive. In deference to this ambiguity, these interactions will be 
referred to ‘polar interactions with hydrogen bond donors.’ Broadly, direct fluorine-
protein interactions may be classified either hydrophobic interactions with lipophilic side 
chains, polar interactions with hydrogen bond donors or orthogonal multipolar 
interactions with a dipolar group (See 2.2 for a review on multipolar interactions).  
 
3.1.4.1 Hydrophobic Interactions of Fluorine 
The IUPAC definition of hydrophobic interactions is as follows: 
 
‘the tendency of hydrocarbons (or of lipophilic hydrocarbon-like group in solutes) 
to form intermolecular aggregates in an aqueous medium, and the analogous 
intramolecular interaction.’409 
 
It is the driving force behind a plethora of effects, such as: why an oil/water mixture 
spontaneously separates, why soluble proteins fold with a hydrophobic core and a 
hydrophilic outer surface, and importantly, why small molecules associate in protein 
binding pockets with mutual burial of hydrophobic surfaces.410–412 The hydrophobic 
effect can be visualized by considering the entropy of ligand-protein association. A 
hydrophobic solute (ligand, hydrophobic pocket of protein) disrupts the structure of bulk 
water and decreases entropy because of stronger bonding and ordering of water molecules 
around the solute. These disruptions are minimized upon association of nonpolar solute 
molecules (ligand-protein association). Water then constitutes one larger ‘cage’ structure 
around the combined solutes, whose area is smaller than the combined surface areas of 
isolated solutes. This maximizes the amount of free water and thus the entropy (Figure 
3.7). Hence, the hydrophobic effect is commonly attributed to the large positive entropic 
term associated with the displacement of water molecules arranged around the 
hydrophobic surface.  
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Figure 3.7: The hydrophobic effect explained by an increase in entropy. Figure shows the increased disorder of bulk 
solvent on the association of a guest (ligand), with a host (hydrophobic pocket of target protein). For simplicity, only 
one shell of solvation around the hydrophobic solutes is depicted. 
However, recent studies challenge this simplistic explanation, demonstrating that the 
hydrophobic effect can originate from enthalpy gains as well.413–418 Spectroscopic 
evidence has noted that the hydrogen bonds at hydrophobic surfaces are weaker and hence 
the water molecules are more flexible than presumed using the entropic model of the 
hydrophobic effect.419,420 Complexation thermodynamics that are driven by enthalpy are 
termed the ‘non-classical hydrophobic effect.’421 Homans studied the complexation 
thermodynamics of inhibitors of the mouse major urinary protein (MUP) using a 
combination of ITC, x-ray crystallography and 15N and methyl side-chain 2H relaxation 
measurements.415 Thermodynamics derived from ITC measurements suggested that the 
free energy of binding was driven by favourable enthalpic contributions (Table 3.11). 
ΔG° for binding is complex, involving contributions from desolvation of the ligand and 
binding pocket upon binding, the free energy arising from new ligand-protein interactions 
and, changes in the structural and dynamic properties of the protein and ligand, including 
loss of translational and rotational entropy (S = kBlnΩ, natural logarithm of the number 
of configurations (Ω) multiplied by Boltzmann constant (kB)).422 Using this ITC data, 
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along with calculations of desolvation of the MUP ligands using vapour-water partition 
experiments, the contributions to the overall free binding energy were assessed according 
to the thermodynamic cycle described for the formation of a ligand-protein interaction in 
solvent water (Figure 3.8).422–426 
 
 
Compound ΔG° (kJ/mol) ΔH° (kJ/mol) TΔS° (kJ/mol) kd (µM) 
IBMP -38.5 -47.9 -9.4 0.3 
IPMP -33.9 -44.5 -10.8 1.8 
Table 3.11: ITC determination of the contributions of the overall enthalpy and entropy on the free binding energy of 
MUP inhibitors 2-methoxy-3-isopropylpyrazine (IPMP) and 2-methoxy-3-isobutylpyrazine (IBMP). 
 
Figure 3.8: Thermodynamic cycle for a ligand-protein interaction in solvent water. ΔGb° represents the observed free 
energy of binding, ΔGi° represents the intrinsic solute-solute interaction in the absence of solvent, ΔGsb° and ΔGsu° 
represent the free energy of solvation of the complex and the free species respectively. Since G is a state function, the 
sum over the cycle is zero, so: ΔGb° = ΔGi° + (ΔGsb°- ΔGsu°). Where ΔGsb° is equated with the solvation of the complex 
ΔGsolvPL° and, ΔGsu° comprises the sum of the solvation free energies of the free protein and ligand, hence, ΔGb° = 
ΔGi° + (ΔGsolvPL° - ΔGsolvP° - ΔGsolvL°). Since G is a state function, the sum over the cycle is zero so: ΔGb° = ΔGi° + 
(ΔGsb°- ΔGsu°), where, ΔGsb° is equated with the solvation of the complex ΔGsolvPL° and, ΔGsu° comprises the sum of 
the solvation free energies of the free protein and ligand, hence, ΔGb° = ΔGi° + (ΔGsolvPL° - ΔGsolvP° - ΔGsolvL°). 
To summarize, the major contribution to binding was attributed to the solvent driven 
enthalpic effect of desolvation of the protein binding pocket which arose due to the sub-
optimal occupancy of water in the binding pocket (Table 3.12).415 This was due to the 
occluded cleft structure of the pocket that prevents water from simultaneously occupying 
the pocket and forming hydrogen bonds with bulk water leading to an entropic preference 
to occupy the hydrophobic pocket but an enthalpic preference to form hydrogen bonds 
with their neighbours. Similar observations have been made for hydrophobic pockets of 
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other proteins which bear resemblance with the IPMP-MUP binding pocket (narrow 
hydrophobic cleft).427 
 
Entropic 
contribution 
Description 
Value 
(kJ/mol) 
Enthalpic 
contribution 
Description 
Value 
(kJ/mol) 
TΔSi° 
Protein degrees of 
freedom 
-0.8 ± 3.8 
ΔHi° 
New protein-ligand 
interactions 
~ -76 
Ligand degrees of 
freedom 
~ -37 
Changes in 
ligand/protein 
structure 
~ 0 
-TΔSsolvL° 
Ligand 
desolvation 
+26.7 ± 
8.4 
ΔHsolvL° Ligand desolvation 
+43.8 ± 
8.2 
TΔSsolvPL°- 
TΔSsolvP° 
Desolvation of 
protein/complex 
+0.4 ± 
9.2 
ΔHsolvPL°- 
ΔHsolvP° 
Desolavtion of 
protein/complex 
-12.3 ± 
8.4 
TΔSobs° Observed entropy 
-10.7 ± 
0.5 
ΔHobs° Observed enthalpy 
-44.5 ± 
0.4 
Table 3.12: Thermodynamic decomposition of binding of IPMP to MUP. 
Whilst the understanding behind the classical and non-classical hydrophobic effect is far 
from comprehensive, it appears the key to successful productive utilization is to consider 
the hydration state of the unbound protein pocket to point out key hydrophobic areas that 
can be matched with similarly hydrophobic ligand moieties i.e.’ hydrophobic hotspots’. 
Then, by SAR’s, optimize the relevant ligand atoms/functionalities towards an optimum 
fit to the hydrophobic pocket. This is commonly accomplished through the introduction 
of hydrocarbon chains, and through fluorination. The latter owing to both the hydrophobic 
nature of fluorine (Section 3.1.2.2) and, the larger Van der Waals radii fluorine has 
compared with hydrogen. 
 
Numerous examples of significant improvements in potency through increasing the 
hydrophobic surface area that have been attributed to hydrophobic interactions, many 
involve fluorine. For example, the fluorination of inhibitors of DPP-IV.428 The SI 
specificity pocket of DPP-IV is composed of several hydrophobic side chains (Val, Trp 
and Tyr). Substitution of the meta-phenyl hydrogen for a fluoromethyl group led to a 400-
fold improvement in binding affinity (Figure 3.9). An x-ray structure of 3.4 bound to 
DPP-IV shows the formation of five short hydrophobic contacts between the CH2F group 
and the surrounding lipophilic side chains. The marked improvement in affinity of the 
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fluoromethylated analogue 3.4c over the methylated analogue 3.4b was attributed the 
slightly larger volume that fluorine occupies compared with hydrogen, and the commonly 
observed higher hydrophobic interaction strength that fluorine has respective to 
hydrogen.  
 
 
 
 
 
 
 
 
 
3.1.4.2 Polar interactions with hydrogen bond donors 
Systematic scans of crystallographic databases (PDB, CSD) found polar interactions of 
the type C-F…H-X, where X is O, N, or C, occur frequently.322,323,407,429–436 The nature of 
these interactions is still the subject of some debate, with some authors attributing it as a 
weak hydrogen bond and others as a multipolar interaction.407,429,430,432,433 However, 
regardless of the exact nature of the interaction, they are, in general, found to contribute 
weakly to the free energy of binding, typically possessing interaction energies of < 3 
kcal/mol.323,437 Hence, molecular recognition and association ascribed to organofluorine 
forming polar interactions with hydrogen bond donors are at risk of overinterpretation.  
 
At the core of the ambiguity seems to be whether these interactions are hydrogen bonds 
or not. Pauling described the hydrogen bond in his classic work of 1931, The Nature of 
the Chemical Bond, as, 
 
‘Only the most electronegative atoms (such as N, O, F) should form hydrogen 
bonds (denoted X-H…Y), and the strength of the bond should increase with 
increase in the electronegativity of the two bonded atoms,’ 
Compound R Kd (nM) 
3.4a H 200 
3.4b CH3 4.6 
3.4c CH2F 0.5 
A B 
Figure 3.9: SAR of DPP-IV inhbitors 3.4a-c. (A) Structure and Kd’s of compounds 3.4ab-c. (B) X-ray structure of 
3.4c bound to DPP-IV (PDB: 3KWJ). Short hydrophobic contacts are displayed in dashed red lines. 
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concluding that it must be electrostatic in nature and not chemical (covalent).392 Since 
then, chemists have identified numerous examples of hydrogen bonding which do not fit 
with Pauling’s definition. From Pauling’s definition, fluorine, the most electronegative 
element, should form strong hydrogen bonds with strongly acidic protons. Indeed, anionic 
fluoride ions form some of the strongest hydrogen bonds (H-F-H)- and are frequently cited 
in textbooks as illustrative examples of hydrogen bonding.438 However, C-F…H-X 
interactions are typically very weak, challenging this definition of hydrogen bonding.  
 
Introduction of a hydrogen bond acceptor into a ligand in the rational design of more 
potent compounds, seeking to form a strong hydrogen bond, can lead to a smaller gain in 
free energy of binding than expected. Intuitively, this may be explained by several 
reasons, for example, the higher desolvation penalty associated with polar functional 
groups. Studies correlating hydrogen bond acceptor strength with proton basicity show 
that highly basic acceptors do not form the strongest hydrogen bonds, challenging the 
historic definition of increasing hydrogen bond strength with increasing 
electronegativity.439 Instead, properties such as high proton affinity and high 
polarizability play a role in determining the strength of the acceptor. This can be used to 
explain the weak strength of interactions involving fluorine as an acceptor as it has a low 
proton affinity and low polarizability.  
 
Recently, Desiraju et al. redefined the hydrogen bond as 
 
‘An attractive interaction between a hydrogen atom from a molecule or a 
molecular fragment H-X, in which X is more electronegative than H, and an atom 
or group of atoms in the same or different molecule, in which there is evidence 
for bond formation.’440,441 
 
This includes the possibility that either donor or acceptor is weak or possesses moderate 
electronegativity. This definition amends the range of hydrogen bond stabilization 
energies to include the very strong hydrogen bonds (170 kJ/mol), formed between ionic 
acceptors and acidic donors, and the very weak hydrogen bonds(2 kJ/mol), formed by 
weak donors and acceptors. Desiraju differentiates the weak hydrogen bond from a Van 
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der Waals interaction stating that weak hydrogen bonds display directionality, whereas 
Van der Waals interactions do not.442 This expands the definition to allow for the weak 
hydrogen bond acceptor nature of fluorine as well as providing grounds to differentiate 
whether an interaction can be classified as a hydrogen bond or as a Van der Waals 
interaction. 
 
Despite the increasing interest in the formation of weak interactions, a predictive model 
for the formation of C-F…H-X remains elusive. Most studies have sought to draw 
statistical relevance from database searches for C-F…H-X, where the Van der Waals 
radius is less than the sum of the respective atoms. These searches are generally in 
agreement that these interactions are weak and have a subtle effect on protein-ligand 
recognition and association.  
 
Vulpetti et al. have developed a local environment of fluorine (LEF) library which can 
be used to probe for fluorphillic environments. This library was constructed using a local 
environment to fluorine (LEF) rule of shielding.443,444 This LEF rule was based on the 
observation that compounds with similar local-fluorine environments tend to have similar 
chemical shifts, and that these shifts are modulated by the number of oxygen, nitrogen 
and halogen atoms that are situated α, β, and γ with respect to fluorine. In general, the 19F 
chemical shift correlates with the type of interaction that fluorine is prone to make with 
the protein, where highly shielded fluorine observed frequently in contact with hydrogen 
bond donors (Figure 3.10). Comparison of protein-ligand x-ray structures present in the 
PDB and CSD support the proposed correlation between 19F chemical shift and the 
amphipathic character of fluorine (formation of weak hydrogen bonds, multipolar 
interactions or hydrophobic interactions).  
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HYDROPHOBICITY/ 
MULTIPOLAR 
-226 
 
POLAR/ 
ENTHALPIC 
Figure 3.10: Type of interaction formed by organofluorine as a function of 19F chemical shift. 
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Several illustrative examples of organofluorine forming polar interactions with HX are 
frequently cited in review articles, seeking to demonstrate how these weak interactions 
can be used in rational drug discovery towards modest improvements in affinity. Ortho 
fluorination of the aromatic ring of an sitagliptin analogue 3.5a to form a 2,4,5-fluroinated 
phenyl ring (3.5b) results in the formation of two polar contacts with Arg125 and Asn710 
NH2 moieties (Figure 3.11).400 Comparison with the 3,4-difluoro substituted analogue 
reveals that ortho-fluorination results in an improvement in potency from 455 nM (3.5a) 
to 68 nM (3.5b).  
Figure 3.11: Increase in potency by fluorination of sitagliptin analogue 3.5a. (A) Chemical structure of sitagliptin 
analogues 3.5a and 3.5b. (B) Structure of 3.5b bound to DPP-IV (PDB: 1X70). For simplicity, just the polar interactions 
between the ortho-fluorine are shown (blue dashed lines).  
A systematic fluorine scan of the phenyl ring of the thrombin inhibitor (Figure 3.12) 
revealed that the 4-substituted analogue showed increased selectivity and potency.445 An 
x-ray structure of inhibitor 3.6d bound to thrombin revealed that the fluorophenyl group 
forms 5 short contacts with Glu97 and Asn98 (multipolar) and Ile174 (polar interaction 
with hydrogen bond donor) below the Van der Waals radii. The authors reasoned that the 
formation of these contacts was responsible for the improved selectivity and affinity. 
 
B A 
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These illustrative examples establish two key point on these interactions. Observed polar 
interactions between fluorine and hydrogen bond donors are seldom isolated interactions 
and typically occur in conjunction with other interactions (orthogonal multipolar) in 
particularly fluorophilic environments. Whilst these interactions are weak in nature, 
modest to large improvements in affinity can be gained through targeting these 
fluorophillic environments through subtle fluorine-protein interactions and through 
indirect electronic effects. 
 
3.2 Design of fluorinated PK083 analogues to target p53-Y220C 
Undoubtedly, the formation of direct fluorine-protein interactions can improve potency 
and selectivity. However, as these interactions are weak in nature and not fully 
understood, targeting ‘fluorophilic’ pockets or sub-pockets, rather than seeking to form 
specific polar interactions with hydrogen bond donors, hydrophobic interactions or 
multipolar interactions, constitutes a more general strategy towards seeking to use direct 
fluorine-protein interactions towards affinity improvements. 
 
Compound F- position Ki  
(µM) 
Selectivity  
(%) 
3.6a - 0.31 15 
3.6b 2 0.50 9.8 
3.6c 3 0.36 26 
3.6d 4 0.057 67 
3.6e 2,6 0.61 9.0 
3.6f 3,5 0.59 25 
3.6g 1,2,3,4,5 0.27 44 
Figure 3.12: Increase in potency through a 
systematic fluorine scan of Thrombin inhibitor 
3.6. (A) Structure of fluorinated thrombin 
inhibitor and table showing activity. Uncertainty 
in Ki values is ± 20%. Selectivity is relative to 
trypsin. (B) Structure of 3.6d bound to thrombin 
(PDB: 1OYT). Polar interactions with hydrogen 
bond donors shown in blue dashed lines. 
Multipolar interactions shown in green dashed 
lines. 
A B 
3.6 
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Section 2.3 described the discovery of fragment 2.9 in which two fragments occupied the 
Y220C mutation site with the trifluoromethyl groups oriented toward Cys220 (Figure 
2.14C).291 This is indicative of the Cys220 mutation site being potentiallly fluorophilic. 
Figure 3.13 highlights this hotspot and identifies the best position of PK083 that can be 
fluorinated to target this potentially fluorophilic hotspot. To assess this hypothesis, DFT-
D calculations were conducted ‡  to computationally assess the fluorophilicity of the 
central mutation cavity.446 
 
3.2.1 DFT-D Calculations 
In the crystal structure of p53-Y220C in complex with PK083 (Figure 3.14A), the ethyl 
moiety of PK083 is near the carbonyl groups of Leu145 and Trp146, and the thiol group 
of Cys220.261 Given the frequent and well-characterized interactions between 
organofluorine groups and protein backbone amides, as well as the less frequently 
observed interactions between fluorine and sulfur atoms,323 investigation as to whether 
gains in binding affinity could be achieved via fluorinated ethyl substituents using DFT-
D calculations at BLYP-D3/def2-SVP level with a truncated model of PK083 bound to 
the p53-Y220C binding pocket (Figure 3.14B). Except for the sulfur atom of Cys220, all 
heavy atoms of the Y220C binding pocket as well as the nitrogen and C-3 atom of the 
pyrrole ligand model were kept frozen during the calculations. 
 
                                               
‡ DFT-D studies were conducted by Dr. Matthias Bauer 
Figure 3.13: Targeting the fluorophilic hotspot of p53-Y220C. (A) Structure of PK083 bound to p53-Y220C (PDB: 
2VUK), potential fluorophilic hotspot highlighted in green. (B) Chemical structure of PK083 showing the area that 
can be fluorinatied to target this hotspot. 
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Figure 3.14: Binding mode of the p53-Y220C stabilizer PK083 and fluorinated model systems (A) Experimentally 
determined binding mode of PK083 (orange sticks) to the mutation-induced surface crevice of the p53 mutant Y220C 
(PDB: 2VUK). (B) Snapshots of DFT-D optimized models of the PK083 N-ethyl group and its fluorinated derivatives 
(orange sticks) bound to the Y220C surface crevice. For the DFT-D optimizations, truncated models of PK083 (N-
ethylpyrrole) and the p53-Y220C pocket (as depicted) were used (only non-hydrogen atoms and polar protons are 
shown). Interaction energies of each ligand model were compared to the N-ethyl reference interaction energy ΔE to 
calculate relative interaction energies (ΔΔE = ΔELigand – ΔEN-ethyl). The three distinct orientations of local minima of 
the 2-fluoroethyl anchor showed different interactions energies, indicating that orientation of the C-F vector towards 
the backbone carbonyl groups of Leu145 and Trp146 yields the most favorable interaction energy.  
Distances between the backbone amides of Leu145 and Trp146 and the nearest C-F 
groups were between 3.0 Å and 3.3 Å in the optimized structures, which is in good 
agreement with typical CF…C=O distances (3.0 Å – 3.7 Å) for orthogonal multipolar 
interactions.408 C-F…S and C-F…HS distances ranged from 2.8 Å to 3.6 Å, which is also 
in good agreement with experimentally observed distances for fluorine-sulfur contacts 
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(2.8 Å – 3.4 Å) in protein structures.323 The DFT-D3 calculations indicated that the 
relative interaction energies (ΔΔE) for all fluorinated ethyl groups improved by at least -
2 kcal/mol compared with the N-ethyl reference energy ΔE (ΔE = Ecomplex - (Ereceptor + 
Eligand)) (Figure 3.14B). The energetically most favorable conformation (ΔΔE = -6.5 
kcal/mol) of the 2-fluoroethyl group was orientation 1 (Figure 3.14B), in which the C-F 
vector points towards the backbone amides of Leu145 and Trp146, predicting two 
potential orthogonal multipolar interactions between the fluorine atom and both carbonyl 
groups. Orientations 2 and 3 of the 2-fluoroethyl group, where the fluorines were oriented 
towards the sulfhydryl group of Cys220, were energetically less favorable, with 
respective ΔΔE values of -2.2 kcal/mol and -3.7 kcal/mol. The relative interaction energy 
of conformation 1 of the difluoro ethyl moiety (ΔΔE = -6.9 kcal/mol) was similar to the 
most favored 2-fluoroethyl conformation, whereas the trifluoro-substituted ethyl anchor 
was energetically less favorable with a ΔΔE value of -4.2 kcal/mol (Figure 3.14B). 
However, the calculated DFT-D3 energies only yield an estimate of the ligand-protein 
interaction at the chosen computational level in a model system of small size and neglect 
other contributions to the free energy of binding such as entropic changes and desolvation 
penalties. 
 
These results confirm the hypothesis that the cys220 mutational hotspot is potentially 
fluorophilic, as such, PK083 analogues bearing fluoroethylated groups at the central 
nitrogen of carbazole (position R, Figure 3.13, Figure 3.14, Figure 3.15) were targeted 
for synthesis toward a PK083 analogue that shows improved affinity potentially through 
direct fluorine-protein interactions. Additionally, by variation of the substitution pattern 
at the level of the pendant amine at R2, additional information on the effect on the overall 
potency can be established.  
 
Figure 3.15: Compounds for targeting Cys220 sub-pocket fluorophillicity. 
96 
 
When R = CH2CH2F and R2 = CH2NHMe, the compound was commercially available 
and hence, was not synthesized.  
3.3 Results and Discussion 
The original strategy towards the synthesis of fluoroethylated analogues of PK083 was to 
use the same synthesis established in Chapter 2.0, starting from 3-bromocarbazole (Figure 
3.16). Lithium-halogen exchange with 3-bromocarbazole to generate a lithiated 
intermediate, followed by reaction with DMF and subsequent hydrolysis to yield 
carbazole-3-carbaldehyde. Reductive amination using sodium triacetoxyborohydride and 
dimethylamine yields privileged intermediate 2.37, which, following a nucleophilic 
substitution reaction between the generated nitrogen anion and iodo-fluoroethane 
electrophiles yields final products.  
 
Figure 3.16: Retrosynthetic disconnection towards compounds targeting subsite I and the fluorophilicity of the 
mutational sub-pocket. 
3.3.1  Alkylation Chemistry 
The synthesis of intermediate 2.37 was conducted according the conditions established in 
Chapter 2 (Scheme 3.1).  
 
Scheme 3.1: Synthesis of intermediate 2.37 from 3-bromocarbazole. (a) NaH, THF, rt then -78 °C, nBuLi, -78 - -35 °C 
then -78 °C, DMF, THF, rt; (b) HNMe2, NaBH(OAc)3, THF, rt. 
Initial attempts at trifluoroethylation via a SN2 reaction between the nitrogen nucleophile, 
and 1-(9-carbazol-3-yl)-N,N-dimethylmethanamine (2.37) led to an inseparable mixture 
(Scheme 3.2).  
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Scheme 3.2: Attempted synthesis of final product 3.7a from intermediate 2.37. (a) NaH, DMF, rt, 30 min then ICH2CF3, 
rt, 18 h. 
This alkylation reaction was further investigated by examining the analogous reaction of 
carbazole with 1-iodo-2,2,2-triflurorethane using sodium hydride as a base at room 
temperature. This yielded the unusual vinylic elimination product 3.8 (Scheme 3.3) the 
structure of which was determined by 1H NMR, HRMS-ESI and X-ray crystallography. 
The experiment was repeated three times under identical conditions and the outcome of 
the reaction was identical. Similar observations of vinylic elimination products formed 
upon trifluoroethylation have been made by Suehiro et al. in the radiosynthesis of a 
tumour hypoxia marker.447 By varying the base, it was found that only the completion of 
the reaction was affected (Table 3.13). It is of note that the yield of the reaction towards 
the elimination product when using a ‘hard’ base was significantly higher than when 
using a ‘soft’ base such as cesium carbonate. Thus, it cannot be discounted that the nature 
of the base may affect the outcome of the reaction.  This reaction proceeded with a high 
degree of isomeric control, with exclusive formation of the E isomer (as determined by 
1H NMR and X-ray crystallography).  
 
Scheme 3.3: Elimination reaction. (a) NaH, DMF, rt then ICH2CF3, 18 h. 
 
Figure 3.17: Crystal structure of vinylic elimination product 3.8 as determined by X-ray crystallography. 
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 Base Solvent Conditions 
Yield  
3.8 Carbazole Trifluoroethylated product 
A NaH DMF Room temperature 40 60 0 
B Cs2CO3 DMF 
Room 
temperature 0 100 0 
C PS-BEMP DMF Room temperature 0 100 0 
D Et3N DMF Room temperature 0 100 0 
E NaH DMF 
150°C, 
microwave 
irradiation, 30 
minutes 
69 27 4 
F Cs2CO3 DMF 
150°, 
microwave 
irradiation, 30 
minutes 
12 81 6 
G Et3N DMF 
150°, 
microwave 
irradiation, 30 
minutes 
0 100 0 
Table 3.13: Reaction optimisation of trifluoroethylation of carbazole. Yields determined by 1H NMR (DMSO-d6). The 
trifluoroethylation reagent was 1-iodo-2,2-trifluoroethane in each case. 
Using microwave-assisted chemistry it was found that the trifluoroethylated product 
could be isolated, ableit in a low yield (Table 3.13, entries E-G). This implies that the 
elimination reaction has a lower enthalpy of reaction than for the simple SN2 reaction. 
This is contrary to initial expectations as the enthalpy of breaking two C-F bonds (880 kJ  
mol-1) is far in excess of one C-I bond (240 kJ mol-1). It has been shown by fluorination 
studies, that the effect of replacing each of the C-H bonds on C2 of iodoethane with C-F 
bonds effectively decreases the electrophilic character of C1 as the electrophilic character 
of C2 increases exponentially.  
 
The competition between nucleophilic attack at C1 and C2 was circumvented in favour 
of nucleophilic attack at C1 by the use of trifluoroethyltosylate.447 As the tosylate is the 
‘harder’ electrophile it is more reactive in a SN2 displacement and less reactive in E2 
compared with the iodide and hence nucleophilic attack took place solely at C1 (Figure 
3.18).  
 
Figure 3.18: Structures of trifluoroethylation reagents used.  
The optimum conditions were obtained when using 9H-carbazole-3-carbaldehyde as a 
starting material (electron-withdrawing aldehyde at 3- position) with Cs2CO3 or NaH as 
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a base, DMF as a solvent and stirring under microwave irradiation at 150°C for 30 
minutes (Scheme 3.4). 
 
Scheme 3.4: Reaction scheme for the optimised procedure for trifluoroethylation. (a) TsOCH2CF3, Cs2CO3, DMF, 
microwave irradiation, 150 °C, 30 min. 
These optimum conditions were extended to N-alkylation with 1-iodo-2,2-difluoroethane 
as a reagent, which interestingly did not show the same reverse reactivity as for 1-iodo-
2,2,2-trifluoroethane (Scheme 3.5).  
 
Scheme 3.5: The generic reaction scheme for the synthesis of mono- and di-fluoroethylated aldehydes.  
Analogues of PK083, where R2 = CH2NHMe were synthesised in parallel by reductive 
amination from the respective aldehydes to give the final products 3.7a and 3.7b (Scheme 
3.6).  
 
Scheme 3.6: General procedure for the reductive amination of N-fluorinated aldehydes 3.9a and 3.9b to give final 
products 3.7b and 3.7c.(a) Ti(OiPr)4, MeNH2, NEt3,  DCM, EtOH 1:1, 18 h, rt then NaBH4, 8 h , rt.  
 
3.3.2 Effect of the substitution at R on Potency 
The stabilizing effect of compounds 3.7a and 3.7b on p53-Y220C, along with the mono-
fluorinated analogue that was commercially available, were tested by DSF and ITC and 
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are summarized in Table 3.14.446 Correlation between the two assays was adaquate, 
showing a negative correlation of -0.75. 
 
Compound R DSF ΔTm [125 µM] ITC Kd (µM) 
PK083 CH2CH3 0.8 124 
PK9241 CH2CH2F 0.4 138 ± 35.2 
PK9254 (3.7c) CH2CHF2 0.3 101 ± 10.8 
PK9255 (3.7b) CH2CF3 1.2 28 ± 2.6 
Table 3.14: DSF thermal shift and ITC Kd determination for PK083, and N-fluoroethylated analogues PK9241, PK9254 
(3.7c) and PK9255 (3.7b). DSF and ITC assay conditions are described in Chapter 6. Correlation between DSF 
stabilization and ITC dissociation constant = -0.75. 
The N-2,2,2-trifluoroethyl substituted carbazoles PK9255 (3.7b) increased stability of the 
p53-Y220C DBD by 1.2 K at a compound concentration of 125 µM, showing a clear 
improvement over their N-ethyl substituted counterparts PK083. In contrast, the 
difluorinated (3.7c) and mono- fluorinated carbazoles PK9254 and PK9241 were 
significantly worse than the parent compound in terms of protein stabilization, with 
respective thermal shifts of 0.3 and 0.4 K.  
 
The trifluoro-substituted carbazole PK9255 (3.7b) was the most potent compound and 
showed ITC KD value of 28 µM (Table 3.14), which corresponds to a 5-fold increase in 
affinity compared to PK083. Despite prediction of improved interaction energies by DFT-
D calculations, the mono- and difluorinated analogues, PK9241 and PK9254 (3.7c), failed 
to display improved affinities. They had Kd values of 101 µM and 138 µM, respectively.  
 
3.3.3 Variation at R2 
A dimethylated benzylic amine analogue of the most potent trifluoroethyl substituted 
carbazole, PK9255 (3.7b) was synthesized from intermediate 3.9a by reductive amination 
with dimethylamine (Scheme 3.7). 
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Scheme 3.7: Reductive amination of 3.9a with dimethylamine to yield the PK9255 analogue 3.7a. (a) Ti(OiPr)4, 
HNMe2, NEt3, DCM:EtOH 1:1, 18 h, rt then NaBH4, rt, 8 h.  
The stabilizing effect of 3.7a on p53-Y220C was examined by DSF and the dissociation 
constant was determined by ITC and are summarized in  Table 3.15. 
 
Table 3.15: DSF thermal shift and ITC Kd determination for N-fluoroethylated analogues PK9255 (3.7b) and MB065 
(3.7a). DSF and ITC assay conditions are described in Chapter 6. 
The substitution pattern of the solvent-exposed amine had a minor effect on affinity, with 
the additional methyl group in 5 resulting in a 30% drop in affinity. 
 
3.3.4 X-Ray crystallography 
The binding mode of the carbazoles was almost identical to that of PK083, however, 
variations at R2 caused the benzylic amine to flip, breaking the hydrogen bond with the 
backbone Asp228 C=O, forming a new hydrogen bond with the C=O of Val147 (Figure 
3.19E).  Hence, small differences in the orientation of the central carbazole scaffold can 
be attributed to the different methylation state of the amine moiety. Upon 
monofluorination, the fluorine atom points toward the carbonyl groups of Leu145 and 
Trp146 with a F··· C=O interaction distance of 3.4 Å (Figure 3.19A). The C−F vector 
and the planes of the backbone carbonyl group of Leu145 and Trp146 show a nearly 
orthogonal arrangement, with respective O=C···F angles of 97.5° and 80.1°, which is in 
good agreement with O=C···F angles found in the PDB and CSD for orthogonal 
multipolar interactions. This preferred orientation of the C−F vector in the crystal 
structure is also in good agreement with initial DFT-D predictions (Figure 3.14). Similar 
to the Y220C-PK083 complex, the side chain of Cys220, in immediate vicinity of the 
ethyl anchor, adopts two alternative, albeit very similar conformations. For the N-2- 
Compound R2 DSF ΔTm [125 µM] ITC Kd (µM) 
PK9255 (3.7b) CH2NHMe 1.2 28 ± 2.6 
MB065 (3.7a) CH2NMe2 1.2 37  
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difluoroethyl anchor, there are two alternative conformations in the p53-Y220C binding 
pocket (Figure 3.19B, C). In both conformations, one fluorine atom interacts with the  
Figure 3.19: X-ray structures of p53-Y220C with bound fluoro-
derivatives of PK083. Multipolar fluorine interactions are 
highlighted with magenta broken lines, fluorine−sulfur contacts 
with yellow broken lines and hydrogen bonds with orange broken 
lines (A) Y220C in complex with monofluorinated compound 
PK9241. (B,C) Alternative conformations of the difluorinated 
compound PK9254 in chain B of the Y220C mutant. In chain A 
with only partial occupancy of PK9254, only one of the two side-
chain conformations of Cys220 was observed, with a preferential 
orientation of PK9254 as highlighted in panel B. (D) Y220C in 
complex with MB065 (chain B). (E) Overlay of PK9254 and 
MB065’s binding modes showing the differences in the 
hydrogen bonding of the benzylic amine. Interactions with the 
main conformation of Cys220 are highlighted. The minor 
conformation of Cys220 is observed in chain B only. 
E 
V147 
D228 
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carbonyl groups of Leu145 and Trp146 in an almost identical fashion as observed for the 
monofluorinated analogue. The second fluorine interacts with the thiol group of Cys220, 
pointing either toward Pro151 (Figure 3.19C) or toward Leu145 at the bottom of the 
binding pocket (Figure 3.19B), which is essentially the result of a 120° rotation around 
the ethyl anchor C−C bond. Interestingly, only one of the two Cys conformations was 
observed in chain A, coinciding with a preferential orientation of the difluoroethyl anchor 
in the orientation highlighted in Figure 3.19, whereby the fluorine forms a weak hydrogen 
bond with the SH group of Cys220. In both orientations, the fluorine atom interacts with 
the thiol group at a distance of about 3.2 Å, which is more or less the sum of the van der 
Waals radii of sulfur and fluorine (rF = 1.47 Å; rS = 1.80 Å). In the structure of the most 
potent trifluoromethylated compound, the CF3 group aligns well with the different 
fluorine positions observed for monofluorinated and difluorinated (Figure 3.19D); i.e., it 
interacts with the backbone carbonyl groups of Leu145 and Trp146 as well as with the 
thiol group of Cys220. Analysis of C−S···F angles in the complexes with di- and 
trifluorinated compounds suggests that fluorine interacts with Cys220 via weak hydrogen 
bonding with the polarized proton of the thiol function and via sulfur σ-hole bonding at 
an angle close to 180 °. 
3.4 Conclusions 
Incorporation of fluorine atoms into the N-ethyl anchor of the p53-Y220C stabilizer 
PK083 yielded two compounds, PK9255 and MB065, with substantially increased p53-
Y220C stabilization (1.2 K at 125 µM) and Y220C binding affinity. Compared with the 
parent compounds PK083 and PK8017, the ITC KD values improved by a factor of 5 and 
the free energy of binding by approximately -0.9 kcal/mol (at 293K). Typically, C-
F…C=O orthogonal multipolar interactions with optimal geometry raise the binding free 
enthalpy by about -0.2 to -0.3 kcal/mol,324 which suggests that the observed C-F…C=O 
interactions with the carbonyl groups of Leu145 and Trp146 are the main factor for the 
potency increase of the trifluorinated PK083 derivatives. The DFT-D calculations are 
consistent with the binding modes observed in the crystal structures, as the preferred 
orientation of fluorine towards the backbone carbonyl groups of Leu145 and Trp146 in 
these structures indicates that interactions of the protein carbonyl groups with fluorine 
atoms contribute more strongly to the affinity increase than interactions with the thiol 
group of Cys220 or apolar protons of hydrophobic side chains. The preferred interaction 
with the protein backbone then seems to direct the orientation of additional fluorine atoms 
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in the binding pocket, interacting with the thiol group of Cys220 via either a hydrogen 
bond or a planar sulfur s-hole interaction.  
 
Although DFT-D calculations predicted improved interaction energies for mono-
fluorinated and di-fluorinated PK083 derivatives, this was not reflected in the 
experimentally determined dissociation constants and stability data for compounds 
PK9241 and PK9254, which were close to that of the parent compound PK083. These 
discrepancies between theoretical and experimental data are likely due to different 
desolvation penalties associated with each fluorinated group. Fluorine can act as a weak 
hydrogen-bond acceptor in a 2,2-difluoromethyl group and even more strongly in a 2-
fluoromethyl group, although hydrogen-bond strength was found to be significantly 
weaker than for the conventional hydrogen-bond acceptor acetophenone.433 For example, 
difluoroalkyl groups have been used as thiol surrogates in drug discovery because of their 
similar steric properties and the acidity of the terminal hydrogen resulting from the high 
polarization of the C-H bond by the geminal fluorine atoms. 
 
In conclusion, targeting Cys220 and the backbone carbonyl groups of Leu145 and Trp146 
via fluorine bonding helped to further optimize the carbazole scaffold. N-3,3,3-
Trifluoroethyl substituted carbazoles PK9255 and MB065 exhibit a high ligand efficiency 
(LE = 0.3 kcal mol-1 atom-1), although binding is still relatively weak for these fragment-
like molecules. Differences in the methylation state of the benzylic amine had a minimal 
effect on the overall potency, where dimethylation resulted in a reduction in affinity, 
measured by ITC dissociation constant of 37 µM vs 28 µM. Crystallography revealed 
that dimethylation resulted in flip of the benzylic amine, breaking the hydrogen bond 
observed in PK083 analogues between the amine and the backbone C=O of Asp228, 
forming a new hydrogen bond between the protonated amine (HCl) and the backbone 
C=O of Val147.  This provides a rational of the difference in affinity between 
dimethylated analogues (e.g. PK8017) and monomethylated PK083.  
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Chapter 4 :Targeting Subsite II 
Efforts towards improving PK083 potency towards p53-Y220C via targeting the mutant 
specific sub-pocket for affinity improvements resulted in the synthesis of PK9255, which 
shows enhanced affinity through direct fluorine-protein interactions resulting in a Kd = 
28 µM as determined by ITC.446 Subsequent efforts to further enhance the selectivity and 
potency of PK083 through the design of analogues that bear covalent modification 
warheads were unsuccessful (Dr Adam Close, unpublished results). Previous attempts to 
target the solvent exposed subsite I through functionalization at R2 did not exhibit any 
patterns within the SAR. Furthermore, initial attempts to target the transiently open 
subsite III were unsuccessful. Hence, alternative areas of the Y220C pocket were 
examined for areas where potential affinity gains could be made. By examination of the 
x-ray structure of PK083 bound to the Y220C pocket, the position R3 was identified for 
growth that allows targeting the proline-rich subsite II (Figure 4.1).261  
This chapter describes the synthesis of compounds that target the proline rich subsite II 
subpocket through the functionalization of R3, and, using SAR and x-ray crystallography, 
the optimization towards higher affinity PK083 analogues, where the most potent 
substitutions occurred when R3 is a 5-membered heterocycle (Figure 4.1B). 
 
4.1 Properties of Subsite II 
Subsite II is accessed via bridging a narrow gap from the central cavity, formed by 
Cys220 and Pro151. This sub-pocket is composed of a hydrophobic interaction surface 
B A 
Figure 4.1: Summary of the strategies towards improving the affinity of PK083 analogues towards p53-Y220C. (A) X-ray 
structure of PK083 bound to p53-Y220C (PDB: 2VUK) showing subsite II (highlighted in green). (B) Generic chemical 
structure of compounds synthesised to target subsite II. 
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formed by Pro151, Pro152 and Pro153 as well as the backbone carbonyl of Cys220. This 
hydrophobic surface is neighboured by two polar neutral residues, Thr155 and Glu221. 
A structural water (W1) occupies the pocket sitting between Cys220 and Thr155 (Figure 
4.2).261  
Computational studies, such as MD simulations and wrapping studies, have sought to 
probe subsite II, seeking to identify the most efficient means of targeting it.291,448 The 
results of these studies are summarized below. 
 
4.1.1 MD Simulations 
The use of molecular simulations to probe the dynamic properties of proteins using 
isopropanol solvation studies has been demonstrated to be a useful tool in determining 
drug-binding sites and protein-protein interaction interfaces on proteins of 
pharmacological interest.449 For example, the binding mode of two peptide substrates of 
BCL-6. Isopropanol is chosen as it contains both polar and non-polar properties that are 
intended to simulate hydrogen bonding and hydrophobic interactions similarly to that of 
a ligand.450 Basse and Kaar et al. utilized this technique to probe the potential ligand 
binding ‘hotspots’ of p53-Y220C.291  
 
Simulations were performed in a water isopropanol mixture using an isopropanol 
concentration of 20% v/v to assess preferential solvation of the protein. Analysis of the 
isopropanol density isosurface of p53-Y220C found several regions of high density, the 
highest of which was found on the DNA binding domain and a surface patch around 
Pro151 
Pro152 
Pro153 Thr155 
Gly154 
Cys220 
Glu221 
W1 
Figure 4.2: Structure of PK083 bound to p53-Y220C highlighting the residues of subsite II, carbons shown in green 
(subsite II). 
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Leu188 and Leu201.451 However, the fragment screen of small molecules discussed in 
Section 2.3 identified that small molecules tend to bind only the mutation site, hence the 
simulation was restricted to only the Y220C pocket.291  
 
Isopropanol density in the mutation induced cavity was over four times higher than the 
expected value for the bulk mixture, indicating the propensity of solvent binding, and 
hence ligand binding in the pocket. Localization of isopropanol molecules within the 
cavity occurred between Pro153, Pro220 and Cys220 was observed. The hydroxyl group 
of isopropanol formed hydrogen bonds with the backbone carbonyl of Pro151 and Pro152 
with an estimated free energy of binding of -3.9 kcal/mol. Conversely, the area of the 
cavity between side chains of Val147, Pro151 and Pro223, the area usually occupied by 
aromatic rings of fragments that bind Y220C, was devoid of isopropanol (Figure 4.3). 
The authors reasoned that this was due to the increased steric bulk of isopropanol 
compared with planar aromatic rings. These identify subsite II as an area that shows 
druggability.  
Figure 4.3: The density of isopropanol in the cavity contoured at 4 times the density of the bulk mixture. Isopropanol 
oxygen is shown in red and carbon is shown in blue. The distances used to monitor the structural motions are shown in 
dashed black lines. Reproduced from Chemistry and Biology, N. Basse, J. L. Kaar, G. Settanni, A. C. Joerger, T. J. 
Rutherford, and A. R. Fersht, ‘Toward the Rational Design of p-53-Stabilizing Drugs: Probing the Surface of the 
Oncogenic Y220C Mutant,’ 46–56, Copyright (2010), with permission from Elsevier. 
As well as identifying potential binding sites, molecular dynamics simulations allow the 
examination of how structural motions in the cavity affect ligand binding. Analysis of the 
cavity dynamics found that the distance between CαPro153 and CαPro222 varied between 
7-9 Å over the time course of the simulation. In the absence of isopropanol, the cavity 
fluctuated between 5-7 Å, corresponding to an apparent open and closed state. 
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Additionally, the depth of the cavity, which was taken as the distance between the sulfur 
of Cys220 and CαPro222, fluctuated in a range comparable with crystal structures.291 
However, the depth was only significantly altered when isopropanol occupied the cavity 
indicating an induced-fit phenomenon. These results indicate that the central cavity and 
subsite II are highly dynamic.  
 
Furthermore, Basse and Kaar used Gaussian Network Model (GNM) analysis to assess 
whether the binding of fragments alters the plasticity of the cavity.291 GNM represents 
the protein as an elastic network where harmonic springs connect neighbouring nodes 
centred on the Cα atoms of residues. GNM has been proven to be highly accurate in 
reproducing experimental data on structural fluctuations in biological macromolecules 
and is widely used to study the functional consequence of such fluctuations.452–455 The 
results of the GNM analysis indicated that the presence of fragments markedly reduce the 
flexibility of the pocket. The backbone dynamics of p53-Y220C are virtually identical to 
the rest of the protein, thus enhancing the rigidity of the region. The dynamics in the 
absence of the fragments are more flexible. The authors reasoned that this could be 
attributed to the fragments coupling the proline-rich loops that line to mutational cavity 
to the rest of the protein, thus enhancing the rigidity. This is supported by the observation 
that Pro222 exhibits significantly reduced temperature factors in the crystal structures of 
all Y220-ligand complexes compared to structures of the ligand free mutant. Thus, 
targeting subsite II with hydrophobic groups seeking to optimally occupy the sub-pocket, 
should reduce flexibility in the proline loop, enhancing rigidity, reducing entropy and 
improving the temperature sensitive phenotype that this thermodynamically destabilizing 
mutation causes.  
 
4.1.2 Wrapping Effects in the Y220C Pocket  
The wrapping concept was introduced by Prof. Ariel Fernandez, and states that to prevail 
in water environments, soluble proteins must protect their backbone hydrogen bonds from 
the disruptive effect of water attack by clustering non-polar residues around them.456–464 
Underwrapped interactions, termed dehydrons, represent thermodynamically unstable, 
vulnerable sites where the level of underwrapping has been found to correlate with the 
degree of structural disorder.456,461,464 Dehydrons are adhesive, hence, are promoters of 
molecular associations because their inherent stability increases upon approach of 
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additional non-polar groups. Consequently, dehydrons constitute key motifs that signal 
protein binding sites.  
 
Accordino et al. studied the impact of the Y220C mutation in terms of wrapping.465 In 
the wild-type structure, a wrapping interaction is formed between Y220 and Thr155. The 
tyrosine to cysteine mutation results in the loosening of the protein structure, allowing 
water to access the dehydronic Cys220…Thr155 hydrogen bond formed between the 
backbone NH of Cys220 and the side-chain hydroxyl of Thr155 that now wildly 
fluctuates, breaking and reforming over the course of time, thus promoting structural 
destabilization (Figure 4.4A). PK083 only provides partial wrapping as it does not extend 
into subsite II, leaving the hydrogen bond vulnerable to attack. Computational docking 
experiments of PK083 analogues that bear groups that extend into subsite II exhibited an 
increased free energy of binding compared with PK083 (Figure 4.4B).465 
4.1.3 Summary of Computational Results 
The computational results suggest that tyrosine to cysteine mutation results in the loss of 
the stabilizing influence of the tyrosine on the surrounding proline loops, i.e.subsite II, 
leading to much greater flexibility, as suggested by MD simulations and the GNM 
analysis. Additionally, the mutation results in the Cys220-Thr150 dehydronic interaction, 
which is vulnerable to attack from water. Thus, the mutation seems to destabilize subsite 
II, undoubtedly contributing to the thermodynamically unstable phenotype that p53-
Y220C exhibits (greater flexibility of proteins is linked to instability).466 These results 
Figure 4.4: Figure 4: (A) Structure of p53-Y220C (PDB: 2J1X) showing the dehydronic Cys220-Thr155 hydrogen 
bond being disrupted by water.448 Reproduced from Ref. 448. (B) Chemical structure of computationally docked 
PK083 analogues.  
A B 
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suggest targeting subsite II, by enhancing rigidity and providing compensation for the 
dehydronic Thr155-Cys220 interaction, is a viable method of improving PK083 affinity 
and potency.  
 
Initial docking results suggest that significant affinity gains can be made by targeting 
subsite II.465 Below, a summary of fragments that bind Y220C, occupying subsite II are 
discussed, and SAR findings are derived. 
 
4.2 Compounds that bind subsite II 
The available SAR around compounds that target subsite II is substantially smaller than 
that for the central cavity and subsite I. The compounds that bind subsite II can be 
classified broadly as (i) fragments that were discovered as part of a high throughput 
screen, and (ii) iodophenols that were rationally designed to target subsite II.179  
 
4.2.1 Fragments 
As previously discussed in Section 2.3, a fragment screen of 1900 chemically diverse 
compounds against T-p53-Y220C, using water LOGSY, thermal denaturation scanning 
fluorimetry and 15N/1H HSQC, identified 252 hits, 87 of which were confirmed.291 Of the 
latter, several aromatic fragments, upon x-ray crystallography studies, were found to bind 
to both the central cavity and subsite II (Figure 4.5A).258 However, in most cases, the 
electron density for the fragment occupying subsite II was lower, indicating partial 
occupancy and lower affinity for subsite II.  
 
For example, fragment 4.1 binds deep in the central cavity, with its hydroxyl group 
forming hydrogen bonds with the backbone C=O of Leu145 as well as a conserved water 
molecule that bridges Asp228 and Val147. The chlorine faces the narrow hydrophobic 
channel that leads to subsite II. Additional hydrogen bonds are formed between the amide 
C=O and the side chain hydroxyl group of Thr150 as well as the amides NH and the 
structural water. The piperidine moiety points to solvent. The second molecule sits in 
subsite II, where its aromatic ring packs against Pro153 and Pro222. The chloro moiety 
points towards Cys220 (Figure 4.5C).258  
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Similar binding is observed for fragment 1.1, in which the fragment occupying the central 
cavity sits deep in the central cavity between Pro223 and Val147, where the ethyl group 
is buried deep in the hydrophobic mutation site. A hydrogen bond is formed between the 
indole NH and the hydroxyl group of Leu 145. Similarly to 4.1, the piperidine moiety of 
1.1 points direct to solvent. The second fragment that occupies subsite II is also engaged 
in hydrophobic interactions with Pro153 and Pro222, with the aromatic core of indole 
packing against them. The NH of indole forms a hydrogen bond with the backbone 
carbonyl of Pro152 (Figure 4.5B).258  
            
4.2.2 Iodophenols 
The iodophenol (hit compound, 1.2) series was discovered from the same fragment 
screen, where the parent compound does not bind subsite II.291 However, in the process 
of hit-to-lead optimization, rational design of compounds that grow the fragment into 
subsite II resulted in marked improvements in affinity (Figure 4.6A).179 The fragment 
Figure 4.5: Structures of fragments that bind p53-
Y220C. (A) Chemical structure of fragments 4.1 and 1.1. 
(B) Structure of 1.1 bound to p53-Y220C (PDB: 5AB9). 
(C) Structure of 4.1bound to p53-Y220C. (B, C) Two 
molecules bind the mutation-induced surface crevice. 
Colour scheme: 1.1 carbons are represented in pink, 4.1 
carbons are represented in cyan. Hydrogen bonds are 
shown as dashed orange lines.  
A B 
C 
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was grown via an acetylene linker, chosen as it possesses the necessary rigidity and 
planarity to bridge the narrow channel formed by Cys220 and Pro151 into subsite II and  
is synthetically easy to install via a Sonogashira coupling reaction. 
 
Compound 4.2b, which bears a propargylic alcohol, showed similar binding affinity to 
the parent compound, where the authors reasoned that this could be attributed to the loss 
of the bulky iodine being compensated by the interactions formed by the new substituent 
(Figure 4.6B). Surprisingly, comparison of the Boc-protected propargylamine 4.2c with 
the free amine 4.2d reveals that greater affinity gains were achieved through the 
introduction of the Boc-protected compound. The additional desolvation penalty 
Compound R ITC KD (µM) 
4.2a -I 105 
4.2b 
 
107 
4.2c 
 
15.5 
4.2d 
 
1080 (NMR) 
4.2e 
 
20.6 
4.2f 
 
9.7 
A B 
C 
D 
Figure 4.6: SAR of iodophenols that target subsite II via 
acetylene groups. (A) Chemical structures and SAR of 4.2. 
(B) Structure of 4.2b bound to p53-Y220C (PDB: 4AGN); 
(C) Structure of 4.2e bound to p53-Y220C (PDB: 4AGP); 
(D) Structure of 4.2f bound to p53-Y220C. Colour scheme: 
Hydrogen bonds are represented as orange dashed lines, 
halogen bonds are represented as purple dashed lines. 
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associated with the highly polar free-amine account for this observation. Introduction of 
substituents 4.2e and 4.2f that bear aromatic moieties resulted in high improvements in 
affinity (Figure 4.6A). 
 
Examination of the structures reveals that, similarly to that observed for fragments 1.1 
and 4.1, favourable CH-π stacking of the phenyl rings against Pro153 occurs (Figure 
4.6C, D). Substitution of the free phenoxy substituent in 4.2e for the aniline substituent 
in 4.2f resulted in the most potent substitution. Examination of the structure of 4.2f bound 
to p53-Y220C reveals that this is due to the formation of a hydrogen bond between the 
aniline NH and the backbone carbonyl of Pro222 (Figure 4.6D).  
   
4.2.3 Summary of SAR of subsite II binding compounds 
From the above results, the compounds that occupy or target subsite II successfully tend 
to be hydrophobic, most commonly aromatic in nature. Affinity gains tend to be achieved 
via preferential CH-π stacking against Pro153, as well as picking up on hydrogen bonding 
interactions with the backbone carbonyls.  
 
4.3 Design of a Key Intermediate for Targeting Subsite II in the PK083 series  
From visual examination of the crystal structure of PK083 bound to p53-Y220C, subsite 
II can be targeted best through growing PK083 at position R3, therefore, the required 
analogues need to possess a 2,6,9 substitution pattern (Figure 4.7A, B).261 Chemically, 
Figure 4.7: (A) Structure of PK083 bound to p53-Y220C (PDB: 2VUK) showing vector R3 for targeting subsite II. (B) 
Generic chemical structure of PK083 analogues to target subsite II.  
A B 
114 
 
direct functionalization of carbazole to yield a 2-substituted framework is not simple. As 
discussed in Section 2.5.1, carbazoles are reactive towards electrophiles at positions 1,3,6 
and 8.338 2-Isomers are rarely obtained. Therefore, the simplest route to 2-substituted 
carbazoles is via construction of the carbazole using a ring-closing synthesis of the types 
described in Section 2.5.2, where the starting material for such a reaction bears a 
substitution pattern that will yield a 2-substituted product.361,467,468  
 
Furthermore, using the SAR established in Section 4.2, the retrosynthetic disconnection 
of the generic structure shown in Figure 4.7B must result in a privileged intermediate that 
allows for the chemistry to install hydrophobic and aromatic compounds. For example, 
by using an aryl bromide intermediate in metal-catalysed cross coupling reactions such 
as the Suzuki Miyaura or Sonogashira reactions, similarly to the approach adapted for the 
iodophenol series (Scheme 4.1).469 
 
  
Scheme 4.1: Retrosynthetic disconnection of a generic PK083 analogue that shows the required regiochemistry to target 
subsite II to a privelged intermediate 4.3. 
Synthetically, 4.3 can be synthesised starting from commercially available 2-
bromocarbazole according to Scheme 4.2. 
Scheme 4.2: Retrosynthesis of 4.3. (a) H2NMe.HCl, Et3N, Ti(OiPr)4, DCM/EtOH, rt 18 h then NaBH4, rt, 8 h; (b) 
POCl3, DMF, Δ; (c) NaH, THF, rt then EtI. 
Starting from 2-bromocarbazole, ethylation under similar conditions, decribed in 
Chapters 2 and 3, yields the intermediate 4.5 that, when subjected to Vilsmeier-Haack 
formylation conditions, should react in the most electron-rich position, which, due to the 
inductive effect of the 2-bromo substitution, should give the 6- isomer as the major 
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product.470 Reductive amination of 4.4 yields the privileged intermediate 4.3 that can be 
used in a variety of reactions to yield a sterically and electronically diverse selection of 
compounds to probe subsite II. Below, a short review of these reactions is presented, 
concentrating on the Suzuki-Miyaura reaction.  
 
4.4 Reactivity of Aromatic Bromides 
C-C bond formation is one of the most popular reactions in the ‘medicinal chemist’s 
toolbox’, accounting for 11.5% of total transformations in a data set constituted of 7315 
reactions and 3566 test compounds described in 139 publications as carried out by 
Roughley and Jordan.471 Of these reactions, the most popular methodologies for 
achieving this transformation included the Suzuki-Miyaura cross-coupling reaction, 
Sonogashira reaction and as well as other palladium-mediated cross-coupling 
reactions.472,473 Consequently, the preparation of privileged intermediates bearing 
functionalities reactive in these reactions, such as aryl bromides, has been of synthetic 
interest to the pharmaceutical chemistry community.   
 
Aryl bromides can be prepared from an aniline using the Sandmeyer reaction (Scheme 
4.3).474 Diazotization of the aniline to form a diazonium salt, followed by subsequent 
attack by a nucleophile under copper catalytic conditions, yields an aryl bromide.  
 
Scheme 4.3: Sandmeyer reaction for formation of an aryl bromide from an aniline via formation of a diazonium salt.(a) 
HBr, NaNO2, 0 °C; (b) CuBr, 60-100 °C. 
Alternatively, an electrophilic aromatic substitution reaction can be used to directly 
halogenate the aromatic ring (Scheme 4.4).475 Typically, a Lewis acid catalyst is required 
to form a more reactive highly electrophilic complex with bromine.  The regiochemical 
outcome can be influenced through the use of a directing group in order to achieve the 
desired substitution pattern. Furthermore, when the directing group is electron-donating, 
a catalyst is not necessary. 
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Scheme 4.4: Electrophilic aromatic bromination of an aromatic ring where R is electron donating. (a) HBr(aq), DMSO, 
EtOAc, 60 °C, 5 min – 8 h. 
However, due to the high chemoselectivity of poly-halogenated aromatic systems in 
palladium-catalysed cross-coupling reactions, as well as their relative inertness to a vast 
array of nucleophilic and electrophilic reaction conditions (exceptions for strong 
nucleophiles), and the wide availability of a large range of halogenated aromatic starting 
materials, installation of the halogen typically occurs through careful selection of starting 
material.  
 
Despite their relative inertness, aryl bromides are undoubtedly synthetically versatile, 
showing reactivity in Grignard reactions, lithium-halogen exchange reactions, benzyne 
formation as well as reactivity towards a wide variety of metal-mediated cross-coupling 
reactions yielding a diverse group of products (Scheme 4.5).469  
 
Scheme 4.5: Examples of different Palladium-catalyzed cross-coupling reactions of aryl bromides. 
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4.4.1 The Suzuki-Miyaura Reaction 
The Suzuki-Miyaura reaction (SM) was first published in 1979 by Akira Suzuki and has 
become of major importance due to the ubiquity of aromatic and heteroaromatic moieties 
in fine chemical intermediates, pharmaceuticals, agrochemicals and new materials.476 The 
success of the reaction can be attributed to the wide availability of starting materials, 
broad tolerance of palladium catalysts towards various functional groups, and the reliable 
reproducibility of the results, even on an industrial scale. Accordingly, Suzuki shared the 
2010 Nobel Prize for Chemistry with Heck and Negishi for the development of 
palladium-catalysed cross-couplings in organic synthesis.  
 
The SM reaction was first exemplified by the hydroboration of an alkyne with a 
catecholborane followed by palladium(0)-catalysed coupling of the resulting vinyl 
boronate with an aromatic iodide or bromide (Scheme 4.6).477 The hydroboration is 
generally regioselective for the less hindered position and addition of boron and hydrogen 
occurs cis-stereospecifically.  
 
Scheme 4.6: First example of a Suzuki-Miyaura palladium-catalysed cross-coupling reaction. 
The SM reaction describes the palladium-catalysed cross-coupling reaction between an 
aryl bromide and an organoboronic acid (Scheme 4.7). However, this can be extended to 
include the coupling of not just aromatic halides by also alkyl, alkenyl and alkynyl halides 
as well as the coupling of some pseudohalides such as triflates.472 Likewise, alternative 
organoboron compounds such as, potassium trifluoroborates, organoboranes, and 
boronate esters such as MIDA boronates further expand the selection of available starting 
materials, where alternative boron reagents either offer superior bench stability or 
enhance reactivity over organoboronic acids.478  
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Scheme 4.7: Suzuki reaction of a boronic acid with an aryl bromide. (a) 2 eq K2CO3(aq), 3 mol% Pd(PPh3)4, benzene, ∆. 
The mechanism of the reaction is believed to operate by oxidative addition of the halide 
to the palladium(0) complex which generates a palladium (II) intermediate. This then 
undergoes transmetallation with the boronate coupling partner, from which the product is 
formed via reductive elimination, regenerating the palladium (0) catalyst (Scheme 4.8).479  
 
Oxidative addition is often the rate-determining step in the catalytic cycle with a relative 
order of reactivity I > OTf > Br >> Cl. Organohalides in proximity to electron-
withdrawing groups are more reactive than those bearing electron-donating groups.472  
 
It is commonly observed that the rate of the transmetallation step is enhanced by the 
addition of base, typically sodium or potassium ethoxide or hydroxide. The reason behind 
this enhancement is commonly disputed. It is attributed to either facilitating the slow 
transmetallation step by formation of a more reactive boronate species that can interact 
with the Pd center and transmetallate in an intramolecular fashion (Scheme 4.8, cycle 
A),480 or, the base may displace the halide in the coordination sphere of the palladium 
complex, facilitatating an intramolecular transmetallation (Scheme 4.8, cycle B).481  
 
Scheme 4.8: General mechanism of the SM reaction. 
Until around 1998, the SM reaction was conducted almost exclusively by employing a 
triarylphosphine ligand. However, more recently the development of alternative ligands 
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has improved the selectivity and efficiency of these reactions (Figure 4.8). For example, 
bulky dialkylbiaryl phosphines,482,483 trialkylphosphine,484 and N-heterocyclic 
carbenes.485  
 
Figure 4.8: Chemical structures of modern ligands for the SM reaction. 
In most cases the exact nature of the catalyst remains ambiguous, varying from a L2Pd0 
species to a highly reactive mono-ligated LPd species, where the L:Pd ratio can play a 
large role in catalytic performance.486 However, in some cases, such as for palladacycle 
catalysts, the active catalyst is thought to be ligand-free palladium(0), where the 
palladacycle serves as a thermally stable source of ligand-free palladium(0), allowing 
harsher conditions and hence the use of cheaper, less reactive substrates.487 The high 
turnover numbers observed were rationalized in terms of a pre-equilibrium forcing the 
reaction away from the formation of palladium black (Scheme 4.9).    
Despite the remarkable synthetic utility of the SM reaction, there remains some coupling 
partners that pose major problems, such as, unactivated aryl chlorides, heteroaromatics 
and more hindered systems.488–490 For example, heterocyclic substrates hinder the SM 
Scheme 4.9: Pre-equilibrium describing the liberation of ligand-free palladium from a palladacycle catalyst. 
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reaction by co-ordination of the heterocycle substrate or product to the metal centre 
resulting in deactivation of the catalyst.491,492 Furthermore, instability and/or poor 
reactivity of some heterocyclic boronic acids leading to side reactions such as proto-
deborylation or oxidative homocoupling or dehalogenation.493 Fortunately, the 
development of new ligands and catalysts has further expanded the scope of coupling 
partners that can be employed in the SM reaction to include some heterocyclic 
substrates.494–498 However,  electron-rich heterocyclic substituents, such as those bearing 
free NH groups, for example pyrazoles or imidazoles, are still not tolerated due to the low 
reactivity of the oxidative addition complex, inhibition of the Pd(II) starting material or 
instability of the starting material leading to decomposition,  for example, via 
dehalogenation (Scheme 4.10).499,500  
 
Scheme 4.10: Proposed dehalogenation of pyrazole. 
 
However, catalyst deactivation and dehalogenation is not observed for heterocycles that 
are functionalized at NH, meaning that by the use of protecting group chemistry, this 
limitation can be overcome.501  
 
4.4.2 Other Palladium-Catalyzed Cross-Coupling Reactions 
Additionally to the SM reaction, aryl bromides are reactive to a plethora of other 
palladium-catalyzed cross-coupling reactions such as, but by no means limited to, the 
Kumada, Negishi, and Stille, which, similarly to the SM reaction, can yield biaryls, as 
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well as the Heck, Sonogashira and Buchwald-Hartwig cross-coupling reactions that yield 
aromatic alkenyl, alkynyl and amines respectively.469  
 
4.4.2.1 The Kumada Reaction 
The Kumada coupling reaction was first reported by Kumada and Corriu independently 
in 1972 and is the palladium or nickel catalysed cross-coupling reaction of an alkyl, vinyl 
or aryl halide and a Grignard reagent to form a new carbon-carbon bond (Scheme 
4.11).502–504 The Kumada coupling was the first example of metal-catalyzed carbon-
carbon bond formation that inspired the development of many related reaction such as the 
SM and the Negishi in the following years.505 
4.4.2.2 The Negishi Reaction 
The Negishi coupling, discovered in 1977, is very closely related to the Kumada coupling 
reaction, as shown in Scheme 4.12.506 The coupling occurs between an organozinc 
compound with an organohalide. The reaction is not restricted to the formation of 
unsymmetrical biaryls and can be extended to the coupling of alkenyl, aryl, allyl, benzyl, 
and propargyl groups and hence is known for its broad functional group tolerance. The 
Scheme 4.11: General Kumada coupling reaction. (A) General reaction scheme for a Kumada coupling (a) Pd(PPh3)4 
or Ni(dppb)Cl2, solvent, ∆. (B) General catalytic cycle for Kumada coupling of an organohalide and a Grignard 
reagent. 
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following reactivity for palladium-catalyzed cross-coupling reactions according to the 
nucleophilic substrate is Zn > Mg > Li where challenging products can be most often 
obtained by the Negishi reaction.507 
            
4.4.2.3 The Stille Reaction 
The Stille coupling is yet another C-C bond forming reaction between stannanes and 
halides or pseudohalides that has, similarly to the Negishi coupling, very few limitations 
of the nature of R groups that can be coupled.508,509 It follows the same general mechanism 
as that depicted in Scheme 4.8, that follows an oxidative addition, transmetallation, 
trans/cis isomerization follow by reductive elimination. The major drawback of the Stille 
reaction is the toxicity of the tin compounds used as well as their poor solubility in 
water.510 Large advances in SM chemistry, associated with development of ligands that 
show higher efficiency and selectivity as well as the introduction of microwave-assisted 
organic synthesis has led to a decline in the use of the Stille reaction as the organoboron 
coupling partners are not toxic and are reasonably soluble in water.  
 
4.4.2.4 The Heck Reaction 
The Mizoroki-Heck (commonly known as Heck) reaction was developed in 1971 and is 
the palladium-catalyzed cross-coupling reaction that occurs between an aryl halide and a 
vinyl halide, pseudohalide or activated halide (such as methyl acrylate) in the presence of 
Scheme 4.12: Relationship between the Kumada reaction and the Suzuki and Negishi reactions. (a) B(OMe)3 then 
H2SO4(aq); (b)  ZnBr2. 
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a base.511,512 The Heck reaction proceeds under mild conditions with excellent trans-
selectivity and is amenable to scale-up procedures.  
 
Scheme 4.13: Catalytic cycle of the Heck reaction.  
The mechanism of the Heck reaction starts by oxidative addition of the aryl halide 
followed by insertion of the vinylic coupling partner to form a Pd-σ intermediate that, 
upon β-hydride elimination forms a π-complex that eliminates product. Base then 
facilitates reformation of catalytically active Pd0 species (Scheme 4.13). 
 
4.4.2.5 The Sonogashira Reaction 
The Sonogashira reaction is the palladium-catalyzed cross-coupling reaction of terminal 
alkynes with aryl or vinyl halides in the presence of a copper co-catalyst and an amine 
base to yield acetylenic compounds.513 The mechanism is not fully understood, with 
confusion arising from the combined action of two metal catalyst, but is widely believed 
to take place through two independent catalytic cycles, corresponding to palladium and 
copper catalysed transformations.514 The palladium-mediated cycle is believed to be 
analogous to the ‘classical’ palladium-mediated cross-coupling reactions, constituting of 
oxidative addition of the organohalide, transmetallation of the acetylenic moiety followed 
by isomerization to allow reductive elimination to yield the product and catalytically 
active Pd0 (Scheme 4.14).515 By contrast, the copper cycle is poorly known. The base is 
believed to assist in copper acetylide formation via a π-alkyne copper complex (similar 
to Heck). The resultant copper acetylide then transmetallates into the palldium cycle 
(Scheme 4.14). However, this has been complicated by the observation of the formation 
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of CuI-polyphosphane adducts, showing that copper-ligand interactions could also be 
likely.516,517 Furthermore, the role of the amine has be theorized to potentially be multi-
faceted, with involvement not only in deprotonation of the alkyne complex but also 
interfering in oxidative addition, resulting in the formation of a more reactive 
[Pd0L(amine)] complex.518  
 
Scheme 4.14: General catalytic cycles for the Sonogashira reaction. 
  
4.4.2.6 The Buchwald-Hartwig Reaction 
The Buchwald-Hartwig reaction uses palladium-mediated, cross-coupling reactions to 
synthesise anilines from aryl halides and amines (Scheme 4.15).519,520 However, this may 
be extended to include the synthesis of ethers by the replacing the amine with a phenol 
providing an alternative to copper-catlayzed Ullmann and Goldberg couplings.521 
Functional group tolerance is higher than for copper-catalyzed methods, allowing the 
coupling of heteroaromatic halides in good to excellent yields.  
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Scheme 4.15: Catalytic Cycle of the Buchwald-Hartwig amination reaction. 
 
 4.4.3 Summary 
In general, aryl bromides are reactive to a wide range of palladium-catalysed cross-
coupling reactions, leading to the formation of new carbon-carbon, carbon-nitrogen or 
carbon-oxygen bonds depending on the conditions employed.  
Hence, by synthesis of the privileged intermediate 4.3, a diversity-oriented synthetic 
strategy can be utilized, to probe the steric and electronic limits of subsite II, seeking 
optimize PK083 analogues toward p53-Y220C. 
 
4.5 Results and Discussion 
4.5.1 Synthesis of Intermediate 4.3 
The synthetic strategy towards intermediate 4.3 is summarized by the retrosynthesis 
described in Scheme 4.16.       
Scheme 4.16: Reterosynthesis of 4.3. (a) H2NMe.HCl, Et3N, Ti(OiPr)4, DCM/EtOH, rt 18 h then NaBH4, rt, 8 h; (b) 
POCl3, DMF, Δ; (c) NaH, THF, rt then CH3CH2I. 
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The ethylation of 2-bromocarbazole yielded 2-bromo-9-ethyl-9H-carbazole in an 
excellent yield. Vilsmeier-Haack formylation of 2-bromo-9-ethyl-9H-carbazole yielded 
two regio-isomeric products, 7-bromo-9-ethyl-9H-carbazole-3-carbaldehyde and 2-
bromo-9-ethyl-9H-carbazole-3-carbaldehyde, where the desired product was the major 
isomer formed.470 Reductive amination with both methylamine and dimethylamine 
yielded 2-bromo PK083 and PK8017 analogues respectively (Scheme 4.17).367 
 
Scheme 4.17: Synthesis of 4.3a and 4.3b. (a) NaH, DMF, rt, 30 min then CH3CH2I; (b) POCl3, DMF, 70 °C 18 h; (c) 
amine.HCl, Et3N, Ti(OiPr)4, DCM/EtOH, rt 18 h then NaBH4, rt, 8 h.  
4.5.2 Synthesis of a trifluoroethylated intermediate 
The two privileged intermediates, 4.3a and 4.3b, constitute the brominated analogues of 
PK083 and PK8017. However, application of this three-step synthesis to the synthesis of 
a 2-bromominated analogue of the most potent PK083 analogue described so far, 
PK9255, that bears an N-trifluoroethylated functionality, was unsuccessful (Scheme 
4.18).  
 
Trifluoroethylation of 2-bromocarbazole according to the procedure established in 
chapter 3 afforded 2-bromo-9-(2,2,2-trifluoroethyl)-9H-carbazole in a moderate yield. 
Vilsmeier-Haack formylation of 2-bromo-9-(2,2,2-trifluoroethyl)-9H-carbazole was 
unsuccessful under a variety of conditions (higher equivalents of Vilsmeier salt and 
microwave conditions) (Scheme 4.18).  
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Scheme 4.18: Attempted synthesis of 4.7. (a) TsOCH2CF3, Cs2CO33, DMF, µwave, 150 °C, 30 min; (b) POCl3, DMF, 
Δ. 
The Vilsmeier-Haack formylation reaction is the reaction between an electron-rich 
aromatic group and the Vilsmeier salt, which, upon work up results in the formation of 
an aldehyde according the mechanism described in Scheme 4.19. 
 
The powerful electron-withdrawing effect of the trifluoroethyl group of 4.6 versus the 
ethyl group of 4.5 may inductively prevent the lone pair of the nitrogen of carbazole from 
delocalizing in the ring to attack the Vilsmeier salt according to the mechanism described 
in Scheme 4.19. 
 
Synthetically this may be overcome by installation of the aldehyde prior to N-
functionalization. This cannot be accomplished simply by Vilsmeier-Haack on 2-
bromocarbazole, as carbazole’s bearing a free NH group have been shown to exhibit a 
Scheme 4.19: Mechanism of Vilsmeier-Haack formylation. 
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preference for N-formylation, conversely to the reactivity exhibited by indole (Section 
2.5.1, Scheme 2.4). Therefore, synthesis of the required intermediate 4.7 may be 
accomplished through reductive cyclization of the biaryl described in Scheme 4.20, which 
in turn can be accessed through the Suzuki-Miyaura reaction of the two commercially 
available starting materials, 4-bromo-1-iodo-2-nitrobenzene and 3-formylphenyl boronic 
acid according to a literature procedure exemplified in Table 4.1.  
 
Scheme 4.20: Possible routes to intermediate 4.8. Red, Vilsmeier-Haack of 2-bromocarbazole (not possible). Blue, 
reductive cyclization of the biaryl 4.9 formed by a Suzuki reaction between the building blocks 4-bromo-1-iodo-2-
nitrobenzene and 3-formyl boronic acid. 
Following the literature conditions established by Chaitanya et al., the nitrobiphenyl was 
obtained in a poor yield (conditions A, Table 4.1).470 Reaction optimization, by variation 
of the catalyst and the conditions, resulted in conditions E, which gave the desired biaryl 
4.9 in an 84% yield. Note, the more reactive C-I bond couples, but not the C-Br. 
 
Reductive cyclization of intermediate 4.9 under classical Cadogan conditions i.e. 
solventless conditions using triethylphosphite, did not yield the desired product under 
reflux or microwave irradiation.357 However, using triphenylphosphine in DMA under 
reflux conditions yielded the product as a mixture of regioisomers (Scheme 4.22).522  
 
Failure of the ‘classical’ reagent, triethyl phosphite, to be effective for the cyclization was 
attributed to the fact that it can react with the aldehyde in a manner similar to dimethyl 
acetal aldehyde protection (Scheme 4.23).  
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Scheme 4.21: Synthesis of 4.9. 
Entry Catalyst Base Solvent 
Conditions  
(°C) 
Yield 4.9 
(%) 
Aa Pd(OAc)2, PPh3 K2CO3 Toluene, H2O 70 6 
B Pd(PPh3)4 K2CO3 Toluene, H2O 70 3 
C Pd(PPh3)4 K2CO3 Toluene, H2O 150 (µwave irradiation) 12 
D Pd(dppf)Cl2.CH2Cl2 K2CO3 Toluene, H2O 70 46 
E Pd(dppf)Cl2.CH2Cl2 K2CO3 Toluene, H2O 90 84 
F Pd-118 K2CO3 Toluene, H2O 70 0 
G Pd-118 K2CO3 Toluene, H2O 25 18 
Table 4.1: Reaction optimization of the Suzuki-Miyaura reaction described in Scheme 0.15. aConditions according to 
Chaitanya et al.470 
 
 
Scheme 4.22: Reductive cyclization of 4.9 (a) P(OEt)3, Δ; (b) PPh3, DMA, 165 °C, 18 h. 
 
Scheme 4.23: Proposed mechanism for reaction of triethyl phosphite with 4.9.  
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Trifluoroethylation of 4.8 yielded the desired product, which, when subjected to reductive 
amination, yielded the intermediate 4.10, that constitutes the 2-bromo analogue of 
PK9255 (Scheme 4.24). 
 
Scheme 4.24: Synthesis of 4.10. (a) TsOCH2CF3, Cs2CO3, DMF, µwave, 150 °C, 30 min; (b) H2NMe.HCl, Ti(OiPr)4, 
NEt3, DCM, EtOH rt 18 h then NaBH4, rt, 8 h. 
 
4.5.3 Synthesis of a small library of intermediates via Cadogan Cyclization 
Advantages of using the Cadogan synthesis, using triphenylphosphine as a reagent, 
include the high functional group tolerance of the substituents around the 
nitrobiphenyl.522 Accordingly, this expands the choice of reactive groups that form 
intermediates that can be used to target subsite II at position R3 (Figure 4.9). Hence, the 
choice of intermediates may be greater expanded in order to further enhance the diversity 
possible by reaction at R3.  
 
The reactive groups at R3 were selected for their differing reactivity versus an aryl 
bromide. Table 4.2 summarizes the expansion of intermediates and their associated 
reactivity that allows for the diverse reactivity at R3.  
 
Figure 4.9: Retrosynthetic disconnection of a generic intermediate to commercially available building blocks. 
R3 X Reaction 
OH (4.19) Br Ullmann ether synthesis, Williamson ether synthesis 
Br (4.8) I Pd-catalyzed cross-coupling reactions, benzyne formation, Grignard and lithiation reactions 
MeO2C (4.12) Br Amide synthesis, nucleophilic substitution reactions 
Table 4.2: Comparison of the nature of the nitro building block at X and R3 and the associated reactivity of the resulting 
carbazole intermediate. 
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 Using the optimized conditions developed in the synthesis of 4.10, the synthesis of 
compounds 4.12 and 4.19 was attempted. 
Scheme 4.25: Synthesis of compound 4.14 via formation of intermediate 4.12. (a) Pd(dppf)Cl2.CH2Cl2, K2CO3, toluene, 
H2O, 90 °C, 1 h; (b) PPh3, DMA, reflux; (c) NaH, DMF, rt, 30 min then CH3CH2I, 18 h; (d) H2NMe.HCl, Ti(OiPr)4, 
NEt3, DCM, EtOH rt 18 h then NaBH4, rt, 8 h. 
The Suzuki-Miyaura cross coupling reaction between 4-bromo-3-nitrobenzoate and 3-
formylphenyl boronic acid yielded the nitrobiphenyl 4.11 in an 85% yield, Reductive 
cyclization yielded the product in a 34% yield as a mixture of regioisomers. Ethylation 
followed by reductive amination yielded the compound 4.14 (Scheme 4.25).  
 
Scheme 4.26: SM reaction of 4-bromo-3-nitrophenol. (a) Pd(dppf)Cl2.CH2Cl2, K2CO3, toluene, H2O, 90 °C. 
Conversely, initial attempts at the synthesis of the phenol intermediate 4.15 were 
unsuccessful. The Suzuki-Miyaura cross-coupling between 4-bromo-3-nitrophenol and 
3-formylphenyl boronic acid was low yielding (37% product formation) and led to an 
inseparable complex mixture of products (Scheme 4.26). Phenols are reactive in metal-
catalyzed cross-coupling reactions, for example, the Chan-Lam (phenol and boronic acid) 
and Ullmann diaryl ether synthesis (phenol and bromide). Protection of the phenol to a 
tert-butyldimethylsilyl ether 4.17 limited the side reaction and yielded a silyl protected 
biaryl 4.08 as well as the unprotected phenol biaryl 4.15 (Scheme 4.27). Cleavage of the 
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silyl ether is postulated to occur thermolytically after the completion of the Suzuki 
reaction upon sustained heating (overnight).  
 
Scheme 4.27: Silyl protection of 4-bromo-3-nitrophenol. (a) TBDMSCl, Et3N, DCM, 0 – 20 °C (b) 
Pd(dppf)Cl2.CH2Cl2, K2CO3, toluene, H2O, 90 °C; (c) TBAF, THF, 0 °C – rt, 20 min. 
Reductive cyclization of both 4.18 and 4.15 afforded the carbazole 4.19, where 
desilylation was proposed to occur thermolytically under the reductive cyclization 
conditions. Chemoselective N-ethylation was attempted, using conditions reported for 
ethylation of 2-hydroxycarbzole, however, these conditions failed to yield the desired N-
ethylated free phenolic product, favouring the diethylated carbazole 4.20 (Scheme 4.28).  
 
Scheme 4.28: Reductive cyclization of 4.15 and 4.18 yields 4.19. (a) PPh3, DMA, reflux; (b) NaH, DMF, THF, rt, 10 
min, then CH3CH2I, THF, dropwise.  
Whilst protection of the phenol to a silyl ether provides an adequate solution for 
increasing the yield of 4.15, it does not offer a solution for the lack of chemoselectivity 
in the synthesis of 4.20 due to thermolytic cleavage of the silyl ether under the harsh 
conditions required for reduction cyclization. Thus, a more thermally stable, robust 
benzyl protecting group was tested for its amenability to these optimized conditions 
(Scheme 4.29). 
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Scheme 4.29: Synthesis of a benzyl ether. (a) BnBr, NaH, DMF, rt; (b) Pd(dppf)Cl2.CH2Cl2, K2CO3, toluene, H2O, 90 
°C; (c) PPh3, DMA, reflux; (d) NaH, DMF, rt, 30 min then CH3CH2I; (e) Pd/C, H2, THF, rt. 
Whilst this strategy was both effective at minimizing side products in the Suzuki reaction, 
and circumventing chemoselectivity problems, the harsh deprotection conditions led to 
reduction of the aldehyde to a tolyl group. 
 
One method of circumventing this is to use early stage functionalization, i.e. installation 
of the subsite II group, through either a Williamson ether synthesis of Ullmann diaryl 
ether synthesis of the biaryl phenol intermediate 4.15. This technique overcomes the lack 
of chemoselectivity in the attempted ethylation of 4.23 by installing the desired subsite II 
targeting group earlier in the synthesis before reductive cyclization (Scheme 4.30). 
 
Scheme 4.30: Comparison of early-stage and late-stage funcitonalization techniques. 
Ullmann coupling of biaryl 4.15 proceeded in a good yield to yield the early-stage 
functionalized pyridine ether 4.25, which, upon reductive cyclization yielded the 
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carbazole 4.26. N-Ethylation, followed by reductive amination, yielded the final product 
4.28 (Scheme 4.31). 
 
 
Scheme 4.31: Synthesis of ether product 4.28 by early-stage functionalization of intermediate 4.15. (a) 2-
Bromopyridine, 2-picolinic acid, Cu(I)I, K3PO4, DMSO, 100 °C, 3 h; (b) PPh3, DMA, reflux; (c) NaH, DMF, rt, 30 
min then CH3CH2I; (d) H2NMe.HCl, Ti(OiPr)4, NEt3, DCM, EtOH rt 18 h then NaBH4, rt, 8 h. 
From the above reactions, a small library of late-stage and one early stage intermediate 
was synthesised that allow diversification at position R3 to target subsite II (Figure 4.10). 
 
 
Figure 4.10: Summary of synthesised intermediates for either early or late stage functionalization. 
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4.5.4. Initial Diversification  
Using the intermediates depicted in Figure 4.10, reaction conditions towards the 
generation of a structurally diverse library were sought. Late-stage intermediates were 
prioritized due to their amenability towards rapid library generation over early-stage 
diversification that is hindered by and bottlenecks such as repetitive chemistry, work-ups 
and purifications. 
 
The reactivity of aryl bromides is summarized in Section 4.4, and includes a wide range 
of metal-catalyzed cross-coupling reactions as well as Grignard or lithiation chemistry. 
Initial attempts to use intermediate 4.3b in a lithiation and Grignard reaction, under a 
range of conditions, to afford product 4.29 were unsuccessful (Scheme 4.32).  
 
Scheme 4.32: Initial attempt at late-stage diversification of 4.3b through Grignard and lithiation chemistry. (a) Mg, I2, 
THF then 1-trityl-1H-imidazole-2-carbaldehyde, THF; (b) iPrMgCl.LiCl, THF, -40 °C then 1-trityl-1H-imidazole-2-
carbaldehyde, THF, rt; (c) nBuLi, -78 °C, THF, 30 min then 1-trityl-1H-imidazole-2-carbaldehyde, THF, -78 °C – rt.  
Both the ‘classical’ Grignard and turbo-Grignard (iPrMgCl.LiCl) conditions failed to 
initiate, resulting in full recovery of starting material.523 Lithiation of 4.3b with nBuLi at 
-78 °C in THF followed by nucleophilic attack of the organo-lithiate with the aldehyde 
of 1-trityl-1H-imidazole-2-carbaldehyde led to an inseparable mixture (Scheme 4.32). 
The complexity of the latter was presumably due to competition with chelation-controlled 
ortho-lithiation assisted by the benzylic amine.  
 
The unsuccessful attempts at utilizing intermediate 4.3b in Grignard and lithiation 
chemistry led to the exploration of 4.4’s reactivity toward metal-mediated cross-coupling 
reactions. Using intermediate 4.4, which possesses an aldehyde rather than the benzylic 
amine of 4.3, simplifies the purification of the amine product.  
 
The SM cross-coupling reaction between intermediate 4.4 and heterocyclic-2-boronic 
acid’s, according to the procedure established by Moseley et al., yielded intermediates 
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4.30a and 4.30b in a 57 and 56% yield respectively. Reductive amination yielded the final 
products 4.31a and 4.31b (12%, 46% yields respectively) (Scheme 4.33). 
 
Scheme 4.33: Diversification of 4.4 using a SM reaction with heterocyclic boronic acids. (a) thiophene-2-boronic acid 
or furan-2-boronic acid, Pd-118, K2CO3, MeCN, 90 °C, 2 h; (b) H2NMe, NaBH(OAc)3, THF, rt. 
The SM reaction was also conducted under aqueous conditions and gave similar results. 
Pd-118, a highly active ferrocenyl phosphine palladium precatalyst, t that is commonly 
used to couple unactivated aryl chlorides, is sufficient to couple the electron-rich 
heteroaromatic boronic acids. The advantage of using  Pd-118 over Pd(NHC) complexes 
is its superior stability to oxygen and water, whilst still being very active in SM 
reactions.524  
 
Similarly to that conducted for aryl bromides, reaction conditions were sought with which 
to synthesise a diverse library based on the methyl ester intermediate 4.13. Methyl esters 
are reactive to a plethora of reactions, such as amide couplings (via carboxylic acid) and 
nucleophilic substitution reactions. Synthesis of the related carboxylic acid was 
accomplished through base hydrolysis in a quantitative yield. Amide coupling using 
HATU as a coupling reagent yielded the simple amides 4.33a and b, after which, 
reductive amination yielded the final products 4.34a and b (Scheme 4.34).  
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Scheme 4.34: Development of conditions for an amide coupled library. (a) LiOH, MeOH, H2O, 90 °C, 2 h; (b) HNMeR, 
HATU, NEt3, DMF, rt; (c) H2NMe.HCl, Ti(OiPr)4, NEt3, DCM, EtOH rt 18 h then NaBH4, rt, 8 h. 
In both cases, for the SM library and amide library, only two simple final products were 
synthesised, as the feasibility of perusing each library of compounds was intended to be 
established, through SAR, before the synthesis of many diverse examples, i.e. is an amide 
linker tolerated in the narrow gap that bridges the central cavity and subsite II? 
 
4.5.5 Initial Subsite II SAR  
The synthesised products, from the SM library and amide library optimization, as well as 
all late stage intermediates, were assessed for their effect on the p53-Y220C DNA-
binding domain using differential scanning fluorimetry as an initial assay. Any 
compounds that showed a marked improvement were reconfirmed, and their dissociation 
constants determined, using isothermal scanning calorimetry (Table 4.3).§ Correlation 
between the two assays was good, showing a negative correlation of -0.84.  
Compound 
ID 
Structurea 
DSF 
TM 
[250 
uM] 
ITC 
KD 
[uM] 
Compound 
ID 
Structurea 
DSF 
TM 
[250 
uM] 
ITC 
KD 
[uM] 
PK083 
 
1.1 124 
PK9286 
(4.34a) 
 
0.9 - 
PK9318 
(4.31a) 
 
3.6 
3.3 ± 
0.3 
PK9287 
(4.34b) 
 
0.2 - 
                                               
§ All biophysical assays were performed at the LMB by Dr Matthias Bauer. 
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Compound 
ID 
Structurea 
DSF 
TM 
[250 
uM] 
ITC 
KD 
[uM] 
Compound 
ID 
Structurea 
DSF 
TM 
[250 
uM] 
ITC 
KD 
[uM] 
PK9320 
(4.31b) 
 
3.7 
2.8 ± 
0.7 
PK9288 
(4.14) 
 
2.6 - 
PK9255 
(3.61) 
 
1.4 
35 ± 
2.6 
PK9295 
(4.35) 
 
1.3 
62 ± 
6.5 
PK9284 
(4.3a) 
 
3.0 
14.2 
± 2.0  
PK9296 
(4.36) 
 
1.9 - 
PK9285 
(4.3b) 
 
2.9 - 
PK9304 
(4.28) 
 
-0.6 - 
PK9301 
(4.10) 
 
3.7 5.9      
Table 4.3: Initial SAR of synthesised PK083 analogues that target subsite II. a All compounds were assayed as the 
amine.HCl salt to aid aqueous solubility. DSF and ITC assay conditions are described in Chapter 6. Correlation between 
DSF stabilization and ITC dissociation constant = -0.84. 
Generally, most compounds summarized in Table 4.3 show increased stabilization of the 
p53-Y220C DNA binding domain over PK083, except in the case of the amides and 
pyridine ether. This is reasoned to be due to the increased steric bulk in direct proximity 
to the central carbazole ring clashing with the narrow gap that bridges the central cavity 
and subsite II. 
 
The largest improvements in affinity occur when R3 is heterocyclic or a bromide. 
Furthermore, the subsite II analogue of PK9255, PK9301, where R3 is a bromide showed 
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an additive improvement in affinity. The binding modes of PK9284, PK9318 and PK9320 
were determined by x-ray crystallography (Figure 4.11).**  
 
For all three cases, there were two molecules in the asymmetric unit (corresponding to 
chains A and B). In all cases, electron density corresponding to the ligand was detected 
in both chains, where the ligand binding modes were identical. However, for PK083, 
electron density of the ligand was higher in chain B, hence, to draw comparisons with 
PK083, all numbers refer to chain B.  
 
The binding mode of all three subsite II targeting carbazoles were almost identical to 
PK083, where the benzylic amine forms a hydrogen bond with the backbone C=O of 
Asp228. A slight shift of the carbazole in PK9318 and PK9320 compared to PK083 was 
observed in order to accommodate the 5-membered ring in subsite II (Figure 4.11). 
 
 Binding affinity can be dissected into two components, enthalpic and entropic. 
Contributions that are enthalpic arise from specific molecular interactions, whereas, 
entropic binding arises from nonspecific interactions, such as hydrophobic interactions 
and Van der Waals. In all three cases, the observed increase in binding affinity cannot be 
ascribed to any newly formed specific ligand-protein interaction so the increase in affinity 
is attributed to entropic gains. In the case of PK9284, substitution of the (ar)C-H for an 
aryl bromide can be viewed as affecting two properties, steric bulk and lipophilicity, 
where affinity gains arise from hydrophobic interactions with the lipophilic subsite II (See 
Section 3.1.4.1 for review of hydrophobic interactions).  
 
The structures of PK9318 and PK9320 are virtually identical. Incorporation of the 
heterocyclic ring results in a shift of the Cys220 backbone carbonyl as well as a flip of 
Glu221 in order to accommodate the heteroaromatic moiety. For PK9318, an observed 
sulfur-sulfur contact of 3.7 Å occurs. Similarly to PK9284, increases in binding affinity 
can be attributed to hydrophobic interactions between the aromatic ring and the 
hydrophobic interaction surface of subsite II (Figure 4.11).    
       
                                               
** X-ray crystallography was carried out by Dr Andreas Joerger at LMB. 
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However, close examination of the structures of PK9318 and PK9320 reveals that the 
heterocyclic ring sub-optimally occupies subsite II, hence, binding affinity may be 
increased by extension of the aromatic ring (Figure 4.11). Furthermore, the cLogP of 
these compounds is very high which, in combination with the most potent substitution at 
position R (trifluoroethyl), as accomplished in PK9301,  results in a dramatic decrease in 
aqueous solubility (Table 4.4). Hence, further optimization of the heterocyclic ring should 
seek to (i) modulate the lipophilicity toward more soluble compounds and (ii) establish 
the steric limits by synthesis of bulkier heterocycles. 
 
Figure 4.11: Co-crystal structure of PK9284 (A, pink), PK9318 (C, cyan) and PK9320 (E, green) bound to p53-Y220C 
determined at a resolution of 1.55, 1.24 and 1.32 Å respectively. (B) Comparison of PK9284 with PK083 (yellow), 
PK9318 with PK083 (D) and PK9318 and PK9320 (F). Hydrogen bonds are shown in orange dashed lines. 
A 
F E 
D 
B 
C 
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Compound 
ID 
Structure 
ITC 
Kd 
(µM) 
cLogP 
Compound 
ID 
Structure ITC 
Kd 
(µM) 
cLogP 
PK083 
 
124 3.23 PK9318 
 
3.3 4.65 
PK9284 
 
14.2 4.00 PK9320 
 
2.8 3.94 
PK9301 
 
5.9 4.60 
    
Table 4.4: cLogP of highlighted subsite II targeting compounds that show higher potency toward p53-Y220C. 
Calculations were performed using logP prediction in MarvinSketch 14.8.25.0. 
 
Figure 4.12: Strategies in optimization of the heterocyclic ring. 
4.5.6 Optimization of Heterocyclic ring 
Optimization of the heterocyclic ring, as outlined in Figure 4.12, was conducted firstly 
by establishing the most potent heterocyclic substitution and secondly, through 
exploration of the steric and electronic limits.  
 
In order to expand the choice of heterocyclic coupling partners, (limited availability of 
heterocyclic boronic acids compared with heterocyclic bromides), the intermediate 4.37 
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was synthesised from 4.4 using a Miyaura borylation reaction in an excellent yield 
(Scheme 4.35). 
. 
Scheme 4.35: Miyaura borylation of 4.4. (a) (BPin)2, Pd(dppf)Cl2.CH2Cl2, KOAc, 1,4-dioxane, 80 °C, 1h  
In the case that the desired heterocyclic coupling partner was not commercially available, 
e.g. 5-bromo-2,3-thiophene, bromination was carried out using the conditions 
summarized in Scheme 4.36. 
 
Scheme 4.36: Bromination of methyl-thiophenes. (a) NBS, DCM, rt, 18 h. 
Using the optimized procedure outlined in Scheme 4.33, a number of different 
heterocyclic products were synthesised in varying yields (Table 4.5). In general, coupling 
of all unprotonated heterocycles (thiazole, furan, thiophene, isoxazole) proceeded in good 
yields. Coupling of protonated heterocycles, such as pyrazole, was unsuccessful and led 
to recovery of starting material. As outlined in Scheme 4.10, unprotected protonated 
heterocycles can undergo side reactions / cause inactivation of the catalyst. This problem 
can be circumvented by coupling the N-H protected analogues. Coupling of N-boc-
pyrazole-4-boronic acid pinacol ester with intermediate 4.30h, which upon reductive 
amination yielded the desired final product 4.31h after treatment with HCl to both 
deprotect and synthesise the amine hydrochloride salt.  
  
Scheme 4.37: Generic scheme for the synthesis of subsite II heterocycles. (a) Het-R1, K2CO3, Pd-118, MeCN, H2O, 90 
°C; (b) H2NMe, NaBH(OAc)2, THF, rt. 
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Step A Step B 
Compound R Het-R1 Yield (%) Compound Het Yield (%) 
4.30c 
Br 
 
74 
4.31c 
 
22 
4.30d 
Br 
 
59 
4.31d 
 
61 
4.30e 
BPin 
 
99 
4.31e 
 
48 
4.30f 
BPin 
 
30 
4.31f 
 
10 
4.30g 
Br 
 
49 
4.31g 
 
18 
4.30h 
Br 
 
16 
4.31h 
 
29 
4.30i 
Br 
 
46 
4.31i 
 
quant 
4.30j 
Br 
 
38 
4.31j 
 43 
4.30k 
Br 
 
90 
4.31k 
 
28 
4.30l 
BPin 
 
75 
4.31l 
 
39 
4.30m 
BPin 
 
46 
4.31m 
 
47 
4.30n 
BPin 
 
88 
4.31n 
 
14 
4.30o 
BPin 
 
70 
4.31o 
 
19 
Table 4.5: Subsite II heterocycle library synthesis. 
In the case of 4.30o, where the coupling partner contained a benzylic alcohol, the reaction 
led to a complicated mixture of products. Protection of the alcohol as a silyl ether limited 
side-reactivity and resulted in the formation of the desired product. Reductive amination 
followed by silyl ether deprotection yielded the final product 4.31o. 
 
Scheme 4.38: Sily protection of a benyl alcohol functionalized thiophene. (a) TBDMSCl, Et3N, DCM, 0 °C to rt. 
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4.5.7 SAR of Heterocyclic Optimization 
Compounds 4.31c-o were assayed, using the same standard procedure as described 
previously, against p53-Y220C using DSF as a primary screen and ITC to validate hits. 
Correlation between the two assays was good, showing a negative correlation of -0.85.†† 
Compound 
ID 
Structurea 
DSF 
TM 
[250 
uM] 
ITC 
KD 
[uM] 
Compound 
ID 
Structurea 
DSF 
TM 
[250 
uM] 
ITC 
KD 
[uM] 
PK083 
 
1.1 124 
PK9322 
(4.31f) 
 
3.0 
8.3 ± 
2.6 
PK9255 
(3.61) 
 
1.4 
35 ± 
2.6 
PK9325 
(4.31o) 
 
1.9 - 
PK9318 
(4.31a) 
 
3.6 
3.3 ± 
0.3 
PK9324 
(4.31g) 
 
1.8 - 
PK9320 
(4.31b) 
 
3.7 
2.8 ± 
0.7 
PK9326 
(4.31h) 
 
0.8 - 
PK9323 
(4.31e) 
 
3.4 
3.9 ± 
0.4 
PK9319 
(4.31c) 
 
0.5 - 
PK9321 
(4.31d) 
 
3.2 
5.6 ± 
1.1 
PK9305 
(4.31i) 
 
0.3 - 
                                               
†† DSF and ITC data were determined by Dr Matthias Bauer. 
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Compound 
ID 
Structurea 
DSF 
TM 
[250 
uM] 
ITC 
KD 
[uM] 
Compound 
ID 
Structurea 
DSF 
TM 
[250 
uM] 
ITC 
KD 
[uM] 
PK9327 
(4.31j) 
 
3.1 - 
PK9328 
(4.31l) 
 
3.3 
1.8 ± 
0.7 
PK9331 
(4.31k) 
 
1.7 - 
PK9329 
(4.31m) 
 
0.1 - 
PK9332 
(4.31l) 
 
2.4 -     
Table 4.6: SAR of subsite II heterocyclic group scan. aCompounds were assayed as the amine.HCl salt to aid aqueous 
solubility. DSF and ITC assay conditions are described in Chapter 6. Correlation between DSF stabilization and ITC 
dissociation constant = -0.84.  
The DSF and ITC data summarized in Table 4.6 reveal that, by varying the heterocyclic 
ring, no substantial improvements of PK9318 and K9320 were made. The regio-isomeric 
3-furan and 3-thiophene substitutions both resulted in a reduction in affinity. 
Interestingly, the 3-thiophenic substitution resulted in loss of binding whereas 3-furan 
retained activity (5.6 µM). PK9323 and PK9322, which correspond to 4-thiazole and 2-
thiazole substitutions respectively, are both potent binders (3.9 and 8.3 µM respectively), 
albeit slightly less potent than PK9318 and PK9320. Attempts to modulate the cLogP 
through introduction of more ‘polar’ heterocycles, for example, 4-pyrazole (PK9326) 
were unsuccessful, further reinforcing that lipophilic substitutions are most potent in 
subsite II. Furthermore, 6-membered heterocycles were not tolerated in the subsite II 
position, as exemplified by PK9305. Therefore, attempts to further increase affinity 
through functionalization of the heterocyclic ring were conducted using the 2-thiophenic 
building blocks owing to the fact that PK9318 is one of the most potent analogues and 
the desired building blocks were easy to obtain commercially or via a one-step 
bromination reaction (Scheme 4.36). 
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A chlorinated-thiophene in position-5 led to a reduction in affinity compared to 5-methyl 
(PK9327) indicating an upper lipophilicity threshold for subsite II substitutions.  
Introduction of a methyl group (PK9331) and benzylic alcohol (PK9325) at position 3-
were generally not well tolerated, resulting in a reduction of stabilization by DSF, 
indicating that sterically-hindered substituentsat this position are not favoured. 
 
Methylation of the thiophene ring in either the 4- or 5- position led to an improvement in 
affinity, for example, 4-methyl thiophene (PK9328) exhibited a dissociation constant of 
1.8 µM. However, methylation of both positions 4,5- (PK9329) resulted in loss of 
binding.  
 
The structures of PK9327 and PK9328 bound to p53-Y220C were solved in order to 
provide structural reasoning for the differences in potency between the di-methylated 
PK9329 and the mono-methylated PK9327 and PK9328 (Figure 4.13).‡‡ Comparison of 
binding modes of PK9327 and PK9328 with PK9318 reveals that the carbazole core 
adopts a virtually identical position in the central cavity between Val147, Pro223, Pro222 
and Pro151. In both cases the benzylic amine forms a hydrogen bond between the N-H 
and the backbone carbonyl of Asp228 (Figure 4.13C, D). Comparison of a 4-methyl 
thiophene (PK9328) with thiophene (PK9318) substituent reveals that, in order to 
accommodate the methyl substituent, the thiophene ring rotates 15° relative to carbazole, 
away from the hydrophobic interaction surface formed by Pro152, Pro153, departing 
from the coplanar geometry exhibited in PK9318 (Figure 4.13A). Comparison of 5-
methyl thiophene (PK9327) with PK9318 reveals that, similarly to PK9328, the thiophene 
ring rotates in order to accommodate the methyl substituent, however, this time toward 
the hydrophobic interaction surface causing the side-chain of Glu221 (E221) to flip 
(Figure 4.13B, F).  
 
Examination of the structures of PK9327 and PK9328 reveals that 4,5-methyl substitution 
cannot be tolerated as it would cause a steric clash either with the backbone carbonyl of 
Cys220 or Pro152 (Figure 4.13E).   
                                               
‡‡ The crystallography was carried out by Dr Andreas Joerger, LMB. 
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Figure 4.13: Structures of PK9327 and PK9328 bound to p53-Y220C. Structures of the binding modes of PK9328 (A, 
1.32 Å resolution) and PK9327 (B, 1.25 Å resolution) compared to PK9318. Structures of PK9328 (C) and PK9327 (D) 
bound to p53-Y220C. Comparison of the binding modes of PK9327 and PK9328 (E) and highlighted induced E221 flip 
(F). Colour scheme: hydrogen bonds are represented as orange dashed lines. 
C 
E 
A B 
F 
D 
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4.5.8 Cell-Based Assays 
Previously, identification of p53-activating compounds by using antibody and cell-based 
assays has resulted in false positives, where apparent p53 reactivation of mutants has later 
been attributed to the more general effects of cytotoxicity (such as DNA intercalators), or 
more specific effects that manifest themselves as p53 reactivation. 
 
The results presented in this thesis so far present the optimization of PK083 analogues 
towards the p53-Y220C mutation-induced pocket, seeking to increase affinity using 
biophysical techniques such as ITC or 15N/1H HSQC as an assessment for compound 
potency. Whilst this, in combination with crystallography studies, confirms that PK083 
analogues bind the mutation-induced pocket, they fail to establish whether the optimized 
compounds show Y220C specificity, manifesting as upregulation of p53 target genes in 
cell-based assays, or inhibit p53 aggregation. The utilization of these two techniques 
(biophysical and cell-based) in parallel helps to establish the most potent, selective 
compounds towards a lead compound optimized using a multi-parameter approach.  
 
4.5.8.1 Cell Viability 
 Cell viability assays measure the ability of cells to maintain or recover viability where 
viability ranks on an index between 0 and 1 corresponding to cell life and death. Hence, 
cell viability can provide insight into compound toxicity. Furthermore, in the case of p53, 
by comparison of cell viability in cell lines that display a Y220C mutation and wt-p53 
cell lines, the selectivity of compounds can be crudely established.  
 
Figure 4.14 describes the viability of a wt-p53 cell line, NUGC-4 versus viability of a 
gastric adenocarcinoma cell line that carries a Y220C mutation, NUGC-3 upon treatment 
with PK9318, PK9320, PK9323 and PK9328.§§ Generally, all compounds appear to cause 
cell death at 20 µM in a non-specific manner, indicating compound toxicity. This pattern 
is observed at a ligand concentration of 10 µM for PK9318, PK9320 and PK9328. 
However, PK9323 appears to show some Y220C selectivity, with almost complete cell 
death of Y220C cells vs 40% viability of the wild-type associated cell-line. At 3 µM, this 
                                               
§§ Cell viability assays were carried out by Dr Matthias Bauer. 
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Y220C-specific effect is further exemplified, with p53-Y220C cell-lines retaining 40% 
viability versus 85% viability for the wild-type associated cell-line.  
 
Figure 4.14: Cell Viability of PK9318, PK9320, PK9323 and PK9328. 
In summary, the cell viability assays indicate that the subsite II heterocyclic compounds 
all show behaviour indicative of inherent non-specific toxicity at higher concentrations, 
with only PK9323 exhibiting Y220C specific effects at lower concentrations. 
Speculatively, the toxicity of the carbazole series may be due to:  
i) Genotoxicity related to DNA-intercalation owing to the planar structure of 
PK083 and analogues. N.B. Carbazoles constitute a commonly used motif for 
the design of cytotoxic agents.525 
ii) Formation of reactive decomposition products arising from loss of benzylic 
amine that is assisted by the carbazole lone pair. Commonly observed by mass 
spectrometry (Scheme 4.39). 
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Scheme 4.39: Postulated formation of a reactive decomposition product of PK083. 
 
4.5.8.2 Initial Compound PK Properties 
Additionally to cell viability, some pharmokinetic properties of PK9318, PK9320 and 
PK9323 were determined (Table 4.7).***Assays such as microsomal stability, plasma 
protein binding, and HepG2 cytotoxicity, aimed at assessing and predicting PK083 
analogues metabolic liability, in vivo hepatic clearance, bioavailability, preponderance 
towards hERG inhibition, and toxicity were conducted to provide results with which to 
inform future compound design. Below, desirable PK083 analogue ADME and toxicity 
parameters are outlined. 
 
i) Microsomal turnover (human/rat) to assess metabolic liability, to predict in 
vivo hepatic clearance, looking for low intrinsic clearance values (<2 
µg/min/mg protein). 
ii) Plasma protein binding to assess unbound (bioavailable) drug: desirable 
<95%; undesirable high binding (>95%). High plasma protein binding is 
indicative of low bioavailability (lower concentration of drug in bloodstream 
as bound to plasma proteins) and a high preponderance towards hERG/toxic 
effects (via inhibition of the hERG K+channel, where SAR indicates 
hydrophobic or cationic moieties as toxicophores within drugs).526  
iii) HepG2 Cytotoxicity to assess off-target toxicity. Desirable EC50 (HepG2) > > 
EC50 (p53-Y220C) to ensure compounds has a therapeutic rather than toxic 
effect.    
                                               
*** Assays were carried out at Selcia Ltd.,by Dr Martin Walker 
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The microsomal stability assay assesses metabolic stability using microsomes obtained 
by homogenization of a liver followed by centrifugation of the homogenate to yield a 
supernatant fraction (S9 or S10). A microsomal pellet is then prepared by centrifugation 
of the S9 or S10 fraction and contains the smooth endoplasmic reticulum where the 
enzymes responsible for phase I oxidation, including the cytochrome P450 
monooxygenases, reside. With the exception of uridine 5’-diphospho-
glucuronosyltransferase (UGT), most phase II enzymes are cytosolic are, therefore, 
absent from liver microsomes. Microsomes are supplemented with the cofactor NADPH. 
With the exception of PK9320, the subsite II substitution generally increases microsomal 
stability from a half-life of 45 minutes for PK083 to 61 minutes and 74 minutes for 
PK9318 and PK9323 respectively. In all most cases, except for PK9323, degradation of 
compound was related to CYP450 metabolism, however, degradation of PK9323 in the 
Compound Structure Microsome Stabilitya 
Plasma Protein 
Bindingb 
HepG2 Cytotoxicity 
  
T1/2 
(min) 
Intrinsic 
Clearance 
(µg/min/mg 
protein) 
% 
unbound 
% 
Bound 
EC50 
(µM) 
% inhibition at 
top 
concentrationc 
PK083 
 
45.6 30 9.0 91.0 23.0 100.0 
PK9318 
 
61.6 22 0.0 100.0 3.5 99.9 
PK9320 
 
24.8 56 0.2 99.8 4.8 100.1 
PK9323 
 
74.9 18.5 3.0 97.0 1.1 100.0 
Table 4.7: Pharmacokinetic properites of PK083, PK9318, PK9320 and PK9323. aThe species used was mouse. The 
assay contained 0.20% DMSO and 5 µM compound f/c. bThe species used was mouse. The assay contained 10 µM 
compound and 0.1% DMSO f/c.  cTop concentration of 100 µM. Colour scheme: yellow, medium; red, high. 
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NADPH sample was similar to the +NADPH sample, suggesting non-CYP450 
metabolism (Figure 4.15). 
          
Another helpful parameter that can be determined that aids in estimating oral 
bioavailability is plasma protein binding. Human serum albumin (HAS) is the most 
prominent protein in plasma and binds different classes of ligands at different sites, for 
example, bulky heterocyclic anions bind to Sudlow’s site I, whereas, aromatic 
carboxylates Sudlow’s site II.527  HSA provides a depot for many compounds, where the 
extent to which compounds are bound can adversely affect the pharmokinetics and 
pharmodynamics of drugs. The subsite II modifications of PK9318, PK9320 and PK9323 
adversely affect plasma protein binding compared to PK083, with 91% bound versus 100, 
99.8 and 97% respectively.  
 
Inhibition of HepG2 is commonly used to identify cytotoxic compounds. Results of the 
HepG2 inhibition assay further reinforce the observed off-target toxicity observed in the 
cell viability data, where all compounds showed enhanced toxicity over PK083.  
 
4.5.8.3 H2AX Phosphorylation Assay  
In order to further elucidate the potential underlying mechanism/s behind the observed 
non-specific off-target effects that the compounds exhibited in the cell viability assay, as 
Figure 4.15 Mouse microsomal stability. 
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well as the observed cytotoxicity identified by the HepG2 assay, a histone H2AX 
phosphorylation assay was conducted. In response to ionizing radiation or DNA-
damaging chemotherapeutic agents, double-stranded breaks (DSBs) are generated that 
rapidly result in the phosphorylation of histone H2A variant H2AX. Because 
phosphorylation of H2AX at Ser139 (γ-H2AX) is abundant, fast and correlates with 
DSBs, it is the most sensitive marker for identification of DNA damage and the 
subsequent repair. Therefore, it is commonly used to identify compounds that are 
genotoxic. 528          
Figure 4.16: H2AX phosphorylation assay. Experiment. Cells (MCF7 breast cancer) plated in triplicate in 12-well dish 
– 100,000 cells/well. Cells were allowed to settle for 2d, then treated with the indicated concentration of compound. 
After 20 h, the cells were lysed with 1X SDS-loading buffer, heated to 95 °C for 5 min, sonicated, clarified by 
centrifugation (13 KRPM, 10 min), and proteins separated by SDS-PAGE. Proteins were then transferred to PVDF 
membrane and blotted with the indicated mouse derived antibody. Goat derived, anti-mouse HRP-conjugated antibody 
(DAKO) was used as a secondary antibody for luminescent detection of proteins using ImageQuant. 
 
Compounds PK083, PK9320 and PK9323 were tested for their genotoxicity using the 
H2AX phosphorylation described in .†††PK083 and PK9320 do not induce DNA damage, 
                                               
††† Assay was carried out by Dr Cory Ocasio.  
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however, PK9320 showed a great deal of cytotoxicity as Tubulin levels decrease 
dramatically, indicating cell death or inhibition of cell growth (unpublished results, 
Tony). Paradoxically, PK9323 was identified as highly genotoxic, with an EC50 of 2.2 
µM, out-performing Cisplatin (EC50 = 4 µM). By comparison with cell viability results 
that show PK9323 had a Y220C specific effect at 10 µM, which is associated with a 
reduction in off-target toxicity compared the other compounds, the H2AX 
phosphorylation assay show it is the most genotoxic. Efforts are ongoing to attempt to 
rationalize this observation by elucidation of the toxicity mechanism(s) to inform 
subsequent compound design.       
                         
4.6 Conclusions 
Targeting subsite II for affinity gains through functionalization of R3 of the generic 
carbazole based on PK083 represented in Figure 4.1 proved successful. Synthesis of a 2-
brominated PK083 analogue, 4.44, via a two-step synthesis, provided a rapid synthesis 
toward a late-stage intermediate for funcitonalization, where reductive amination of the 
resulting diversified library provided a nice handle for purification of the final products. 
However, application of this synthetic strategy to the synthesis of the late-stage 
intermediate 4.10, which is an analogue of PK9255, proved unsuccessful, where the 
powerful inductive electron-withdrawing nature of the N-3,3,3-trifluoroethyl group 
caused the intermediate 4.7 to be unreactive towards Vilsmeier-Haack formylation 
conditions. Synthesis of 4.7 was accomplished through a 3-step synthesis, based on 
reductive cyclization of the nitrobiphenyl 4.9, in which the aldehyde functionality was 
already installed.  
 
Biophysical characterization of an initial library of subsite II carbazoles, using DSF as a 
primary screen and ITC to validate hits, identified the compounds PK9318 and PK9320, 
synthesised by Suzuki-Miyaura reaction of intermediate 4.4 with 2-thiophene boronic 
acid and 2-furan-boronic acid respectively, that showed enhanced stabilization of p53-
Y220C (3.6 K and 3.7 K at 250 µM respectively) and Y220C binding affinity (KD = 3.3 
and 2.8 µM). Structural characterization of the Y220C binding modes revealed that the 
observed enhance binding affinity cannot be attributed to specific protein-ligand 
interactions and hence enhancements are attributed to favourable entropy arising from 
‘the hydrophobic effect.’ This initial screen also identified the compounds PK9284 and 
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PK9301, which constitute the 2-brominated analogues of PK083 and PK9255, which 
showed enhanced p53-Y220C stabilization and binding affinity. Similarly to PK9318 and 
PK9320, enhancements were attributed to entropic effects via structural characterization 
of the Y220C binding mode of these compounds. 
 
Furthermore, through library synthesis and the resulting SAR, the most potent 
heterocyclic substitution was identified as the original hits, where introduction of more 
‘polar’ heterocycles as well as 6-membered rings were not tolerated. Methylation of the 
thiophene ring in positions 5- and 4- yielded the compounds PK9327 and PK9328 that 
showed enhanced stabilization and binding affinity, with DSF Tm = 3.1 (PK9327), 3.3 
(PK9328) K. The dissociation constant was determined as 1.8 µM (ITC) for PK9328.  
 
Whilst these compounds show enhanced stabilization and binding affinity of p53-Y220C 
through DSF and ITC, validation of enhanced p53-Y220C stabilization and Y220C 
specificity is still to be decisively established using cellular assays. Cell viability of 
compounds PK9318, PK9320, PK9323 and PK9328 was examined in an Y220C cell line 
vs a wild-type p53 cell line. Generally, at high concentrations (20 µM) these compounds 
reduce cell viability to 0 in both Y220C and wt-p53 cell-lines. However, at a lower 
compound concentration of 3 µM, both PK9323 and PK9328 reduce cell viability in the 
Y220C associated cells over the wild-type, indicating a Y220C specific effect. However, 
through HepG2 cytotoxicity and H2AX phosphorylation assays, PK9323 was identified 
as both highly cytotoxic and genotoxic, where PK9323 was determined to have an EC50 
of 2.2 µM in the H2AX phosphorylation assay (MCF7 breast cancer cell line).  
 
Future efforts to further optimize the PK083 fragment to p53-Y220C will concentrate on 
a multi-parameter optimization approach, in which affinity gains will be considered 
equally against cell viability as well as compound PK and toxicity. Strategies toward this 
are outlined in Chapter 5. 
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Chapter 5 : Conclusions and Future Directions  
The aims of this thesis were to develop chemistry towards compounds based on the hit 
compound PK083 that show enhanced potency and selectivity towards the thermally 
unstable oncogenic p53 mutant Y220C, using SAR and x-ray crystallography to inform 
compound design. Ultimately, the aim of this project is to develop a small molecule p53-
Y220C stabilizing drug, based on PK083 or other identified hits, as a personalized 
medicine approach to cancer therapy.  
 
Examination of the structure of PK083 bound to p53-Y220C revealed that the PK083 
binding site could be subdivided into 4 distinct sub-pockets (Figure 5.1), the central cavity 
(cyan) and subsites, I (red), II (green) and III (pink), which could be targeted through 
different strategies.  
 
Figure 5.1: PK083 bound to p53-Y220C (PDB: 2VUK). Mutation induced cavity is subdivided into: Subsite I (red), 
Subsite II (green), central cavity (cyan), Y220C mutation (yellow) and subsite III (pink). 
The solvent exposed subsite I had previously been targeted for affinity gains through 
targeting Asp228 (hydrogen bonding) and Trp1146 (π-π interactions) through 
diversification of the benzylic amine moiety. Despite a large amount of compounds 
purchased or synthesised, no significant improvements were made. Accordingly, other 
areas of the PK083 binding site were targeted for affinity improvements.  
 
157 
 
Chapter’s 2 and 3 describe the synthesis of compounds to target the mutant specific, 
hydrophobic Cys220 sub-pocket through functionalization of R and R1, which were 
accessed through alkylation chemistry (R) or reductive cyclization of the appropriate 
nitrobiaryl (R1)  (Figure 5.1, yellow).   
 
Figure 5.2: Structure of a generic carbazole with key growth vectors highlighted. 
The steric limit of the mutational sub-pocket was defined through reductive amination of 
commercially available N-functionalized carbazole aldehydes. The SAR defined that R< 
nPr or iPr, providing a limit to inform compound design.  
 
Attempts to target Cys220 through halogenation of R1 via S…Cl or fluorine 
multipolar/hydrogen bonding were unsuccessful and led to a reduction in Y220C 
stabilization. However, incorporation of fluorine into the N-ethyl anchor at R proved more 
successful, yielding two compounds, PK9255 and MB065, with substantially increased 
p53-Y220C stabilization (1.2 K at 125 µM) and Y220C binding affinity. Compared with 
the parent compounds PK083 and PK8017, the ITC KD values improved by a factor of 5. 
The structures of PK9255 and MB065 bound to Y220C confirmed that the binding mode 
of the carbazoles was almost identical to that of PK083, however, variations at R2 caused 
the benzylic amine to flip, breaking the hydrogen bond with the backbone Asp228 C=O, 
forming a new hydrogen bond with the C=O of Val147. This was reasoned to be 
responsible for affinity differences between mono- and dimethylated PK083 analogues 
synthesised in this thesis. The CF3 group interacts with the backbone carbonyl groups of 
Leu145 and Trp146 as well as with the thiol group of Cys220. Analysis of C−S···F angles 
in the complexes with di- and trifluorinated compounds suggests that fluorine interacts 
with Cys220 via weak hydrogen bonding with the polarized proton of the thiol function 
and via sulfur σ-hole bonding at an angle close to 180 °.  
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Following unsuccessful attempts to enhance affinity through targeting the transiently 
open subsite III by arylation of R via Ullmann coupling, subsite II (Figure 5.1, green) was 
targeted for affinity improvements via functionalization of R3 (Figure 5.2).   
 
Synthesis of privileged intermediates based on PK083 and PK9255, brominated at R3 (4.4 
and 4.10), was accomplished via functionalization of 2-bromocarbazole (PK083) or 
reductive cyclization of the appropriate nitrobiphenyl (PK9255), and provided reactive 
intermediates to target subsite II. Additionally, the available chemical space for targeting 
subsite II was expanded by synthesis of other PK083 analogues, using the same method 
as for the synthesis of 4.10, in which R3 was a methyl ester (amide library). Attempts to 
synthesise a PK083 analogue where R3 = OH, were unsuccessful. However, early-stage 
diversification of the nitrobiphenyl, for example, by Ullmann coupling, yielded a 
diversified product that followed by reductive cyclization, ethylation and reductive 
amination yielded an Ullmann coupled PK083 analogue. Conditions were sought for 
diversification of 4.4 (SM reaction) and 4.13 (amide coupling) and a few examples in 
each class synthesised.  
 
Biophysical characterization of an initial library of subsite II carbazoles, comprised of R3 
functionalized PK083 late stage intermediates as well as initial SM (4.4) and amide 
coupled (4.13) analogues identified compounds PK9318 and PK9320, in which R3 is 
heterocyclic, as the most potent substitution. PK9318 and PK9320 both showed enhanced 
stabilization of Y220C (3.6 K and 3.7 K at 250 µM) and Y220C binding affinity (KD = 
3.3 and 2.8 µM respectively). Structural characterization of the Y220C binding mode of 
these compounds confirmed the binding mode was almost identical to PK083, with both 
compounds forming a hydrogen bond between the backbone C=O of Asp228 and the NH 
of the benzylic amine. A slight shift of the carbazole ring is observed in order to 
accommodate the heterocyclic substitutions is subsite II. Introduction of the heterocycle 
does not result in the formation of specific protein-ligand interactions and hence, the 
observed enhanced affinity is attributed to entropic gains.  
 
Optimization of the heterocyclic ring was accomplished by firstly, establishing the most 
potent heterocyclic substitution and secondly, through exploration of the steric and 
electronic limits of functionalization of the heterocyclic ring. Variation of the 
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heterocyclic ring revealed that the original hits, PK9318 and PK9320 were the most 
potent, with a 4-thiazole analogue (PK9323) exhibiting comparable Y220C stabilization 
(3.4 K at 250 µM) and dissociation constant (ITC KD = 5.6 µM). Methylation of the 
thiophene ring, (PK9318) seeking to identify the steric limits of functionalization of the 
heterocyclic ring, revealed that positions 5 and 4 were both tolerated, where the 4-isomer 
(PK9328) showed enhanced binding affinity with an ITC determined KD = 1.8 µM.  
 
Whilst PK083 binding affinity has been successfully enhanced, conclusive validation that 
these more potent PK083 analogues stabilize p53-Y220C and show specificity (activation 
of p53 target genes and cell death, also inhibit aggregation) in cellular assays is yet to be 
determined. Generally, at high compound concentrations (20 µM), these compounds 
reduce cell viability to 0 in both Y220C and wild-type p53 cell lines, which is indicative 
of non-specific toxicity. However, at lower compound concentrations (3 µM), both 
PK9323 and PK9328 exhibit a Y220C specific effect, reducing cell viability in cell lines 
with Y220C p53 status over wt-p53 cell lines. Assessment of toxicity, using a HepG2 
cytotoxicity assay, indicated that all subsite II targeting compounds were, to some extent, 
cytotoxic. Furthermore, a histone H2AX phosphorylation assay, which is commonly used 
to identify genotoxic compounds, identified PK9323 as highly genotoxic, inducing DNA 
damage in a breast cancer cell line (MCF7, N.B. MCF7 has wt-p53 status) with and EC50 
of 4.4 µM. These results challenge the findings of the cell viability assay, paradoxically 
suggesting that PK9323 is highly toxic.  
Studies are ongoing to attempt to elucidate the mechanism(s) behind this toxicity. 
Speculatively, the observed toxicity may be attributed to: 
i) DNA intercalation owing to the planarity of the carbazole system (N.B. 
carbazoles constitute a commonly used compound class with which to design 
cytotoxic agents).529 
ii) Formation of reactive decomposition products (e.g. that may arise from loss 
of the benzylic amine) forming protein-adducts leading to off-target toxicity 
(Scheme 4.39).   
Future compound design should seek to: 
i) Identify the mechanism behind the series toxicity. 
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ii) Increase compound aqueous solubility by modulating the cLogP to allow 
incorporation of the most potent subsite II substitution with the most potent 
mutational sub-pocket substitution.  
iii) Further improve compound potency and selectivity, as assessed both through 
biophysical and cellular techniques. 
Figure 5.3 demonstrates some strategies that could be used in order to improve PK083 
analogue potency and selectivity. The genotoxicity of PK083 analogues has already been 
assessed by histone H2AX phosphorylation assay. As all compounds were not identified 
as genotoxic, non-specific toxicity cannot be solely attributed to the extended planarity 
of PK083 analogues causing genotoxicity through DNA intercalation. Alternatively, 
these analogues cause toxicity through formation of reactive decomposition products via 
loss of the benzylic amine leading to a Michael acceptor. By synthesis of the compound 
highlighted in Figure 5.3 in the yellow box, assessment of the contribution of the benzylic 
amine to the toxicity observed for PK083 analogues may be accomplished.  
 
Figure 5.3: Summary of simple strategies to improve aqueous solubility and probe the mechanism behind the non-
specific toxicity that PK083 analogues exhibited in cellular assays.   
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Chapter 6 :Experimental 
All reactions were carried out in air unless otherwise stated, using commercial grade 
starting materials, solvents and reagents. The progress of all reactions was monitored by 
TLC using commercially available glass silica gel plates (60 Å, F254). The mobile phase 
was generally a solvent mixture and the visualisation was undertaken using UV light. 
Microwave reactions were conducted in a CEM discovery microwave reactor. All NMR 
spectra were measured on either a Varian NMR 600, 500, or 400 MHz spectrometer. 
Chemical shifts are quoted in parts per million (ppm) (δ relative to a residual solvent peak 
for 1H and 13C). Chromatographic purifications were undertaken using an ISCO 
purification unit, Combi Flash RF 75 PSI, using Biotage silica gel columns. LC-MS 
purity analyses were undertaken using a 5 µm C18 110 Å column. Percentage purities 
were performed using a 30 min method in water/acetonitrile with 0.1% formic acid (5 
min at 5%, 5–95% over 20 min, 5 min at 95% or 5 minutes at 30%, 30-90% over 20 
minutes, 5 min at 90%) with the UV set to 254 nm unless otherwise indicated. All mass 
spectrometry was carried out at either the EPSRC UK National Mass Spectrometry 
Facility (NMSF) using a Thermo Scientific LTQ Orbitrap XL spectrometer or by Dr. Alaa 
Abdul-Sada at the University of Sussex. Caclulations of compound m/z for MS-EI were 
carried out using ChemDraw Ultra 12.0.3.1216.  
6.1 Chapter 2 
General Procedure A 
Representative procedure for reductive amination using titanium (IV) isopropoxide as a 
reagent  
Synthesis of 1-(9-Ethyl-9H-carbazol-3-yl)-N,N-dimethylmethanamine (2.23). 
 
To a solution of 9-ethyl-9H-carbazole-3-carbaldehyde (98 mg, 0.44 mmol) in anhydrous 
EtOH/DCM (10 mL) was added dimethylamine hydrochloride (71 mg, 0.88 mmol), 
triethylamine (91 µL, 0.66 mmol), and titanium(IV) isopropoxide (260 µL, 0.88 mmol). 
The resulting solution was stirred at RT for 18 h before the addition of sodium 
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borohydride (33 mg, 0.88 mmol). The solution was stirred at RT for 8 h before pouring 
into 2 M aqueous ammonia (25 mL). The suspension was filtered through Celite, and to 
the filtrate was added H2O. Crude product was extracted with DCM, dried over anhydrous 
K2CO3. The suspension was filtered, and the filtrate was concentrated in vacuo to yield 
crude product that was purified by chromatography on silica gel using DCM/MeOH 9:1 
as an eluent to yield the product as a white solid, yield 82% (91 mg, 0.36 mmol).  
1H NMR (500 MHz, Chloroform-d) δ 8.14−8.10 (m, 1H, ar CH), 8.06 (s, 1H, ar CH), 
7.51− 7.34 (m, 4H, ar CH), 7.26−7.20 (m, 1H, ar CH), 4.37 (q, J = 7.2 Hz, 2H, CH2), 3.64 
(s, 2H, CH2), 2.33 (s, 6H, CH3), 1.45 (t, J = 7.2 Hz, 3H, CH3) ppm.  
13C NMR (126 MHz, Chloroform-d) δ 140.2, 139.3, 129.3, 127.1, 125.5, 122.9 (2C), 
121.0, 120.4, 118.7, 108.4, 108.1, 64.7, 45.3 (2C), 37.5, 13.8 ppm.  
HRMS-ESI (m/z) found 208.1120 [M]+, calcd 208.1121 for [C15H14N]+ (loss of NMe2). 
LC-MS purity 97% (UV), ret. time = 11.36 min.  
 
Synthesis of 1-(9-Methyl-9H-carbazol-3-yl)-N,N-dimethylmethanamine (2.24). 
 
Synthesised according to general procedure A. 9-Methyl-9H-carbazole-3-carbaldehyde 
(305 mg, 1.46 mmol), dimethylamine hydrochloride (2 equiv.; 246 mg, 3 mmol, 2 equiv.), 
triethylamine (303 mg, 3 mmol), titanium isopropoxide (850 mg, 3 mmol) and sodium 
borohydride (85 mg, 2.3 mmol). Product isolated as a beige solid, yield 20% (68 mg, 0.28 
mmol). 
1H NMR (500 MHz, Chloroform-d) δ 8.11 (d, J = 7.8 Hz, 1H, ar CH), 8.05 (s, 1H, ar 
CH), 7.51 – 7.42 (m, 3H, ar CH), 7.40 (d, J = 8.2 Hz, 1H, ar CH), 7.36 (d, J = 8.2 Hz, 
1H, ar CH), 7.24 (t, J = 7.4 Hz, 1H, ar CH), 3.86 (s, 3H, CH3), 3.64 (s, 2H, CH2), 2.32 (s, 
6H, CH3). 
13C NMR (126 MHz, Chloroform-d) δ 141.2, 140.4, 127.1, 125.6, 122.7, 122.6, 120.9, 
120.3, 118.8, 108.3, 108.0, 64.6, 45.2 (2C), 29.1 ppm (missing one quarternay carbon).  
HRMS-ESI (m/z) found 194.0964 [M]+, calcd 194.0964 for [C14H12N]+ (loss of NMe2). 
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Synthesis of 1-(9-Propyl-9H-carbazol-3-yl)-N,N-dimethylmethanamine (2.25) 
 
Synthesised according to general procedure A. 9-Propyl-9H-carbazole-3-carbaldehyde 
(980 mg, 4.13 mmol), dimethylamine hydrochloride (673 mg, 8.26 mmol), triethylamine 
(626 mg, 863 µL, 6.19 mmol), titanium isopropoxide (2.347 g, 2.445 µL, 8.26 mmol) and 
sodium borohydride (312 mg, 8.26 mmol). Product isolated as a brown oil, yield 27% 
(298 mg, 1.11 mmol).  
1H NMR (500 MHz, Chloroform-d) δ 8.11 (d, J = 7.8 Hz, 1H, ar CH), 8.05 (s, 1H, ar 
CH), 7.49 – 7.43 (m, 3H, ar CH), 7.41 (d, J = 8.2 Hz, 1H, ar CH), 7.38 (d, J = 8.3 Hz, 
1H, ar CH), 7.25 – 7.19 (m, 1H, ar CH), 4.28 (t, J = 7.2 Hz, 2H, CH2), 3.67 (s, 2H, CH2), 
2.35 (s, 6H, CH3), 1.93 (h, J = 7.4 Hz, 2H, CH2), 1.00 (t, J = 7.4 Hz, 3H, CH3) ppm.  
13C NMR (126 MHz, Chloroform-d) δ 140.8, 139.9, 127.1, 125.5, 122.7, 122.7, 121.0, 
120.3, 118.7, 108.7, 108.4, 64.5, 45.0 (2C), 44.7, 22.3, 11.8 ppm. 
HRMS-ESI (m/z) found 222.1266 [M]+, calcd 222.1277 for [C16H16N]+ (loss of NMe2). 
 
 
Synthesis of 1-(9-Isopropyl-9H-carbazol-3-yl)-N, N-dimethylmethanamine (2.26) 
 
Synthesised according to general procedure A. 9-Isoropyl-9H-carbazole-3-carbaldehyde 
(498 mg, 2.1 mmol), dimethylamine hydrochloride (342 mg, 4.2 mmol), triethylamine 
(318 mg, 439 µL, 3.15 mmol), titanium isopropoxide (1.193 g, 1.243 mL, 4.2 mmol) and 
sodium borohydride (158 mg, 4.2 mmol). Product isolated as an orange oil, yield 29% 
(162 mg, 0.6 mmol).  
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1H NMR (500 MHz, Chloroform-d) δ 8.12 (d, J = 7.8 Hz, 1H, ar CH), 8.10 (s, 1H, ar 
CH), 7.54 – 7.49 (m, 5H, ar CH), 7.49 – 7.41 (m, 2H, ar CH), 7.25 – 7.18 (m, 2H, ar CH), 
4.99 (p, J = 7.0 Hz, 1H, CH), 3.85 (s, 2H, CH2), 2.46 (s, 6H, CH3), 1.71 (d, J = 7.0 Hz, 
6H, CH3) ppm. 
13C NMR (126 MHz, Chloroform-d) δ 139.8, 139.2, 127.1, 125.5, 123.3, 123.0, 121.6, 
120.4, 118.7, 110.0, 63.7, 46.8, 44.1 (2C), 20.8 (2C) ppm. 
HRMS-ESI (m/z) found 222.1265 [M]+, calcd 222.127 for [C16H16N]+ (loss of NMe2). 
 
Synthesis of 1-(9-Benzyl-9H-carbazol-3-yl)-N, N-dimethylmethanamine (2.27) 
 
Synthesised according to general procedure A. 9-Benzyl-9H-carbazole-3-carbaldehyde 
(1.426 g, 5.0 mmol), dimethylamine hydrochloride (815 mg, 10.0 mmol), triethylamine 
(758 mg, 1.045 mL, 7.5 mmol), titanium isopropoxide (2.842 g, 2.960 mL, 10.0 mmol) 
and sodium borohydride (378 mg, 10.0 mmol). Product isolated as a yellow solid, yield 
54% (850 mg, 2.7 mmol).  
1H NMR (500 MHz, Chloroform-d) δ 2.32 (6H, s), 3.63 (2H, s), 5.52 (2H, s), 7.17-7.44 
(12H, m), 8.08 (1H, s), 8.13 (1H, d, J= 8 Hz) ppm.  
13C NMR (126 MHz, Chloroform-d) δ 46.3, 46.6, 64.7, 108.6, 108.9, 119.1, 120.5, 121.0, 
122.9, 123.0, 125.8, 126.4, 127.3, 127.4, 128.8, 137.2, 140.1, 141.1 ppm.  
HRMS-ESI (m/z) found 270.1264 [M]+, calcd 270.1277 for [C20H16N]+ (loss of NMe2). 
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General Procedure B 
Representative procedure for reductive aminations using sodium triacetoxyborohydride 
Synthesis of 1-(9-Ethyl-8-fluoro-9H-carbazol-3-yl)-N,N-dimethylmethanamine (2.34) 
 
To a solution of 9-fluoro-9H-carbazole-3-carbaldehyde (2.32) (21 mg, 0.09 mmol) and 
methylamine (67 µL, 2M in THF, 0.13 mmol) in anhydrous THF (2 mL) was added 
sodium triacetoxyborohydride (46 mg, 0.21 mmol). The resulting suspension was stirred 
at room temperature for 18 h. THF was removed under a reduced pressure and to the 
residue was added DCM (10 mL) and H2O (10 mL). The solution was filtered through a 
hydrophobic frit, solvent was removed in vacuo and crude product was purified by 
chromatography on silica gel (crude product loaded onto silica) using a gradient of 100% 
DCM to 9:1 DCM:MeOH over 15 minutes as an eluent. Product was isolated as a pale 
yellow solid, yield 89% (21 mg, 0.08 mmol).  
 
1H NMR (500 MHz, Chloroform-d) δ 8.08 (s, 1H, ar CH), 7.86 (d, J = 7.4 Hz, 1H, ar 
CH), 7.55 (d, J = 8.4 Hz, 1H, ar CH), 7.43 (d, J = 8.4 Hz, 1H, ar CH), 7.21 – 7.09 (m, 
2H, ar CH), 4.54 (q, J = 7.1 Hz, 2H, CH2), 4.03 (s, 2H, CH2), 2.54 (s, 6H, CH3), 1.47 (t, 
J = 7.1 Hz, 3H, CH3) ppm. 
13C NMR (126 MHz, Chloroform-d) δ 149.4 (d, 1JFC = 242.8 Hz), 140.5, 128.4, 128.0, 
128.0, 126.3 (d, 4JFC = 4.8 Hz), 122.6, 119.3 (d, 3JFC = 6.4 Hz), 116.1 (d, 4JFC = 3.3 Hz), 
112.0 (d, 2JFC = 18.5 Hz), 109.9, 109.0, 62.4, 42.8, 40.0 (d, 4JFC = 6.1 Hz), 15.0 ppm. 
Missing one quaternary carbon. 
HRMS-ESI (m/z) found 226.1018 [M]+, calcd 226.1027 for [C15H13FN]+ (loss of NMe2). 
LC-MS purity 92% (UV), ret. time = 11.83 min. 
 
 
 
 
 
166 
 
Synthesis of 1-(9-Ethyl-8-chloro-9H-carbazol-3-yl)-N,N-dimethylmethanamine (2.35) 
 
Synthesised according to general procedure B. 8-Chloro-9-ethyl-9H-carbazole-3-
carbaldehyde (2.33) (11 mg, 0.045 mmol), methylamine (33 µL, 2M in THF, 0.067), 
anhydrous THF (2 mL), sodium triacetoxyborohydride (22 mg, 0.010 mmol). Product 
was isolated as an orange solid, yield 84% (11 mg, 0.038 mmol). 
1H NMR (500 MHz, Chloroform-d) δ 8.12 (s, 1H, ar CH), 8.00 (d, J = 7.7 Hz, 1H, ar 
CH), 7.59 (d, J = 8.4 Hz, 1H, ar CH), 7.45 (d, J = 8.7 Hz, 1H, ar CH), 7.42 (d, J = 8.0 Hz, 
1H, ar CH), 7.14 (t, J = 7.7 Hz, 1H, ar CH), 4.79 (q, J = 7.2 Hz, 2H, CH2), 4.01 (s, 2H, 
CH2), 2.56 (s, 6H, CH3), 1.49 (t, J = 7.2 Hz, 3H, CH3) ppm.  
13C NMR (126 MHz, Chloroform-d) δ 140.9, 135.8, 128.4, 127.9, 125.7, 122.8, 122.2, 
119.9, 118.9, 115.9, 109.2, 62.9, 43.3 (2C), 39.4, 15.6 ppm. Missing one quaternary 
carbon. 
HRMS-ESI (m/z) found 242.0716 [M]+, calcd 242.0731 for [C15H13ClN]+ (loss of 
NMe2). 
LC-MS purity > 99% (UV), ret. time = 12.31 min.  
 
Synthesis of 1-(9H-carbazol-3-yl)-N,N-dimethylmethanamine (2.37) 
 
Synthesised according to general procedure B. 9H-carbazol-3-carbaldehyde (45 mg, 0.26 
mmol), dimethylamine (130 µL, 2.0 M solution in THF, 0.26 mmol), anhydrous THF (5 
mL), sodium triacetoxyborohydride (80 mg, 0.39 mmol). Product was isolated as a pale 
yellow solid, yield 88% (51 mg, 0.22 mmol).  
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1H NMR (500 MHz, Chloroform-d) δ 8.59 (br s, 1H, NH), 8.09 – 8.03 (m, 1H, ar CH), 
8.02 (s, 1H, ar CH), 7.46 – 7.38 (m, 3H, ar CH), 7.38 – 7.33 (m, 1H, ar CH), 7.25 – 7.18 
(m, 1H, ar CH), 3.77 (s, 2H, CH2), 2.40 (s, 6H, CH3) ppm. 
13C NMR (126 MHz, Chloroform-d) δ 139.9, 139.2, 127.5, 126.8, 125.9, 123.3, 123.0, 
121.4, 120.3, 119.4, 110.7, 110.6, 63.9, 44.2 (2C) ppm. 
HRMS-ESI (m/z) found 180.0805 [M]+, calcd 180.0808 for [C13H10N]+ (loss of NMe2). 
 
Synthesis of 9H-carbazole-3-carbaldehyde (2.36) 
 
Synthesised according to a known procedure.530  
1H NMR (500 MHz, DMSO-d6) δ 11.82 (s, 1H, NH), 10.04 (s, 1H, CHO), 8.73 (s, 1H, 
ar CH), 8.32 – 8.16 (m, 1H, ar CH), 7.93 (d, J = 8.4 Hz, 1H, ar CH), 7.63 (d, J = 8.4 Hz, 
1H, ar CH), 7.59 – 7.52 (m, 1H, ar CH), 7.52 – 7.43 (m, 1H, ar CH), 7.31 – 7.19 (m, 1H, 
ar CH) ppm.  
13C NMR (126 MHz, DMSO-d6) δ 191.9 (CHO), 149.4, 143.6, 140.5, 128.3, 126.7, 
126.4, 122.6, 120.8, 119.9, 111.7, 111.5, 109.6 ppm.  
HRMS-ESI (m/z) found 196.0756 [M+H]+, calcd. 196.0757 for [C13H9NO+H]+. The 
above data were identical to literature data.531  
 
General Procedure C 
Representative procedure for the Suzuki-Miyaura cross-coupling of 1-bromo-2-nitro-3-
halogenated benzenes with 3-formylphenyl boronic acid  
Synthesis of 3’-Fluoro-2’-nitro-[1,1’-biphenylbiphenyl]-3-carbaldehyde (2.28) 
 
To a two-necked round bottomed flask was added 1-fluoro-3-iodo-2-nitrobenzene (2.000 
g, 9.0 mmol), (3-formylphenyl)boronic acid (1.635 g, 10.9 mmol) and 
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Pd(dppf)Cl2.CH2Cl2 (371 mg, 0.45 mmol) . The flask was evaculated and backfilled with 
argon 3 times and anhydrous toluene (10 mL) was added. A solution of potassium 
carbonate (2.512 g, 18.1 mmol) in degassed H2O (10 mL) was added and the resulting 
solution was stirred at 90 °C until TLC indicated completion (4/1 hexane/EtOAc). The 
solution was cooled and filtered through celite. EtOAc (50 mL) and H2O (50 mL) were 
added and crude product was extracted with EtOAc (3 X 30 mL). The organic extracts 
were dried over anhydrous MgSO4, filtered and the filtrate was concentrated under a 
reduced pressure to afford crude product that was purified by chromatography on silica 
gel (EtOAc/hexane 1/9 to 3/7 over 25 minutes). Product was isolated as a pale yellow 
crystalline solid, yield 64% (1.418 g, 5.7 mmol). 
1H NMR (500 MHz, Chloroform-d) δ 10.06 (s, 1H, CHO), 7.96 (t, J = 4.4 Hz, 1H, ar 
CH), 7.89 (s, 1H, ar CH), 7.65 – 7.62 (m, 2H, ar CH), 7.59 (td, J = 8.1, 5.4 Hz, 1H, ar 
CH), 7.33 (t, J = 8.8 Hz, 1H, ar CH), 7.28 (d, J = 8.8 Hz, 1H, ar CH) ppm. 
13C NMR (126 MHz, Chloroform-d) δ 191.3, 153.8 (d, 1JFC = 258.4 Hz), 139.1 (d, 2JFC 
= 19.2 Hz), 136.9, 136.2 (d, 4JFC = 2.0 Hz), 135.4, 133.5, 131.9 (d, 3JFC = 8.3 Hz), 130.1, 
129.7, 129.1, 126.3 (d, 4JFC = 3.5 Hz), 166.6 (d, 3JFC =19.1 Hz) ppm.  
MS-EI (m/z) found 245 [M]+, calcd 245.  
 
Synthesis of 3’-Chloro-2’-nitro-[1,1’-biphenyl]-3-carbaldehyde (2.29) 
 
Synthesised according to general procedure C. 1-Bromo-3-chloro-2-nitrobenzene (500 
mg, 2.11 mmol), (3-formylphenyl)boronic acid (380 mg, 2.53 mmol), 
Pd(dppf)Cl2.CH2Cl2 (86 mg, 0.10 mmol), potassium carbonate (584  mg, 4.22 mmol), 
anhydrous toluene (2.5 mL), degassed H2O (2.5 mL). Product was isolated as white 
crystalline solid, yield 92 % (514 mg, 1.96 mmol). 
1H NMR (500 MHz, Chloroform-d) δ 10.06 (s, 1H, CHO), 8.00 – 7.94 (m, 1H, ar CH), 
7.88 (s, 1H ar CH), 7.66 – 7.61 (m, 2H, ar CH), 7.61 – 7.50 (m, 2H, ar CH), 7.41 – 7.35 
(m, 1H, ar CH) ppm. 
13C NMR (126 MHz, Chloroform-d) δ 191.3, 148.0, 136.8, 136.3, 134.7, 133.6, 130.9, 
130.1, 130.1, 129.6, 129.3, 129.3, 125.6 ppm. 
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MS-EI (m/z) found 261 [M]+, calcd 261. 
 
General Procedure D 
Representative procedure for the reductive cyclization of intermediates 2.28 and 2.29  
Symthesis of 9-Fluoro-9H-carbazole-3-carbaldehyde (2.30) 
 
To a 15 mL microwave vial was added 3’-Fluoro-2’-nitro-[1,1’-biphenyl]-3-
carbaldehyde (2.28) (1.000 g, 4.07 mmol), triphenylphosphine (2.674 g, 10.19 mmol) and 
DMA (2 mL). The resulting solution was stirred under microwave irradiation at 200 °C 
for 2 h. The solution was cooled and diluted with EtOAc (50 mL) and H2O (50 mL). 
Crude product was extracted with EtOAc (3 X 30 mL). The organic extracts were washed 
with brine (3 X 50 mL) and dried over anhydrous MgSO4. The suspension was filtered 
and the filtrate was concentrated under a reduced pressure to yield crude product that was 
purified by column chromatography on silica gel (DCM/hexane gradient from 3/7 to 6/4 
over 30 minutes). Product was isolated as an orange solid, yield 34% (298 mg, 1.39 
mmol). 
1H NMR (500 MHz, DMSO-d6) δ 12.28 (s, 1H, NH), 10.03 (s, 1H, CHO), 8.75 (s, 1H, 
ar CH), 8.07 (d, J = 7.8 Hz, 1H, ar CH), 7.96 (d, J = 8.4 Hz, 1H), 7.63 (d, J = 8.4 Hz, 1H, 
ar CH), 7.36 – 7.28 (m, 1H, ar CH), 7.25 – 7.18 (m, 1H, ar CH) ppm. 
13C NMR (126 MHz, DMSO-d6) δ 192.3, 149.1 (d, 1JFC = 243.1 Hz), 144.2, 129.1, 128.50 
(d, 2JFC = 13.8 Hz), 127.4, 126.69 (d, 3JFC = 5.2 Hz), 125.30 (d, 2JFC = 12.3 Hz), 122.9 (d, 
4JFC = 2.6 Hz), 117.32 (d, 3JFC = 7.2 Hz), 112.38 (d, 4JFC = 4.4 Hz), 122.2, 112.1 ppm. 
MS-EI (m/z) found 213 [M]+, calcd 213.  
 
Synthesis of 8-Chloro-9H-carbazole3-carbaldehyde (2.31) 
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Synthesised according to general procedure D. 3’-Chloro-2’-nitro-[1,1’-biphenyl]-3-
carbaldehyde (2.29) (769 mg, 2.9 mmol), triphenylphosphine (1.927 g, 7.3 mmol) and 
DMA (1 mL). Product was isolated as a pale orange solid, yield, 9% (62 mg, 0.26 mmol).  
1H NMR (500 MHz, DMSO-d6) δ 12.12 (s, 1H, NH), 10.06 (s, 1H, CHO), 8.78 (s, 1H, 
ar CH), 8.25 (d, J = 7.7 Hz, 1H, ar CH), 7.99 (d, J = 8.6 Hz, 1H, ar CH), 7.69 (d, J = 8.4 
Hz, 1H, ar CH), 7.56 (d, J = 7.7 Hz, 1H, ar CH), 7.28 (t, J = 7.8 Hz, 1H, ar CH) ppm.  
MS-EI (m/z) found 229 [M]+, calcd 229. 
 
General Procedure E 
Representative procedure for the N-alkylation of intermediates 2.30 and 2.31 
Synthesis of 9-Fluoro-9H-carbazole-3-carbaldehyde (2.32) 
 
 To a solution of 9-Fluoro-9H-carbazole-3-carbaldehyde (2.30) (160 mg, 0.78 mmol) in 
anhydrous DMF (3 mL) was added sodium hydride (62 mg, 60 % suspension in mineral 
oil, 1.56 mmol). The resulting suspension was stirred at room temperature for 30 minutes. 
Ethyl iodide (120 µL, 1.56 mmol) was added and the solution was stirred for 18 hours. 
The solution was diluted by EtOAc (20 mL) and H2O (20 mL) and crude product was 
extracted with EtOAc (3 X 20 mL). The organic extracts were washed with brine (3 X 20 
mL), dried over anhydrous MgSO3 and filtered. The filtrate was concentrated under a 
reduced pressure and the resulting crude product was purified by chromatography on 
silica gel (DCM/hexane 2/8 to 1/1 over 20 minutes) to yield product as a pale yellow 
solid, yield 44% (80 mg, 0.33 mmol) that was carried on to the next step.  
1H NMR (500 MHz, Chloroform-d) δ 10.10 (s, 1H, CHO), 8.58 (s, 1H, ar CH), 8.07 – 
8.01 (m, 1H, ar CH), 7.94 – 7.86 (m, 1H, ar CH), 7.52 – 7.45 (m, 1H, ar CH), 7.25 – 7.16 
(m, 2H, ar CH), 4.56 (q, J = 7.2 Hz, 2H, CH2), 1.50 (t, J = 7.2 Hz, 3H, CH3) ppm. 
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Synthesis of 8-Chloro-9-ethyl-9H-carbazole-3-carbaldehyde (2.33) 
 
Synthesised according to general procedure E. 8-Chloro-9H-carbazole3-carbaldehyde 
(2.31) (60 mg, 0.26 mmol), anhydrous DMF (1 mL), sodium hydride (20 mg, 60 % 
suspension in mineral oil, 0.52 mmol), ethyl iodide (42 µL, 0.52 mmol). Product was 
isolated as a beige solid, yield 70% (47 mg, 0.016 mmol) that was carried on to the next 
step.  
1H NMR (500 MHz, Chloroform-d) δ 10.12 (s, 1H, CHO), 8.60 (s, 1H, ar CH), 8.09 – 
8.02 (m, 2H, ar CH), 7.56 – 7.52 (m, 1H, ar CH), 7.49 (d, J = 7.7 Hz, 1H, ar CH), 7.23 (t, 
J = 7.7 Hz, 1H, ar CH), 4.85 (q, J = 7.1 Hz, 2H, CH2), 1.53 (t, J = 7.1 Hz, 3H, CH3) ppm. 
13C NMR (100 MHz, Chloroform-d) δ 191.4, 129.2, 128.6, 127.7, 126.1, 125.9, 123.7, 
122.7, 120.9, 119.1, 116.3, 109.9, 109.1, 39.8, 15.6 ppm. 
 
Synthesis of N,N-dimethyl-1-(9-(thiazol-2-yl)-9H-carbazol-3-yl)methanamine (2.38) 
 
To a microwave vial containing 1-(9H-carbazol-3-yl)-N,N-dimethylmethanamine (2.37) 
(100 mg, 0.44 mmol) and Cs2CO3 (145 mg, 0.44 mmol) under argon was added anhydrous 
DMF (2 mL), 2-bromothiazole (43 µL, 0.48 mmol) and CuI (8 mg, 0.04 mmol). The vial 
was purged with argon for 5 minutes before heating under microwave irradiation at 220 
°C for 40 minutes. The solution was cooled and diluted with saturated ammonium 
chloride (30 mL) and EtOAc (30 mL). Crude product was extracted with EtOAc (2 X 30 
mL), the organic extracts were washed with brine (3 X 30 mL) and dried over anhydrous 
MgSO4. The suspension was filtered and the filtrate was concentrated under a reduced 
pressure to yield crude product that was purified by chromatography on silica gel using 
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DCM/MeOH 1/0 to 9/1 over 20 minutes as an eluent to yield product as a brown oil, yield 
53% (72 mg, 0.23 mmol).  
 
1H NMR (500 MHz, Chloroform-d) δ 8.07 – 8.03 (m, 2H, ar CH), 7.93 (s, 1H, ar CH), 
7.43 – 7.40 (m, 3H, ar CH), 7.38 – 7.35 (m, 1H, ar CH), 7.32 – 7.28 (m, 1H, ar CH), 7.01 
– 6.98 (m, 1H, ar CH), 4.16 (s, 2H, CH2), 3.04 (s, 6H, CH3) ppm. 
MS-ESI (m/z) found 308.050 (LC-MS) [M+H]+, calcd 308.118 for [C18H17N3S+H]+.  
LC-MS purity = 89 % (UV), ret time = 12.60 min.  
6.2 Chapter 3 
Synthesis of  (E)-9-(1-fluoro-2-iodovinyl)-9H-carbazole (3.8)  
 
Synthesised according to general procedure E using modified conditions withcarbazole 
(84 mg, 0.5 mmol), 1,1,1-trifluoro-2-iodoethane (99 µL, 1 mmol), sodium hydride (40 
mg, 60% suspension in mineral oil, 1 mmol), anhydrous DMF (1 mL). The solution was 
heated at 150 °C for 30 minutes under microwave irradiation. Purified by trituration with 
hexane to yield product as a white crystalline solid, yield 69% (116 mg, 0.34 mmol). The 
structure was confirmed by x-ray crystallography. 
1H NMR (600 MHz, Chloroform-d) δ 8.07 (d, J = 7.8 Hz, 2H, ar CH), 7.50 (ddd, J = 8.2, 
7.2, 1.2 Hz, 2H, ar CH), 7.47 – 7.42 (m, 2H, ar CH), 7.38 – 7.33 (m, 2H, ar CH), 6.49 (d, 
J = 4.5 Hz, 1H, CH) ppm. 
MS-EI found 337 [M]+, calcd 337.  
 
 
Synthesis of 9-(2,2,2-trifluoroethyl)-9H-carbazole-3-carbaldehyde (3.9a) 
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Synthesised according to general procedure E using modified conditions. Reaction was 
conducted under microwave irradiation at 150 °C for 30 minutes using 2,2,2-
trifluoroethyl p-toluenesulfonate as an electrophile and 2.36 as a starting material. 
Reaction carried out on a 0.48 mmol scale. Pale yellow solid, yield 50% (68 mg, 0.24 
mmol).  
1H NMR (500 MHz, DMSO-d6) δ 10.07 (s, 1H, CHO), 8.75 (s, 1H, ar CH), 8.28 (d, J = 
8.3 Hz, 1H, ar CH), 8.02 (d, J = 8.5 Hz, 1H, ar CH), 7.90 (d, J = 8.5 Hz, 1H, ar CH), 7.80 
(d, J = 8.3 Hz, 1H, ar CH), 7.61 – 7.49 (m, 1H, ar CH), 7.40 – 7.25 (m, 1H, ar CH), 5.51 
(q, 3JFH = 9.3 Hz, 2H, CH2) ppm. 
13C NMR (126 MHz, DMSO-d6) δ 192.3, 144.2, 141.3, 129.8, 127.5, 127.4, 125.4 (q, 
1JFC = 281.8 Hz), 124.0 123.3, 122.9, 121.5, 121.2, 110.9, 110.8, 44.1 (q, 2JFC = 33.5 Hz) 
ppm.  
HRMS-ESI (m/z) found 278.0789 [M+H]+, calcd 278.0787 for [C15H10F3NO+H]+. 
 
Synthesis of 9-(2,2-difluoroethyl)-9H-carbazole-3-carbaldehyde (3.9b) 
 
Synthesised according to general procedure E using modified conditions. Reaction was 
conducted under microwave irradiation at 150 °C for 30 minutes using 1-iodo-2,2-
difluoroethane as an electrophile using 2.36 as a starting material. Reaction carried out 
on a 1.3 mmol scale. Yellow crystalline solid, yield 44% (115 mg, 0.44 mmol).   
1H NMR (500 MHz, DMSO-d6) δ 10.06 (s, 1H, CHO), 8.73 (s, 1H, ar CH), 8.33 – 8.17 
(m, 1H, ar CH), 7.99 (d, J = 8.4 Hz, 1H, ar CH), 7.81 (d, J = 8.4 Hz, 1H, ar CH), 7.76 – 
7.66 (m, 1H, ar CH), 7.60 – 7.47 (m, 1H, ar CH), 7.36 – 7.24 (m, 1H, ar CH), 6.50 (tt, 
2JFH = 54.5 Hz, 3JHH = 3.2 Hz, 1H, CH), 4.97 (td, 3JFH = 16.1 Hz, 3JHH = 3.2 Hz, 2H, CH2) 
ppm. 
13C NMR (126 MHz, DMSO-d6) δ 192.3, 144.6, 141.7, 129.4, 127.3, 127.2, 124.0, 123.0, 
122.8, 121.1, 121.0, 115.1 (t, 1JFC = 241.9 Hz), 110.9, 110.8, 45.0 (t, 2JFC = 24.5 Hz) ppm.  
HRMS-ESI (m/z) found 260.0884 [M+H]+, calcd 260.0881 for [C15H11F2NO+H]+. 
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Synthesis of 1-(9-(2,2,2-trifluoroethyl)-9H-carbazol-3-yl)-N-methylmethanamine (3.7b) 
 
Synthesised according to general procedure A using 3.81 as a starting material and 
methylamine hydrochloride as an amine. Reaction carried out on a 0.31 mmol scale. 
Product isolated as a pale yellow solid, yield 40% (37 mg, 0.12 mmol).  
1H NMR (500 MHz, Acetonitrile-d3) δ 8.20 – 8.14 (m, 1H, ar CH), 8.12 (s, 1H, ar CH), 
7.64 – 7.58 (m, 1H, ar CH), 7.58 – 7.47 (m, 3H, ar CH), 7.36 – 7.28 (m, 1H, ar CH), 5.07 
(q, 3JFH = 9.1 Hz, 2H, CH2), 3.89 (s, 2H, CH2), 2.43 (s, 3H, CH3) ppm. 
13C NMR (126 MHz, DMSO-d6) 140.9, 140.2, 128.3, 127.7, 126.6, 126.1 (q, 1JFC = 281.2 
Hz), 122.9 122.8, 121.3, 120.6, 120.5, 110.4, 110.1, 53.9, 44.05 (q, 2JFC = 33.4 Hz), 34.1 
ppm.  
LC-MS purity = 97% (UV), ret. time = 11.55 min.  
HRMS-ESI (m/z) found 293.1259 [M+H]+, calcd 293.1260 for [C16H15F3N2+H]+.  
 
Synthesis of 1-(9-(2,2-difluoroethyl)-9H-carbazol-3-yl)-N-methylmethanamine (3.7c) 
 
Synthesised according to general procedure A using 3.82 as a starting material and 
methylamine hydrochloride as an amine. Reaction carried out on a 0.28 mmol scale. 
Product isolated as a yellow oil, yield 58% (46 mg, 0.16 mmol).  
1H NMR (500 MHz, Acetonitrile-d3) δ 8.19 – 8.13 (m, 1H, ar CH), 8.10 (s, 1H, ar CH), 
7.62 – 7.56 (m, 1H, ar CH), 7.56 – 7.45 (m, 3H, ar CH), 7.32 – 7.25 (m, 1H, ar CH), 6.31 
(tt,2JFH = 55.0 Hz,  3JHH = 3.2 Hz, 1H, CH), 4.76 (td, 3JFH = 15.6 Hz, 3JHH = 3.2 Hz, 2H, 
CH2), 3.89 (s, 2H, CH2), 2.43 (s, 3H, CH3) ppm. 
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13C NMR (126 MHz, Acetonitrile-d3) δ 141.1, 139.9, 132.5, 126.6, 125.9, 122.9, 122.8, 
120.1, 119.7, 119.6, 114.8 (t, 1JFC = 241.9 Hz), 109.3, 109.0, 55.7, 44.9 (t, 2JFC = 25.6 
Hz), 35.1 ppm.  
LC-MS purity = 96% (UV), ret. time = 11.01 min.  
HRMS-ESI (m/z) found 275.1353 [M+H]+, calcd 275.1354 for [C16H16F2N2+H]+.  
 
Synthesis of 1-(9-(2,2,2-trifluoroethyl)-9H-carbazol-3-yl)-N,N-dimethylmethanamine 
(3.7a) 
 
Synthesised according to general procedure A using 3.81 as a starting material and 
methylamine hydrochloride as an amine. Reaction carried out on a 0.10 mmol scale. 
Product isolated as a white solid, yield 56% (17 mg, 0.05 mmol).  
1H NMR (500 MHz, Chloroform-d) δ 8.04 – 8.00 (m, 1H, ar CH), 7.99 (s, 1H, ar CH), 
7.45 – 7.39 (m, 2H, ar CH), 7.37 – 7.29 (m, 2H, ar CH), 7.27 – 7.20 (m, 1H, ar CH), 4.73 
(q, 3JFH = 8.7 Hz, 2H, CH2), 3.62 (s, 2H, CH2), 2.28 (s, 6H, CH3) ppm.  
13C NMR (126 MHz, Chloroform-d) δ 140.9, 140.1, 129.8, 127.8, 126.4, 124.3 (q, 1JFC 
= 281.5 Hz), 123.6, 123.4, 121.3, 120.6, 120.4, 108.7, 108.5, 45.3 (q, 2JFC = 35.7 Hz), 
44.9 (2C) ppm.   
LC-MS purity > 99% (UV), ret. time = 11.68 min.  
HRMS-ESI (m/z) found 307.1419 [M+H]+, calcd 307.1417 for [C16H17F3N2+H]+.  
6.3 Chapter 4 
Synthesis of 2-bromo-9-ethyl-9H-carbazole (4.5) 
 
Synthesised according to general procedure E. 2-bromocarbazole (5.000 g, 20.31 mmol), 
anhydrous DMF (20 mL), sodium hydride (1.625 g, 40.63 mmol), ethyl iodide (3.266 
mL, 40.63 mmol). Crude product was isolated as a beige crystalline solid and assessed to 
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have a purity > 95% (1H NMR), hence was not purified using the procedure outline in 
general procedure E. Yield, quantitative (5.53 g, 20.17 mmol). 
1H NMR (500 MHz, Chloroform-d) δ 8.08 (d, J = 6.8 Hz, 1H, ar CH), 7.95 (d, J = 8.2 
Hz, 1H, ar CH), 7.57 (s, 1H, ar CH), 7.51 (t, J = 8.2, 7.2, 1.1 Hz, 2H, ar CH), 7.42 (d, J = 
8.2 Hz, 1H, ar CH), 7.35 (d, J = 8.2, 1.6 Hz, 1H, ar CH), 7.27 (t, 2H, ar CH), 4.33 (q, J = 
7.2 Hz, 2H, CH2), 1.45 (t, J = 7.2 Hz, 3H, CH3) ppm. 
13C NMR (126 MHz, Chloroform-d) δ 140.7, 140.0, 126.0, 122.4, 121.9, 121.5, 120.4, 
119.3, 119.2, 111.5, 108.6, 37.6, 13.7 ppm. 
HRMS-ESI (m/z) found 274.0226 [M+H]+, calcd 274.0226 for [C14H12BrN+H]+.  
 
Synthesis of 7-bromo-9-ethyl-9H-carbazole-3-carbaldehyde (4.4) 
 
To a flask of anhydrous DMF (10 mL) under argon at 0 °C was added phosphorous (V) 
oxychloride (5.963 mL, 63.97 mmol) dropwise. The resulting solution was allowed to 
warm to room temperature. To the resulting solution was added a solution of 2-bromo-9-
ethyl-9H-carbazole (4.5) (5.846 g, 21.32 mmol) in anhydrous DMF (10 mL) dropwise 
and the resulting solution was heated at 80 °C for 18 h. The solution was cooled to room 
temperature and was poured into ice water (50 mL). The solution was neutralized by 
addition of 10% w/v NaOH(aq). Crude product was extracted with EtOAc (3 X 100 mL). 
The organic extracts were washed with brine (3 X 50 mL), dried over anhydrous MgSO4 
and concentrated under a reduced pressure to yield crude product that was purified by 
column chromatography on silica gel (EtOAc/hexane 0/1 to 1/4). Product was isolated as 
a beige flocculent solid, yield 46% (3.00 g, 9.9 mmol). 
1H NMR (500 MHz, Chloroform-d) δ 10.08 (s, 1H, CHO), 8.55 (s, 1H, ar CH), 8.02 (d, 
J = 8.5 Hz, 1H, ar CH), 7.97 (d, J = 8.3 Hz, 1H, ar CH), 7.59 (s, 1H, ar CH), 7.46 (d, J = 
8.5 Hz, 1H, ar CH), 7.41 (d, J = 8.3 Hz, 1H, ar CH), 4.34 (q, J = 7.3 Hz, 2H, CH2), 1.45 
(t, J = 7.3 Hz, 3H, CH3) ppm.   
13C NMR (126 MHz, Chloroform-d) δ 191.6, 143.6, 141.4, 128.9, 127.5, 123.8, 123.4, 
122.6, 121.9, 121.8, 120.3, 112.3, 108.9, 38.0, 13.7 ppm. 
HRMS-ESI (m/z) found 302.0180 [M+H]+, calcd 302.0175 for [C15H12BrNO+H]+. 
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Synthesis of 1-(7-bromo-9-ethyl-9H-carbzol-3-yl)-N-methylmethanamine (4.3a) 
 
Synthesised according to general procedure A. 7-Bromo-9-ethyl-9H-carbazole-3-
carbaldehyde (4.4) (50 mg, 0.17 mmol), methylamine hydrochloride (23 mg, 0.34 mmol), 
trimethylamine (36 µL, 0.26 mmol), titanium (IV) isopropoxide (101 µL, 0.34 mmol), 
sodium borohydride (13 mg, 0.34 mmol), DCM (1.5 mL), EtOH (1.5 mL). Product was 
isolated as a white solid, yield 52% (28 mg, 0.088 mmol).  
1H NMR (500 MHz, Chloroform-d) δ 8.06 (s, 1H, ar CH), 7.91 (d, J = 8.2 Hz, 1H, ar 
CH), 7.52 – 7.47 (m, 2H, ar CH), 7.35 – 7.29 (m, 2H, ar CH), 4.26 (q, J = 7.2 Hz, 2H, 
CH2), 3.98 (s, 2H, CH2), 2.52 (s, 3H, CH3), 1.38 (t, J = 7.2 Hz, 3H, CH3) ppm. 
LC-MS purity = 98 % (UV), ret. time = 6.81 min. 
MS-ESI (m/z) found 286.1 [M]+ (LC-MS), calcd 286.2 (loss of NHMe).   
 
Synthesis of 1-(9-bromo-9-ethyl-9H-carbazol-3-yl)-N,N-dimethylmethanamine (4.3b) 
 
Synthesised according to general procedure B. 7-Bromo-9-ethyl-9H-carbazole-3-
carbaldehyde (4.4) (700 mg, 2.32 mmol), dimethylamine (1.165 mL, 2 M solution in 
THF, 2.32 mmol), anhydrous THF (15 mL), sodium triacetoxyborohydride (738 mg, 3.48 
mmol). Product was isolated as a pale orange oil, yield 84% (647 mg, 1.95 mmol).  
1H NMR (500 MHz, Chloroform-d) δ 8.02 (s, 1H, ar CH), 7.93 (d, J = 8.2 Hz, 1H, ar 
CH), 7.55 (s, 1H, ar CH), 7.48 (d, J = 8.2 Hz, 1H, ar CH), 7.36 (d, J = 8.4 Hz, 1H, ar CH), 
7.33 (d, J = 8.2 Hz, 1H, ar CH), 4.30 (q, J = 7.1 Hz, 2H, CH2), 3.69 (s, 2H, CH2), 2.36 (s, 
6H, CH3), 1.43 (t, J = 7.2 Hz, 3H, CH3) ppm. 
13C NMR (126 MHz, Chloroform-d) δ 141.0, 139.5, 128.7, 127.6, 122.4, 121.9, 121.7, 
121.6, 121.1, 119.2, 111.5, 108.4, 64.3, 44.9 (2C), 37.7, 13.7 ppm. 
178 
 
HRMS-ESI (m/z) found 286.0216 [M]+, calcd 286.0226 for [C15H13BrN]+ (loss of 
NMe2). 
LC-MS purity = 95% (UV), ret. time = 12.50 min.  
 
Synthesis of 2-bromo-9-(2,2,2-trifluoroethyl)-9H-carbazole (4.6) 
 
 
Synthesised according to general procedure E using modified conditions. Reaction was 
conducted under microwave irradiation at 150 °C for 30 minutes using 2,2,2-
trifluoroethyl p-toluenesulfonate as an electrophile. 2-Bromocarbazole (719 mg, 2.92 
mmol), 2,2,2-trifluoroethyl p-toluenesulfonate (1.4263 g, 5.84 mmol), cesium carbonate 
(1.9040 g, 5.84 mmol), anhydrous DMF (10 mL). Purification by chromatography on 
silica gel using DCM/ hexane 0/1 to 1/9 over 20 minutes as an eluent. Product was 
isolated as a white solid, yield 36% (347 mg, 1.05 mmol).  
1H NMR (500 MHz, Chloroform-d) δ 8.05 (d, J = 8.1 Hz, 1H, ar CH), 7.92 (d, J = 8.2 
Hz, 1H, ar CH), 7.56 (s, 1H, ar CH), 7.52 (t, J = 7.7 Hz, 1H, ar CH), 7.43 – 7.39 (m, 2H, 
ar CH), 7.32 (t, J = 7.5 Hz, 1H, ar CH), 4.74 (q, 3JFH = 8.6 Hz, 2H, CH2) ppm. 
13C NMR (126 MHz, Chloroform-d) δ 141.3, 140.5, 126.75, 123.6, 123.51 (q, 1JFC = 
280.7 Hz), 122.9, 122.5, 121.5, 120.8, 120.4, 119.8, 111.9, 108.8, 45.2 (q, 2JFC = 35.6 Hz) 
ppm. 
MS-EI (m/z) found 327 [M]+, cacld 327. 
 
Synthesis of 4’-bromo-2’-nitro-[1,1’-biphenyl]-3-carbalehyde (4.9) 
 
Synthesised according to general procedure C. 4-Bromo-1-iodo-2-nitrobenzene (4.000 g, 
12.19 mmol), (3-formylphenyl)boronic acid (2.012 g, 13.41 mmol), potassium carbonate 
(3.372 g, 24.39 mmol), Pd(dppf)Cl2.CH2Cl2 (498 mg, 0.60 mmol), anhydrous toluene (20 
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mL), degassed H2O (10 mL). Crude product was purified by chromatography on silica 
gel using DCM/hexane 0/1 to 1/1 over 30 minutes as an eluent. Product was isolated as 
an orange oil, yield 84% (3.1592 g, 10.32 mmol). 
1H NMR (500 MHz, Chloroform-d) δ 10.05 (s, 1H, CHO), 8.11 (s, 1H, ar CH), 7.94 (d, 
J = 8.4 Hz, 1H, ar CH), 7.84 – 7.78 (m, 2H, ar CH), 7.61 (t, J = 7.6 Hz, 2H, ar CH), 7.54 
(d, J = 8.5 Hz, 1H, ar CH), 7.34 (d, J = 8.2 Hz, 1H, ar CH) ppm. 
13C NMR (126 MHz, Chloroform-d) δ 191.3, 149.1, 137.6, 136.8, 135.7, 134.0, 133.6, 
133.1, 129.8, 129.4, 128.7, 127.4, 122.2 ppm. 
HRMS-ESI (m/z) found 305.9757 [M+H]+, calcd. 305.9760 for [C13H8BrNO3+H]+. 
 
Synthesis of 7-bromo-9H-carbazole-3-carbaldehyde (4.8) 
 
Synthesised according to general procedure D using modified conditions. Reaction was 
stirred at 165 °C for 18 h.  4’-Bromo-2’-nitro-[1,1’-biphenyl]-3-carbalehyde (4.9) (3.1592 
g, 10.32 mmol), triphenylphosphine (6.7671 g, 25.8 mmol), DMA (10 mL). Crude 
product was purified by chromatography on silica gel using EtOAc/hexane 0/1 to 1/4 over 
40 minutes. Product was isolated as an orange solid, yield 22% (629 mg, 2.29 mmol).  
1H NMR (500 MHz, DMSO-d6) δ 11.94 (s, 1H, NH), 10.02 (s, 1H, CHO), 8.72 (s, 1H, 
ar CH), 8.18 (d, J = 8.3 Hz, 1H, ar CH), 7.94 (d, J = 8.4 Hz, 1H, ar CH), 7.74 (s, 1H, ar 
CH), 7.63 (d, J = 8.4 Hz, 1H, ar CH), 7.37 (d, J = 8.3 Hz, 1H, ar CH) ppm. 
13C NMR (126 MHz, DMSO-d6) δ 192.3, 144.1, 141.8, 129.1, 127.2, 124.8, 123.1, 122.9, 
122.4, 122.1, 119.6, 114.7, 112.2 ppm. 
MS-EI (m/z) found 273 [M]+, calcd 273. 
 
Synthesis of 7-bromo-9-(2,2,2-trifluoroethyl)-9H-carbazole-3-carbaldehyde (4.7) 
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Synthesised according to general procedure E using modified conditions. Reaction was 
conducted under microwave irradiation at 150 °C for 30 minutes using 2,2,2-
trifluoroethyl p-toluenesulfonate as an electrophile.  7-Bromo-9H-carbazole-3-
carbaldehyde (4.8) (200 mg, 0.72 mmol), 2,2,2-trifluoroethyl p-toluenesulfonate (356 
mg, 1.45 mmol), cesium carbonate (475 mg, 1.45 mmol), anhydrous DMF (3 mL). Crude 
product was purified by chromatography on silica gel using EtOAc/hexane ¼ to 1/1 over 
20 minutes. Product was isolated as a white solid, yield 52% (134 mg, 0.37 mmol).  
1H NMR (500 MHz, DMSO-d6) δ 10.06 (s, 1H, CHO), 8.78 (s, 1H, ar CH), 8.25 (d, J = 
8.3 Hz, 1H, ar CH), 8.14 (s, 1H, ar CH), 8.05 (d, J = 8.6 Hz, 1H, ar CH), 7.91 (d, J = 8.6 
Hz, 1H, ar CH), 7.49 (d, J = 8.3 Hz, 1H, ar CH), 5.55 (q, 3J FH = 9.2 Hz, 2H, CH2) ppm. 
13C NMR (126 MHz, DMSO-d6) δ 192.3, 144.3, 142.3, 130.2, 127.9, 125.3 (q, 1JFC = 
281.7 Hz), 124.5, 124.2, 123.0, 122.7, 122.1, 120.4, 113.9, 11.2, 44.1 (q, 2JFC = 33.0 Hz) 
ppm. 
MS-EI (m/z) found 355 [M]+, calcd 355. 
 
Synthesis of 1-(7-bromo-9-(2,2,2-trifluoroethyl)-9H-carbazol-3-yl)-N-
methylmethanamine (4.10) 
 
Synthesised according to general procedure A. 7-Bromo-9-(2,2,2-trifluoroethyl)-9H-
carbazole-3-carbaldehyde (4.7) (85 mg, 0.24 mmol), methylamine hydrochloride (32 mg, 
0.48 mmol), Et3N (49 µL, 0.35 mmol), titanium (IV) isopropoxide (141 µL, 0.48 mmol), 
DCM (1 mL), EtOH (1 mL), sodium borohydride (18 mg, 0.48 mmol). Product was 
isolated as a beige solid, yield 36% (32 mg, 0.08 mmol). 
1H NMR (500 MHz, DMSO-d6) δ 8.32 (s, 1H, ar CH), 8.08 (s, 1H, ar CH), 8.05 (d, J = 
8.3 Hz, 1H, ar CH), 7.80 (d, J = 8.4 Hz, 1H, ar CH), 7.69 (d, J = 8.4 Hz, 1H, ar CH), 7.44 
(d, J = 8.3 Hz, 1H, ar CH), 5.49 (q, 3J FH= 9.2 Hz, 2H, CH2), 4.23 (s, 2H, CH2), 2.53 (s, 
3H, CH3) ppm. 
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13C NMR (126 MHz, DMSO-d6) δ 141.9, 140.9, 128.9, 124.5, 123.7, 123.4 (q, 1JFC = 
285.3 Hz), 122.8, 122.4, 122.3, 121.8, 119.8, 113.6, 110.8, 51.9, 43.9 (q, 2JFC = 33.2 Hz), 
32.2 ppm. 
HRMS-ESI (m/z) found 339.9470 [M]+, calcd 339.9943 for [C15H10BrF3N]+ (loss of 
NHMe).  
LC-MS purity = 97% (UV), ret. Time = 12.55 min. 
 
Synthesis of methyl-3’-formyl-2-nitro-[1,1’-biphenyl]-4-carboxylate (4.11) 
 
 
Synthesised according to general procedure C. Methyl-4-bromo-3-nitrobenzoate (260 
mg, 1 mmol), (3-formylphenyl)boronic acid (165 mg, 1.1 mmol), potassium carbonate 
(276 mg, 2 mmol), Pd(dppf)Cl2.CH2Cl2 (40 mg, 0.05 mmol), anhydrous toluene (2 mL), 
degassed H2O (1 mL). Crude product was purified by chromatography on silica gel using 
DCM/hexane 0/1 to 1/1 as an eluent. Product was isolated as a white solid, yield 85% 
(242 mg, 0.85 mmol).  
1H NMR (500 MHz, Chloroform-d) δ 10.07 (s, 1H, CHO), 8.59 (s, 1H, ar CH), 8.32 (d, 
J = 8.0 Hz, 1H, ar CH), 7.97 (d, J = 7.6 Hz, 1H, ar CH), 7.87 (s, 1H, ar CH), 7.64 (t, J = 
7.6 Hz, 1H, ar CH), 7.57 (t, J = 8.3 Hz, 2H, ar CH), 4.02 (s, 3H, CH3) ppm. 
13C NMR (126 MHz, Chloroform-d) δ 191.3, 164.6, 148.9, 139.0, 137.7, 136.8, 133.5, 
133.1, 132.2, 131.2, 130.0, 129.4, 128.7, 125.5, 52.8 ppm. 
MS-EI (m/z) found 285 [M]+, calcd 285. 
 
Synthesis of methyl-6-formyl-9H-carbazole-2-carboxylate (4.12) 
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Synthesised according to general procedure D using modified conditions. Reaction was 
stirred at 165 °C for 18 h. Methyl-6-formyl-9H-carbazole-2-carboxylate (4.12) (1.300 g, 
4.5 mmol), triphenyl phosphine (2.988 g, 11.4 mmol), DMA (3 mL). Crude product was 
purified by chromatography on silica gel using EtOAc/hexane 0/1 to 1/1 as an eluent. 
Product was isolated as a white solid, yield 34% (394 mg, 1.5 mmol).  
1H NMR (500 MHz, DMSO-d6) δ 12.10 (s, 1H, NH), 10.04 (s, 1H, CHO), 8.81 (s, 1H, 
ar CH), 8.36 (d, J = 8.2 Hz, 1H, ar CH), 8.15 (s, 1H, ar CH), 7.99 (d, J = 8.5 Hz, 1H, ar 
CH), 7.85 (d, J = 8.2 Hz, 1H, ar CH), 7.69 (d, J = 8.5 Hz, 1H, ar CH), 3.89 (s, 3H, CH3) 
ppm. 
13C NMR (126 MHz, DMSO-d6) δ 192.3, 167.0, 145.0, 140.2, 129.1, 127.7, 126.7, 125.9, 
122.1, 121.2, 120.8, 117.7, 113.3, 112.4, 52.6 ppm. 
MS-EI (m/z) found 253 [M]+, calcd 253.  
 
Synthesis of methyl-9-ethyl-6-formyl-9H-carbazole-2-carboxylate (4.13) 
 
 
Synthesised according to general procedure E. Methyl-6-formyl-9H-carbazole-2-
carboxylate (4.12) (78 mg, 0.30 mmol), anhydrous DMF (2 mL), sodium hydride (14 mg, 
60% suspension in mineral oil, 0.34 mmol), ethyl iodide (27 µL, 0.34 mmol). Crude 
product was isolated as an orange solid and assessed to have a purity > 95% (1H NMR). 
Yield, quantitative (86 mg, 0.30 mmol).  
1H NMR (500 MHz, DMSO-d6) δ 10.08 (s, 1H, CHO), 8.85 (s, 1H, ar CH), 8.42 (d, J = 
8.1 Hz, 1H, ar CH), 8.27 (s, 1H, ar CH), 8.07 (d, J = 8.6 Hz, 1H, ar CH), 7.91 (d, J = 8.1 
Hz, 1H, ar CH), 7.86 (d, J = 8.6 Hz, 1H, ar CH), 4.60 (q, J = 7.1 Hz, 2H, CH2), 3.93 (s, 
3H, CH3), 1.36 (t, J = 7.1 Hz, 3H, CH3) ppm. 
13C NMR (126 MHz, Chloroform-d) δ 191.4, 167.4, 144.6, 140.1, 128.9, 128.1, 128.0, 
126.7, 124.9, 122.3, 121.4, 120.4, 117.7, 110.9, 109.9, 109.1, 52.3, 38.1, 13.9 ppm. 
MS-EI (m/z) found 281 [M]+, calcd 281. 
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Synthesis of methyl-9-ethyl-6-((methylamino)methyl)-9H-carbazole-2-carboxylate 
(4.14) 
 
Synthesised according to general procedure A. Methyl-9-ethyl-6-formyl-9H-carbazole-
2-carboxylate (4.13) (50 mg, 0.17 mmol), methylamine hydrochloride (24 mg, 0.35 
mmol), trimethylamine (35 µL, 0.25 mmol), titanium (IV) isopropoxide (104 µL, 0.35 
mmol), DCM (2 mL), EtOH (2 mL), sodium borohydride (13 mg, 0.35 mmol). Product 
was isolated as a white solid, yield 16% (8 mg, 0.026 mmol).  
1H NMR (500 MHz, Chloroform-d) δ 8.15 – 8.08 (m, 3H, ar CH), 7.92 (d, J = 8.1 Hz, 
1H, ar CH), 7.52 (d, J = 8.4 Hz, 1H, ar CH), 7.40 (d, J = 8.4 Hz, 1H, ar CH), 4.41 (q, J = 
7.2 Hz, 2H, CH2), 3.99 (s, 2H, CH2), 3.96 (s, 3H, CH3), 2.53 (s, 3H, CH3), 1.45 (t, J = 7.2 
Hz, 3H, CH3) ppm. 
13C NMR (126 MHz, Chloroform-d) δ 167.8, 140.7, 139.6, 127.8, 127.1, 126.5, 122.2, 
121.1, 120.0, 120.0, 110.3, 109.9, 108.7, 55.7, 53.3, 52.0, 37.7, 13.8 ppm. 
HRMS-ESI (m/z) found 266.1163 [M]+, calcd 266.1176 for [C17H17NO2]+ (loss of 
NHMe).  
LC-MS purity = 97% (UV), ret. time = 11.60 min. 
 
Synthesis of 4’-hydroxy-2’-nitro-[1,1’-biphenyl]-3-carbaldehyde (4.15) 
 
 
To a solution of 4’-((tert-Butyldimethylsilyl)oxy)-2’-nitro-[1,1’-biphenyl]-3-
carbaldehyde (4.18) (2.515 g, 7.03 mmol) in THF (10 mL) at 0 °C was added tert-
butylammonium fluoride (20.8 mL, 1M solution in THF, 20.68 mmol). The solution was 
allowed to warm to room temperature before it was diluted with H2O (20 mL) and 
acidified with 1 N HCl (aq) to pH 4. Crude product was extracted with EtOAc (3 X 30 
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mL), washed with H2O (30 mL) and dried over anhydrous MgSO4. The suspension was 
filtered and the filtrate was concentrated under a reduced pressure to yield product as a 
yellow solid, yield 96% (1.657 g, 6.81 mmol).  
1H NMR (500 MHz, DMSO-d6) δ 10.62 (br s, 1H, OH), 10.02 (s, 1H, CHO), 7.89 (d, J 
= 7.4 Hz, 1H, ar CH), 7.78 (s, 1H, ar CH), 7.63 (t, J = 7.5 Hz, 1H, ar CH), 7.59 (d, J = 
7.7 Hz, 1H, ar CH), 7.39 (d, J = 8.4 Hz, 1H, ar CH), 7.36 (s, 1H, ar CH), 7.16 (d, J = 8.4 
Hz, 1H, ar CH) ppm. 
13C NMR (126 MHz, DMSO-d6) δ 193.3, 158.2, 149.4, 138.7, 136.8, 134.3, 133.4, 129.9, 
129.2, 128.9, 125.1, 120.6, 111.2 ppm. 
MS-EI (m/z) found 243 [M]+, calcd 243.  
 
Synthesis of (4-bromo-3-nitrophenoxy)(tert-butyl)dimethylsilane (4.17) 
 
To a solution of 4-bromo-3-nitrophenol (436 mg, 2 mmol) and tert-butyldimethylsilyl 
chloride (331 mg, 2.2 mmol) in anhydrous DCM (4 mL) was added trimethylamine (418 
µL, 3 mmol) at 0 °C. The solution was allowed to warm to room temperature and was 
stirred until TLC indicated completion (2 h). The suspension was poured into saturated 
sodium hydrogen carbonate and DCM was added. The solution was filtered through a 
hydrophobic frit and the organic extract was filtered through a silica plug, eluting product 
with DCM. Solvent was removed under a reduced pressure to yield product as a yellow 
oil, yield 98% (656 mg, 1.97 mmol).  
1H NMR (500 MHz, Chloroform-d) δ 7.55 (d, J = 8.7 Hz, 1H, ar CH), 7.30 (s, 1H, ar 
CH), 6.92 (d, J = 8.7 Hz, 1H, ar CH), 0.98 (s, 9H, CH3), 0.24 (s, 6H, CH3) ppm. 
13C NMR (126 MHz, Chloroform-d) δ 155.5, 135.4, 125.2, 117.2, 105.2, 25.4 (3C), 
18.16, -4.53 (2C) ppm. 
MS-EI (m/z) found 333 [M]+, calcd 333.  
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Synthesis of 4’-((tert-butyldimethylsilyl)oxy)-2’-nitro-[1,1’biphenyl]-3-carbaldehyde 
(4.18) 
 
Synthesised according to general procedure C. (4-Bromo-3-nitrophenoxy)(tert-
butyl)dimethylsilane (4.17) (384 mg, 1.15 mmol), (3-formylphenyl)boronic acid (190 
mg, 1.27 mmol), potassium carbonate (317 mg, 2.3 mmol), Pd(dppf)Cl2.CH2Cl2 (47 mg, 
0.057 mmol), anhydrous toluene (2 mL) and H2O (1 mL). Crude product was purified by 
chromatography on silica gel using DCM/hexane 0/1 to 1/1 as an eluent. Product was 
isolated as a yellow oil, yield 60% (248 mg, 0.69 mmol).  
1H NMR (500 MHz, Chloroform-d) δ 10.04 (s, 1H, CHO), 7.89 (d, J = 7.2 Hz, 1H, ar 
CH), 7.81 (s, 1H, ar CH), 7.60 – 7.50 (m, 3H, ar CH), 7.41 (s, 1H, ar CH), 7.30 (d, J = 
8.3 Hz, 1H, ar CH), 7.13 (d, J = 8.3 Hz, 1H, ar CH), 1.03 (s, 9H, CH3), 0.29 (s, 6H, CH3). 
13C NMR (126 MHz, Chloroform-d) δ 191.6, 156.0, 149.3, 138.6, 136.7, 133.9, 132.7, 
132.6, 129.2, 129.1, 129.0, 127.9, 124.3, 115.8, 25.5 (3C), 18.1, -4.4 (2C) ppm. 
 
Synthesis of 7-hydroxy-9H-carbazole-3-carbaldehyde (4.19) 
 
Synthesised according to general procedure D using modified conditions. Reaction was 
stirred at 165 °C for 18 h. 4’-Hydroxy-2’-nitro-[1,1’-biphenyl]-3-carbaldehyde (4.15) (90 
mg, 0.37 mmol), triphenylphosphine (242 mg, 0.92 mmol) and DMA (2 mL). Crude 
product was purified by chromatography on silica gel using EtOAc/hexane 0/1 to 1/1. 
Product was isolated as a white solid, yield 21% (17 mg, 0.08 mmol). 
1H NMR (500 MHz, DMSO-d6) δ 11.53 (s, 1H, NH), 9.97 (s, 1H, CHO), 9.61 (s, 1H, 
OH), 8.50 (s, 1H, ar CH), 7.97 (d, J = 7.4 Hz, 1H, ar CH), 7.78 (d, J = 7.6 Hz, 1H, ar 
CH), 7.48 (d, J = 7.4 Hz, 1H, ar CH), 6.85 (s, 1H, ar CH), 6.70 (d, J = 7.6 Hz, 1H, ar CH) 
ppm. 
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13C NMR (126 MHz, DMSO-d6) δ 192.3, 157.7, 143.9, 142.6, 128.5, 125.6, 123.6, 121.9, 
115.4, 111.1, 110.1, 97.3 ppm. 
MS-EI (m/z) found 211 [M]+, calcd 211. 
 
Synthesis of 7-ethyoxy-9-ethyl-9H-carbazole-3-carbaldehyde (4.20) 
 
Synthesised according to general procedure E modifying the solvent according to 
Compain-Batissou et al.532 7-Hydroxy-9H-carbazole-3-carbaldehyde (4.19) (80 mg, 0.37 
mmol), anhydrous THF (10 mL), anhydrous DMF (54 µL, 0.70 mmol), sodium hydride 
(36 mg, 60% dispersion in mineral oil, 0.92 mmol), ethyl iodide (32 µL, 0.40 mmol). 
Crude product was purified by chromatography on silica gel using EtOAc/hexane 1/4 to 
1/1. Product was isolated as a pale yellow solid, yield 17% (17 mg, 0.063 mmol).  
1H NMR (500 MHz, DMSO-d6) δ 10.03 (s, 1H, CHO), 8.61 (s, 1H, ar CH), 8.14 (d, J = 
8.5 Hz, 1H, ar CH), 7.90 (d, J = 9.4 Hz, 1H, ar CH), 7.71 (d, J = 8.4 Hz, 1H, ar CH), 6.89 
(d, J = 10.3 Hz, 1H, ar CH), 4.47 (q, J = 7.4 Hz, 2H, CH2), 4.18 (q, J = 7.0 Hz, 2H, CH2), 
1.40 (t, J = 6.9 Hz, 3H, CH3), 1.32 (t, J = 7.1 Hz, 3H, CH3) ppm. 
13C NMR (126 MHz, Chloroform-d) δ 191.9, 129.9, 123.4, 122.7, 122.7, 121.5, 117.7, 
108.8, 108.3, 105.6, 95.6, 94.4, 64.0, 37.8, 14.9, 13.6 ppm. Missing one quaternary 
carbon. 
MS-EI (m/z) found 267 [M]+, calcd 267.  
 
Synthesis of 4-(benzyloxy)-1-bromo-2-nitrobenzene (4.21) 
 
To a solution of 4-bromo-3-nitrophenol (800 mg, 3.66 mmol) in anhydrous THF (5 mL) 
was added sodium hydride (161 mg, 60% dispersion in mineral oil, 4.03 mmol). The 
resulting suspension was stirred for 30 minutes at room temperature. Benzyl bromide 
(478 µL, 4.03 mmol) was added and the resulting solution was stirred at 30 °C until TLC 
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indicated completion (18 h). Solvent was removed under a reduced pressure and EtOAc 
(50 mL) and H2O (50 mL) were added to the residue. Crude product was extracted with 
EtOAc (3 X 20 mL) and the organic extracts were washed with H2O (30 mL) and dried 
over anhydrous MgSO4. The suspension was filtered and the filtrate was concentrated 
under a reduced pressure to yield crude product that was purified by chromatograpy on 
silica gel using EtOAc/hexane 1/4 to 1/1 as an eluent. Product was isolated as a white 
solid, yield 80% (905 mg, 2.93 mmol). 
1H NMR (399 MHz, DMSO-d6) δ 7.77 (d, J = 8.9 Hz, 1H, ar CH), 7.71 (d, J = 3.0 Hz, 
1H, ar CH), 7.48 – 7.31 (m, 5H, ar CH), 7.26 (dd, J = 8.9, 3.0 Hz, 1H, ar CH), 5.18 (s, 
2H, CH2) ppm. 
13C NMR (126 MHz, Chloroform-d) δ 158.2, 150.1, 135.5, 135.3, 128.8 (2C), 128.5, 
127.5 (2C), 120.5, 111.9, 104.8, 70.9 ppm. 
MS-EI (m/z) found 307 [M]+, calcd 307.  
 
Synthesis of 4’-(benzyloxy)-2’-nitro-[1,1’-biphenyl]-3-carbaldehyde (4.22) 
 
Synthesised according to general procedure C. 4-(Benzyloxy)-1-bromo-2-nitrobenzene 
(4.21) (616 mg, 2 mmol), (3-formylphenyl)boronic acid (329 mg, 2.2 mmol), potassium 
carbonate (552 mg, 4 mmol), Pd(dppf)Cl2.CH2Cl2 (81 mg, 0.1 mmol), anhydrous toluene 
(2 mL) and degassed H2O (1 mL). Crude product was purified by recrystallization in 
EtOAc/hexane. Product was isolated as a beige crystalline solid, yield 54% (528 mg, 1.64 
mmol).  
1H NMR (500 MHz, Chloroform-d) δ 10.06 (s, 1H, CHO), 7.91 (d, J = 8.7 Hz, 1H, ar 
CH), 7.82 (s, 1H, ar CH), 7.62 – 7.51 (m, 3H, ar CH), 7.50 – 7.41 (m, 3H, ar CH), 7.42 – 
7.33 (m, 1H, ar CH), 7.30 – 7.23 (m, 1H, ar CH), 5.19 (s, 2H, CH2) ppm. 
13C NMR (126 MHz, Chloroform-d) δ 191.6, 158.7, 149.3, 138.6, 136.7, 135.5, 134.0, 
132.8, 129.1, 129.1, 128.8 (2C), 128.4, 127.6, 127.5 (2C), 119.6, 110.5, 70.8 ppm. 
Missing one quarternary carbon. 
HRMS-ESI (m/z) found 356.0892 [M+Na]+, calcd 356.0893 for [C20H15NO4+Na]+. 
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Synthesis of 7-(benzyloxy)-9H-carbazole-3-carbaldehyde (4.23) 
 
 
Synthesised according to general procedure D using modified conditions. Reaction was 
stirred at 165 °C for 18 h. 4’-(Benzyloxy)-2’-nitro-[1,1’-biphenyl]-3-carbaldehyde (4.22) 
(368 mg, 1.1 mmol), triphenylphosphine (723 mg, 2.75 mmol) and DMA (2 mL). Crude 
product was purified by chromatography on silica gel using EtOAc/hexane 1/4 to 1/1 as 
an eluent. Product was isolated as an orange solid, yield 37% (119 mg, 0.39 mmol). 
1H NMR (500 MHz, DMSO-d6) δ 11.69 (s, 1H, NH), 10.01 (s, 1H, CHO), 8.60 (s, 1H, 
ar CH), 8.12 (d, J = 8.5 Hz, 1H, ar CH), 7.85 (d, J = 8.4 Hz, 1H, ar CH), 7.56 (d, J = 8.4 
Hz, 1H, ar CH), 7.50 (d, J = 7.6 Hz, 3H, ar CH), 7.41 (t, J = 7.6 Hz, 3H, ar CH), 7.35 (d, 
J = 7.1 Hz, 1H, ar CH), 7.12 (s, 1H, ar CH), 6.96 (d, J = 8.5 Hz, 1H, ar CH), 5.22 (s, 2H, 
CH2) ppm. 
 
Synthesis of 7-(benzyloxy)-9-ethyl-9H-carbazole-3-carbaldehyde (4.24) 
 
Synthesised according to general procedure E. 7-(Benzyloxy)-9H-carbazole-3-
carbaldehyde (4.23) (119 mg, 0.39 mmol), anhydrous DMF (1 mL), sodium hydride (31 
mg, 60% dispersion in mineral oil, 0.78 mmol) and ethyl iodide (62 µL, 0.78 mmol). 
Crude product was purified by chromatography on silica gel using EtOAc/hexane 1/4 to 
1/1 as an eluent. Product was isolated as yellow solid, yield 56% (74 mg, 0.22 mmol). 
1H NMR (500 MHz, DMSO-d6) δ 10.03 (s, 1H, CHO), 8.62 (s, 1H, ar CH), 8.16 (d, J = 
8.5 Hz, 1H, ar CH), 7.91 (d, J = 8.5 Hz, 1H, ar CH), 7.72 (d, J = 8.5 Hz, 1H, ar CH), 7.53 
(d, J = 7.6 Hz, 2H, ar CH), 7.42 (t, J = 7.6 Hz, 2H, ar CH), 7.37 – 7.34 (m, 2H, ar CH), 
6.98 (d, J = 9.7 Hz, 1H, ar CH), 5.26 (s, 2H, CH2), 4.47 (q, J = 7.2 Hz, 2H, CH2), 1.32 (t, 
J = 7.1 Hz, 3H, CH3) ppm. 
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Synthesis of 2’-nitro-4’-(pyridine-2-yloxy)-[1,1’-biphenyl]-3-carbaldehyde  (4.25) 
 
To an oven-dried carosel tube was added 4’-hydroxy-2’-nitro-[1,1’-biphenyl]-3-
carbaldehyde (4.15) (400 mg, 1.64 mmol), 2-picolinic acid (40 mg, 0.32 mmol), K3PO4 
(698 mg, 3.28 mmol) and copper (I) iodide (31 mg, 0.16 mmol). The tube was evacuated 
and backfilled with argon three times. A solution of 2-bromopyridine (188 µL, 1.97 
mmol) in DMSO was added and the solution was stirred at 100 °C until TLC indicated 
completion (3 h). The reaction was cooled and diluted with EtOAc (20 mL) and H2O (20 
mL) and was filtered through celite. Crude product was extracted with EtOAc (3 X 20 
mL), the organic extracts were washed with H2O (20 mL) and dried over anhydrous 
sodium sulfate. The suspension was filtered and the filtrate was concentrated under a 
reduced pressure to yield crude product that was purified by chromatography on silica gel 
using EtOAc/hexane 0/1 to 1/4 as an eluent. Product was isolated as a pale yellow solid, 
yield 64% (341 mg, 1.06 mmol). 
1H NMR (500 MHz, Chloroform-d) δ 10.05 (s, 1H, CHO), 8.25 – 8.18 (m, 1H, ar CH), 
7.95 – 7.89 (m, 1H, ar CH), 7.92 – 7.74 (m, 3H, ar CH), 7.71 – 7.53 (m, 2H, ar CH), 7.56 
– 7.41 (m, 2H, ar CH), 7.15 – 7.04 (m, 2H, ar CH) ppm. 
13C NMR (126 MHz, Chloroform-d) δ 191.7, 162.3, 154.0, 149.0, 147.5, 140.1, 138.4, 
136.6, 133.9, 132.8, 131.0, 129.3, 129.3, 129.1, 125.5, 119.7, 117.3, 112.3 ppm. 
MS-EI (m/z) found 320 [M]+, calcd 320.  
 
Synthesis of 1-(9-ethyl-7-(pyridine-2-yloxy)-9H-carbazol-3-yl)-N-methylmethanamine 
(4.28) 
 
Via a three step-synthesis starting from 2’-nitro-4’-(pyridine-2-yloxy)-[1,1’-biphenyl]-3-
carbaldehyde  (4.25). The cyclized carbazole, 1-(9-ethyl-7-(pyridine-2-yloxy)-9H-
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carbazole-3-carbaldehdye (4.26), was synthesised according to general procedure D using 
modified conditions. Reaction was stirred at 165 °C for 4 h. 2’-Nitro-4’-(pyridine-2-
yloxy)-[1,1’-biphenyl]-3-carbaldehyde  (4.25) (341 mg, 1.06 mmol), triphenyl phosphine 
(698 mg, 2.66 mmol) and DMA (1 mL). Crude product was purified by chromatography 
on silica gel using EtOAc/hexane 1/4 to 1/1 as an eluent. Product was isolated as a mixture 
with starting material (224 mg). Presence of product was confirmed by observation of the 
NH proton by 1H NMR.  
1H NMR (500 MHz, DMSO-d6) δ 11.84 (s, 1H, NH), 10.22 (d, J = 1.1 Hz, 1H), 10.07 (s, 
1H), 8.48 (d, J = 7.6 Hz, 1H), 8.25 – 8.14 (m, 3H), 8.01 – 7.91 (m, 3H), 7.93 – 7.83 (m, 
3H), 7.75 – 7.63 (m, 3H), 7.66 – 7.58 (m, 1H), 7.46 – 7.36 (m, 2H), 7.26 – 7.18 (m, 2H), 
7.19 – 7.11 (m, 1H), 7.08 – 6.98 (m, 2H). Total 24 x 1H corresponding to both 4.25 and 
4.26 in approximately a 1:1 ratio. 
9-Ethyl-7-(pyridine-2-yloxy)-9H-carbazole-3-carbaldehyde (4.27) was synthesised 
according to general procedure E. A mixture of 1-(9-ethyl-7-(pyridine-2-yloxy)-9H-
carbazole-3-carbaldehdye (4.26) and 2’-nitro-4’-(pyridine-2-yloxy)-[1,1’-biphenyl]-3-
carbaldehyde  (4.25) (114 mg, 0.39 mmol), anhydrous DMF (2 mL), sodium hydride (17 
mg, 60% suspension in mineral oil, 0.43 mmol) and ethyl iodide (34 µL, 0.43 mmol). 
Crude product was purified by chromatography on silica gel using DCM as an eluent.  
Product was isolated as a mixture where the reaction was confirmed by the presence of 
CH2 and CH3 of the ethyl peak and disappearance of the NH proton. 
1H NMR (500 MHz, Chloroform-d) δ 10.32 (s, 1H), 10.19 (s, 1H), 8.35 – 8.19 (m, 3H), 
8.10 (d, J = 8.3 Hz, 2H), 7.92 (dd, J = 7.6, 1.3 Hz, 1H), 7.85 – 7.69 (m, 2H), 7.42 – 7.25 
(m, 3H), 7.16 – 6.93 (m, 4H), 4.76 (q, J = 7.1 Hz, 2H, CH2), 1.44 (t, J = 7.1 Hz, 3H, CH3). 
Synthesis of 1-(9-ethyl-7-(pyridine-2-yloxy)-9H-carbazol-3-yl)-N-methylmethanamine 
(4.28) was accomplished using general procedure A. 9-Ethyl-7-(pyridine-2-yloxy)-9H-
carbazole-3-carbaldehyde (4.27) (15 mg, 0.047 mmol), methylamine hydrochloride (7 
mg, 0.094 mmol), trimethylamine (10 µL, 0.071 mmol), titanium (IV) isopropoxide (28 
µL, 0.094 mmol), DCM (1 mL), EtOH (1 mL) and sodium borohydride (4 mg, 0.094 
mmol). Product was isolated as a brown oil, yield 66% (10.6 mg, 0.030 mmol).  
1H NMR (500 MHz, Chloroform-d) δ 8.27 – 8.22 (m, 1H, ar CH), 8.06 (d, J = 8.3 Hz, 
1H, ar CH), 8.01 (d, J = 7.7 Hz, 1H, ar CH), 7.73 – 7.66 (m, 1H, ar CH), 7.32 (d, J = 7.3 
Hz, 1H, ar CH), 7.21 (s, 1H, ar CH), 7.17 (t, J = 7.5 Hz, 1H, ar CH), 7.04 – 6.98 (m, 2H, 
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ar CH), 6.92 (d, J = 8.8 Hz, 1H, ar CH), 4.64 (q, J = 7.2 Hz, 2H, CH2), 4.13 (s, 2H, CH2), 
2.56 (s, 3H, CH3), 1.43 (t, J = 7.1 Hz, 3H, CH3) ppm. 
13C NMR (126 MHz, Chloroform-d) δ 152.9, 147.9, 141.6, 139.2, 128.3, 120.7, 120.3, 
119.7, 118.8, 118.2, 117.7, 115.2, 113.0, 111.1, 109.9, 106.6, 101.7, 65.3, 48.8, 39.3, 15.4 
ppm.  
HRMS-ESI (m/z) found 301.1331 [M]+, calcd 301.1335 for [C20H17N2O]+ (loss of 
NHMe).  
LC-MS purity = 90% (UV), ret time = 12.08 min. 
 
General Procedure F 
Synthesis of 9-ethyl-7-(thiophen-2-yl)-9H-carbazole-3-carbaldehyde (4.30a) 
 
 
To an oven-dried carosel tube was added 7-bromo-9-ethyl-9H-carbazole-3-carbaldehyde 
(4.4) (500 mg, 1.65 mmol), thiophene-2-boronic acid (254 mg, 1.98 mmol), potassium 
carbonate (457 mg, 3.30 mmol) and Pd-118 (10 mg, 0.016 mmol). The tube was 
evacuated and backfilled with argon three times before anhydrous MeCN (2.5 mL) and 
degassed H2O (2.5 mL) were added. The solution was heated to 80 °C and stirred for 2 h. 
The reaction was cooled to room temperature and diluted with EtOAc (30 mL) and H2O 
(30 mL). Crude product was extracted with EtOAc (3 X 10 mL), washed with brine (30 
mL) and dried over anhydrous MgSO4. The suspension was filtered and the filtrate was 
concentrated under a reduced pressure to yield crude product that was purified by 
chromatography on silica gel using EtOAc/hexane 1/4 to 1/1 as an eluent (over 15 
minutes). Product was isolated as a yellow solid, yield 57 % (288 mg, 0.94 mmol). 
1H NMR (500 MHz, Chloroform-d) δ 10.08 (s, 1H, CHO), 8.56 (s, 1H, ar CH), 8.10 (d, 
J = 8.1 Hz, 1H, ar CH), 7.99 (d, J = 8.4 Hz, 1H, ar CH), 7.62 (s, 1H, ar CH), 7.58 (d, J = 
8.1 Hz, 1H, ar CH), 7.45 (d, J = 8.6 Hz, 1H, ar CH), 7.43 (d, J = 2.5 Hz, 1H, ar CH), 7.33 
(d, J = 4.7 Hz, 1H, ar CH), 7.14 (t, J = 4.2 Hz, 1H, ar CH), 4.40 (q, J = 7.2 Hz, 2H, CH2), 
1.48 (t, J = 7.2 Hz, 3H, CH3) ppm. 
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13C NMR (126 MHz, Chloroform-d) δ 191.6, 144.9, 144.0, 141.1, 133.2, 128.7, 128.1, 
127.2, 125.0, 123.8, 123.4, 122.9, 122.4, 121.1, 118.9, 108.7, 106.2, 37.9, 13.8 ppm. 
HRMS-ESI (m/z) found 306.0947 [M+H]+, cald 306.0947 for [C19H15NOS+H]+. 
 
Synthesis of 9-ethyl-7-(furan-2-yl)-9H-carbazole-3-carbaldehyde (4.30b) 
 
Synthesised according to general procedure F. 7-Bromo-9-ethyl-9H-carbazole-3-
carbaldehyde (4.4) (500 mg, 1.65 mmol), furan-2-boronic acid (222 mg, n1.98 mmol), 
potassium carbonate (457 mg, 3.30 mmol), Pd-118 (10 mg, 0.16 mmol), anhydrous 
MeCN (2.5 mL) and degassed H2O (2.5 mL). Product was isolated as a yellow solid, yield 
56% (271 mg, 0.93 mmol). 
1H NMR (500 MHz, Chloroform-d) δ 10.10 (s, 1H, CHO), 8.58 (s, 1H, ar CH), 8.13 (d, 
J = 8.5 Hz, 1H, ar CH), 8.01 (d, J = 8.5 Hz, 1H, ar CH), 7.77 (s, 1H, ar CH), 7.63 (d, J = 
8.2 Hz, 1H, ar CH), 7.54 (s, 1H, ar CH), 7.47 (d, J = 8.5 Hz, 1H, ar CH), 6.79 (d, J = 3.1 
Hz, 1H, ar CH), 6.57 – 6.48 (m, 1H, ar CH), 4.44 (q, J = 7.2 Hz, 2H, CH2), 1.51 (t, J = 
7.2 Hz, 3H, CH3) ppm. 
13C NMR (126 MHz, DMSO-d6) δ 192.2, 154.1, 144.1, 143.3, 141.2, 129.4, 128.9, 127.1, 
124.3, 122.6, 122.0, 121.8, 116.6, 112.7, 110.0, 106.7, 104.8, 37.8, 14.2 ppm. 
HRMS-ESI (m/z) found 312.0991 [M+Na]+, calcd 312.0995 for [C19H15NO2+Na]+.  
 
Synthesis of 1-(9-ethyl-7-(thiophen-2-yl)-9H-carbazol-3-yl)-N-methylmethanamine 
(4.31a) 
 
Synthesised according to general procedure B. 9-Ethyl-7-(thiophen-2-yl)-9H-carbazole-
3-carbaldehyde (4.30a) (100 mg, 0.32 mmol), methylamine (163 µL, 2M solution in THF, 
193 
 
0.32 mmol), anhydrous THF (5 mL) and sodium triacetoxyborohydride (104 mg, 0.49 
mmol). Product isolated as a pale yellow solid, yield 12 % (13 mg, 0.040 mmol). 
1H NMR (500 MHz, Chloroform-d) δ 8.05 (d, J = 8.3 Hz, 1H, ar CH), 8.04 (s, 1H, ar 
CH), 7.58 (s, 1H, ar CH), 7.51 – 7.48 (m, 1H, ar CH), 7.46 – 7.42 (m, 1H, ar CH), 7.41 
(d, J = 3.6 Hz, 1H, ar CH), 7.35 (d, J = 8.3 Hz, 1H, ar CH), 7.32 – 7.27 (m, 1H, ar CH), 
7.13 (d, J = 3.6 Hz, 1H, ar CH), 7.12 (d, J = 3.6 Hz, 1H, ar CH), 4.37 (q, J = 7.2 Hz, 2H, 
CH2), 3.95 (s, 2H, CH2), 2.53 (s, 2H, CH2), 1.44 (t, J = 7.2 Hz, 3H, CH3) ppm. 
13C NMR (126 MHz, Chloroform-d) δ 145.6, 140.6, 139.9, 132.1, 128.4, 127.9, 126.4, 
124.4, 123.0, 122.8, 122.3, 120.7, 120.3, 117.6, 108.4, 105.7, 55.9, 37.5, 35.3, 13.7 ppm. 
HRMS-ESI (m/z) found 290.0992 [M]+, calcd 290.0998 [C19H16NS]+ (loss of NHMe). 
LC-MS purity > 99% (UV), ret. time = 12.73 min. 
 
Synthesis of 1-(9-ethyl-7-(furan-2-yl)-9H-carbazol-3-yl)-N-methylmethanamine (4.31b) 
  
 
Synthesised according to general procedure B. 9-Ethyl-7-(furan-2-yl)-9H-carbazole-3-
carbaldehyde (4.30b) (100 mg, 0.34 mmol), methylamine (259 µL, 2 M solution in THF, 
0.51 mmol), anhydrous THF (4 mL) and sodium triacetoxyborohydride (183 mg, 0.86 
mmol). Product isolated as an orange solid, yield 46% (48 mg, 0.15 mmol). 
1H NMR (500 MHz, Chloroform-d) δ 8.06 (d, J = 8.1 Hz, 1H, ar CH), 8.03 (s, 1H, ar 
CH), 7.72 (s, 1H, ar CH), 7.54 (d, J = 8.2 Hz, 1H, ar CH), 7.53 – 7.50 (m, 1H, ar CH), 
7.42 (d, J = 8.1 Hz, 1H, ar CH), 7.35 (d, J = 8.2 Hz, 1H, ar CH), 6.75 (d, J = 3.3 Hz, 1H, 
ar CH), 6.55 – 6.51 (m, 1H, ar CH), 4.38 (q, J = 7.2 Hz, 2H, CH2), 3.93 (s, 2H, CH2), 
2.53 (s, 3H, CH3) and 1.45 (t, J = 7.2 Hz, 3H, CH3) ppm. 
13C NMR (126 MHz, Chloroform-d) δ 155.0, 141.7, 140.5, 139.8, 130.4, 128.5, 126.3, 
122.9, 122.1, 120.6, 120.1, 115.4, 111.7, 108.3, 104.8, 103.6, 56.2, 37.5, 35.7 and 13.8 
ppm. 
HRMS-ESI (m/z) found 274.1219 [M]+, calcd 274.1226 [C19H16NO]+ (loss of NHMe). 
LC-MS purity > 99% (UV), ret. time = 12.38 min. 
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Synthesis of 9-ethyl-6-formyl-9H-carbazole-2-carboxylic acid (4.33) 
 
To a solution of methyl-9-ethyl-6-formyl-9H-carbazole-2-carboxylate (4.13) (138 mg, 
0.49 mmol) in MeOH (10 mL) and H2O (10 mL) was added lithium hydroxide (58 mg, 
2.50 mmol) and the resulting solution was heated at 90 °C for 2 h. The solution was 
cooled and diluted with H2O (10 mL) and neutralized with 1 N HCl. Crude product was 
extracted with EtOAc (3 X 10 mL) and dried over anhydrous MgSO4. The suspension 
was filtered and the filtrate was concentrated under a reduced pressure to yield product 
as a white solid, yield 80% (106 mg, 0.40 mmol).  
1H NMR (500 MHz, DMSO-d6) δ 13.06 (s, 1H, CO2H), 10.06 (s, 1H, CHO), 8.84 (s, 1H, 
ar CH), 8.39 (d, J = 8.1 Hz, 1H, ar CH), 8.25 (s, 1H, ar CH), 8.05 (d, J = 8.6 Hz, 1H, ar 
CH), 7.88 (d, J = 8.1 Hz, 1H, ar CH), 7.85 (d, J = 8.6 Hz, 1H, ar CH), 4.58 (q, J = 7.1 Hz, 
2H, CH2), 1.34 (t, J = 7.1 Hz, 3H, CH3) ppm. 
13C NMR (126 MHz, DMSO-d6) δ 192.2, 168.1, 140.2, 129.1, 127.9, 126.3, 125.5, 122.0, 
121.4, 121.2, 113.8, 111.6, 110.5, 109.9, 37.9, 14.2 ppm. 
MS-EI (m/z) found 266 [M]-, calcd 266.  
 
General Procedure G 
Synthesis of 9-ethyl-6-formyl-N-methyl-9H-carbazole-2-carboxamide (4.33a) 
 
 
 
To an oven-dried two-neck flask was added 9-ethyl-6-formyl-9H-carbazole-2-carboxylic 
acid (4.33) (30 mg, 0.11 mmol), HATU (42 mg, 0.11 mmol) and the flask was evacuated 
and backfilled with argon 3 times. Anhydrous DMF (1 mL) and trimethylamine (31 µL, 
0.22 mmol) were added and the solution was stirred at rt for 5 minutes. Methylamine 
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hydrochloride was added and the solution was stirred until TLC indicated completion (18 
h). The solution was diluted with EtOAc (30 mL) and H2O (30 mL) and crude product 
was extracted with EtOAc (3 X 30 mL). The organic extracts were washed with saturated 
NaHCO3, dried over anhydrous MgSO4, filtered and the filtrate was concentrated under 
a reduced pressure to yield crude product. Product was purified by chromatography on 
silica gel using DCM/MeOH 9/1 as an eluent to yield product as a yellow solid, yield 
90% (27 mg, 0.096 mmol).  
1H NMR (500 MHz, Chloroform-d) δ 10.12 (s, 1H, CHO), 8.64 (s, 1H, ar CH), 8.17 (d, 
J = 8.1 Hz, 1H, ar CH), 8.11 – 8.03 (m, 2H, ar CH), 7.59 (d, J = 8.1 Hz, 1H, ar CH), 7.53 
(d, J = 8.5 Hz, 1H, ar CH), 6.33 (br s, 1H, NH ), 4.47 (q, J = 7.3 Hz, 2H, CH2), 3.11 (s, 
3H, CH3), 1.50 (t, J = 7.3 Hz, 3H, CH3) ppm. 
HRMS-ESI (m/z) found 281.1285 [M+H]+, calcd 281.1245 for [C17H16N2O2+H]+. 
 
Synthesis of 9-ethyl-6-formyl-N,N-dimethyl-9H-carbazole-2-carboxamide (4.33b) 
 
Synthesised according to general procedure G. 9-Ethyl-6-formyl-9H-carbazole-2-
carboxylic acid (4.33) (30 mg, 0.11 mmol), HATU (42 mg, 0.11 mmol), anhydrous DMF 
(1 mL), triethylamine (31 µL, 0.22 mmol) and dimethylamine hydrochloride (11 mg, 0.13 
mmol). Product was isolated as an orange oil, yield 84% (28 mg, 0.095 mmol).   
1H NMR (500 MHz, Chloroform-d) δ 10.09 (s, 1H, CHO), 8.61 (s, 1H, ar CH), 8.14 (d, 
J = 7.9 Hz, 1H, ar CH), 8.03 (d, J = 8.5 Hz, 1H, ar CH), 7.59 (s, 1H, ar CH), 7.50 (d, J = 
8.5 Hz, 1H, ar CH), 7.35 (d, J = 7.9 Hz, 1H, ar CH), 4.41 (q, J = 7.2 Hz, 2H, CH2), 3.12 
(s, 6H, CH3), 1.47 (t, J = 7.2 Hz, 3H, CH3) ppm. 
HRMS-ESI (m/z) found 317.1265 [M+Na]+, calcd 317.1260 for [C18H18N2O2+Na]+. 
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Synthesis of 9-ethyl-N-methyl-6-((methylamino)methyl)-9H-carbazole-2-carboxamide 
(4.34a) 
 
Synthesised according to general procedure A. 9-Ethyl-6-formyl-N-methyl-9H-
carbazole-2-carboxamide (4.33a) (12 mg, 0.04 mmol), methylamine hydrochloride (6 
mg, 0.08 mmol), triethylamine (9 µL, 0.06 mmol), titanium (IV) isopropoxide (25 µL, 
0.08 mmol), DCM (2 mL), EtOH, (2 mL) and sodium borohydride (3 mg, 0.08 mmol). 
Product was isolated as a yellow solid, yield 27% (3 mg, 0.010 mmol).  
1H NMR (500 MHz, Chloroform-d) δ 8.11 – 8.03 (m, 2H, ar CH), 7.98 (s, 1H, ar CH), 
7.48 (d, J = 8.2 Hz, 2H, ar CH), 7.39 (d, J = 8.3 Hz, 1H, ar CH), 6.37 (br s, H, NH), 4.39 
(q, J = 7.2 Hz, 2H, CH2), 3.94 (s, 2H, CH2), 3.09 (d, J = 4.7 Hz, 3H, CH3), 2.53 (s, 3H, 
CH3), 1.43 (t, J = 7.2 Hz, 3H, CH3) ppm. 
MS-ESI (m/z) found 265.2 [M]+ (LC-MS), calcd 265.1 for [C17H17N2O]+ (loss of 
NHMe). 
LC-MS purity > 99% (UV), ret time = 3.02 min.  
 
Synthesis of 9-ethyl-N,N-dimethyl-6-((methylamino)methyl)-9H-carbazole-2-
carboxamide (4.34b) 
 
Synthesised according to general procedure A. 9-Ethyl-6-formyl-N,N-dimethyl-9H-
carbazole-2-carboxamide (4.33b) (28 mg, 0.09 mmol), methylamine hydrochloride (13 
mg, 0.19 mmol), triethylamine (18 µL, 0.135 mmol), titanium (IV) isopropoxide (56 µL, 
0.19 mmol), DCM (1 mL), EtOH (1 mL) and sodium borohydride (7 mg, 0.19 mmol). 
Product was isolated as an orange oil, yield 14% (4 mg, 0.012 mmol).  
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1H NMR (500 MHz, Chloroform-d) δ 8.12 – 8.03 (m, 2H, ar CH), 7.52 (s, 1H, ar CH), 
7.47 (d, J = 8.3 Hz, 1H, ar CH), 7.38 (d, J = 8.3 Hz, 1H, ar CH), 7.25 (d, J = 7.9 Hz, 1H, 
ar CH), 4.37 (q, J = 7.1 Hz, 2H, CH2), 3.94 (s, 2H, CH2), 3.12 (br s, 6H, CH3), 2.52 (s, 
2H, CH2), 1.68 (s, 3H, CH3), 1.44 (t, J = 7.1 Hz, 3H, CH3) ppm. 
MS-ESI (m/z) found 279.2 [M]+ (LC-MS), calcd 272.1 for [C18H19N2O]+ (loss of 
NHMe). 
LC-MS purity > 99% (UV), ret time = 2.84 min.  
 
Synthesis of 9-ethyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-9H-carbazole-3-
carbaldehyde (4.37) 
 
To a solution of 7-bromo-9-ethyl-9H-carbazole-3-carbaldehyde (4.4) (900 mg, 2.9 
mmol), bispinacolato diboron (1.134 g, 4.4 mmol) and KOAc (876 mg, 8.9 mmol) in 1,4-
dioxane (10 mL) under argon was added Pd(dppf)Cl2.CH2Cl2 (243 mg, 0.29 mmol). The 
resulting solution was stirred at 80 °C for 2 hours. The solution was cooled and H2O was 
added (50 mL). Crude product was extracted with EtOAc (3 X 50 mL). The organic 
extracts were washed with brine (50 mL) then dried over anhydrous MgSO4. The 
suspension was filtered and the filtrate was concentrated under a reduced pressure to yield 
crude product which was purified by chromatography on silica gel (hexane/EtOAc 4/1 as 
an eluent). Product isolated as a pale yellow solid, yield 95% (966 mg, 2.76 mmol).  
1H NMR (500 MHz, DMSO-d6) δ 10.04 (s, 1H, CHO), 8.76 (s, 1H, ar CH), 8.28 (d, J = 
7.8 Hz, 1H, ar CH), 8.00 (d, J = 8.5 Hz, 1H, ar CH), 7.91 (s, 1H, ar CH), 7.79 (d, J = 8.6 
Hz, 1H, ar CH), 7.61 (d, J = 7.8 Hz, 1H, ar CH), 4.53 (q, J = 6.9 Hz, 2H, CH2), 1.33 (m, 
15H, CH3) ppm. 
13C NMR (126 MHz, DMSO-d6) δ 192.2, 143.9, 140.2, 128.8, 127.5, 126.3, 125.4, 125.1, 
122.4, 120.8, 116.0, 110.3, 84.2 (2C), 37.8, 25.2 (4C), 14.2 ppm. 
HRMS-ESI (m/z) found 372.1745 [M+Na]+, calcd 372.1741 for [C21H24BNO3+Na]+. 
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Synthesis of 5-bromo-2,3-dimethylthiophene (4.38) 
 
Synthesised according to a literature procedure.533 To a solution of 2,3-dimethylthiophene 
(500 µL, 4.4 mmol) in DCM (10 mL) was added N-bromosuccinimide (872 mg, 4.9 
mmol). The resulting solution was stirred at room temperature for 18 h. The solution was 
diluted with DCM (10 mL) and silica was added. Solvent was removed under a reduced 
pressure to yield crude product loaded on silica. Crude product was purified by 
chromatography on silica gel using hexane as an eluent to yield product as a light brown 
oil in a quantitative yield (840 mg, 4.39 mmol). 
1H NMR (500 MHz, Chloroform-d) δ 6.75 (s, 1H, ar CH), 2.31 (s, 3H, CH3), 2.13 (s, 3H, 
CH3) ppm. Consistent with the literature values.534 
 
Synthesis of ((2-bromothiophen-3-yl)methoxy)(tert-butyl)dimethylsilane (4.39) 
 
To a solution of ((2-bromo-thiophen-3-yl)methoxy)(tert-butyl)dimethylsilane (533 mg, 
2.76 mmol) and tert-butyldimethylsilyl chloride (457 mg, 3.03 mmol) in anhydrous DCM 
(5 mL) was added trimethylamine (577 µL, 4.14 mmol) at 0 °C. The solution was allowed 
to warm to room temperature and was stirred until TLC indicated completion (18 h). The 
suspension was poured into saturated sodium hydrogen carbonate and DCM was added. 
The solution was filtered through a hydrophobic frit and the organic extract was filtered 
through a silica plug, eluting product with DCM. Solvent was removed under a reduced 
pressure to yield product as a colourless liquid yield 53% (454 mg, 1.47 mmol).  
1H NMR (500 MHz, Chloroform-d) δ 7.23 (d, J = 5.6 Hz, 1H, ar CH), 7.04 (d, J = 5.6 
Hz, 1H, ar CH), 4.67 (s, 2H, CH2), 0.97 (s, 9H, CH3), 0.14 (s, 6H, CH3) ppm. Consistent 
with the literature values.  
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Synthesis of 9-ethyl-7(thiophen-3-yl)-9H-carbazole-3-carbaldehyde (4.30c) 
 
Synthesised according to general procedure F. 7-Bromo-9-ethyl-9H-carbazole-3-
carbaldehyde (4.4) (500 mg, 1.65 mmol), thiophene-3-boronic acid (254 mg, 1.98 mmol), 
potassium carbonate (457 mg, 3.30 mmol), Pd-118 (10 mg, 0.016 mmol), anhydrous 
MeCN (2.5 mL) and degassed H2O (2.5 mL). Product was isolated as a orange solid, yield 
74% (374 mg, 1.22 mmol). 
1H NMR (500 MHz, Chloroform-d) δ 10.10 (s, 1H, CHO), 8.60 (s, 1H, ar CH), 8.15 (d, 
J = 8.0 Hz, 1H, ar CH), 8.01 (d, J = 8.5 Hz, 1H, ar CH), 7.63 (s, 1H, ar CH), 7.61 – 7.55 
(m, 2H, ar CH), 7.51 (d, J = 4.8 Hz, 1H, ar CH), 7.48 (d, J = 8.5 Hz, 1H, ar CH), 7.45 (d, 
J = 2.9 Hz, 1H, ar CH), 7.45 (d, J = 3.0 Hz, 1H, ar CH), 4.44 (q, J = 7.2 Hz, 2H, CH2), 
1.50 (t, J = 7.2 Hz, 3H, CH3) ppm. 
13C NMR (126 MHz, Chloroform-d) δ 191.5, 144.0, 142.8, 141.2, 134.9, 128.8, 127.1, 
126.6, 126.3, 123.7, 123.1, 122.1, 121.0, 120.6, 119.4, 108.6, 106.8, 37.9, 13.8 ppm. 
HRMS-ESI (m/z) found 328.0768 [M+Na]+, calcd 328.0767 [C19H15NOS+Na]+. 
 
Synthesis of 9-ethyl-7-(furan-3-yl)-9H-carbazole-3-carbaldehyde (4.30d) 
 
Synthesised according to general procedure F. 7-Bromo-9-ethyl-9H-carbazole-3-
carbaldehyde (4.4) (500 mg, 1.65 mmol), furan-3-boronic acid (221 mg, 1.98 mmol), 
potassium carbonate (457 mg, 3.30 mmol), Pd-118 (10 mg, 0.016 mmol), anhydrous 
MeCN (2.5 mL) and degassed H2O (2.5 mL). Product was isolated as a pale yellow solid, 
yield 59% (283 mg, 0.97 mmol). 
1H NMR (500 MHz, Chloroform-d) δ 10.08 (s, 1H, CHO), 8.57 (s, 1H, ar CH), 8.11 (d, 
J = 8.0 Hz, 1H, ar CH), 7.99 (d, J = 8.5 Hz, 1H, ar CH), 7.85 (s, 1H, ar CH), 7.54 (d, J = 
1.6 Hz, 1H, ar CH), 7.50 (s, 1H, ar CH), 7.48 – 7.42 (m, 2H, ar CH), 6.85 – 6.81 (m, 1H, 
ar CH), 4.41 (q, J = 7.2 Hz, 2H, CH2), 1.48 (t, J = 7.3 Hz, 3H, CH3) ppm. 
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13C NMR (126 MHz, Chloroform-d) δ 191.7, 143.9, 143.8, 141.2, 138.7, 131.3, 128.6, 
127.1, 127.0, 123.7, 123.0, 122.0, 121.1, 118.7, 109.1, 108.6, 106.1, 37.9, 13.8 ppm. 
HRMS-ESI (m/z) found 312.0991 [M+Na]+, calcd 312.0995 for [C19H15NO2+Na]+. 
 
Synthesis of 9-ethyl-7-(thiazol-4-yl)-9H-carbazole-3-carbaldehyde (4.30e) 
 
Synthesised according to general procedure F. 9-Ethyl-7-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)-9H-carbazole-3-carbaldehyde (4.37) (470 mg, 1.34 mmol), 4-
bromothiazole (100 µL, 1.12 mmol), potassium carbonate (308 mg, 2.23 mmol), Pd-118 
(36 mg, 0.05 mmol), anhydrous MeCN (5 mL) and degassed H2O (5 mL). Product was 
isolated as a brown oil, yield 99% (408 mg, 1.33 mmol).  
1H NMR (500 MHz, Chloroform-d) δ 10.03 (s, 1H), 8.90 (d, J = 1.6 Hz, 1H), 8.50 (s, 
1H), 8.08 – 8.04 (m, 2H), 7.94 (d, J = 8.5 Hz, 1H), 7.73 (d, J = 8.8 Hz, 1H), 7.60 (d, J = 
1.8 Hz, 1H), 7.38 (d, J = 8.5 Hz, 1H), 4.35 (q, J = 7.3 Hz, 2H), 1.42 (t, J = 7.3 Hz, 3H) 
ppm. 
HRMS-ESI (m/z) found 307.0889 [M+H]+, calcd 307.0860 for [C18H14N2OS+H]+. 
 
Synthesis of 9-ethyl-7-(thiazol-2-yl)-9H-carbazole-3-carbaldehyde (4.30f) 
 
Synthesised according to general procedure F. 9-Ethyl-7-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)-9H-carbazole-3-carbaldehyde (4.37) (500 mg, 1.4 mmol), 2-
bromothiazole (86 µL, 0.95 mmol), potassium carbonate (262 mg, 1.90 mmol), Pd-118 
(31 mg, 0.004 mmol), anhydrous MeCN (4 mL) and degassed H2O (4 mL). Product was 
isolated as a orange solid, yield 30% (132 mg, 0.43 mmol). 
1H NMR (500 MHz, Chloroform-d) δ 10.10 (s, 1H, CHO), 8.60 (s, 1H, ar CH), 8.16 (s, 
2H, ar CH), 8.03 (d, J = 8.4 Hz, 1H, ar CH), 7.92 (s, 1H, ar CH), 7.85 (d, J = 8.1 Hz, 1H, 
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ar CH), 7.49 (d, J = 8.5 Hz, 1H, ar CH), 7.38 (s, 1H, ar CH), 4.46 (q, J = 7.2 Hz, 2H, 
CH2), 1.50 (t, J = 7.2 Hz, 3H, CH3) ppm. 
HRMS-ESI (m/z) found 307.0900 [M+H]+, calcd 307.0900 for [C18H14N2OS+H]+. 
 
Synthesis of 9-ethyl-7-(isoxazol-4-yl)-9H-carbazole-3-carbaldehyde (4.30g) 
 
Synthesised according to general procedure F under anhydrous conditions, using 
potassium phosphate tribasic as a base. 7-Bromo-9-ethyl-9H-carbazole-3-carbaldehyde 
(4.4) (107 mg, 0.35 mmol), isoxazole-4-boronic acid (120 mg, 1.06 mmol) K3PO4 (300 
mg, 1.41 mmol), Pd-118 (11 mg, 0.01 mmol), anhydrous MeCN (2 mL). Product was 
isolated as an orange solid, yield 31% (32 mg, 0.11 mmol).  
1H NMR (500 MHz, DMSO-d6) δ 10.05 (s, 1H, CHO), 9.55 (s, 1H, ar CH), 9.31 (s, 1H, 
ar CH), 8.75 (s, 1H, ar CH), 8.33 (d, J = 8.1 Hz, 1H, ar CH), 8.08 (s, 1H, ar CH), 7.99 (d, 
J = 9.9 Hz, 1H, ar CH), 7.78 (d, J = 8.5 Hz, 1H, ar CH), 7.64 (d, J = 8.1 Hz, 1H, ar CH), 
4.54 (q, J = 7.2 Hz, 2H, CH2), 1.38 (t, J = 7.2 Hz, 3H, CH3) ppm. 
13C NMR (126 MHz, DMSO-d6) δ 192.2, 155.5, 148.9, 144.0, 141.4, 129.0, 127.5, 127.2, 
124.3, 122.7, 122.3, 122.0, 121.9, 119.1, 110.1, 107.9, 37.9, 14.2 ppm. 
HRMS-ESI (m/z) found 291.1124 [M+H]+, calcd for [C18H14N2O2+H]+.  
 
Synthesis of 9-ethyl-7-(1H-pyrazol-4-yl)-9H-carbazole-3-carbaldehyde (4.30h) 
 
Synthesised according to general procedure F. 7-Bromo-9-ethyl-9H-carbazole-3-
carbaldehyde (4.4) (500 mg, 1.65 mmol), tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)-1H-pyrazole-1-carboxylate (584 mg, 1.98 mmol), potassium 
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carbonate (457 mg, 3.30 mmol), Pd-118 (10 mg, 0.016 mmol), anhydrous MeCN (2.5 
mL) and degassed H2O (2.5 mL). The below data refer to the Boc-protected product. 
1H NMR (500 MHz, Chloroform-d) δ 10.08 (s, 1H, CHO), 8.58 (s, 1H, ar CH), 8.42 (s, 
1H, ar CH), 8.14 (d, J = 8.0 Hz, 1H, ar CH), 8.11 (s, 1H, ar CH), 8.00 (d, J = 8.4 Hz, 1H, 
ar CH), 7.54 (s, 1H, ar CH), 7.52 – 7.41 (m, 2H, ar CH), 4.42 (q, J = 6.9 Hz, 2H, CH2), 
1.70 (s, 9H, CH3), 1.49 (t, J = 6.9 Hz, 3H, CH3) ppm. 
13C NMR (126 MHz, Chloroform-d) δ 191.7, 144.0, 142.0, 141.1, 129.5, 128.7, 127.3, 
126.6, 126.0, 123.8, 122.9, 122.4, 121.3, 118.7, 108.7, 106.2, 85.8, 37.9, 27.9 (3C), 24.8, 
13.8 ppm. 
HRMS-ESI ( m/z) found 412.1650 [M+Na]+, calcd 412.1632 for [C23H23N3O3+Na]+. 
Boc- deprotection using 4 N HCl in dioxane (2 mL) yielded product as a white solid, 
where successful deprotection was confirmed by 1H NMR, yield 16% (103 mg, 0.26 
mmol). 
1H NMR (500 MHz, DMSO-d6) δ 12.95 (s, 1H, NH), 10.04 (s, 1H, CHO), 8.69 (s, 1H, 
ar CH), 8.33 (s, 1H, ar CH), 8.22 (d, J = 8.1 Hz, 1H, ar CH), 8.08 (s, 1H, ar CH), 7.98 – 
7.89 (m, 2H, ar CH), 7.74 (d, J = 8.5 Hz, 1H, ar CH), 7.57 (d, J = 8.1 Hz, 1H, ar CH), 
4.53 (q, J = 7.0 Hz, 2H, CH2), 1.36 (t, J = 7.0 Hz, 3H, CH3) ppm. 
 
Synthesis of 9-ethyl-7-(pyrimidin-5-yl)-9H-carbazole-3-carbaldehyde (4.30i) 
 
Synthesised according to general procedure F under anhydrous conditions, using 
potassium phosphate tribasic as a base. 7-Bromo-9-ethyl-9H-carbazole-3-carbaldehyde 
(4.4) (97 mg, 0.32 mmol), pyrimidine-5-boronic acid (120 mg, 0.96 mmol), K3PO4 (272 
mg, 1.28 mmol), Pd-118 (10 mg, 0.01 mmol), anhydrous MeCN (2 mL). Product isolated 
as an orange solid, yield 46% (45 mg, 0.149 mmol).  
1H NMR (500 MHz, Chloroform-d) δ 10.11 (s, 1H, CHO), 9.24 (s, 1H, ar CH), 9.07 (s, 
2H, ar CH), 8.64 (s, 1H, ar CH), 8.27 (d, J = 8.0 Hz, 1H, ar CH), 8.05 (d, J = 8.5 Hz, 1H, 
ar CH), 7.61 (s, 1H, ar CH), 7.52 (d, J = 8.6 Hz, 1H, ar CH), 4.47 (q, J = 7.1 Hz, 2H, 
CH2), 1.52 (t, J = 7.2 Hz, 3H, CH3) ppm. 
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13C NMR (126 MHz, Chloroform-d) δ 191.4, 157.4, 155.1 (2C), 144.1, 141.2, 134.9, 
132.9, 129.1, 127.8, 124.1, 123.6, 122.6, 121.7, 119.3, 108.7, 107.5, 38.0, 13.8 ppm. 
HRMS-ESI (m/z) found 302.1286 [M+H]+, calcd 302.1288 for [C19H15N3O+H]+. 
 
Synthesis of 9-ethyl-7-(5-methylthiophen-2-yl)-9H-carbazole-3-carbaldehyde (4.30j) 
 
Synthesised according to general procedure F. 7-Bromo-9-ethyl-9H-carbazole-3-
carbaldehyde (4.4) (180 mg, 0.59 mmol), (5-methylthiophen-2-yl)boronic acid (254 mg, 
1.79), potassium carbonate (164 mg, 1.19 mmol), Pd-118 (4 mg, 0.005 mmol), anhydrous 
MeCN (2 mL) and degassed H2O (2 mL). Product was isolated as a brown solid, yield 
38% (73 mg, 0.22 mmol). 
1H NMR (500 MHz, Chloroform-d) δ 10.08 (s, 1H, CHO), 8.55 (s, 1H, ar CH), 8.07 (d, 
J = 8.0 Hz, 1H, ar CH), 7.98 (d, J = 8.4 Hz, 1H, ar CH), 7.58 – 7.49 (m, 2H, ar CH), 7.44 
(d, J = 8.4 Hz, 1H, ar CH), 7.23 (s, 1H, ar CH), 6.82 – 6.73 (m, 1H, ar CH), 4.39 (q, J = 
6.9 Hz, 2H, CH2), 2.55 (s, 3H, CH3), 1.47 (t, J = 7.1 Hz, 3H, CH3) ppm. 
13C NMR (126 MHz, Chloroform-d) δ 191.7, 144.0, 142.4, 141.1, 139.8, 133.5, 128.7, 
127.1, 126.3, 123.7, 123.3, 123.0, 122.0, 121.0, 118.5, 108.6, 105.7, 37.9, 15.5, 13.8 ppm. 
HRMS-ESI (m/z) found 342.0917 [M+Na]+, calcd 342.0923 for [C20H17NOS+Na]+.  
 
Synthesis of 9-Ethyl-7-(4-methylthiophene-2-yl)-9H-carbazole-3-carbaldehyde (4.30k) 
 
 
Synthesised according to general procedure F. 7-Bromo-9-ethyl-9H-carbazole-3-
carbaldehyde (4.4) (300 mg, 0.99 mmol), (4-methylthiophen-2-yl)boronic acid (422 mg, 
2.97 mmol), potassium carbonate (274 mg, 1.98 mmol), Pd-118 (6 mg, 0.009 mmol), 
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anhydrous MeCN (5 mL) and degassed H2O (5 mL). Product was isolated as a brown 
solid, yield 90% (285 mg, 0.89 mmol).  
1H NMR (500 MHz, Chloroform-d) δ 10.09 (s, 1H, CHO), 8.59 (s, 1H, ar CH), 8.12 (d, 
J = 8.0 Hz, 1H, ar CH), 8.01 (d, J = 8.5 Hz, 1H, ar CH), 7.61 (s, 1H, ar CH), 7.57 (d, J = 
8.0 Hz, 1H, ar CH), 7.48 (d, J = 8.5 Hz, 1H, ar CH), 6.91 (s, 1H, ar CH), 4.44 (q, J = 7.0 
Hz, 2H, CH2), 2.33 (s, 3H, CH3), 1.50 (t, J = 7.0 Hz, 3H, CH3) ppm. 
HRMS-ESI (m/z) found 342.0932 [M+Na]+, calc 342.0923 for [C20H17NOS+Na]+. 
 
Synthesis of 9-ethyl-7-(3-methylthiophen-2-yl)-9H-carbazole-3-carbaldehyde (4.30l) 
 
Synthesised according to general procedure F. 7-Bromo-9-ethyl-9H-carbazole-3-
carbaldehyde (4.4) (150 mg, 0.49 mmol), (3-methylthiophen-2-yl)boronic acid (211 mg, 
1.48 mmol), potassium carbonate (137 mg, 0.99 mmol), Pd-118 (4 mg, 0.004 mmol), 
anhydrous MeCN (2 mL) and degassed H2O (2 mL). Product was isolated as a brown 
solid, yield 75% (120 mg, 0.37 mmol).  
1H NMR (500 MHz, Chloroform-d) δ 10.10 (s, 1H, CHO), 8.61 (s, 1H, ar CH), 8.16 (d, 
J = 8.0 Hz, 1H, ar CH), 8.02 (d, J = 8.5 Hz, 1H, ar CH), 7.52 (s, 1H, ar CH), 7.49 (d, J = 
8.5 Hz, 1H, ar CH), 7.44 (d, J = 8.0 Hz, 1H, ar CH), 7.29 – 7.23 (m, 2H, ar CH), 6.99 (d, 
J = 5.1 Hz, 1H, ar CH), 4.42 (q, J = 7.1 Hz, 2H, CH2), 2.41 (s, 3H, CH3), 1.49 (t, J = 7.2 
Hz, 3H, CH3) ppm. 
13C NMR (126 MHz, Chloroform-d) δ 191.7, 144.0, 140.8, 138.3, 133.4, 133.3, 131.2, 
128.7, 127.3, 123.9, 123.7, 122.9, 122.1, 121.7, 120.7, 109.5, 108.7, 38.0, 15.0, 13.8 ppm. 
HRMS-ESI (m/z) found 320.1091 [M+H]+, calcd 320.1104 for [C20H17NOS+H]+.  
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Synthesis of 7-(4,5-dimethylthiophen-2-yl)-9-ethyl-9H-carbazole-3-carbaldehyde 
(4.30m) 
 
Synthesised according to general procedure F. 5-Bromo-2,3-dimethylthiophene (4.38) 
(121 mg, 0.63 mmol), 9-ethyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-9H-
carbazole-3-carbaldehyde (4.37) (332 mg, 0.95 mmol), potassium carbonate (174 mg, 
1.26 mmol), Pd-118 (4 mg, 1.26 mmol), anhydrous MeCN (1 mL) and degassed H2O (1 
mL). Product was isolated as a brown solid, yield 46 % (153 mg, 0.45 mmol). 
1H NMR (500 MHz, Chloroform-d) δ 10.07 (s, 1H, CHO), 8.53 (s, 1H, ar CH), 8.06 (d, 
J = 8.0 Hz, 1H, ar CH), 7.97 (d, J = 8.5 Hz, 1H, ar CH), 7.56 – 7.47 (m, 2H, ar CH), 7.43 
(d, J = 9.2 Hz, 1H, ar CH), 7.13 (s, 1H, ar CH), 4.37 (q, J = 7.0 Hz, 2H, CH2), 2.40 (s, 
3H, CH3), 2.19 (s, 3H, CH3), 1.46 (t, J = 6.6 Hz, 3H, CH3) ppm. 
13C NMR (126 MHz, Chloroform-d) δ 191.7, 144.0, 141.1, 139.6, 134.3, 133.5, 132.9, 
128.6, 127.1, 126.3, 123.7, 123.0, 121.9, 121.0, 118.4, 108.6, 105.5, 37.8, 13.8 (2C), 13.2 
ppm. 
HRMS-ESI (m/z) found 334.1262 [M+H]+, calcd 334.1260 for [C21H19NOS+H]+. 
 
Synthesis of 7-(5-chlorothiophen-2-yl)-9-ethyl-9H-carbazole-3-carbaldehyde (4.30n) 
 
Synthesised according to general procedure F. 7-Bromo-9-ethyl-9H-carbazole-3-
carbaldehyde (4.4) (150 mg, 0.49 mmol), (5-chlorothiophen-2-yl)boronic acid (241 mg, 
1.48 mmol), potassium carbonate (137 mg, 0.99 mmol), Pd-118 (4 mg, 0.004 mmol), 
anhydrous MeCN (2 mL) and degassed H2O (2 mL). Product was isolated as a yellow 
solid, yield 88% (96 mg, 0.28 mmol). 
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1H NMR (500 MHz, Chloroform-d) δ 10.06 (s, 1H, CHO), 8.52 (s, 1H, ar CH), 8.04 (d, 
J = 8.0 Hz, 1H, ar CH), 7.97 (d, J = 8.4 Hz, 1H, ar CH), 7.46 (s, 1H, ar CH), 7.44 – 7.37 
(m, 2H, ar CH), 7.18 – 7.13 (m, 1H, ar CH), 6.95 – 6.87 (m, 1H, ar CH), 4.34 (q, J = 7.0 
Hz, 2H, CH2), 1.45 (t, J = 7.2 Hz, 3H, CH3) ppm. 
13C NMR (126 MHz, Chloroform-d) δ 191.6, 144.0, 143.4, 141.0, 132.3, 129.2, 128.8, 
127.4, 127.2, 123.8, 122.8, 122.6, 122.5, 121.2, 118.3, 108.7, 105.8, 37.9, 13.8 ppm. 
MS-EI (m/z) found 339 [M]+, calcd 339. 
 
Synthesis of 7-(3-(((tert-butyldimethylsilyl)oxy)methyl)thiophen-2-yl)-9-ethyl-9H-
carbazole-3-carbaldehyde (4.30o) 
 
Synthesised according to general procedure F. ((2-Bromothiophen-3-yl)methoxy)(tert-
butyl)dimethylsilane (4.38) (300 mg, 0.97 mmol), 9-ethyl-7-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)-9H-carbazole-3-carbaldehyde (4.37) (511 mg, 1.46 mmol), potassium 
carbonate (268 mg, 1.94 mmol), anhydrous MeCN (5 mL) and degassed H2O (5 mL). 
Product was isolated as a beige solid, yield 70% (309 mg, 0.68 mmol).  
1H NMR (500 MHz, Chloroform-d) δ 10.10 (s, 1H, CHO), 8.60 (s, 1H, ar CH), 8.15 (d, 
J = 8.0 Hz, 1H, ar CH), 8.02 (d, J = 8.5 Hz, 1H, ar CH), 7.67 (s, 1H, ar CH), 7.50 – 7.44 
(m, 2H, ar CH), 7.31 (d, J = 5.2 Hz, 1H, ar CH), 7.22 (d, J = 5.2 Hz, 1H, ar CH), 4.79 (s, 
2H, CH2), 4.41 (q, J = 7.2 Hz, 2H, CH2), 1.48 (t, J = 7.2 Hz, 3H, CH3), 0.96 (s, 9H, CH3), 
0.12 (s, 6H, CH3) ppm. 
13C NMR (126 MHz, Chloroform-d) δ 191.7 (CHO), 144.0, 142.1, 140.8, 136.8, 132.2, 
129.5, 128.7, 127.5, 124.7, 123.9, 122.6, 121.8, 120.9, 120.8, 109.8, 108.9, 58.9, 38.0, 
25.6 (3C), 18.1, 13.8, -2.96 (2C) ppm.  
HRMS-ESI (m/z) found 472.1748 [M+Na]+, calcd 472.1737 for [C26H31NOSSi+Na]+. 
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Synthesis of 1-(9-ethyl-7-(thiophen-3-yl)-9H-carbazol-3-yl)-N-methylmethanamine 
(4.31c) 
 
 
Synthesised according to general procedure B. 9-Ethyl-7(thiophen-3-yl)-9H-carbazole-3-
carbaldehyde (4.30c) (200 mg, 0.65 mmol), methylamine (491 µL, 2M solution in THF, 
0.98 mmol), anhydrous THF (10 mL) and sodium triacetoxyborohydride (346 mg, 1.63 
mmol). Product was isolated as an orange solid, yield 22 % (47 mg, 0.14 mmol). 
1H NMR (500 MHz, Chloroform-d) δ 8.15 – 8.08 (m, 2H, ar CH), 7.59 (s, 1H, ar CH), 
7.58 – 7.52 (m, 3H, ar CH), 7.52 – 7.47 (m, 1H, ar CH), 7.47 – 7.42 (m, 1H, ar CH), 7.41 
– 7.36 (m, 1H, ar CH), 4.41 (q, J =7.0 Hz, 2H, CH2), 3.83 (s, 2H, CH2), 2.35 (s, 3H, CH3), 
1.47 (t, J = 7.0 Hz, 3H, CH3) pp,. 
13C NMR (126 MHz, Chloroform-d) δ 143.4, 140.7, 139.9, 133.6, 127.2, 126.8, 126.0, 
122.8, 122.0, 121.1, 120.7, 120.0, 117.9, 108.2, 106.2, 61.9, 41.8, 37.5, 13.8 ppm. 
HRMS-ESI (m/z) found 290.0997 [M]+, calcd 290.0998 [C19H16NS]+ (loss of NHMe). 
LC-MS purity > 99% (UV), ret. time = 16.60 min. 
 
Synthesis of 1-(9-ethyl-7-(furan-3-yl)-9H-carbazol-3-yl)-N-methylmethanamine (4.31d) 
 
Synthesised according to general procedure B. 9-Ethyl-7-(furan-3-yl)-9H-carbazole-3-
carbaldehyde (4.30d) (200 mg, 0.69 mmol), methylamine (518 µL, 2M solution in THF, 
1.03 mmol), anhydrous THF (10 mL) and sodium triacteoxyborohydride (366 mg, 1.72 
mmol). Product was isolated as an orange solid, yield 61% (129 mg, 0.42 mmol). 
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1H NMR (500 MHz, Chloroform-d) δ 8.04 (d, J = 8.0 Hz, 1H, ar CH), 8.02 (s, 1H, ar 
CH), 7.82 (s, 1H, ar CH), 7.52 (s, 1H, ar CH), 7.44 (s, 1H, ar CH), 7.41 (d, J = 8.3 Hz, 
1H, ar CH), 7.36 (d, J = 8.0 Hz, 1H, ar CH), 7.33 (d, J = 8.3 Hz, 1H, ar CH), 6.82 (s, 1H, 
ar CH), 4.34 (q, J = 7.2 Hz, 2H, CH2), 3.94 (s, 2H, CH2), 2.51 (s, 3H, CH3), 1.42 (t, J = 
7.2 Hz, 3H, CH3) ppm. 
13C NMR (126 MHz, Chloroform-d) δ 143.5, 140.7, 139.7, 138.4, 130.1, 127.4, 126.3, 
122.9, 121.9, 120.7, 120.3, 117.3, 109.9, 109.2, 108.3, 105.5, 55.6, 37.5, 34.9, 13.7 ppm. 
HRMS-ESI (m/z) found 274.1222 [M]+, calcd. 274.1226 for [C19H16NO]+ (loss of 
NHMe). 
LC-MS purity = 90 % (UV), ret. time = 12.68 min. 
 
Synthesis of 1-(9-ethyl-7-(thiazol-4-yl)-9H-carbazol-3-yl)-N-methylmethanamine 
(4.31e) 
 
Synthesised according to general procedure B. 9-Ethyl-7-(thiazol-4-yl)-9H-carbazole-3-
carbaldehyde (4.30e) (342 mg, 1.11 mmol), methylamine (836 µL, 1.67 mmol), 
anhydrous THF (15 mL) and sodium triacetoxyborohydride (591 mg, 2.79 mmol). 
Product was isolated as a beige solid, yield 48% (172 mg, 0.53 mmol). 
1H NMR (500 MHz, Chloroform-d) δ 8.90 (d, J = 1.8 Hz, 1H, ar CH), 8.07 – 8.03 (m, 
1H, ar CH), 8.03 – 7.99 (m, 2H, ar CH), 7.68 – 7.62 (m, 1H, ar CH), 7.55 (d, J = 1.7 Hz, 
1H, ar CH), 7.42 – 7.36 (m, 1H, ar CH), 7.30 – 7.23 (m, 1H, ar CH), 4.28 (q, J = 7.2 Hz, 
2H, CH2), 3.94 (s, 2H, CH2), 2.47 (s, 3H, CH3), 1.35 (t, J = 7.2 Hz, 3H, CH3) ppm. 
13C NMR (126 MHz, Chloroform-d) δ 157.1, 152.6, 140.6, 140.2, 131.9, 126.8, 126.6, 
122.8, 122.6, 121.1, 120.7, 117.5, 112.2, 108.5, 106.7, 54.4, 37.5, 33.6, 13.8 ppm. 
HRMS-ESI (m/z) found 291.0948 [M]+, calcd. 291.0950 for [C18H15N2S]+ (loss of 
NHMe). 
LC-MS purity > 99% (UV), ret. time = 11.35 min. 
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Synthesis of 1-(9-ethyl-7-(thiazol-2-yl)-9H-carbazol-3-yl)-N-methylmethanamine 
(4.31f) 
 
Synthesised according to general procedure B. 9-Ethyl-7-(thiazol-2-yl)-9H-carbazole-3-
carbaldehyde (4.30f) (130 mg, 0.42 mmol), methylamine (315 µL, 2M solution in THF, 
0.63 mmol), anhydrous THF (7 mL) and sodium triacetoxyborohydride (224 mg, 1.06 
mmol). Product was isolated as a beige solid, yield 10% (13 mg, 0.04 mmol). 
1H NMR (500 MHz, Chloroform-d) δ 8.15 (s, 1H, ar CH), 8.03 (d, J = 8.0 Hz, 1H, ar 
CH), 7.93 (s, 1H, ar CH), 7.87 (d, J = 3.2 Hz, 1H, ar CH), 7.66 (d, J = 8.0 Hz, 1H, ar CH), 
7.56 (d, J = 7.6 Hz, 1H, ar CH), 7.31 (d, J = 3.2 Hz, 1H, ar CH), 7.26 (d, J = 8.0 Hz, 1H, 
ar CH), 4.21 (q, J = 6.9 Hz, 2H, CH2), 4.07 (s, 2H, CH2), 2.53 (s, 3H, CH3) and 1.29 (t, J 
= 6.9 Hz, 3H, CH3) ppm. 
13C NMR (126 MHz, Chloroform-d) δ 169.1, 143.5, 141.0, 140.3, 131.4, 128.1, 123.8, 
122.9, 122.7, 121.0, 120.6, 118.6, 118.4, 109.1, 106.2, 52.6, 37.6, 31.2, 13.7 ppm. 
HRMS-ESI (m/z) found 291.0941 [M]+, calcd 291.0950 for [C18H15N2S]+ (loss of 
NHMe). 
LC-MS purity > 99 % (UV), ret. time = 11.93 min. 
 
Synthesis of 1-(9-ethyl-7-(isoxazol-4-yl)-9H-carbazol-3-yl)-N-methylmethanaime 
(4.31g) 
 
Synthesised according to general procedure B. 9-Ethyl-7-(isoxazol-4-yl)-9H-carbazole-
3-carbaldehyde (4.30h) (200 mg, 0.68 mmol), methylamine (516 µL, 2M solution in 
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THF, 1.03 mmol), anhydrous THF (10 mL) and sodium triacetoxyborohydride (365 mg, 
1.72 mmol). Product was isolated as a brown oil, yield 18% (38 mg, 0.12 mmol). 
1H NMR (500 MHz, Chloroform-d) δ 8.68 (s, 1H, ar CH), 8.58 (s, 1H, ar CH), 8.04 (s, 
1H, ar CH), 7.95 (d, J = 8.0 Hz, 1H, ar CH), 7.43 (d, J = 8.3 Hz, 1H, ar CH), 7.28 (d, J = 
7.9 Hz, 2H, ar CH), 7.19 (d, J = 7.9 Hz, 1H, ar CH), 4.23 (q, J = 7.1 Hz, 2H, CH2), 4.07 
(s, 2H, CH2), 2.54 (s, 3H, CH3), 1.34 (t, J = 7.1 Hz, 2H, CH3) ppm. 
HRMS-ESI (m/z) found 275.1181 [M]+, calcd 275.1179 for [C18H15N2O]+ (loss of 
NHMe). 
 
Synthesis of 1-(9-Ethyl-7-(1H-pyrazol-4-yl)-9H-carbazol-3-yl)-N-methylmethanaime 
(4.31h) 
 
Synthesised according to general procedure B. 9-Ethyl-7-(1H-pyrazol-4-yl)-9H-
carbazole-3-carbaldehyde (4.30h) (45 mg, 0.15 mmol), methylamine (116 µL, 2M 
solution in THF, 0.23 mmol), anhydrous THF (2 mL) and sodium triacetoxyborohydride 
(82 mg, 0.23 mmol). Product was isolated as a white solid, yield 29% ( 14 mg, 0.045 
mmol). 
1H NMR (500 MHz, Chloroform-d) δ 8.16 – 8.10 (m, 4H), 8.08 (s, 1H), 7.70 (d, J = 8.1 
Hz, 1H), 7.40 (d, J = 8.3 Hz, 1H), 6.85 (d, J = 2.8 Hz, 1H), 4.44 (q, J = 7.1 Hz, 2H), 3.84 
(s, 2H), 2.35 (s, 3H), 1.47 (t, J = 7.1 Hz, 3H) ppm. 
HRMS-ESI (m/z) found 274.1340 [M]+, calcd 274.1339 for [C18H16N3]+ (loss of NHMe). 
LC-MS purity = 96 % (UV), ret. time = 13.13 min. 
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Synthesis of 1-(9-ethyl-7-(pyrimidin-5-yl)-9H-carbazol-3-yl)-N-methylmethanamine 
(4.31i) 
 
Synthesised according to general procedure A. 9-Ethyl-7-(pyrimidin-5-yl)-9H-carbazole-
3-carbaldehyde (4.30i) (21 mg, 0.06 mmol) methylamine hydrochloride (9 mg, 0.13 
mmol), triethylamine (14 µL, 0.10 mmol), titanium (IV) isopropoxide (41 µL, 0.13 
mmol), DCM (1 mL), EtOH (1 mL) and sodium borohydride (5 mg, 0.13 mmol). Product 
was isolated as an orange oil in a quantitative yield (22 mg, 0.06 mmol).  
 1H NMR (500 MHz, DMSO-d6) δ 9.28 (s, 2H, ar CH), 9.17 (s, 1H, ar CH), 8.24 (d, J = 
7.8 Hz, 1H, ar CH), 8.17 (s, 1H, ar CH), 8.07 (s, 1H, ar CH), 7.64 – 7.54 (m, 2H, ar CH), 
7.49 (d, J = 9.5 Hz, 1H, ar CH), 4.51 (q, J = 7.0 Hz, 2H, CH2), 3.93 (s, 2H, CH2), 2.39 (s, 
3H, CH3), 1.33 (t, J = 6.8 Hz, 3H, CH3) ppm. 
13C NMR (126 MHz, Chloroform-d) δ 157.1, 155.1 (2C), 140.6, 140.0, 135.24, 131.6, 
127.7 127.2, 123.3, 121.4, 121.3, 120.8, 117.8, 108.6, 106.7, 55.6, 40.6, 37.7, 13.8 ppm. 
HRMS-ESI (m/z) found 286.1334 [M]+, calcd [C19H16N3]+ (loss of NHMe). 
LC-MS purity = 92 % (UV), ret. time = 10.86 min. 
 
Synthesis of 1-(9-Ethyl-7-(5-methylthiophen-2-yl)-9H-carbazol-3-yl)-N-
methylmethanamine (4.31j) 
 
Synthesised according to general procedure B. 9-Ethyl-7-(5-methylthiophen-2-yl)-9H-
carbazole-3-carbaldehyde (4.30j) (73 mg, 0.23 mmol), methylamine (171 µL, 2M 
solution in THF, 0.34 mmol), anhydrous THF (2 mL) and sodium triacetoxyborohydride 
N
HN
N
N
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(122 mg, 0.57 mmol). Product was isolated as a pale yellow solid, yield 43% (33 mg, 
0.09 mmol).  
1H NMR (500 MHz, Chloroform-d) δ 8.03 – 7.99 (m, 2H, ar CH), 7.49 (s, 1H, ar CH), 
7.44 (d, J = 8.1 Hz, 1H, ar CH), 7.41 (d, J = 8.3 Hz, 1H, ar CH), 7.30 (d, J = 8.2 Hz, 1H, 
ar CH), 7.20 (d, J = 3.4 Hz, 1H, ar CH), 6.78 (d, J = 2.3 Hz, 1H, ar CH), 4.31 (q, J = 7.2 
Hz, 2H, CH2), 3.94 (s, 2H, CH2), 2.55 (s, 3H, CH3), 2.50 (s, 2H, CH2), 1.40 (t, J = 7.2 Hz, 
3H, CH3) ppm. 
13C NMR (126 MHz, DMSO-d6) δ 142.3, 140.9, 140.6, 139.3, 132.6, 128.1, 127.2, 124.1, 
122.8, 122.6, 122.4, 121.4, 121.2, 117.4, 109.7, 105.8, 52.1, 37.5, 32.2, 15.5, 14.1 ppm. 
HRMS-ESI (m/z) found 304.1154 [M]+, calcd 304.1154 for [C20H18NS]+ (loss of 
NHMe). 
LC-MS purity = 92% (UV), ret. time = 13.69 min. 
 
Synthesis of 1-(9-Ethyl-7-(4-methylthiophen-2-yl)-9H-carbazol-3-yl)-N-
methylmethanamine (4.31k) 
 
Synthesised according to general procedure B. 9-Ethyl-7-(4-methylthiophene-2-yl)-9H-
carbazole-3-carbaldehyde (4.30k) (285 mg, 0.89 mmol), methylamine (668 µL, 2M 
solution in THF, 1.33 mmol), anhydrous THF (5 mL), sodium triacetoxyborohydride (472 
mg, 2.23 mmol). Product was isolated as a pale yellow solid, yield 28% (85 mg, 0.25 
mmol). 
1H NMR (500 MHz, Chloroform-d) δ 8.05 – 8.00 (m, 2H, ar CH), 7.54 (s, 1H, ar CH), 
7.49 – 7.45 (m, 1H, ar CH), 7.42 (d, J = 8.3 Hz, 1H, ar CH), 7.32 (d, J = 8.3 Hz, 1H, ar 
CH), 7.23 (s, 1H, ar CH), 6.89 (s, 1H, ar CH), 4.34 (q, J = 7.2 Hz, 2H, CH2), 3.94 (s, 2H, 
CH2), 2.51 (s, 2H, CH2), 2.34 (s, 3H, CH3), 1.42 (t, J = 7.2 Hz, 3H, CH3) ppm.  
13C NMR (126 MHz, cdcl3) δ 145.24, 140.65, 140.05, 138.62, 132.43, 126.60, 125.45, 
122.90, 122.17, 120.73, 120.68, 119.92, 117.50, 108.44, 105.50, 55.14, 37.56, 34.39, 
15.86, 13.77 ppm. Missing one quaternary carbon. 
HRMS-ESI (m/z) found 304.1157 [M]+, calcd 304.1154 for [C20H18NS]+ (loss of NHMe). 
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LC-MS purity > 99% (UV), ret. time = 13.69 min. 
 
Synthesis of 1-(9-Ethyl-7-(3-methylthiophen-2-yl)-9H-carbazol-3-yl)-N-
methylmethanamine (4.31l) 
 
9-Ethyl-7-(3-methylthiophen-2-yl)-9H-carbazole-3-carbaldehyde (4.30l) (120 mg, 0.37 
mmol), methylamine (282 µL, 2M solution in THF, 0.56 mmol), anhydrous THF (4 mL) 
and sodium triacetoxyborohydride (199 mg, 0.93 mmol). Product was isolated as an 
orange solid, yield 39% (48 mg, 0.14 mmol). 
1H NMR (500 MHz, Chloroform-d) δ 8.09 (d, J = 8.0 Hz, 1H, ar CH), 8.07 (s, 1H, ar 
CH), 7.44 (d, J = 7.3 Hz, 2H, ar CH), 7.34 (d, J = 8.2 Hz, 2H, ar CH), 7.25 (d, J = 5.1 Hz, 
1H, ar CH), 6.98 (d, J = 5.1 Hz, 1H, ar CH), 4.33 (q, J = 7.2 Hz, 2H, CH2), 3.98 (s, 2H, 
CH2), 2.50 (s, 2H, CH2), 2.41 (s, 3H, CH3), 1.41 (t, J = 7.2 Hz, 3H, CH3) ppm. 
13C NMR (126 MHz, DMSO-d6) δ 140.6, 140.4, 138.2, 133.4, 132.4, 131.9, 128.3, 124.6, 
122.8, 122.2, 121.4, 120.9, 120.5, 117.7, 109.7, 109.6, 52.0, 37.5, 32.0, 15.3, 14.1 ppm. 
MS-EI (m/z) found 335 [M+H]+, calcd 335.  
LC-MS purity 96% (UV), ret. time = 13.22 min. 
 
Synthesis of 1-(7-(4,5-dimethylthiophen-2-yl)-9-ethyl-9H-carbazol-3-yl)-N-
methylmethanamine (4.31m) 
 
Synthesised according to general procedure B. 7-(4,5-Dimethylthiophen-2-yl)-9-ethyl-
9H-carbazole-3-carbaldehyde (4.30m) (118 mg, 0.35 mmol), methylamine (265 µL, 2M 
solution in THF, 0.53 mmol), anhydrous THF (2 mL) and sodium triacetoxyborohydride 
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(187 mg, 0.88 mmol). Product was isolated as a pale brown solid, yield 46 % (59 mg, 
0.17 mmol).  
1H NMR (500 MHz, Chloroform-d) δ 8.08 (s, 1H, ar CH), 8.04 (d, J = 7.7 Hz, 1H, ar 
CH), 7.58 (d, J = 8.0 Hz, 2H, ar CH), 7.52 (s, 1H, ar CH), 7.45 (d, J = 8.0 Hz, 1H, ar CH), 
7.39 (d, J = 8.0 Hz, 1H, ar CH), 7.14 (s, 1H, ar CH), 4.37 (q, J = 6.3 Hz, 2H, CH2), 4.05 
(s, 2H, CH2), 2.48 – 2.36 (m, 6H, CH3), 2.21 (s, 3H, CH3), 1.46 (t, J = 6.7 Hz, 3H, CH3) 
ppm. 
13C NMR (126 MHz, DMSO-d6) δ 140.9, 140.8, 139.4, 134.5, 132.7, 132.4, 129.2, 127.0, 
124.0, 122.5, 121.3, 120.7, 117.7, 117.2, 109.7, 105.5, 59.2, 38.1, 37.5, 14.2, 13.9, 13.3 
ppm. 
HRMS-ESI (m/z) found 318.1312 [M]+, calcd 318.1311 for [C21H20NS]+ (loss of 
NHMe). 
LC-MS purity = 95% (UV), ret. time = 18.57 min. 
 
Synthesis of 1-(7-(5-chlorothiophen-2-yl)-9-ethyl-9H-carbazol-3-yl)-N-
methylmethanamine (4.31n) 
 
7-(5-Chlorothiophen-2-yl)-9-ethyl-9H-carbazole-3-carbaldehyde (4.30n) (96 mg, 0.28 
mmol), methylamine (211 µL, 2M solution in THF, 0.42 mmol), anhydrous THF (2 mL) 
and sodium triacetoxyborohydride (149 mg 0.70 mmol). Product was isolated as a bright 
yellow solid, yield 14% (14 mg, 0.039 mmol).  
1H NMR (500 MHz, Chloroform-d) δ 8.04 – 7.98 (m, 3H, ar CH), 7.43 (d, J = 8.3 Hz, 
2H, ar CH), 7.41 (s, 1H, ar CH), 7.36 (d, J = 8.2 Hz, 1H, ar CH), 7.30 (d, J = 8.3 Hz, 1H, 
ar CH), 7.14 (d, J = 3.8 Hz, 1H, ar CH), 6.93 (d, J = 3.8 Hz, 2H, ar CH), 4.29 (q, J = 7.2 
Hz, 2H, CH2), 3.95 (s, 2H, CH2), 2.50 (s, 3H, CH3), 1.38 (t, J = 7.2 Hz, 3H, CH3) ppm. 
13C NMR (126 MHz, DMSO-d6) δ 143.8, 140.8, 131.3, 128.6, 128.4, 127.4, 124.0, 122.9, 
122.8, 122.2, 122.1, 121.4, 117.7, 117.4, 109.8, 106.3, 52.1, 37.5, 32.2, 14.1 ppm.  
MS-EI (m/z) found 354 [M]+, calcd 354.  
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LC-MS purity = 94% (UV), ret. time = 13.73 min.  
 
Synthesis of (2-(9-ethyl-6-((methylamino)methyl)-9H-carbazol-2-yl)thiophen-3-
yl)methanol (4.31o) 
 
 
Synthesised according to general procedure B. 7-(3-(((tert-
Butyldimethylsilyl)oxy)methyl)thiophen-2-yl)-9-ethyl-9H-carbazole-3-carbaldehyde 
(4.30o) (270 mg, 0.6 mmol), methylamine (450 µL, 2M solution in THF, 0.9 mmol), 
anhydrous THF (10 mL) and sodium triacetoxyborohydride (317 mg, 1.5 mmol). Crude 
product was purified by chromatography on silica gel using DCM/MeOH 9/1 as an eluent 
to yield 1-(7-(3-(((tert-butyldimethylsilyl)oxy)methyl)thiophen-2-yl)-9-ethyl-9H-
carbazol-3-yl)-N-methylmethanamine as a brown oil, yield 26% (74 mg, 0.15 mmol). 
1H NMR (500 MHz, Chloroform-d) δ 8.11 – 8.08 (m, 1H, ar CH), 8.08 (s, 1H, ar CH), 
7.57 (s, 1H, ar CH), 7.47 – 7.40 (m, 1H, ar CH), 7.38 – 7.34 (m, 3H, ar CH), 7.29 (s, 1H, 
ar CH), 7.29 – 7.25 (m, 1H, ar CH), 7.22 – 7.17 (m, 1H, ar CH), 4.78 (s, 2H, CH2), 4.36 
(q, J = 7.2 Hz, 2H, CH2), 3.97 (s, 2H, CH2), 2.52 (s, 3H, CH3), 1.43 (t, J = 7.2 Hz, 3H, 
CH3), 0.94 (s, 9H, CH3), 0.08 (s, 6H, CH3) ppm. 
13C NMR (126 MHz, Chloroform-d) δ 141.2, 140.3, 139.9, 137.2, 131.5, 129.6, 128.8, 
126.7, 123.7, 122.7, 122.2, 120.6, 120.5, 120.3, 109.1, 108.4, 59.6, 55.4, 37.6, 34.7, 25.9 
(3C), 18.3, 13.7, -5.1 (2C) ppm. 
HRMS-ESI (m/z) found 434.1963 [M]+, calcd. 434.1968 for [C26H32NOSSi]+ (loss of 
NHMe). 
1-(7-(3-(((tert-butyldimethylsilyl)oxy)methyl)thiophen-2-yl)-9-ethyl-9H-carbazol-3-yl)-
N-methylmethanamine (70 mg, 0.15 mmol) was dissolved in anhydrous THF (1 mL) and 
cooled to 0 °C. TBAF (300 µL, 1M solution in THF, 0.30 mmol) was added dropwise 
and the solution was allowed to warm to room temperature. H2O (10 mL) and EtOAc (10 
mL) was added and product was extracted with EtOAc (3 X 10 mL). The organic extracts 
were washed with H2O, dried over anhydrous MgSO4, filtered and the filtrate was 
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concentrated under a reduced pressure to yield product that was purified by trituration 
with DCM. Product was isolated as a pale yellow solid, yield 19% (10 mg, 0.028 mmol). 
Successful removal of the silyl group was confirmed by 1H NMR and mass spectrometry. 
1H NMR (500 MHz, Chloroform-d) δ 8.20 (s, 1H, ar CH), 8.09 (d, J = 8.0 Hz, 1H, ar 
CH), 7.62 (d, J = 8.6 Hz, 1H, ar CH), 7.49 (s, 1H, ar CH), 7.36 – 7.29 (m, 3H, ar CH), 
7.23 (d, J = 5.2 Hz, 1H, ar CH), 4.70 (s, 2H, CH2), 4.28 – 4.18 (m, 2H, CH2), 4.13 (s, 2H, 
CH2), 2.53 (s, 3H, CH3), 1.33 (t, J = 7.2 Hz, 3H, CH3) ppm. 
 HRMS-ESI (m/z) found 320.1097 [M]+, calcd. 320.1104 for [C20H18NOS]+ (loss of 
NHMe). 
LC-MS purity = 94% (UV), ret. time = 12.53 min. 
Assay Conditions 
All DSF, ITC and cell viability measurements were performed by Dr. Matthias Bauer at 
the MRC Laboratory of Molecular Biology according to these conditions.  
 
DSF 
The effect of compounds on the melting temperature of T-p53C-Y220C was monitored 
using SYPRO Orange (Invitrogen) as the fluorescent probe, which quantitatively binds to 
the hydrophobic protein patches exposed upon thermal denaturation. Real-time melt 
analysis was performed using a Corbett Rotor-Gene 6000 real-time qPCR thermocycler. 
Excitation and emission filters were set to 460 and 510 nm, respectively. Heating from 
28 to 60 °C, a constant heating rate of 270 K/h was applied. The protein (final 
concentration of 10 µM) was briefly mixed with SYPRO orange (10×) in buffer (25 mM 
KPi pH 7.2, 150 mM NaCl, 1 mM TCEP), and compound (5 mM) dissolved in DMSO 
was added to give a final compound concentration of 250 µM in 5% (v/v) DMSO. The 
melting temperature (Tm) of the protein (10 µM) in presence of compounds was 
determined from the inflection point of the melting curve. Melting temperatures were 
compared with control samples without compound (yielding ΔTm DSF). All samples were 
measured in triplicate. 
 
ITC 
ITC experiments were conducted using a MicroCal (Amherst) iTC200 calorimeter. 
Protein samples used in the cell unit were prepared to a final concentration of 50−200 µM 
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in 25 mM KPi, pH 7.2, 150 mM NaCl, 1 mM TCEP in 5% (v/v) DMSO. Compounds for 
use in the syringe unit were dissolved in the same buffer at 5% (v/v) DMSO. 
Measurements were performed at 20 °C using injection steps of 2 µL at a rate of 0.5 µL/s 
(initial injection: 0.5 µL) and 120 s spacing. Data analysis was performed using MicroCal 
Origin software. 
 
NMR Spectroscopy 
1H/15N-HSQC spectra of uniformly 15N-labelled T-p53-Y220C (75 µM) with and without 
compounds were acquired at 20 °C on a Bruker Avance-800 spectrometer using a 5-mm 
inverse cryogenic probe. Samples were prepared by adding dilutions of compound from 
stock solutions in DMSO-d6 to a final concentration of 5% (v/v) DMSO-d6 in buffer. All 
HSQC spectra were acquired with 8 transients per t1 data point, 1024 data points in t2, 
and 64 complex data points in t1, with spectral widths of 11.0 kHz for 1H and 2.7 kHz for 
15N, and a recycle delay of 800 ms.  After zero filling, forward complex linear prediction 
in f1 and Fourier transformation, the digital resolytion was 0.01 ppm/point for 1H and 0.13 
ppm/point for 15N. Chemicals shifts were considered significant if the average weighted 
1H/15N chemical shift difference ∆δ(1H/15N) = [(∆δ(1H))2 + (∆δ(15N)/5)2]1/2 was greater 
than 0.04 ppm. To determine dissociation constants, at least five 15N/1H HSQC spectra at 
different compound concentrations were measured. Spectra analysis was performed using 
Sparky 3.114 and Bruker Topspin 2.0 software. To derive KD values, a quadratic 
saturation binding equation was fitted to the concentration-dependent chemical shift 
changes of the relevant shifting peaks: 
 !"#$ = !&'( = [*+] + [.+] + /0 − 2([*+] + [.+] + /0)5 − 4 ∙ [.+] ∙ [*+]2 ∙ [.+]  
 
Cell Viability 
Cell viability was measured using the CellTiter-Glo 2.0 assay kit (Promega, USA) 
according to the kit instructions. Cells were seeded in 96 well plates at 5000 cells per well 
and incubated overnight. Samples were prepared in medium with a twice as high 
compound and DMSO concentration then added to an equivalent volume of growth 
medium, yielding a final DMSO concentration of 0.5%. After incubating of cells for 72 
hours and equilibration of the 96-well plate to room temperature for 30 minutes, 
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CellTiter-Glo reagent was added to each well. Luminescence was recorded with a Centro 
XS³ LB 960 microplate luminometer (Berthold Technologies, Germany). Experiments 
were performed in quadruplicate.  
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